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Abstract 
Medulloblastoma is the most common malignant brain tumour of childhood. 
Transcriptomic profiling has revealed the existence of four core molecular subgroups 
(SHH, WNT, Group 3 and Group 4) with distinct clinical, pathologic and molecular 
characteristics. However, the specific molecular events associated with tumour 
development in these groups are poorly understood. DNA methylation plays a key role 
in epigenetic transcriptional regulation, and promoter hypermethylation leading to gene 
silencing is a common feature of medulloblastoma. DNA methylation profiling has 
identified distinct methylomic profiles associated with the four subgroups of 
medulloblastoma, and the wider role of DNA methylation in medulloblastoma now 
requires investigation. Using two high-throughput screening approaches, this project 
therefore undertook a comprehensive investigation into the potential role of specific 
DNA methylation events in the development of the distinct subgroups of 
medulloblastoma.  
Using DNA methylation profiles, which were generated for 216 medulloblastomas 
using the GoldenGate methylation array, the first approach identified 73 CpG 
methylation markers (encompassing 63 genes) which significantly distinguished Group 
3 and/or Group 4 medulloblastomas. Subgroup-specific differential gene expression 
analysis showed that, for the majority of the methylation markers identified, there was 
no clear inverse association between methylation and gene expression. One gene 
(RHOH) was identified which showed strong evidence of epigenetic dysregulation in 
medulloblastomas. RHOH methylation represented a potential epigenetic event in 
Group 4 tumours; 51% of Group 4 medulloblastomas showed aberrant hypomethylation 
of multiple RHOH promoter-associated CpG residues, which was associated with 
upregulated RHOH expression in Group 4 tumours. RHOH was re-expressed in 4 out of 
6 methylated cell lines following treatment with the demethylating agent 5’-aza-2’-
deoxycytidine (5-azaCdR). This study has thus identified a novel putative oncogenic 
role for RHOH in Group 4 medulloblastoma development. 
In the second approach, a functional epigenomics screen identified 283 genes which 
were upregulated in 2 or more cell lines investigated (n=10) following 5-azaCdR 
treatment. Assessment of DNA methylation using the Illumina 450K methylation array 
identified 160 CpG residues (encompassing 21 of the 283 genes) whose methylation 
status was consistent with expression alterations observed after 5-azaCDR, and 
methylation-dependent gene regulation, in cell lines. 9/160 CpG residues (6%) showed 
evidence of subgroup-specific differential methylation which was concordant with 
differential gene expression and potential epigenetic gene regulation in 
medulloblastoma subgroups. These 9 sites represented 5 candidate genes (ACTC1, 
ANXA2, FAM46A, PRPH and S100A4). Aberrant hypermethylation of multiple gene 
body CpG residues was associated with FAM46A silencing in non-SHH tumours, while 
aberrant hypermethylation of multiple promoter-associated residues was associated with 
ACTC1 silencing in Group 3 and Group 4 medulloblastomas. Single site 
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hypomethylation events associated with upregulated expression in WNT tumours were 
identified for ANXA2, PRPH and S100A4.  
This study has identified six genes with putative oncogenic or tumour suppressor roles 
in the development of distinct subgroups of medulloblastoma through their epigenetic 
dysregulation. Further work is now required to validate these findings and to assess 
their functional significance in medulloblastoma subgroups, as well as their potential 
relevance in medulloblastoma sub-classification and prognostication. 
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Chapter 1 Introduction 
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1.1 Cancer 
Cancer defines a heterogeneous group of diseases that are characterised by abnormal 
and uncontrolled cellular growth. Cancer, by definition, is a malignant neoplasm; cells 
have acquired the ability to penetrate and invade into surrounding tissue and to 
metastasise to more distant body sites. Disseminated tumour cells migrate from the 
primary site through the lymphatic system, blood vessels or across body cavities and 
successful metastasis depends on their ability to establish and develop into overt 
secondary tumours at the distant site (Hanahan and Weinberg, 2011). The presence and 
extent of metastases defines tumour stage and is an important prognostic indicator in 
most cancers (NCI, 2013).  
Cancer is a genetic disease and all cancers are caused by somatic mutations, with in 
some cases also germline mutations that carry an inherited predisposition to cancer 
(Alexandrov et al., 2013). While there are many widely recognised environmental 
causative factors in cancer, many of them, such as tobacco tar and ultra-violet (UV) 
radiation, exert their carcinogenic effect by targeting the genetic makeup of cells. In 
normal tissues the rate of cell growth, cell differentiation and cell death are tightly 
regulated to maintain tissue architecture and function. In cancer, a series of mutations 
and other genetic alterations result in the dysregulation of genes that control normal 
cellular growth patterns, leading to the development of large populations of cells that no 
longer obey the rules governing normal tissue growth (Strachan and Read, 2004b). 
Cancers are typically classified according to the tissue of origin; carcinomas are derived 
from epithelial cells, sarcomas from stromal cells and leukaemias and lymphomas from 
blood cell precursors. A histological examination of cells and tissue, as viewed under 
the microscope, is used to diagnose and also to classify tumours (Strachan and Read, 
2004b).  
More than 200 different cancer types have been described and cancer is a leading cause 
of disease and death worldwide (CRUK, 2013a). Improvements in the treatment of 
cancer have seen survival rates double in the UK in the last 40 years, and half of people 
with cancer now survive their disease for at least 5 years (CRUK, 2013a). Intensive 
research over the past two decades has increased understanding of the molecular 
pathology of cancer. This has led to the development of refined classification systems 
for some cancer types and to the development of novel molecularly targeted therapies, 
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which are starting to help deliver the promise of personalised cancer medicine with the 
primary aim of improving cancer survival and cure rates further. However, despite an 
increased understanding of the genetic and lifestyle causes of cancer, incidence rates 
continue to rise, and more than one in three people in the UK will be diagnosed with 
some form of cancer during their lifetime (CRUK, 2013a). 
1.1.1 Cancer incidence and mortality 
In 2010, 324,579 people were diagnosed with cancer in the UK (CRUK, 2013a). Cancer 
is primarily a disease of older people with ~65% of cancers diagnosed in people over 
the age of 65 (Figure 1.1). While incidence is significantly higher in males than in 
females (426 and 374 per 100,000, respectively), incidence rates have increased by 6% 
in females compared with just 2% in males over the last 10 years (CRUK, 2013a).  
Some tissues are more prone to developing cancer than others and cancers of the breast, 
lung, bowel and prostate account for over half of all new cases diagnosed (Figure 1.2). 
Despite being rare in men, breast cancer is the most common cancer in the UK. Prostate 
cancer is the most common cancer in men and accounts for 25% of male cancers. Over 
the last 10 years, cancer types have shown varying trends and have seen large increases 
in the incidence of cancers such as kidney, liver, oral and malignant melanoma with the 
increase most likely attributable to lifestyle choices (CRUK, 2013a). 
Cancer was the cause of 157,275 deaths in the UK in 2010 and accounted for 28% of all 
deaths (CRUK, 2013a). Deaths from cancers of the lung, bowel, breast and prostate are 
the most frequent and contribute 46% of all cancer deaths (Figure 1.3). Owing to an 
increased understanding of cancer causes and improvements in treatment, mortality has 
declined. The rate of decline, however, has slowed over the last 10 years (CRUK, 
2013a). More insights need to be gained from the underlying molecular pathology of 
cancer and better targeted treatments need to be developed in order to improve the 
survival and cure of a disease that is increasing in incidence.  
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Figure 1.1. Average number of new cancers per year increases with age. Figure taken from Cancer Research UK 
cancer stats (CRUK, 2013a). 
 
Figure 1.2. Incidence rates of common cancers. The 20 most commonly diagnosed cancers in the UK in 2010. 
Figure taken from Cancer Research UK cancer stats (CRUK, 2013a). 
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Figure 1.3. Mortality rates of common cancers in the UK. The 20 most common causes of cancer death in the UK 
in 2010. Figure taken from Cancer Research UK cancer stats (CRUK, 2013a). 
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1.2 Cancer biology  
1.2.1 Cancer is a multi-step disease  
Cancer is a highly complex and heterogeneous disease at the genetic level. There are 
many different genes that acquire mutations within and between the different tumour 
types, and it is the interaction between these mutational events that drives uncontrolled 
cellular proliferation and the development of individual cancers (Strachan and Read, 
2004b). 
Most cancers arise by expansion from a single cell (clonal evolution). There is no single 
mutation that can transform a normal cell into a malignant one and it has been estimated 
that any one cell would require on average 6-7 mutations to become malignant. Given 
that the typical mutational rate is 10
-7
 per gene per cell the chances of this occurring are 
very unlikely (Strachan and Read, 2004b). Cancer is the result of an accumulation of 
mutations, with each successive mutation providing the cell with a growth advantage 
and expanding the target population of cells for the next mutation (Figure 1.4). In turn, 
some mutations alter genomic stability and increase the overall mutational rate. As a 
result of this evolutionary process, cancer is a multi-step disease that develops over 
time, driving altered tissue growth through the progressive stages of hyperplasia 
(excessive cell proliferation) and dysplasia (excessive and abnormal growth of 
immature cells), leading ultimately to the development of malignant tumours (Strachan 
and Read, 2004b).  
The differences in clinical behaviour and responses to treatment observed for tumours 
of the same type can, in part, be explained by the tumour heterogeneity that arises as a 
result of the clonal evolution of cancer (Croce, 2008). Furthermore, as well as the initial 
clone and sub-clones, tumours can also contain progenitor cancer cells that will differ in 
their genetic alterations and differentiation states. Tumour heterogeneity makes the 
identification of the initiating steps in the development of cancer critically important for 
the development of rational cancer therapies (Croce, 2008). 
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Figure 1.4. Clonal evolution in tumour cell populations. Successive mutations and clonal expansion result in 
malignant tumour development. Figure adapted from Strachan and Read, 2004. 
 
Advances in whole-genome sequencing technologies have facilitated the identification 
of thousands of somatic mutations in a single cancer sample and have led to a recent 
major breakthrough in understanding the diversity and complexity of mutational 
processes in cancer (Alexandrov et al., 2013). An analysis of over 4 million mutations 
from over 7,000 cancers has revealed the presence of distinct mutational signatures, 
some of which are shared by many cancer types while others describe a single cancer 
type (Alexandrov et al., 2013). It is anticipated that as the number of cancer whole-
genome sequencing studies increases, their findings will hold great promise to advance 
knowledge and understanding of cancer causes with potential important implications for 
treatment and prevention. 
There are two broad categories of genes that are the targets of mutations in cancer: 
oncogenes, the normal activity of which promotes cell proliferation, growth and 
invasion, and tumour suppressor genes whose normal activity inhibits events that lead to 
cancer.  
1.2.2 Oncogenes 
Oncogenes were first identified in the 1960s when it was discovered that some animal 
cancers were caused by viruses, and that the transforming properties of retroviruses 
were entirely due to the possession of one extra gene which became known as the 
oncogene. Viral oncogenes are copies of normal cellular genes called ‘proto-
oncogenes’, that have become activated following their incorporation into the viral 
RNA genome (Strachan and Read, 2004b). Many cellular oncogenes have subsequently 
been identified by transforming immortalised cells in culture with DNA extracted from 
tumour cells. Most human cancers are not caused by viruses and proto-oncogenes 
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become activated and gain oncogenic potential by genetic changes in their coding or 
regulatory sequences or by an increase in copy number, resulting in either qualitative or 
quantitative changes in gene expression. Activation of proto-oncogenes involves a 
dominant gain of function and their altered expression in cancer directly determines the 
development of the malignant phenotype (Strachan and Read, 2004b). Proto-oncogenes 
encode proteins that control cell proliferation and apoptosis and the functional role of 
oncogene products can be classified into six broad groups: transcription factors, growth 
factors, growth factor receptors, signal transducers, chromatin remodellers and 
apoptosis regulators (Croce, 2008). Examples of oncogenes, their function and the 
cancer types they are disrupted in are listed in Table 1.1. 
Oncogene Function Cancer types 
MYC Transcription factor Breast cancer/Burkitt’s 
lymphoma 
MYCN Transcription factor Neuroblastoma/lung 
cancer 
ERBB2 Growth factor receptor Breast cancer/ovarian 
cancer 
RAS Intracellular signalling Colorectal cancer/lung 
cancer/thyroid 
cancer/melanoma  and 
more 
BRAF Intracellular signalling Melanoma/thyroid 
cancer/colorectal cancer 
SRC Tyrosine kinase Colorectal carcinoma 
EGFR Growth factor receptor Glioblastoma/non-small 
cell lung cancer 
Table 1.1. Examples of oncogenes. Oncogenes are listed alongside their normal cellular function and examples of 
cancers in which they become dysregulated. Table adapted from Croce, 2008. 
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Oncogenes can be activated by one of three main mechanisms: amplification, mutation 
and chromosomal rearrangements/translocations. These changes are dominant and 
normally affect only one allele. Activation of proto-oncogenes by gene amplification 
results in cancer cells containing multiple copies of structurally normal oncogenes and 
the over-production of an unaltered gene product (Strachan and Read, 2004b). 
Amplification of the oncogene MYCN is a common feature in neuroblastoma (Schwab, 
1990), while breast cancers often amplify ERBB2 which encodes a cell surface growth 
factor receptor (Strachan and Read, 2004b). 
Activation of proto-oncogenes by point mutation occurs as a result of the production of 
a modified gene product that confers a qualitative gain of function (Strachan and Read, 
2004b). For example, specific activating point mutations in the RAS family genes, 
HRAS, KRAS and NRAS, are frequently found in a variety of tumours (Table 1.1). RAS 
family genes are important mediators of cell signalling and the mutant RAS protein has 
reduced GTPase activity, leading to a slower inactivation of GTP-RAS and an excessive 
cellular response to the signal from the G-protein coupled receptors (Khosravi-Far and 
Der, 1994). 
Proto-oncogene activation can also occur as a result of chromosomal translocations that 
produce a novel chimeric gene product. The best known example of this is the 
Philadelphia (Ph) chromosome which is seen in 90% of patients with chronic myeloid 
leukaemia (CML). The Philadelphia chromosome results from a balanced reciprocal 
9;22 translocation at well-defined breakpoints resulting in the formation of a novel 
fusion gene, BCR-ABL. This chimeric gene produces an abnormal ABL tyrosine kinase 
product with transforming properties (Strachan and Read, 2004b). Alternatively, 
translocation into a transcriptionally active region of chromatin can cause activation of 
proto-oncogenes. Burkitt’s lymphoma is a childhood tumour that is characterised by 
translocations that place the MYC oncogene close to an immunoglobulin locus that is 
actively transcribed in antibody-producing-B-cells, leading to upregulated MYC 
expression (Wiseman, 2006). 
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1.2.2.1 Targeting oncogenic proteins 
Owing to their significant transforming potential, oncogenic proteins represent highly 
attractive therapeutic targets. Considerable progress has been made in the development 
of therapies that target oncogenic tyrosine kinases which are crucial mediators in 
multiple signalling pathways including proliferation and migration (Baselga, 2006). 
Several small molecule inhibitors of tyrosine kinases, most of which act as ATP 
mimetics, have been developed and approved for use in multiple cancers in which 
activation of the targeted oncogene is a significant feature (Imai and Takaoka, 2006) 
(Table 1.2). Accumulating clinical trial results suggest that monotherapy with these 
targeted therapies may be limited, owing to the multiple pathways that can be disrupted 
in cancer cells, and multi-targeting therapy with these agents may be more rational 
(Imai and Takaoka, 2006). At present, many of these targeted therapies are licensed for 
use in combination regimens with conventional chemotherapies, facilitating a potential 
reduction in chemotherapeutic dose and reducing dose-related toxicities. Imatinib 
(Glivec) was one of the first successful small molecule inhibitors developed; it 
inactivates the kinase activity of the BCR-ABL fusion gene in CML and has shown 
remarkable efficacy inducing complete remission in most patients with Philadelphia 
chromosome-positive CML (Druker et al., 2001; Ottmann et al., 2002).  
The development of monoclonal antibodies that target cell surface oncogenic proteins 
by eliciting an immune response has been a significant development in the treatment of 
cancers such as breast cancer and colorectal cancer (Table 1.2). Trastuzumab 
(Herceptin) is the first monoclonal antibody that targets the oncogene ERBB2 (Carter et 
al., 1992). It is approved for the treatment of patients with metastatic breast cancer who 
carry an increased ERBB2 copy number (Krejsa et al., 2006). Trastuzumab shows 
excellent anti-tumour activity, particularly when combined with the cytotoxic agents 
doxorubicin and paclitaxel (Baselga et al., 1998). 
The field of targeted cancer therapy is expanding rapidly and as an increasing number of 
molecular targets are identified, the number of novel therapies entering clinical trials is 
likely to increase. The potential for rational combinations of targeted therapies must 
also be explored with the primary aim of improving survival and limiting the emergence 
of drug resistance which can be seen with single agent use (Imai and Takaoka, 2006). 
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Targeted therapy Molecular target Cancer types 
Small molecule inhibitors   
Imatinib (Glivec, Novartis) ABL, PDGFR, KIT CML/gastrointestinal stromal 
tumours 
Gefitinib (Iressa, 
AstraZeneca) 
EGFR Non-small cell lung cancer 
Erlotinib (Tarceva, 
Genentech) 
EGFR Non-small cell lung cancer 
Sorafenib (Nexavar, 
Bayer/Onyx) 
VEGFR, PDGFR, FLT3 Renal cell carcinoma 
Sunitinib (Sutent, Pfizer) VEGFR, PDGFR, FLT3 Renal cell 
carcinoma/gastrointestinal 
stromal tumours 
Monoclonal antibodies   
Trastuzumab (Herceptin, 
Genentech) 
ERBB2 Breast cancer 
Cetuximab (Erbitux, 
ImClone) 
EGFR Colorectal cancer 
Bevacizumab (Avastin, 
Genentech) 
VEGF Colorectal cancer/non-small 
cell lung carcinoma 
Table 1.2. Examples of cancer therapies that target oncogenic proteins. Targeted therapies are listed by their 
generic drug name alongside their commercial name and the pharmaceutical company that holds the patent. Their 
molecular targets and the cancers they treat are listed. EGFR denotes epidermal growth factor receptor; FLT3 FMS-
like tyrosine kinase 3; PDGFR platelet-derived growth factor receptor; VEGF vascular endothelial growth factor. 
Table adapted from Croce, 2008. 
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1.2.3 Tumour suppressor genes 
Tumour suppressors are inactivated forms of cellular genes. They encode proteins that 
are negative regulators of normal growth and differentiation and have been identified by 
their loss of function in tumours and in studies with transgenic null mice (Strachan and 
Read, 2004b).  
Initial insights into tumour suppressor gene inactivation came from early work carried 
out by Knudson in 1971 on retinoblastoma (Knudson, 1971). Retinoblastoma is an 
aggressive childhood cancer and ~40% of cases represent familial disease which is often 
bilateral compared with sporadic forms which are always unilateral. Knudson noted that 
the age-distribution of bilateral disease was consistent with a single mutation, while 
sporadic cases followed a two-hit mechanism. He reasoned that all retinoblastomas 
involved two hits with one being inherited in the familial cases. Knudson’s hypothesis 
was subsequently proved when it was shown that sporadic and hereditary forms of 
retinoblastoma are characterised by loss of both alleles of the retinoblastoma gene (RB1) 
(Cavenee et al., 1983). 
The two-hit hypothesis proposed by Knudson was established as the paradigm for 
tumour suppressor gene inactivation; tumour suppressor gene loss of function is 
recessive and therefore both copies of the gene must be lost from the cell for the tumour 
suppressor phenotype to be evident (Strachan and Read, 2004b). In their study of 
retinoblastoma, Cavenee et al. observed that somatic genetic changes caused loss of 
heterozygosity (LOH) at markers close to the RB1 locus (Cavenee et al., 1983), and thus 
LOH analysis has been a major approach employed to discover the locations of tumour 
suppressor genes. Since the discovery of the RB1 tumour suppressor gene, a large 
number of tumour suppressor genes have been identified through their association with 
familial and sporadic cancers. Commonly inactivated tumour suppressor genes are listed 
in Table 1.3. 
There are many recognised mechanisms for the inactivation of tumour suppressor genes. 
Tumour suppressor genes may be silenced by whole chromosomal loss, chromosomal 
loss and duplication, gene conversion, gene deletion, mitotic recombination, point 
mutation or by epigenetic inactivation through promoter hypermethylation (Strachan 
and Read, 2004b). Methylation-dependent silencing of tumour suppressor genes is 
discussed in detail in section 1.6. The BRCA1 gene which is inactivated in 
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approximately 10-15% of sporadic breast cancers has been shown to be silenced by 
DNA methylation in some of these tumours (Birgisdottir et al., 2006). Genes that are 
inactivated by epigenetic mechanisms are attractive therapeutic targets owing to the 
reversible nature of epigenetic modifications (see section 1.6). 
TP53 is the gene most frequently altered in human cancers. TP53 encodes the p53 
tumour suppressor protein which protects DNA from damage by blocking proliferation, 
stimulating DNA repair and promoting apoptosis. It is regarded as the ‘guardian of the 
genome’. TP53 inactivation can occur by point mutation and many thousands of 
inactivating mutations have been identified in human cancers (Lim et al., 2007; 
Petitjean et al., 2007). 
Bi-allelic loss of tumour suppressor genes can occur via the same mechanism or by any 
combination of two different mechanisms. Following the identification of genes which 
frequently show loss of function of only one allele which is sufficient to cause an 
abnormal phenotype, it has been postulated that haploinsufficiency may be sufficient to 
cause gene inactivation and provide a growth advantage (Strachan and Read, 2004b). 
This phenomenon is observed in medulloblastoma with loss of one copy of the PTCH1 
gene sufficient to initiate tumour formation (Goodrich et al., 1997), while loss of a 
single allele of the PTEN tumour suppressor gene in prostate cancer has been shown to 
promote tumour progression (Kwabi-Addo et al., 2001). 
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Gene Function Cancer types 
APC Cell-cell recognition Colorectal cancer 
BRCA1 Transcriptional regulation 
and cell cycle control 
Breast cancer/ovarian 
cancer 
TP53 Regulation of DNA repair 
and apoptosis 
Breast cancer/colorectal 
cancer/lung cancer and 
many more 
RB1 Cell cycle control Retinoblastoma 
CDKN2A Cell cycle control Melanoma 
VHL Cell division and 
angiogenesis 
Renal cell carcinoma 
Table 1.3. Examples of tumour suppressor genes. Genes are listed alongside their normal cellular function and 
examples of cancers in which they become dysregulated. Table adapted from Strachan and Read, 2004. 
 
1.2.4 Hallmark capabilities of cancer cells 
The capabilities of a normal cell to undergo malignant transformation depend in large 
part on the accumulation of genetic and also epigenetic alterations that confer a 
selective advantage on subclones of cells, enabling their growth, invasion and eventual 
metastasis (Hanahan and Weinberg, 2011). In 2000, Hanahan and Weinberg described 
six hallmarks of cancer that were acquired by cells to enable their malignant 
transformation (Hanahan and Weinberg, 2000). In a recent update to their initial 
publication, the authors report that the six hallmarks continue to provide a solid 
foundation for understanding cancer biology. The hallmark capabilities are integral 
components of most cancer forms and they provide a framework for understanding the 
significant heterogeneity observed in cancers; the mechanisms by which they are 
acquired are heterogenous both within and across different cancer types (Hanahan and 
Weinberg, 2011). The six hallmarks of cancer are illustrated in Figure 1.5 and described 
below. 
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Figure 1.5. The six hallmark capabilities of cancer necessary for tumour growth. Figure taken from Hanahan and 
Weinberg, 2011. 
 
1.2.4.1 Sustained proliferative signalling 
Normal cells tightly regulate cell cycle processes and maintain a homeostatic state 
between cell growth and cell death. The most fundamental capability of cancer cells is 
their ability to sustain proliferation and this is mediated largely by oncogenic growth 
factors that bind cell surface receptors, typically the tyrosine kinases. There are a 
number of ways by which cancer cells can sustain proliferative signalling; they may 
produce growth factor ligands themselves or they may stimulate normal cells within the 
supporting stroma to produce growth factors. Cancer cells can also become hyper-
responsive to growth factor ligand by increasing the number of receptor proteins on 
their surface. Aberrant and sustained signalling may also take place independent of 
growth factors, through the constitutive activation of signalling pathway components 
that are downstream of the receptors (Hanahan and Weinberg, 2011).  
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1.2.4.2 Evading growth suppressors 
As well as inducing and sustaining growth stimulatory signals, cancer cells must also 
evade programmes that negatively regulate cell proliferation. This hallmark relies 
mainly on the actions of tumour suppressor genes. Examples include the RB1 and TP53 
genes which, as previously described, are prototypical tumour suppressor genes that act 
within key cellular regulatory pathways to control cell proliferation or apoptosis, 
respectively (Hanahan and Weinberg, 2011). 
1.2.4.3 Activating invasion and metastasis 
The capability of cancer cells to invade and metastasise is not yet fully understood. The 
invasion-metastasis cascade depicts successive cellular changes, beginning with local 
invasion, dissemination of cancer cells into neighbouring lymphatic and blood vessels 
followed by their transportation to distant sites. Initially micrometastases form, which 
then colonise and form macroscropic tumours at sites distant from the primary site. 
Cancer cells that have acquired the ability to invade and metastasise have typically 
developed alterations in their shape as well as in their attachment to other cells and to 
the extracellular matrix (ECM). For example, E-cadherin plays a critical role in the co-
ordinated assembly of epithelial cell sheets, and its reduced expression is known to 
promote invasion and metastasis in some human carcinomas, a feature that strongly 
supports its role as a key suppressor of this hallmark capability. Genes encoding other 
cell-cell and cell-ECM adhesion factors are altered in some highly aggressive 
carcinomas, while those favouring cytostasis are downregulated (Hanahan and 
Weinberg, 2011). 
1.2.4.4 Enabling replicative immortality 
Cancer cells require unlimited replicative potential in order to generate large tumour 
masses. In normal lineages cells can undergo only a limited number of successive cell 
growth and division cycles owing to the barriers of senescence and cell death. In cancer 
cells it is thought that telomeres protecting the ends of chromosomes play a key role in 
their ability to proliferate in an unlimited manner. In non-cancerous cells, telomeres 
shorten progressively and eventually lose their ability to protect the ends of 
chromosomal DNA and cells become senescent. Telomerase is the DNA polymerase 
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enzyme that adds telomere repeats to the ends of telomeric DNA and while it is mainly 
absent in normal cells it is activated in ~90% of immortalised cells, including cancer 
cells. The presence of telomerase activity is associated with a resistance to induction of 
both senescence and apoptosis (Hanahan and Weinberg, 2011). 
1.2.4.5 Inducing angiogenesis 
Tumour cells, like normal cells, require nutrients and oxygen and the ability to eliminate 
waste products. In tumours this is achieved via the newly formed tumour-associated 
blood vessels (angiogenesis). In normal adult cells, angiogenesis is transiently active 
during processes such as wound healing and in the female reproductive cycle. In 
contrast, in tumour cells angiogenesis is almost always active supporting the expansion 
of neoplastic growth. For example, the signalling proteins VEGF-A (vascular 
endothelial growth factor-a) and TSP1 (thrombospondin-1) induce and inhibit, 
respectively, the angiogenic process in some cancers by binding to cell surface receptors 
on vascular endothelial cells (Hanahan and Weinberg, 2011). 
1.2.4.6 Resisting cell death 
Programmed cell death by apoptosis is a natural barrier to the development of cancer. 
Apoptotic processes can be triggered in cancer cells by stresses resulting from oncogene 
signalling and from DNA damage. Tumour cells can evade apoptosis through a variety 
of mechanisms. The most common mechanism is through the loss of the TP53 tumour 
suppressor gene which eliminates the critical DNA damage response from apoptotic 
signalling processes. Tumours may also downregulate pro-apoptotic factors such as Bax 
and Bim, leading to increased expression of anti-apoptotic mediators or of survival 
signals (Hanahan and Weinberg, 2011). 
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1.3 Childhood cancer 
In the UK, 1,603 new cases of childhood cancer were diagnosed in 2010 (CRUK, 
2013b). The three most common types of cancer diagnosed in children are leukaemia, 
brain and CNS tumours and lymphomas and they account for approximately two-thirds 
of all childhood cancers (Figure 1.6). The prospects for children with cancer have 
improved dramatically and almost three-quarters of children are now cured of their 
disease compared with a quarter in the late 1960s. Despite this improved survival, 
cancer is the most common cause of disease-related death in children aged 1-14 years, 
and 260 children under the age of 15 die from their disease each year in the UK (CRUK, 
2013b). Survival rates vary according to cancer type and although tumours of the brain 
and CNS rank second in incidence, they are the most common cause of deaths from 
cancer in children (CRUK, 2013b). The majority of childhood cancers are invasive and 
they present significant treatment challenges, including the long-term adverse effects 
associated with current treatment modalities. For example, radiotherapy treatment of 
brain tumours in children is associated with significant long-term neuro-cognitive and 
neuro-endocrine defects and for these reasons is often delayed in very young children 
(Pizer and Clifford, 2009). There is an urgent need to further characterise the aetiology 
and pathogenesis of childhood cancers and to develop better treatments that will 
improve survival further and reduce treatment-related sequelae for long-term survivors. 
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Figure 1.6. Incidence rates of the most common childhood cancers in the UK. Figure taken from Cancer 
Research UK cancer stats (CRUK, 2013b). 
 
1.4 Paediatric tumours of the central nervous system 
Cancers of the central nervous system (CNS) are the second most common cancer type 
in children after leukaemia, and are the leading cause of cancer-related mortality in 
childhood (Pui et al., 2011; Siegel et al., 2013). The latest statistics from Cancer 
Research UK report that astrocytomas, the most common type of glioma, are most 
prevalent and constitute 43% of all brain and CNS tumours in children. Approximately 
76% of astrocytomas diagnosed in children are low grade and 15% are high grade. 
Embryonal tumours of the CNS (see section 1.4.1) are the second most frequent 
subgroup and medulloblastomas make up almost three-quarters of this group (CRUK, 
2013b). Medulloblastoma is the most common malignant brain tumour in childhood and 
accounts for 15-20% of CNS tumours (Pizer and Clifford, 2009). Ependymoma and 
choroid plexus tumours constitute a further 10% of childhood brain and CNS tumours 
(CRUK, 2013b). 
Paediatric tumours of the brain and CNS can present in a myriad of ways and this can 
lead to a delayed diagnosis. Presenting signs and symptoms will depend on the growth 
rate of the tumour, its location in the CNS and the child’s age (Packer et al., 2010). The 
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majority of childhood CNS tumours arise in the brain and for most their exact cause is 
largely unknown. Specific inherited syndromes can predispose children to these 
tumours in a small proportion of cases and this is discussed further in the context of 
medulloblastoma in section 1.5.6.1. The only environmental factor that has consistently 
been associated with the development of brain tumours in children has been exposure to 
radiation therapy (Ron et al., 1988). Compared to brain tumours that arise in adults, 
childhood brain tumours demonstrate greater histological variation, they are more 
frequently metastatic at diagnosis and they are more frequently embryonal in their 
classification (Dolecek et al., 2012). 
The most recent World Health Organisation (WHO) classification of CNS tumours is 
based on a panel of expert neuro-pathologists and geneticists (Louis et al., 2007). It is 
presented as the worldwide standard for the definition of brain tumours and provides 
clearly defined histopathological and clinical diagnostic criteria. The standardised 
classification and grading allows epidemiological studies and clinical trials to be 
conducted on an international scale. Following advances that have been made in 
diagnostic pathology and in tumour genetics, the diagnosis and classification of brain 
tumours now depends on immunohistochemical markers and genetic profiles alongside 
traditional histopathological features (Louis et al., 2007). 
1.4.1 Embryonal tumours of the CNS 
Embryonal brain tumours are characterised by the proliferation of tissue that is normally 
seen only in the developing embryo and may remain in the brain after birth. Originally 
embryonal CNS tumours were grouped under a broad category of primitive 
neuroectodermal tumours (PNETs) based on their common undifferentiated round cell 
morphology (Ellison, 2002). Following progress that was made in understanding their 
distinctive clinical, pathological, molecular and behavioural characteristics, the 2000 
WHO classification separated them into 5 distinct types; medulloblastoma, 
supratentorial PNET, atypical teratoid/rhabdoid tumour (AT/RT), ependymoblastoma 
and medulloepithelioma (Kleihues et al., 2002). Since 2000 the classification of 
embryonal tumours has been further refined with the recognition of 5 histological 
variants of medulloblastoma that are associated with outcome and hence have 
significant clinical utility (Louis et al., 2007; Gilbertson and Ellison, 2008; Gulino et 
al., 2008).  
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Embryonal tumours are classified within the larger group of tumours of neuroepithelial 
tissue (Louis et al., 2007). The current WHO classification (2007) defines three distinct 
types of embryonal tumour; medulloblastoma, CNS primitive neuroectodermal tumour 
(CNS-PNETs) and atypical teratoid/rhabdoid tumours (AT/RTs). Medulloblastoma is 
further subclassified into the 5 histological variants (see section 1.5.1), while CNS-
PNETs encompass CNS neuroblastoma, CNS ganglioneuroblastoma, 
medulloepithelioma and ependymoblastoma. All embryonal CNS tumours are 
malignant neoplasms of WHO grade IV (Louis et al., 2007) and they are associated 
with a comparably high mortality and with significant long-term morbidity for survivors 
(Pfister et al., 2010). They comprise the largest group of malignant brain tumours in 
childhood and medulloblastomas are the most common type (Sarkar et al., 2005). 
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1.5 Medulloblastoma 
Medulloblastoma, by definition, arises in the posterior fossa which is a region of the 
hindbrain that contains the brainstem and the cerebellum (Figure 1.6). It was first 
described in 1925 by Bailey and Cushing as a tumour of primitive origin arising in the 
posterior fossa of young children that was distinct from gliomas (Bailey and Cushing, 
1925). Since its initial description significant progress has been made in understanding 
the biology of medulloblastoma and this has been paralleled by refinements in its 
pathological classification and the recognition of medulloblastoma as a distinct disease 
entity (Louis et al., 2007). 
Medulloblastoma arises in the cerebellum, most often in the roof of the 4
th
 ventricle, 
invading the cerebellar vermis and often invading through the ependyma in the floor of 
the ventricle to enter the brainstem (Raffel, 2004) (Figure 1.6). Less commonly the 
tumour arises in the cerebellar hemisphere, particularly in older children (Pizer and 
Clifford, 2009). Medulloblastoma is now established as a highly heterogeneous disease, 
both at the histopathological and the molecular level (Pizer and Clifford, 2009). The 
current consensus is that medulloblastoma comprises four distinct molecular subgroups 
that most likely arise from different cells of origin (Taylor et al., 2012). Cellular origins 
of medulloblastoma are discussed further in section 1.5.9. 
Medulloblastoma is the most common malignant brain tumour of childhood and it 
accounts for around 10% of all paediatric cancer deaths (Pizer and Clifford, 2009). 
There are approximately 1 in 200,000 children diagnosed with medulloblastoma each 
year (Parsons et al., 2011), with approximately 90 patients diagnosed in the UK each 
year (Pizer and Clifford, 2009). Medulloblastomas are principally diagnosed in children 
less than 15 years of age, and they have a bimodal age distribution, peaking at 3 to 4 
years of age and then again between 8 and 9 years of age. Around 10-15% of cases 
diagnosed are in children under 3 years of age (Packer et al., 1999; Crawford et al., 
2007). For unknown reasons the incidence of medulloblastoma is 1.5-2 times higher in 
males than in females (Crawford et al., 2007). Medulloblastoma is relatively uncommon 
in adults, representing 0.4-1% of adult CNS tumours (Kieran et al., 2010). 
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Figure 1.7. Anatomy of the brain and location of medulloblastoma. A. Sagittal section showing regions of the 
brain. The cerebellum is located in the hindbrain at the top of the brainstem. B. Schematic illustrating the location of 
the tentorium, fourth ventricle and the cerebellum. The tentorium separates the cerebral hemispheres from the 
structures of the posterior fossa. The fourth ventricle which contains cerebrospinal fluid is an expansion of the central 
canal of the medulla oblongata. The cerebellum is highlighted in red and is located in the posterior fossa below the 
tentorium. The roof of the fourth ventricle is formed by the cerebellum Schematic brain sections taken from the 
American Brain Tumour Association website (http://www.abta.org/understanding-brain-tumors/anatomy/physical-
structure.html).    C. T1-weighted sagittal magnetic resonance imaging (MRI) scan following gadolinium of child 
with medulloblastoma. Medulloblastoma is visible as grey staining mass indicated by white arrow. Image kindly 
provided by Professor Simon Bailey (Paediatric Brain Tumour Research Group, Newcastle University, UK). 
 
1.5.1 Histopathological variants of medulloblastoma 
The 2007 WHO classification of CNS tumours defines medulloblastoma as a grade IV 
malignant neoplasm and recognises the tumour heterogeneity that is reflected in its 
diverse histopathology (Louis et al., 2007). Histopathological variants of 
medulloblastoma have been recognised that are associated with distinct molecular 
features and with distinct patterns of clinical behaviour, and are therefore of clinical 
utility in disease classification (Ellison et al., 2003; Ellison, 2010). Based on the diverse 
histological phenotypes and differences in their clinical behaviour, the current WHO 
classification defines 5 distinct histological disease variants: classic medulloblastoma, 
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desmoplastic/nodular (DN) medulloblastoma, medulloblastoma with extensive 
nodularity (MBEN), large cell medulloblastoma and anaplastic medulloblastoma. 
1.5.1.1 Classic medulloblastoma 
Classic medulloblastomas are most numerous and constitute 70-80% of all 
medulloblastomas (McManamy et al., 2007; Gilbertson and Ellison, 2008; Pizer and 
Clifford, 2009). The classic variant comprises sheets of small cells with a high 
nuclear:cytoplasmic ratio and round hyperchromatic nuclei (Ellison, 2002) (Figure 
1.7A). Foci of necrosis and angiogenesis variably interrupt these sheets of 
undifferentiated cells and neuroblastic rosettes which consist of tumour cell nuclei 
arranged in a circular fashion around tangled cytoplasmic processes are observed in less 
than 40% of classic tumours (Ellison, 2002). 
1.5.1.2 Desmoplastic/nodular medulloblastoma 
The desmoplastic/nodular (DN) variant is observed in 10-15% of medulloblastomas 
(Ellison, 2002; McManamy et al., 2007). The DN medulloblastoma is characterised by 
nodules of differentiated neurocytic cells and internodular desmoplasia; uniform 
neurocytic cells are usually round and scattered across reticulin-rich desmoplastic 
regions where tumour cells show more nuclear pleomorphism than intranodular cells 
(McManamy et al., 2007) (Figure 1.7B). The extent of nodularity can be variable and an 
increased nodular density has been associated with an improved prognosis (McManamy 
et al., 2007). 
Desmoplasia is most often observed in very young children, representing up to 50% of 
tumours in infants (< 3 years at diagnosis) and only 5% of tumours in patients over 3 
years of age at diagnosis (McManamy et al., 2007). Several studies have shown that 
desmoplastic medulloblastomas presenting in infancy have a significantly better 
outcome than other histological phenotypes in this age group (Rutkowski et al., 2005; 
McManamy et al., 2007; Rutkowski et al., 2009; Grundy et al., 2010), while the 
significance of desmoplasia in non-infant cases appears less important (McManamy et 
al., 2007). 
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1.5.1.3 Medulloblastoma with extensive nodularity 
Medulloblastoma with extensive nodularity (MBEN) shares fundamental 
histopathological features with the D/N disease variant and it is recognised as a 
desmoplastic medulloblastoma (McManamy et al., 2007). Compared to D/N tumours, 
MBENs comprise large and irregularly shaped nodules that dominate the histology with 
a reduced internodular desmoplastic component (Ellison, 2010) (Figure 1.7C). MBENs 
comprise less than 1% of medulloblastomas and most often present in infants (< 3 years 
of age at diagnosis) (McManamy et al., 2007). They are associated with a favourable 
prognosis (Giangaspero et al., 1999; Suresh et al., 2004). 
1.5.1.4 Large cell medulloblastoma 
The large cell variant of medulloblastoma makes up between 2-4% of medulloblastomas 
(Ellison, 2002; McManamy et al., 2007). It often presents with metastatic disease 
(Gajjar et al., 2004) and is associated with a poor prognosis (Brown et al., 2000; 
Eberhart et al., 2002a; Eberhart and Burger, 2003; McManamy et al., 2003). This 
variant comprises large round cells with a prominent single nucleolus and pleomorphic 
nuclei (Giangaspero et al., 1992) and have a higher mitotic and apoptotic rate than other 
variants (McManamy et al., 2003) (Figure 1.7D). 
1.5.1.5 Anaplastic medulloblastoma 
Anaplastic tumours comprise between 10-20% of medulloblastomas (Gilbertson and 
Ellison, 2008). This phenotype is characterised by marked nuclear pleomorphism 
accompanied by cell moulding, producing a paving-like pattern of nuclei, and cell 
wrapping (Brown et al., 2000; Eberhart et al., 2002a) (Figure 1.7E). These tumours also 
show increased mitotic activity and apoptosis (McManamy et al., 2003). Similar to the 
large cell variant, anaplastic medulloblastomas are associated with a poor prognosis 
(Eberhart et al., 2002a; McManamy et al., 2003). Because the large cell and anaplastic 
medulloblastomas share similar histopathological features and an aggressive biological 
behaviour, they are frequently combined together into a single large cell/anaplastic 
(LCA) type in studies of medulloblastoma (Gilbertson and Ellison, 2008). 
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Figure 1.8. Histopathological subtypes of medulloblastoma. A. Classic medullloblastoma. B. Desmoplastic/nodular (D/N) medulloblastoma. C. Medulloblastoma with extensive nodularity (MBEN). 
D. Large cell medulloblastoma. E. Anaplastic medulloblastoma. Sections were stained with haematoxylin and eosin. Figure taken from Ellison, 2010. 
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1.5.2 Clinical presentation and diagnosis of medulloblastoma 
Children with medulloblastoma typically present with signs and symptoms of 
obstruction of CSF flow and cerebellar dysfunction. Presenting symptoms include wide-
based stance, ataxia and nystagmus. Behavioural changes accompanied by vomiting, 
headache and lethargy are due mainly to hydrocephalus and subsequent raised 
intracranial pressure caused by the tumour mass (Zakhary et al., 2001). Infants with 
medulloblastoma present less characteristically with intermittent vomiting and 
macrocephaly (Packer et al., 1999). In infants, cerebrospinal fluid obstruction with 
ventricular dilatation may result in downward deviation of the eyes, the so-called “sun-
setting sign” (Packer et al., 1999). Although a significant number of children will show 
evidence of metastatic spread at diagnosis, many will be asymptomatic at the time of 
initial presentation (Packer et al., 1999). 
Diagnosis of medulloblastoma is made by either computed tomography (CT) or 
magnetic resonance imaging (MRI). Due to the higher resolution and increased 
sensitivity of MRI it has become the neuroimaging technique of choice (Packer et al., 
1999). On MRI the tumour usually presents as a midline lesion filling the fourth 
ventricle and sometimes extending into the ventricular foramina (Packer et al., 1999) 
(see Figure 1.6). The presence of metastasis at diagnosis confers a poor prognosis in 
medulloblastoma (Bailey et al., 1995; Zeltzer et al., 1999) and it is an established 
prognostic variable that influences patient stratification and treatment (Pizer and 
Clifford, 2009) (see sections 1.5.4 and 1.5.5). For these reasons MRI imaging of the 
entire neuraxis (brain and spinal cord) is required to determine the extent of disease 
dissemination before initiating treatment (Packer et al., 1999).  
1.5.3 Tumour staging 
Approximately 30% of children show evidence of metastatic spread of medulloblastoma 
at diagnosis (Bailey et al., 1995). Metastatic spread occurs mainly via the cerebrospinal 
fluid, leading to a high incidence of spinal and of diffuse leptomeningeal seeding. Solid 
metastases to the supratentorial region also occur. Extraneuraxial metastases are 
relatively uncommon and appear to occur largely as a result of surgical intervention, 
with preferential spread to the bone apparent (Sure et al., 1995). Following MRI and 
possible cytological examination of the CSF, the Chang staging system (Chang et al., 
1969) is used to define the presence or absence of metastases. Depending on the 
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presence and extent of disease dissemination, medulloblastomas are staged M0-M4 as 
described in Table 1.4.  
M stage  
M0 No gross subarachnoid or haematogenous metastasis 
M1 Microscopic tumour cells found in CSF 
M2 Gross nodular seeding in cerebellum, cerebral subarachnoid space, or in 
third or fourth ventricles 
M3 Gross nodular seeding in spinal subarachnoid space 
M4 Extraneuraxial metastasis 
Table 1.4. Chang classification of metastasis stage in medulloblastoma. Based on MRI imaging and cytological 
examination of the CSF, medulloblastomas are staged M0-M4 depending on the presence and extent of metastases as 
detailed. Table adapted from Zeltzer et al., 1999. 
 
1.5.4 Current disease-risk stratification in medulloblastoma  
Since the mid-1990s, the risk stratification of medulloblastoma has been based solely on 
clinical disease features and stratifies patients into “standard risk” / “average risk” and 
“high risk”, depending on their age at diagnosis, extent of surgical resection and 
metastatic status (Pizer and Clifford, 2009).  
The presence of metastases at diagnosis, as defined by the Chang classification system 
(see section 1.5.3), and including spread to other areas of the brain (Chang stage M2) or 
to the spine (Chang stage M3) or as detected in the CSF (Chang stage M1), has 
consistently been found to be the strongest clinical predictor of poor patient outcome 
(Bailey et al., 1995; Zeltzer et al., 1999). The extent of surgical resection has been 
widely demonstrated to be an important prognostic indicator in medulloblastoma, with a 
gross total or near gross total surgical excision conferring a better prognosis (Albright et 
al., 1996; Zeltzer et al., 1999).  
Very young children (< 3 years at diagnosis) have a much poorer prognosis than older 
children and are considered within their own exclusive risk category with different 
management strategies (Pizer and Clifford, 2009) (see section 1.5.5.1.3). The avoidance 
 29 
 
of craniospinal radiotherapy in this age group, due to the severe neurological adverse 
effects of radiotherapy on the developing brain (see section 1.5.5.2), is believed to 
contribute to their poorer survival outcome (Pizer and Clifford, 2009). 
The current risk stratification as recognised by the North American Children’s 
Oncology Group (COG) and the International Society of Paediatric Oncology (SIOP) 
Europe Brain Tumour Committee recognises the following 3 risk categories (Pizer and 
Clifford, 2009): 
(1) Standard risk / Average risk: patients ≥ 3 years of age without evidence of 
metastatic spread (M0) and having ≤1.5cm2 of residual tumour mass after 
surgery. 
(2) High risk: patients ≥ 3 years of age with evidence of disseminated disease (M1-
M3) and/or a less complete surgical resection. 
(3) Patients < 3 years at diagnosis. 
While this clinical staging system has influenced treatment protocols and contributed to 
improved survival rates in medulloblastoma (see section 1.5.5), it is well-observed that 
patients stratified within the same group and thus receiving identical therapies can have 
widely disparate clinical outcomes, owing to biological differences within their tumours 
(Eberhart and Burger, 2003), and the aggressive therapies employed are associated with 
significant long-term adverse effects (see section 1.5.5.2). As a result, much of the 
research over the last 10 years has focused on understanding the biology of 
medulloblastoma and on identifying molecular biomarkers that will facilitate the 
development of a more accurate and refined stratification that will differentiate high risk 
patients from low risk patient and will inform treatment protocols accordingly.  
Significant advances have been made in understanding the molecular pathology of 
medulloblastoma. Molecular disease biomarkers with prognostic significance have been 
identified and validated in clinical trial cohorts (Pizer and Clifford, 2009; Ellison et al., 
2011b) and have since been incorporated into a refined risk stratification model based 
on clinical, pathological and molecular variables that recognises low risk, standard risk 
and high risk disease (Ellison et al., 2011b) (see section 1.5.11). This new revised 
stratification will form the basis of the forthcoming pan-European SIOP clinical trial 
(PNET5) as discussed in section 1.5.11. 
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1.5.5 Treatment of medulloblastoma 
Based on the clinical staging system currently used (see section 1.5.4), a multimodality 
approach consisting of surgery, radiotherapy and chemotherapy has been designed for 
medulloblastomas. Advances in treatment have seen overall survival rates reach 70-80% 
(Northcott et al., 2012a). 
Surgery aims to resect as much of the primary tumour mass as is possible and is guided 
by the anatomy of the lesion. Most medulloblastomas are amenable to total resection if 
they do not extensively infiltrate the cerebellum and brainstem (Packer et al., 1999). 
Radiotherapy remains the single most effective means of postoperative treatment for 
children greater than 3 years of age (Packer et al., 1999) and owing to the tendency of 
medulloblastoma to spread via the CSF it is standard practice to irradiate the entire 
craniospinal axis, as this has been associated with the most significant improvement in 
survival (Landberg et al., 1980; Bouffet et al., 1992; Packer et al., 2012). In children 
less than 3 years of age, radiotherapy is often not given initially due to its well 
documented adverse effects on the developing nervous system (Fouladi et al., 2005; 
Lafay-Cousin et al., 2009) (see section 1.5.5.2). The benefits of chemotherapy in the 
treatment of standard risk disease have been widely demonstrated. The European SIOP 
PNET3 study showed a significant improvement in 3-year event free survival (79% 
versus 64%) for patients with standard risk disease who were treated with pre-
irradiation chemotherapy compared to those treated with radiotherapy alone (Taylor et 
al., 2003a). Meanwhile in another Phase III study, chemotherapy given during and after 
radiotherapy for patients with standard risk medulloblastoma resulted in 5-year event 
free survival (EFS) and overall survival (OS) of 81% and 86% respectively (Packer et 
al., 2006). The benefit of adjuvant chemotherapy in metastatic medulloblastoma has not 
been definitely proven in Phase III studies, although it is given as standard care in high- 
risk disease (Pizer and Clifford, 2009). 
The use of molecular targeted therapies in medulloblastoma is still in its infancy and 
they are not currently included as standard treatments in adjuvant therapies (see section 
1.5.12). 
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1.5.5.1 Treatment protocols 
1.5.5.1.1 Current treatments for standard risk patients 
In standard risk patients, post-surgical radiotherapy comprises a ‘reduced dose’ 
craniospinal dose of 23.4 Gy in addition to a local boost of 54-55.8 Gy to the posterior 
fossa (Pizer and Clifford, 2009). Adverse effects on neurocognitive and endocrine 
functions caused by craniospinal radiation (see section 1.5.5.2) have led to this lowering 
of the radiation dose in standard risk patients (Packer et al., 2006). A current Children’s 
Oncology Group (COG) trial is investigating the effects of lowering the radiation dose 
further to 18 Gy and decreasing the posterior fossa volume boosted in standard risk 
patients (De Braganca and Packer, 2013). Meanwhile, the European SIOP group are 
investigating the use of hyperfractionated radiotherapy (HFRT) using twice daily 
fractions that can theoretically increase the dose to the tumour without an increase in 
adverse effects to the normal CNS (Pizer and Clifford, 2009). The most widely used 
maintenance chemotherapy regimen in standard risk patients is the ‘Packer’ regimen 
which consists of 8 courses of vincristine, lomustine and cisplatin (Pizer and Clifford, 
2009). Cyclophosphamide may also be used with one study reporting no significant 
difference in survival when lomustine was replaced with cyclophosphamide in 
combination with vincristine and cisplatin (Packer et al., 2006). 
1.5.5.1.2 Current treatments for high risk patients 
Patients with high risk medulloblastoma are treated post-surgically with craniospinal 
radiation doses of 35-36 Gy together with a local boost of 18-20 Gy to the posterior 
fossa (Pizer and Clifford, 2009). The optimal chemotherapy regimen for high risk cases 
has yet to be defined (Pizer and Clifford, 2009). Improved survival for patients with 
metastatic disease has been reported with a craniospinal radiation dose of 40 Gy 
together with conventional chemotherapy (Pizer and Clifford, 2009), while in another 
trial improved survival was observed when patients received 39 Gy of craniospinal 
radiation followed by 4 cycles of cyclophosphamide-based, dose-intensive 
chemotherapy (Gajjar et al., 2006). A current COG trial for patients with high risk 
disease is investigating the use of carboplatin as a radiation sensitiser during 
radiotherapy followed by chemotherapy (De Braganca and Packer, 2013). 
Hyperfractionated accelerated radiotherapy (HART) is employed in some protocols for 
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the management of high risk disease with a view to improving tumour control without 
increasing toxicity and has shown promising results with 5-year EFS of 70% reported 
(Gandola et al., 2009). 
1.5.5.1.3 Current treatments for patients under 3 years of age 
Chemotherapy-based strategies are employed to delay or avoid the use of craniospinal 
radiation in very young children (Pizer and Clifford, 2009). Infants and children under 
the age of 3 years of age are treated with high dose chemotherapy using agents 
including cisplatin, cyclophosphamide and vincristine, often supported by stem cell 
rescue (De Braganca and Packer, 2013). Studies have also been conducted that have 
employed alternative treatments using intrathecal and high dose intravenous 
methotrexate and report that it may be equally or more effective in the treatment of 
infants with medulloblastoma (Chi et al., 2004; Rutkowski et al., 2005). The 
introduction of a tightly controlled conformal approach to the delivery of radiation to 
the posterior fossa has led to a renewed interest in using local radiotherapy in the 
management of very young children with medulloblastoma. In a UK study that used this 
approach in combination with moderately intensive chemotherapy, survival of around 
50-60% was reported for non-metastatic patients (Pizer and Clifford, 2009). For 
children under the age of 3 who are treated with surgery and chemotherapy alone, 
overall survival of 60-73% is observed, while for infants with the favourable prognosis 
desmoplastic histology (see section 1.5.1.2) survival rates of up to 90% are seen 
(Rutkowski et al., 2010).  
1.5.5.1.4 Current treatments for relapsing patients 
Despite treatment advances, approximately 40% of children diagnosed with and treated 
for medulloblastoma will experience tumour recurrence (Jones et al., 2012). Patients 
who have not previously received radiotherapy and who relapse can be successfully 
treated with radiotherapy (Ridola et al., 2007). However, for patients whose disease 
recurs after combined radiotherapy and chemotherapy, they have a very poor prognosis 
at relapse and only 2% will survive (Pizer and Clifford, 2009). High dose chemotherapy 
has been shown to cure a subset of patients who have an isolated local relapse and 
maximal resection prior to receiving the high dose chemotherapy (Pizer and Clifford, 
2009). For the majority of patients, treatment will be palliative in the relapse setting. 
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1.5.5.2 Treatment-associated adverse effects 
The long-term neurocognitive and endocrinologic sequelae of treatment of children with 
medulloblastoma have been well documented, and craniospinal irradiation has been 
demonstrated as a major cause of adverse effects (Packer et al., 1989). Neurocognitive 
sequelae are seen in patients of all age groups due to whole brain radiotherapy and 
possibly local boost radiotherapy, with children under 8 years of age appearing more 
vulnerable (Packer and Vezina, 2008). Children between the ages of 3 and 7 years who 
are treated with 36 Gy of radiation have a 20-30 point decrease in overall intelligence 
(Packer and Vezina, 2008), while the reduced dose used in standard risk patients (see 
section 1.5.5.1.1) still results in a significant decline of 10-15 IQ points (Mulhern et al., 
2005). Many long-term survivors are at high risk of psychosocial difficulties including 
forming stable relationships and obtaining employment (Packer et al., 1999). Growth 
hormone deficiency is the most common endocrinologic sequela of radiotherapy and 
hypothyroidism also occurs relatively commonly and may be caused by either 
hypothalamic radiation or scattered irradiation received by the thyroid gland (Packer et 
al., 1987). Sexual hormone dysfunction may also occur, leading to delayed development 
(Packer et al., 1999). Some long-term survivors require hearing aids due to hearing loss 
caused by radiotherapy and cisplatin chemotherapy (De Braganca and Packer, 2013). 
Secondary tumours such as gliomas and meningiomas are rare complications of therapy 
but can lead to significant morbidity and mortality in survivors (Packer et al., 2013). 
Owing to these significant treatment-associated adverse effects, the follow-up care of 
survivors is complex and patients will attend long-term survival clinics for monitoring 
and support. 
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1.5.6 Genetic basis of medulloblastoma 
Significant progress has been made in the last 10 years in understanding the genetic 
basis of medulloblastoma. Studies of familial cancer syndromes provided the first 
insights into the molecular processes that underlie the disease (see section 1.5.6.1), 
while in recent years, disease profiling using multiple genome-wide approaches has 
revealed the presence of molecular subgroups of medulloblastoma that are associated 
with distinct genetic abnormalities and with distinct clinicopathological features and 
clinical outcomes (Thompson et al., 2006; Kool et al., 2008; Cho et al., 2011; Northcott 
et al., 2011b; Kool et al., 2012) (see section 1.5.8). Such progress has paved the way for 
patient stratification and treatment based on tumour biology as well as clinical and 
histopathological features (see section 1.5.12). It is envisaged that molecular 
stratification will facilitate the delivery of personalised therapies tailored to a more 
accurate disease risk prediction, as well as the development and delivery of novel 
molecularly targeted therapies, with the primary aim of improving patient outcomes and 
reducing the long-term sequelae associated with current treatments (Pizer and Clifford, 
2009; Ellison, 2010; Ellison et al., 2011b). 
1.5.6.1 Familial syndromes predisposing to medulloblastoma 
While less than 5% of medulloblastomas are associated with an inherited cancer 
syndrome, studies of the genetic defects that cause these syndromes have revealed their 
extensive involvement in the development of sporadic medulloblastomas. These studies 
have provided significant insights into the role of two key developmental signalling 
pathways, the Sonic hedgehog (SHH) pathway and the WNT pathway, that are now 
known to define distinct molecular subgroups of sporadic medulloblastoma (see section 
1.5.8), as well as a role for TP53 in medulloblastoma development. 
Gorlin syndrome (Nevoid basal cell carcinoma syndrome) is an autosomal dominant 
disorder that predisposes to both cancer and developmental defects and is caused by 
mutations in the patched homologue 1 gene (PTCH1) (Hahn et al., 1996). PTCH1 is a 
key component of the SHH signalling pathway (see section 1.5.7.1) and patients with 
Gorlin syndrome have a 3-5% lifetime risk of developing medulloblastoma 
(Ramaswamy et al., 2011). Recurrent somatic mutations in PTCH1 have been identified 
in approximately 10% of sporadic medulloblastomas (Pietsch et al., 1997; Raffel et al., 
1997), and overall aberrant activation of the SHH signalling pathway is observed in up 
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to one third of all medulloblastomas owing to recurrent mutations or copy number 
aberrations that target multiple pathway components (Northcott et al., 2012a) (see 
section 1.5.7.1). 
Turcot syndrome is characterised by the concurrence of multiple colorectal adenomas 
and a primary tumour of the CNS (Hamilton et al., 1995). In a subtype of Turcot 
syndrome, type II, it has been shown that an increased risk of colorectal carcinoma and 
of medulloblastoma development is attributable to inactivating germline mutations in 
the adenomatous polyposis coli (APC) gene (Hamilton et al., 1995). The APC gene is a 
tumour suppressor gene that negatively regulates β-catenin, a key transcriptional 
activator and effector of the WNT signalling pathway (see section 1.5.7.2). Aberrant 
activation of the WNT signalling pathway caused by somatic mutations of the β-catenin 
gene (CTNNB1) is recognised to occur in approximately 10% of sporadic 
medulloblastomas, with rarer mutations in other WNT pathway components also 
observed (Pizer and Clifford, 2009) (see section 1.5.7.2). 
Li-Fraumeni syndrome (LFS) is an autosomal dominant hereditary disorder that is 
associated with a dramatically increased incidence and early onset of a number of 
cancers, including medulloblastoma (Li and Fraumeni, 1969). Most patients with LFS 
harbour germline TP53 mutations (Malkin et al., 1990). The role of the tumour 
suppressor gene TP53 in driving cancers has been well documented and somatic TP53 
mutations are frequently observed in most human cancers (Lim et al., 2007; Petitjean et 
al., 2007) (see section 1.2.3). While early reports have found TP53 mutations to be rare 
in medulloblastoma, recent studies have identified up to 10-15% of medulloblastomas 
with TP53 mutations (Tabori et al., 2010; Lindsey et al., 2011; Zhukova et al., 2013). 
Data concerning the prognostic role of TP53 mutation in medulloblastomas has been 
contradictory. One study reported a significantly adverse prognosis for TP53-mutated 
medulloblastomas independent of clinical presentation (Tabori et al., 2010). However, 
more recent studies suggest that the role of TP53 mutation in medulloblastoma is 
pleiotropic and dependent on the molecular subgroup of tumours in which it occurs 
(Pfaff et al., 2010; Lindsey et al., 2011; Rausch et al., 2012; Zhukova et al., 2013). 
Enrichment of TP53 mutations has been reported in the distinct subgroup of 
medulloblastomas that exhibit SHH pathway activation (Zhukova et al., 2013) and in 
the distinct subgroup of tumours that exhibit WNT pathway activation (Pfaff et al., 
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2010; Lindsey et al., 2011; Zhukova et al., 2013). It has been well established that the 
subgroup of medulloblastomas with WNT pathway activation are associated with a 
good prognosis (Ellison et al., 2005; Fattet et al., 2009; Ellison et al., 2011b), and 
where somatic TP53 mutations were observed in WNT tumours the favourable 
prognosis associated with this subgroup remained (Pfaff et al., 2010; Lindsey et al., 
2011; Zhukova et al., 2013). In contrast, TP53 mutations in SHH medulloblastomas 
were associated with a poor outcome (Zhukova et al., 2013). Furthermore, several 
studies have reported that patients with a TP53 mutation associated with the SHH 
subtype and a poor prognosis, harboured germline TP53 mutations and were LFS 
patients, indicating that the impact of TP53 mutations is dependent on the clinical 
(familial versus sporadic disease) and the molecular contexts in which they arise 
(Lindsey et al., 2011; Rausch et al., 2012; Zhukova et al., 2013).  
1.5.6.2 Recurrent chromosomal abnormalities and gene amplifications 
Using fluorescent in situ hybridisation (FISH), array CGH and more recently genome-
wide SNP arrays and loss of heterozygosity (LOH) analyses, recurrent and non-random 
chromosomal losses and gains have been identified in medulloblastoma. Studies carried 
out in recent years that have recognised the distinct molecular subgroups of 
medulloblastoma (see section 1.5.8), have identified many of these characteristic 
abnormalities to be enriched in specific disease subgroup(s) (Kool et al., 2012). 
Isochromosome 17q (i17q) is the most frequent chromosomal abnormality in 
medulloblastoma, occurring in 30-40% of cases (Bigner et al., 1988; Lamont et al., 
2004; Pfister et al., 2009). An isochromosome 17 results in the loss of the short arm 
(17p) and duplication of the long arm (17q), leading to a single copy of 17p and three 
copies of 17q. The role of i17q in medulloblastoma has yet to be realised. Recent next 
generation sequencing studies have identified only one gene, CTDNEP1, located on 
chromosome 17p13.1 to be a recurrent target of homozygous mutation in tumours with 
17p deletion, suggesting a potential tumour suppressor role for this gene on 17p 
(Parsons et al., 2011; Jones et al., 2012; Pugh et al., 2012; Robinson et al., 2012). The 
TP53 gene, which is located at 17p13.1, has not been found to be mutated more 
commonly in tumours with i17q compared to those without (Tabori et al., 2010). In 
addition, regions of high level amplification on 17q have not been identified (Pfister et 
al., 2009). It is possible that epigenetic events such as DNA methylation (see section 
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1.6) may target tumour suppressor genes on 17p; epigenetic inactivation of the HIC1 
gene which is located at 17p13.3 has been associated with 17p loss in medulloblastoma 
(Rood et al., 2002). It has also been postulated that i17q may drive clonal selection of 
tumours through haploinsufficiency for genes on 17p and a modest increase of 
expression of genes on chromosome 17q (Cunningham et al., 2006). i17q is now 
recognised to occur most frequently in non-SHH/non-WNT medulloblastomas (Kool et 
al., 2012) (see section 1.5.8.2). A poor prognosis associated with chromosome 17 
aberrations has previously been demonstrated in several studies investigating 
medulloblastoma as a single disease (Lamont et al., 2004; Pan et al., 2005; Pfister et al., 
2009), and more recently it has been shown to remain an independent prognostic factor 
within distinct molecular subgroups of the disease (Kool et al., 2012) (see section 
1.5.8.2). An important role for i17q has been suggested following the observation that 
recurrent medulloblastomas show increased levels of 17q gain compared with the 
original diagnostic tumour (Korshunov et al., 2008). 
Other prevalent cytogenetic abnormalities that have been identified in many studies in 
medulloblastoma include monosomy 6, deletion of chromosomes 9q, 10q and 16q, and 
gain of chromosomes 1q, 7 and 18 (Northcott et al., 2012a). Loss of chromosome 6 has 
been shown to be significantly associated with the subgroup of ‘favourable outcome’ 
WNT-activated medulloblastomas (Clifford et al., 2006; Fattet et al., 2009) (see section 
1.5.8). Loss of chromosome 9q is most frequently observed in SHH-activated 
medulloblastomas (Kool et al., 2012; Northcott et al., 2012c) (see section 1.5.8). The 
PTCH1 gene, a negative regulator of SHH signalling, is located on chromosome 
9q22.32 and has been shown to be the most frequently mutated gene and the most 
frequent target of focal deletion in SHH medulloblastomas (Northcott et al., 2012c).  
Alongside gross chromosomal abnormalities, recurrent focal amplification of specific 
oncogenes has been identified in medulloblastomas. The oncogenes MYC (at 8q24) and 
MYCN (at 2p24) are the most commonly amplified loci in medulloblastoma, with each 
reported in approximately 4-10% of cases (Pfister et al., 2009). Multiple studies have 
confirmed that MYC amplification is significantly associated with a poor prognosis and 
with the large cell and anaplastic histology (Brown et al., 2000; Aldosari et al., 2002a; 
Eberhart et al., 2002b; Lamont et al., 2004; Pfister et al., 2009), and amplification of 
MYC is now an established molecular marker of poor clinical outcome in 
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medulloblastoma (see section 1.5.10) MYC amplifications are enriched in a distinct 
subgroup of non-SHH/non-WNT medulloblastomas that are associated with the worst 
clinical outcome (Cho et al., 2011; Kool et al., 2012) (see section 1.5.8). MYCN 
amplified medulloblastomas are clinically more heterogeneous than MYC amplified 
cases (Pfister et al., 2009), although they are often found in large cell and anaplastic 
tumours (Aldosari et al., 2002a; Eberhart et al., 2002b). MYCN amplification, like MYC, 
is associated with a worse prognosis (Pfister et al., 2009; Kool et al., 2012; Ryan et al., 
2012), however, its significance as a prognostic marker has not yet been proven in large 
trial cohorts (Rutkowski et al., 2007; Ellison et al., 2011b). MYC and MYCN belong to 
the MYC family of cellular oncogenes and encode transcription factors involved in the 
control of cell proliferation, apoptosis and transformation (Grandori et al., 2000). While 
the biological role of increased MYC expression in tumours is not yet clear, it has been 
shown in vitro to promote proliferation of cerebellar granule cells in mouse models and 
an anaplastic histology in cell lines (Fults et al., 2002; Stearns et al., 2006). Increased 
MYCN expression has been reported to drive the formation of metastatic 
medulloblastoma in mouse models (Swartling et al., 2010). 
Other oncogenes recurrently amplified in medulloblastoma include OTX2, which is 
commonly amplified in non-SHH and non-WNT tumours (de Haas et al., 2006), the cell 
cycle progression factor CDK6 (Mendrzyk et al., 2005), and the SHH-associated GLI2 
oncogene (Northcott et al., 2009; Northcott et al., 2011a).  
In a recent study that investigated genomic gains and losses in a cohort of 212 
medulloblastomas using high-resolution SNP genotyping, focal amplications of 15 
known oncogenes and focal deletions of 20 known tumour suppressor genes were 
identified (Northcott et al., 2009). A significant finding of this study was the 
identification of novel and recurrent homozygous deletions and amplifications of genes 
targeting histone lysine methylation, particularly histone 3, lysine 9 (H3K9) (Northcott 
et al., 2009). Post-translational modifications of histone proteins is an epigenetic 
mechanism that regulates gene transcription by establishing transcriptionally active 
(open) or silent (closed) chromatin conformations (see section 1.6). This finding is 
particularly interesting in light of recent genome-wide sequencing studies that have 
identified recurrent mutations in several chromatin-associated genes (see section 
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1.5.6.3), suggesting that deregulation of the epigenome is an important step in the 
pathogenesis of medulloblastoma. 
The largest study of somatic copy number aberrations in medulloblastomas has recently 
been carried out by the Medulloblastoma Advanced Genomics International Consortium 
(MAGIC) which consists of world-wide medulloblastoma experts (Northcott et al., 
2012c). MAGIC investigated copy number events in 1,087 medulloblastomas by SNP 
arrays and concluded that somatic copy number aberrations were common in 
medulloblastoma and were largely enriched in distinct molecular subgroups of the 
disease (Northcott et al., 2012c). As well as confirming well characterised copy number 
events, this study by Northcott et al. also identified novel genes which are recurrently 
affected by copy number changes in specific subgroups. These recent novel findings are 
discussed further in the context of their respective subgroup in section 1.5.8. 
1.5.6.3 Genetic mutations in medulloblastoma 
Until recently, there were only a small number of genes known to be recurrently 
mutated in medulloblastomas; these included the SHH pathway genes PTCH1, SUFU 
and SMO (see section 1.5.7.1), the WNT pathway gene CTNNB1 (see section 1.5.7.2) 
and TP53 (see section 1.5.6.1) (Northcott et al., 2012a).  
In recent years, whole exome and whole genome sequencing studies have significantly 
increased our understanding of genetic mutations in medulloblastoma, and while results 
suggest that paediatric medulloblastomas are characterised by fewer somatic mutations 
compared with adult solid tumours, these studies have identified novel recurrent 
mutations that may play critical roles in the development and progression of 
medulloblastoma (Parsons et al., 2011; Jones et al., 2012; Pugh et al., 2012; Robinson 
et al., 2012). The study conducted by Parsons et al. was the first whole-exome 
sequencing study of medulloblastoma and was carried out using Sanger sequencing 
technology on a cohort of 22 medulloblastomas (Parsons et al., 2011). In addition to 
mutations in components of the SHH and WNT signalling pathways, this study 
identified recurrent inactivating mutations in MLL2 and MLL3 in 16% of patients, 
implying a probable tumour suppressor role in medulloblastoma (Parsons et al., 2011). 
These genes are members of the MLL family of histone 3, lysine 4 (H3K4) 
trimethylases which regulate gene transcription through the methylation of H3K4 and 
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the propagation of active (open) transcriptional chromatin states (Vermeulen and 
Timmers, 2010) (see section 1.6). This study also identified mutations in KDM6B which 
encodes a histone lysine demethylase and in 2 further chromatin–associated genes, 
namely the SWI/SNF chromatin remodelling complex family members SMARCA4 and 
ARID1A (Parsons et al., 2011). In all cases the mutations identified were clearly 
distinguishable from passenger events, suggesting a critical role for histone modifiers 
and other chromatin-associated genes in medulloblastoma development (Parsons et al., 
2011).  
Following the initial study by Parsons et al., a series of three independent next-
generation whole exome and whole genome sequencing studies of medulloblastoma 
were completed (Jones et al., 2012; Pugh et al., 2012; Robinson et al., 2012). As well as 
confirming the findings reported by Parsons et al., these studies have identified a 
common set of novel recurrent mutations that target distinct subgroups of 
medulloblastoma, and include additional histone modifying and other chromatin-
associated genes (Jones et al., 2012; Pugh et al., 2012; Robinson et al., 2012). Their 
findings are discussed further in the context of their respective disease subgroup in 
section 1.5.8.  
Alongside copy number aberrations and mutations, epigenetic dysregulation of genes by 
DNA methylation has also been reported in medulloblastoma and is discussed in detail 
in section 1.6. 
1.5.7 Aberrant activation of developmental signalling pathways 
The Sonic hedgehog (SHH) and WNT/Wingless signalling pathways are embryonal 
developmental pathways that have been shown to regulate the proliferation of neural 
stem and/or progenitor cells in the developing cerebellum and are thus essential for 
normal neural and cerebellar development (Fan and Eberhart, 2008; Gilbertson and 
Ellison, 2008). The SHH and WNT pathways were first implicated in medulloblastoma 
tumourigenesis with the discovery of germline mutations in pathway components in rare 
inherited familial disorders Gorlin syndrome and Turcot syndrome, respectively (see 
section 1.5.6.1). Somatic mutations and other pathway-activating aberrations were 
subsequently identified in significant proportions of sporadic medulloblastomas, and 
SHH-activated and WNT-activated medulloblastomas are now firmly established as 
well defined discrete molecular subgroups of medulloblastoma which are associated 
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with distinct clinical, histopathological and genomic features as well as different clinical 
outcomes (Thompson et al., 2006; Kool et al., 2008; Pizer and Clifford, 2009; Cho et 
al., 2011; Northcott et al., 2011b; Kool et al., 2012) (see section 1.5.8). In addition to 
their key roles in early development and differentiation, the SHH and WNT signalling 
pathways play important roles in the normal growth and patterning of fast-renewing 
epithelial tissues, such as the skin and intestinal lining, and therefore their aberrant 
regulation is also implicated in adult tumours (Taipale and Beachy, 2001). 
1.5.7.1 Sonic hedgehog signalling pathway 
The SHH signalling pathway, discovered in Drosophila, is a major developmental 
pathway in many organisms (Nusslein-Volhard and Wieschaus, 1980). Three 
mammalian hedgehog genes have been identified, sonic hedgehog (SHH), indian 
hedgehog (IHH) and desert hedgehog (DHH) (Huangfu and Anderson, 2005). SHH 
plays a key role in the development of the cerebellum where it regulates the 
proliferation of granule neurone precursor (GNP) cells (Wechsler-Reya and Scott, 
1999). 
SHH pathway activation occurs when the SHH ligand, which is secreted by Purkinjie 
neurons in the developing cerebellum (see section 1.5.7.1.1), binds to the Patched (Ptch) 
transmembrane receptor, abrogating its inhibitory effect on the associated G-protein 
coupled smoothened (Smo) receptor. (Saran, 2009). Upon its release, Smo translocates 
to specialised membrane structures (cilium) where it initiates a mitogenic signalling 
cascade, culminating in the nuclear translocation and activation of the Gli family of 
transcription factors and upregulated expression of several SHH target genes, including 
GLI1 and PTCH1 itself, as well as cyclin D1 and MYCN (Saran, 2009; Hatten and 
Roussel, 2011). When the SHH pathway is inactive, suppressor of fused (Sufu) binds 
the Gli2 and Gli3 transcription factors in the cytoplasm (Saran, 2009). Following 
activation Gli2 translocates to the nucleus where it is a transcriptional activator, while 
Gli3 acts as both an activator and a repressor of downstream signalling (Huangfu and 
Anderson, 2005) (Figure 1.9). 
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1.5.7.1.1 Sonic hedgehog signalling in cerebellar development 
The cerebellum develops from granule neuron precursor (GNP) cells in the rhombic lip 
of the foetal brain. These cells migrate from the rhombic lip to form the external granule 
layer (EGL), where they undergo significant postnatal proliferation (Gilthorpe et al., 
2002). The SHH ligand is secreted by Purkinje neuron cells beneath the EGL (Dahmane 
and Ruiz i Altaba, 1999), activating the mitogenic SHH signalling pathway as described 
above and driving the extensive proliferation of GNPs in the EGL. Following extensive 
proliferation, GNPs migrate inwards past the Purkinje cells to become mature granule 
neurons in the internal granule layer, and the EGL no longer exists as cell proliferation 
stops (Saran, 2009) (Figure 1.10). 
The role of SHH signalling in medulloblastoma tumourigenesis has been extensively 
supported by several mouse models in which the SHH pathway has been aberrantly 
activated and spontaneous medulloblastomas have developed that are similar to 
sporadic human medulloblastomas (Goodrich et al., 1997; Zurawel et al., 2000; 
Hallahan et al., 2004; Lee et al., 2007). The majority of published mouse models of 
medulloblastoma are based on SHH pathway activation and provided some of the 
earliest insights into the GNP cell as the most likely cell of origin for SHH activated 
medulloblastomas (Hatten and Roussel, 2011) (see section 1.5.9). 
1.5.7.1.2 Aberrant activation of the SHH pathway in medulloblastoma 
Aberrant activation of the SHH pathway in medulloblastoma results in enhanced 
expression of oncogenes, such as cyclin D1 and MYCN (see section 1.5.7.1), and leads 
to uncontrolled proliferation of GNPs in the EGL of the developing cerebellum (Figure 
1.10). Aberrant pathway activation in sporadic tumours is associated with inactivating 
mutations in PTCH1, which have been observed in 20-30% of SHH-activated 
medulloblastomas (Schwalbe et al., 2011; Jones et al., 2012; Pugh et al., 2012; 
Robinson et al., 2012). Activating mutations in SMO have been reported in 
approximately 5% of cases, while SUFU mutations have also been reported in a small 
number of SHH tumours (Pizer and Clifford, 2009). High-level amplification of SHH 
downstream effectors GLI1 and GLI2 have also been reported in medulloblastomas 
(Northcott et al., 2009). Recently the MAGIC consortium identified amplification of 
GLI2 and focal deletion of PTCH1 specifically enriched in SHH tumours, reporting 
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PTCH1 as the most frequent target of focal deletion in the distinct subgroup of SHH 
tumours (Northcott et al., 2012c).  
Overall SHH pathway activation is observed in approximately one third of all 
medulloblastomas and they represent a discrete molecular subgroup of tumours that are 
discussed in detail in section 1.5.8.  
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Figure 1.9. SHH and WNT signalling pathways. When the SHH pathway is inactive, Patched (Ptch) receptors 
inhibit Smoothened (Smo) receptors (inactive Smo receptors shown in red) and prevent access of Smoothened to the 
primary cilium. Suppressor of fused (Sufu) binds the downstream effectors of the SHH pathway (Gli2 and Gli3) in 
the cytoplasm and primary cilium. Gli2 is also targeted for degradation by the proteosomal pathway. When the SHH 
pathway is active, Ptch ceases to repress Smoothened (active Smo receptors-shown in green) and it moves into the 
primary cilium and initiates a mitogenic signalling cascade. Sufu no longer binds Gli2 and Gli3 and Gli2 translocates 
to the nucleus where it activates transcription of genes including the oncogenes MYC and cyclin D1. Activation of 
the canonical WNT pathway is initiated by binding of the secreted WNT ligand to the Frizzled receptor on the cell 
surface (active Frizzled receptors-shown in green). When the WNT pathway is inactive, cytosolic concentrations of 
downstream effector β-catenin are kept low as a result of phosphorylation and subsequent degradation via the 
APC/axin/Gsk3β protein complex. When the WNT pathway is active, active Frizzled receptors (shown in green) 
phosphorylate the dishevelled potein (Dsh) which inactivates the protein degradation complex and blocks β–catenin 
degradation, allowing β-catenin to translocate to the nucleus where it activates the transcription of proliferative target 
gene. The SFRP family of proteins negatively regulate the WNT pathway by binding WNT and preventing binding to 
the Frizzled receptor. Figure taken from Ellison, 2010.                                         
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Figure 1.10. The role of SHH signalling in cerebellar development. A. Granule neuronal precursors (GNPs) 
migrate from the rhombic lip and may use the SHH pathway in a transient autocrine manner. B. Immature Purkinje 
neurons and Bergmann glia migrate from the ventricular zone towards the external granule layer (EGL). C. SHH 
secreted from Purkinje neurons induces maturation of Bergmann glia. D. SHH secreted by Purkinje neurons beneath 
the EGL drives the extensive proliferation of GNPs in the EGL. Following extensive proliferation, mature glia 
promote the differentiation of granule neurons and antagonise the effects of SHH. Granule cells migrate on glial 
fibres across the molecular and Purkinje layers to form the internal granule layer (IGL) of the cerebellum. E. 
Maintained SHH signalling in EGL cells can lead to the development of medulloblastoma. Figure adapted from 
Dahmane and Ruiz i Altaba, 1999. 
 
1.5.7.2 WNT/Wingless signalling pathway 
The WNT pathway plays a key role in the development of the central nervous system, 
regulating proliferation and differentiation and maintaining neural stem and precursor 
cell populations (Ciani and Salinas, 2005). 
WNT pathway activity is directly related to the amount of free cytosolic β-catenin 
which is a key downstream effector of the WNT signalling pathway. Activation of the 
canonical WNT pathway is initiated by binding of the secreted WNT ligand to the 
frizzled receptor on the cell surface. In the absence of WNT, cytosolic concentrations of 
β-catenin are kept low as a result of complex formation with APC and axin with 
subsequent phosphorylation by glycogen synthase kinase 3β and casein kinase Ia 
(CKIa) which targets it for degradation via the ubiquitin-proteasome pathway. Upon 
binding the WNT ligand, frizzled phosphorylates the dishevelled protein (Dsh) which 
causes inactivation of the axin/Gsk3β/APC complex which targets β-catenin for 
phosphorylation and subsequent degradation and blocks β-catenin degradation. This 
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results in increased nuclear translocation of β-catenin where it binds to the gene 
regulatory protein Tcf/Lef and regulates the transcription of WNT target genes which 
include the proliferation genes cyclin D1 and Myc (Saran, 2009).The secreted frizzled-
related protein (SFRP) comprises a family of WNT inhibitors that can bind the WNT 
ligand and prevent it binding to frizzled receptor (Kongkham et al., 2010a) (Figure 1.9). 
1.5.7.2.1 WNT signalling in cerebellar development 
The significance of the WNT signalling pathway in cerebellar development is not fully 
understood, however, it has been shown that deletion of Wnt-1 from mice completely 
blocks cerebellar development (McMahon and Bradley, 1990; Thomas and Capecchi, 
1990). A recently developed mouse model which targeted expression of CTNNB1 to 
progenitor cells of the lower rhombic lip, a germinal matrix situated between the neural 
tube and roofplate of the fourth ventricle of the developing cerebellum and gives rise to 
diverse neuronal brainstem lineages, developed tumours that transcriptionally resembled 
human WNT medulloblastomas (Gibson et al., 2010). These tumours arose from the 
dorsal brainstem, the hindmost region of the brainstem, and provides very strong 
evidence that the WNT subgroup of tumours are anatomically distinct from the EGL-
derived SHH medulloblastomas and arise outside the cerebellum from progenitor cells 
of the dorsal brainstem (Gibson et al., 2010) (see section 1.5.9). 
1.5.7.2.2 Aberrant activation of the WNT pathway in medulloblastoma 
Activating mutations in the CTNNB1 gene that encodes β-catenin are observed in 
approximately 10% of sporadic medulloblastomas (Kool et al., 2012) and in up to 90% 
of WNT-activated medulloblastomas (Schwalbe et al., 2011; Jones et al., 2012; Pugh et 
al., 2012; Robinson et al., 2012). Activating mutations in CTNNB1 leads to upregulated 
transcription of oncogenic WNT target genes. Other less common mutations have been 
found in the genes encoding APC and axin, each affecting approximately 2.5% of cases 
(Pizer and Clifford, 2009). Aberrant pathway activation has also been identified as a 
result of epigenetic silencing of the SFRP family of WNT inhibitors by DNA 
methylation, suggesting a potential tumour suppressor role for this gene family in 
medulloblastoma development and a possible mechanism by which some 
medulloblastomas may aberrantly activate the WNT signalling pathway (Kongkham et 
al., 2010a). 
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WNT-activated medulloblastomas are significantly associated with loss of chromosome 
6 (Clifford et al., 2006; Fattet et al., 2009). A nucleopositive β-catenin phenotype has 
been shown to correlate strongly with β-catenin mutations and to identify a subset of 
tumours with a favourable clinical outcome (Ellison et al., 2005; Fattet et al., 2009), and 
thus represents a marker of good prognosis that can be readily applied in the clinical 
setting to identify the favourable risk WNT-activated medulloblastomas (see section 
1.5.10). WNT-activated medulloblastomas represent a discrete subgroup of tumours that 
are discussed in detail in section 1.5.8. 
1.5.8 High-throughput analysis of the medulloblastoma genome and 
transcriptome 
Significant advances have been made in the field of medulloblastoma genomics in 
recent years. Tumour profiling using high density expression and SNP arrays, and more 
recently next generation sequencing technologies, have provided significant insights 
into the molecular heterogeneity that underpins medulloblastoma. This has led to the 
firm recognition that medulloblastoma comprises distinct molecular subgroups, which 
behave very differently and will therefore require accurate diagnosis and different 
therapeutic approaches in the clinic. 
1.5.8.1 Transcriptional profiling of medulloblastoma 
Several groups have carried out transcriptomic profiling of moderate to large 
independent cohorts of primary medulloblastomas and revealed the existence of distinct 
subgroups of the disease based on their gene expression profiles (Thompson et al., 
2006; Kool et al., 2008; Cho et al., 2011; Northcott et al., 2011b). All groups 
unequivocally identified the presence of mutually exclusive SHH-activated and WNT-
activated subgroups, but they differed in the number of non-SHH/non-WNT subgroups 
that were found; Thompson et al, and Northcott et al. identified two further 
transcriptomic subgroups while Kool et al. identified three and Cho et al. identified four 
additional groups. Across the studies, clinico-pathological and genetic features were 
found to significantly differ between the molecular subgroups identified. All groups 
reported significant enrichment of monosomy 6 in WNT tumours as previously reported 
(Clifford et al., 2006; Fattet et al., 2009). The WNT subgroup was associated with a 
classic histology, while SHH tumours were enriched for chromosome 9q loss, the 
desmoplastic nodular phenotype and represented the majority of infant (< 3 years) cases 
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(Thompson et al., 2006; Kool et al., 2008; Cho et al., 2011; Northcott et al., 2011b). 
While a variable number of non-SHH/non-WNT subgroups were identified, they were 
associated with similar features across the different studies. The non-SHH/non-WNT 
tumour subgroups represented approximately 60% of all medulloblastomas, and while 
they were not found to be associated with any specific signalling pathways, they did 
show upregulated expression of neuronal and photoreceptor genes. These tumour 
subgroups were associated with the chromosomal abnormality i17q and with LCA 
histology (Kool et al., 2008; Cho et al., 2011; Northcott et al., 2011b). The majority of 
metastatic cases fell into the non-SHH/non-WNT tumour subgroups (Kool et al., 2008; 
Cho et al., 2011; Northcott et al., 2011b), with metastasis an established clinical 
predictor of poor patient outcome (Bailey et al., 1995; Zeltzer et al., 1999). In their 
study, Cho et al., identified a specific non-SHH/non-WNT subgroup that was enriched 
for MYC amplification and displayed a particularly aggressive behaviour (Cho et al., 
2011).  
Several groups have designed assays that could be applied in the clinical setting to 
diagnose individual subgroups of medulloblastoma. In one study, 
immunohistochemistry, using validated subgroup-specific immunohistochemical 
markers, successfully distinguished SHH, WNT and non-SHH/WNT tumours (Ellison 
et al., 2011a). Northcott et al. designed a novel four antibody approach that reliably 
assigned 98% of formalin-fixed paraffin embedded (FFPE) tumour samples to their four 
previously defined transcriptomic subgroups (Northcott et al., 2011b). Minimal mRNA 
expression signatures have been designed and validated that reliably distinguish distinct 
medulloblastoma subgroups, and can routinely and rapidly be applied in the clinical 
setting requiring only small amounts of RNA (Schwalbe et al., 2011; Northcott et al., 
2012d). The ability to accurately and rapidly diagnose specific medulloblastoma 
subgroups in the clinic will be vital for future clinical trials that will tailor therapies and 
employ novel molecularly targeted therapies according to tumour biology. 
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1.5.8.2 Four core molecular subgroups of medulloblastoma 
As a result of the variable number of molecular subgroups that were identified from the 
series of transcriptomic profiling studies undertaken (see section 1.5.8.1), a consensus 
conference was held in the autumn of 2010 and after reviewing all the evidence, 
medulloblastoma experts from around the world reached a consensus that there are four 
core molecular subgroups of medulloblastoma, namely SHH, WNT, Group 3 and Group 
4 (Taylor et al., 2012). The WNT and SHH subgroups were named after the key 
signalling pathways thought to play significant roles in their pathogenesis; less is known 
about the underlying biology of the remaining two subgroups and so they were given 
generic names until they can be further refined molecularly (Taylor et al., 2012). The 
evidence strongly suggests that there are subtypes within the core subgroups but as yet 
their exact number, nature and composition are unknown (Taylor et al., 2012). 
Based on the consensus four subgroups (SHH, WNT, Group 3 and Group 4), Kool et al. 
carried out a meta-analysis of all molecular and clinical data that was available from 
independent studies for a total of 550 primary medulloblastomas, and from this they 
defined the key clinical, histological and genomic features of the four subgroups. They 
also performed a comprehensive survival analysis, assessing the prognostic significance 
of subgroup status and the prognostic relevance of molecular markers significantly 
enriched within distinct subgroups (Kool et al., 2012). This meta-analysis represents the 
largest series of biology data on medulloblastoma reported to date. 
Northcott et al. conducted a meta-analysis of a series of three medulloblastoma next-
generation sequencing studies that have recently been completed (Jones et al., 2012; 
Pugh et al., 2012; Robinson et al., 2012), and defined a common set of novel and 
known recurrent mutations targeting distinct medulloblastoma subgroups (Northcott et 
al., 2012a). They also included in their analysis the large-scale copy number study 
recently completed by the MAGIC consortium (Northcott et al., 2012c) and defined the 
most prevalent copy number aberrations targeting distinct subgroups (Northcott et al., 
2012a). The key features that define the four core subgroups of medulloblastoma, as 
described by the aforementioned extensive meta-analysis studies, are described below 
and are summarised in Table 1.5. 
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1.5.8.2.1 SHH subgroup of medulloblastoma 
The SHH subgroup represents approximately 28% of all medulloblastomas (Kool et al., 
2012). They are an intermediate prognosis subgroup, with overall survival rates ranging 
from ~60% to 80% (Cho et al., 2011; Northcott et al., 2011a; Northcott et al., 2011b; 
Kool et al., 2012). SHH medulloblastomas occur almost equally in males and females 
and they exhibit a bimodal age distribution, accounting for the majority of both infant 
and adult medulloblastomas but only for a minority of childhood cases. There is a 
strong association between infant SHH tumours and desmoplastic/nodular histology, 
and SHH tumours have a better outcome in infants compared to children and adults 
(Kool et al., 2012) (Table 1.5). These findings are consistent with previous studies 
reporting the association between desmoplastric/nodular histology, infant 
medulloblastoma and favourable prognosis (see section 1.5.1.2).  
There are frequent deletions of chromosomes 9q and 10q in SHH tumours (Kool et al., 
2012). Copy number aberrations affecting the SHH target genes, MYCN and GLI2 and 
mutations of PTCH1 are typical of this subgroup (Northcott et al., 2012a) (Table 1.5). 
Mutations affecting the histone modifier MLL2 (Parsons et al., 2011) were enriched in 
both SHH and WNT medulloblastomas compared with Group 3 and Group 4 (Northcott 
et al., 2012a). Mutations in BCOR and LDB1, components of the nuclear receptor co-
repressor (N-CoR) complex which is associated with histone deacetylase (HDAC) 
activity, were mutually exclusive in SHH tumours (Northcott et al., 2012a). While gene 
mutations were generally low frequency (Table 1.5), these findings suggest that 
disruption of the histone code and chromatin organisation may be a significant feature 
of SHH medulloblastoma (Table 1.5). 
1.5.8.2.2 WNT subgroup of medulloblastoma 
WNT tumours represent the smallest subgroup (11%). They occur almost equally in 
males and females and are rare in infants, typically occurring in children over the age of 
3 years. WNT medulloblastomas have the best survival outcome of all the subgroups 
and this has been firmly established in several studies (Ellison et al., 2005; Gajjar et al., 
2006; Fattet et al., 2009; Kool et al., 2012), with over 95% of patients surviving their 
disease (Kool et al., 2012). WNT tumours are mainly classic histology and are 
infrequently metastatic (Kool et al., 2012) (Table 1.5). 
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WNT medulloblastomas are characterised by loss of chromosome 6 (Clifford et al., 
2006; Kool et al., 2012). Apart from this, they exhibit very few other chromosomal 
abnormalities or copy number events (Kool et al., 2012) (Table 1.5). Mutations in 
CTNNB1 are almost exclusively found in WNT tumours; CTNNB1 is the most 
frequently mutated gene in medulloblastoma and is mutated in 91% of WNT tumours 
(Northcott et al., 2012a). DDX3X is the second most frequently mutated gene and 
mutations are found in approximately 50% of WNT tumours as well as in SHH 
medulloblastomas (Northcott et al., 2012a). DDX3X is involved in multiple cellular 
processes including cell cycle regulation, and it is thought that it is required to maintain 
the lineage of progenitors of the lower rhombic lip (Robinson et al., 2012), which are 
the proposed cell of origin of WNT medulloblastomas (see section 1.5.9). As well as 
enrichment of mutations in MLL2, mutations in the chromatin modifier SMARCA4 are 
frequently found in WNT tumours (Northcott et al., 2012a) (Table 1.5). 
1.5.8.2.3 Group 3 medulloblastomas 
Group 3 medulloblastomas currently have the worst outcome of the four subgroups 
(Cho et al., 2011; Northcott et al., 2011b; Kool et al., 2012). They are more common in 
males, are rarely found in adult populations and are frequently of the LCA histological 
subtype. Group 3 tumours are frequently metastatic at presentation (Kool et al., 2012) 
(Table 1.5).  
MYC amplification is highly enriched in Group 3 tumours and is observed in 
approximately 17% of Group 3 medulloblastomas (Cho et al., 2011; Kool et al., 2012). 
i17q is frequently found in these tumours (Table 1.5). Multiple studies have confirmed 
that MYC amplification is significantly associated with a poor prognosis and with the 
large cell and anaplastic histology (Brown et al., 2000; Aldosari et al., 2002a; Eberhart 
et al., 2002b; Lamont et al., 2004; Pfister et al., 2009). In their meta-analysis, Kool et 
al. reported that all patients with MYC or MYCN amplification had a worse prognosis 
compared to cases without amplification. However, in the context of Group 3 tumours, 
they found that patients without MYC do equally poor as those carrying the 
amplification (Kool et al., 2012). 
In recent studies, an aberrant H3K27 (histone 3, lysine 27) methylation state was 
reported to occur specifically in Group 3 and Group 4 medulloblastomas, further 
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implicating disruption of the histone code as a significant oncogenic feature in 
medulloblastomas (Robinson et al., 2012; Dubuc et al., 2013). Recurrent mutations in 
the histone modifiers MLL2 and MLL3 and in the chromatin modifier SMARCA4 are 
found in Group 3 tumours (Northcott et al., 2012a). Gene mutations are, however, low 
frequency, and many tumours are not defined by mutations, leaving many driver events 
still undetected (Table 1.5). 
1.5.8.2.4 Group 4 medulloblastomas 
Group 4 are the most common medulloblastoma subgroup and they have an 
intermediate prognosis similar to SHH tumours. They are more common in males and 
are mainly of classic histology, although they can be LCA. Metastases are found in 
approximately one third of patients (Kool et al., 2012) (Table 1.5). Group 4 
medulloblastomas that present with metastases have been shown to have a poorer 
clinical outcome compared with those without (Kool et al., 2012). 
i17q is frequently found in Group 4 tumours (Kool et al., 2012) and loss of one copy of 
chromosome X in female Group 4 medulloblastomas has also been reported (Northcott 
et al., 2012a). The proto-oncogenes MYCN and CDK6 are recurrently amplified in 
Group 4 tumours (Northcott et al., 2012a) (Table 1.5), and MYCN amplification was 
associated with a worse outcome (Kool et al., 2012). Additionally, chromosome 17 
aberrations in Group 4 tumours were associated with a worse outcome (Kool et al., 
2012). 
Recurrent mutations in the histone modifying genes, MLL2 and MLL3, are present in 
Group 4 medulloblastomas (Northcott et al., 2012a) (Table 1.5). While gene mutations 
are generally low frequency, of particular interest was the finding that KDM6A, a 
H3K27 demethylase, is the most frequently mutated gene in Group 4. An additional 
chromatin remodelling gene, ZMYM3, is also recurrently mutated in Group 4 (Northcott 
et al., 2012a) (Table 1.5). As previously mentioned, aberrant H3K27 methylation has 
been found to be prevalent in both Group 3 and Group 4 medulloblastomas (Robinson 
et al., 2012; Dubuc et al., 2013), suggesting that dysregulation of epigenetic processes 
may be a significant feature of Group 3 and Group 4 pathology. 
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 SHH WNT Group 3 Group 4 
Clinical features     
Prevalence 28% 11% 27% 34% 
Gender ratio 
(male/female) 
~1/1 ~1/1 ~2/1 ~2/1 
Age adults>infants>children children>adults children>infants; 
rarely adults 
children>adults; 
rarely infants 
Histology classic>D/N>LCA classic; rarely LCA classic>LCA; 
rarely D/N 
classic; rarely LCA 
; rarely D/N 
Metastasis ~15% ~10% ~30% ~30% 
Overall survival 
(5 years) 
~60% 
(Infant SHH ~75%) 
~95% ~50% ~60% 
Genomic features     
Expression 
signature 
SHH 
MYCN/minimal MYC 
WNT Photoreceptor 
MYC/minimal 
MYCN 
 
Neuronal 
MYCN/minimal 
MYC 
Cytogenetics -9q; -10q; -11;-16; -17p; 
+3q 
-6 -8; -10q; -16q;-
17p; +1q; +7; 
+17q; i17q 
-8; -11; -16q;-17p; 
+7; +17q; i17q 
Driver genes 
Recurrent 
mutations 
PTCH1 (24%) 
MLL2 (12%) 
TP53 (11%) 
DDX3X (11%) 
BCOR (7%) 
LDB1 (7%) 
TCF4 (5%) 
 
CTNNB1 (91%) 
DDX3X (50%) 
SMARCA4 (25%) 
MLL2 (13%) 
TP53 (13%) 
SMARCA4 (11%) 
SPTB (6%) 
MLL2 (5%) 
CTDNEP1 (5%) 
LRP1B (5%) 
TNXB (5%) 
KDM6A (12%) 
MLL3 (5%) 
ZMYM3 (5%) 
CBFA2T2 (3%) 
Driver genes 
Focal SCNAs 
MYCN (8%) 
GLI2 (5%) 
PTCH1 (4%) 
 MYC (17%) 
 
MYCN (6%) 
CDK6 (5%) 
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Table 1.5. Summary of the clinical, histopathological and genetic features associated with the four molecular 
subgroups of medulloblastoma. Clinical features, expression signatures and cytogenetic features were described by 
Kool et al. following their meta-analysis of clinical and molecular data for 550 primary medulloblastomas (Kool et 
al., 2012). Subgroup-specific mutational events and copy number events are summarised along with their prevalence 
within each subgroup, adapted from (Northcott et al., 2012a). Medulloblastoma is characterised by relatively few 
somatic mutational events which are generally low frequency and many driver events have yet to be detected, 
particularly in the Group 3 and Group 4 subgroups. D/N: desmoplastic nodular; LCA: large cell anaplastic. 
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1.5.9 Cellular origins of medulloblastoma 
Current evidence in mouse models of medulloblastoma suggests that the four molecular 
subgroups of medulloblastoma most likely have different cellular origins. The vast 
majority of mouse models available recapitulate the SHH subgroup of tumours (Hatten 
and Roussel, 2011) and have been available for more than a decade. Inactivation of 
Ptch1 (Ptch1
+/-
) (Goodrich et al., 1997; Wetmore et al., 2000) and activation of 
smoothened (Smoa1) (Hallahan et al., 2004; Hatton et al., 2008) are the most commonly 
used initiating events to generate tumours replicating human SHH medulloblastomas in 
mice. Using models such as these, SHH medulloblastomas have been shown to arise in 
cerebellar granule neuron precursors (GNPs) of the cerebellar external granule cell layer 
(EGL) (Schuller et al., 2008; Yang et al., 2008) (see Figure 1.10). 
Mice that express an activated mutant β-catenin allele alongside TP53 deletion develop 
tumours that recapitulate human WNT medulloblastomas and have identified lower 
rhombic lip progenitors of the dorsal brainstem as the cell of origin for WNT tumours 
(Gibson et al., 2010). 
Against a background of TP53 deletion, MYC-driven mouse models of Group 3 
medulloblastomas have recently been developed, that have aggressive phenotypes 
similar to the human Group 3 tumours (Kawauchi et al., 2012; Pei et al., 2012). These 
models have identified 3 potential cells of origin for Group 3 tumours: atonal 
homologue 1 (ATOH1)-positive GNPs from the EGL (Kawauchi et al., 2012); ATOH1-
negative GNPs from the EGL (Kawauchi et al., 2012) and prominin 1(PROM1)-
positive, lineage negative neural stem cells (NSCs) (Pei et al., 2012). Meanwhile the 
cellular origin of Group 4 medulloblastomas is still unknown. 
These findings that distinct subgroups arise from different cellular origins will have 
important implications for the study of abnormal tumour-specific events in 
medulloblastoma. Normal control cerebellar tissue comprises a heterogeneous 
population of cells and signals generated will represent an average of these cell 
populations, and may not be reflective of the precise cell of origin of the tumour. In 
order to make rational and accurate assessments of primary tumour versus normal it will 
be necessary to account for subgroup-specific differences. This presents a significant 
challenge in the field of medulloblastoma research as the cellular origins of Group 4 and 
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the precise cell of origin of Group 3 tumours are not yet known and also acquiring such 
cell-type specific controls will not be easy.  
1.5.10 Medulloblastoma molecular markers as prognostic indicators 
As previously discussed, positive nuclear staining for the WNT pathway marker β-
catenin (Ellison et al., 2005; Fattet et al., 2009) and amplification of the MYC oncogene 
(Brown et al., 2000; Aldosari et al., 2002a; Eberhart et al., 2002b; Lamont et al., 2004; 
Pfister et al., 2009) are firmly established molecular prognostic markers in 
medulloblastoma. Both markers have been validated in multiple clinical trials cohorts 
and have subsequently been incorporated into a new risk stratification model that 
recognises low-risk (favourable risk), standard-risk and high-risk categories of 
medulloblastoma, and will form the basis of the forthcoming PNET5 clinical trial (Pizer 
and Clifford, 2009) (see section 1.5.11).  
While no other molecular markers have been validated in trials cohorts, progress is 
being made and it is anticipated that as more biological insights are gained and 
molecular subclassification further refined, markers will be identified that will predict 
survival both between and within molecular subgroups and more accurately inform 
treatment choices for patients in the clinical setting.  
FSTL5 expression has recently been identified as a marker of poor prognosis both 
within and across medulloblastoma subgroups (Remke et al., 2011). Remke et al. 
reported subgroup-specific expression patterns for FSTL5, with lowest expression in the 
favourable-risk WNT tumours and over-expression in a subset of non-SHH/non-WNT 
tumours which are associated with a poorer clinical outcome. Immunostaining for 
FSTL5 confirmed that its expression was prognostic across the subgroups in univariate 
and multivariate survival models, and also within the non-SHH/non-WNT tumours 
(Remke et al., 2011). FSTL5 expression represents a promising marker for identifying a 
subset of high-risk and lower-risk non-SHH/non-WNT tumours for more effective 
therapeutic stratification.  
In another study, upregulated expression of the histone deacetylases, HDAC5 and 
HDAC9, has been shown to correlate with poor prognostic medulloblastoma subgroups 
(defined as tumours with balanced chromosome 6 or gain of 6q or 17q) and to be 
associated with poor overall survival (Milde et al., 2010). Over-expression of both 
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HDAC5 and HDAC9 was identified as independent high-risk indicators and their 
knockdown in medulloblastoma cells reduced growth and induced apoptosis, suggesting 
a potential prognostic and functional role for HDAC5 and HDAC9 expression in 
medulloblastoma (Milde et al., 2010). Recently, independent high-risk DNA 
methylation biomarkers have been identified in medulloblastoma (Schwalbe et al., 
2013) (see section1.7.2.2). 
1.5.11 Improved risk stratification models and future clinical trials in 
medulloblastoma 
It is clear that the identification of prognostically important histological and molecular 
features offers significant potential for improved stratification of medulloblastoma. 
Molecular subclassification is refining the discovery of prognostic biomarkers as well as 
novel therapeutic targets (see section 1.5.12) and it is beginning to inform the 
therapeutic management of medulloblastoma. 
Before prognostic markers can be incorporated into a stratification model for future 
clinical trials they must be robustly validated in independent patient cohorts. Table 1.6 
details the molecular and histopathological markers that have shown significant 
associations with prognosis in ≥ 2 clinical trials and have been incorporated into an 
improved stratification model alongside current clinical risk variables (see section 
1.5.4). The new refined stratification model identifies three distinct medulloblastoma 
risk groups: high-risk, standard risk and low-risk (favourable-risk) (Pizer and Clifford, 
2009). The utility of the molecular markers alongside clinicopathological disease 
features in disease outcome prediction was validated in a primary medulloblastoma 
cohort of 207 patients (3-16 years) from the SIOP PNET3 trial (Ellison et al., 2011b).  
This new stratification model will form the basis of the forthcoming PNET5 clinical 
trial which will test whether children (3-16 years of age) with favourable-risk disease 
may benefit from de-escalated therapy, with the aim of maintaining survival rates while 
reducing the late effects of treatment. This trial will also aim to improve survival rates 
in the standard-risk group following removal of the favourable-risk cases (Pizer and 
Clifford, 2009). 
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 Disease marker 
Low-risk β-catenin nucleopositive and 
No MYC amplification and 
Total surgical resection and 
No evidence of metastatic disease (M0) and 
Classic or D/N histology 
 
Standard-risk β- catenin nucleonegative and  
No MYC amplification and  
Total surgical resection and 
No evidence of metastatic disease and  
Classic or D/N histology 
High-risk β-catenin nucleopositive or  
nucleonegative and 
MYC amplification or 
Sub-total surgical resection or 
Evidence of metastatic disease (M1-M3) or 
LCA histology 
Table 1.6. Refined risk stratification model for children (3-16 years) with medulloblastoma. Proposed new 
stratification model for non-infant children with medulloblastoma based on validated clinical, histopathological and 
molecular disease biomarkers. This model will be used to inform treatment strategies in the forthcoming PNET5 
clinical trial. Table adapted from Pizer and Clifford, 2009.  
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1.5.12 Molecular targeted therapy in medulloblastoma 
The use of molecularly targeted therapies in medulloblastoma is still in its infancy. The 
greatest advances have been made in targeting the SHH signalling pathway and small 
molecule inhibitors of the SHH pathway have been developed, most of which act on 
smoothened (SMO) (Low and de Sauvage, 2010; Ng and Curran, 2011). SMO-
inhibitors have recently entered clinical trials for SHH-driven medulloblastomas. 
Despite showing a pronounced initial response, studies have shown that both humans 
and mice with PTCH-and SMO-driven tumours quickly develop resistance, suggesting 
these agents may be ineffective as monotherapy (Rudin et al., 2009; Metcalfe and de 
Sauvage, 2011). Furthermore, SMO-inhibitors are unlikely to be active against tumours 
driven by amplifications and mutations in downstream pathway components such as 
SUFU and GLI (Ramaswamy et al., 2011). A mutation in SMO has also been identified 
that has no effect on SHH signalling but disrupts drug binding, reducing its effect and 
leading to disease recurrence (Yauch et al., 2009). While SMO-inhibitors may be 
ideally suited to young infants with germline PTCH1 mutations, such as those observed 
in Gorlin syndrome medulloblastoma (see section 1.5.6.1), there are concerns of 
developmental complications with their use in young infants, with SHH pathway 
inhibition found to disrupt bone growth in young mice (Kimura et al., 2008).  
A targeted WNT pathway inhibitor (XAV939) has also been developed and is thought 
to inhibit WNT signalling through the stabilisation of axin, which is a key component of 
the β-catenin destruction complex (Huang et al., 2009) (see section1.5.7.2). The 
application of this therapy to medulloblastoma is unclear as the majority of WNT 
medulloblastomas are characterised by activating mutations in β-catenin, which acts 
downstream of axin. Furthermore consideration must be given to the importance of 
WNT signalling in maintaining stem cell populations (Ciani and Salinas, 2005) and the 
wide ranging adverse effects that would be associated with its inhibition. 
Owing to the identification of recurrent mutations in histone modifiers and other 
chromatin-modifying genes (see section 1.5.6.3 and 1.5.8.2), an exciting avenue that is 
currently being explored is the use of targeted epigenetic therapy in medulloblastoma. 
Epigenetic modifications, which include the addition of methyl groups to DNA and the 
post-translational addition of among others acetyl and methyl groups to core histone 
proteins, are discussed in section 1.6. Briefly, the interaction between these different 
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epigenetic mechanisms plays a key role in establishing chromatin architecture and 
regulating gene expression (see section 1.6). Epigenetic modifications are reversible 
making them an attractive therapeutic target (Dawson and Kouzarides, 2012) and this is 
currently an area of active interest in the pharmaceutical industry, particularly in the 
development of drugs targeting histone lysine post-translational modifications. Such 
targeted agents offer the potential for altering transcriptional programmes in cancer 
cells. Targeted epigenetic therapy has shown considerable promise for the indirect 
targeting of the MYC oncogene, the inhibition of which has proved very challenging to 
scientists over the years (Batora et al., 2013). A recently developed small-molecule 
bromodomain inhibitor, JQ1, has been shown to downregulate MYC expression (Mertz 
et al., 2011; Loven et al., 2013). Bromodomains are commonly found in chromatin-
associated proteins that recognise and selectively bind to acetyl-lysine residues, 
mediating their transcriptional effects (Filippakopoulos and Knapp, 2012). JQ1 
interferes with the capacity of bromodomain-containing proteins to bind acetylated 
lysines and through this mechanism downregulates the expression of MYC (Mertz et al., 
2011; Loven et al., 2013). JQ1 represents an exciting and promising treatment for the 
poor prognostic Group 3 medulloblastomas and in vitro testing in medulloblastoma is 
currently underway (Batora et al., 2013). DZNep (3-Deazaneplanocin A) is another 
targeted epigenetic therapy that is soon to be tested in upcoming Phase II clinical trials 
in America in subsets of medulloblastoma (Gajjar et al., 2013). DZNep is an inhibitor of 
EZH2 which encodes a histone lysine methyltransferase and functions within the 
Polycomb repressive complex 2 (PRC2) to promote histone 3, lysine 27 trimethylation 
(H3K27me3), a mark of transcriptionally silent chromatin (Batora et al., 2013) (see 
section 1.6). As previously discussed in section 1.5.8.2, an aberrant H3K27 methylation 
state has been reported to occur specifically in Group 3 and Group 4 meduloblastomas 
and DZNep, therefore, represents an exciting novel targeted therapy for Group 3 and 
Group 4 patients harbouring these defects.  
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1.5.13 Summary 
Significant advances in the field of medulloblastoma genomics have led to the 
recognition of medulloblastoma as a disease comprising four very distinct molecular 
subgroups, which will require accurate diagnosis in the clinic and different therapeutic 
strategies. While these genomic advances will translate to improved risk stratification 
and to improved treatment options for patients with medulloblastoma, it is becoming 
increasingly clear that the molecular pathogenesis of the disease cannot be completely 
attributed to genetic events. Recent whole exome and whole genome sequencing studies 
have shown that medulloblastoma is characterised by relatively few somatic mutational 
events, and events identified are generally low frequency (Parsons et al., 2011; Jones et 
al., 2012; Pugh et al., 2012; Robinson et al., 2012). As a result, there are many currently 
undetected driver events in medulloblastoma pathogenesis, particularly in the Group 3 
and Group 4 tumour subgroups (see section 1.5.8.2).  
There is increasing recognition that epigenomic deregulation may play a critical role in 
the development of medulloblastoma (Jones et al., 2013). Tumour suppressor genes that 
are silenced by DNA methylation in medulloblastoma have been known for quite some 
time (see section 1.6.3.1) and, as discussed, several chromatin modifying genes which 
are targeted by mutation in medulloblastoma have recently been identified (see sections 
1.5.6.3 and 1.5.8.2). Comprehensive characterisation of the medulloblastoma 
epigenome offers considerable potential for the identification of further driver events 
involved in tumour initiation and progression. Studies of epigenetic deregulation in 
medulloblastoma have gained considerable interest and pace in recent years and have 
been paralleled with advances in the technology for studying genome-wide DNA 
methylation. DNA methylation is a critical epigenetic mechanism of gene regulation 
and its importance in cancer has been widely established (Jones and Laird, 1999; Jones 
and Baylin, 2002; Baylin and Jones, 2011). The role of DNA methylation in regulating 
gene expression during normal development and during tumourigenesis is discussed in 
detail in the sections that follow.  
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1.6 Epigenetics 
Epigenetics is defined as heritable changes in gene activity and expression that occur 
without a change in the primary DNA sequence (Bird, 2007; Goldberg et al., 2007). 
Epigenetic mechanisms, which include DNA methylation (Feinberg and Tycko, 2004; 
Jones and Baylin, 2007), histone modifications (Kouzarides, 2007; Li et al., 2007), 
nucleosome remodelling (Li et al., 2007) and the impact of non-coding RNAs (Mattick 
and Makunin, 2006), play major roles in regulating gene activity and expression during 
development and differentiation as well as in disease (Jones and Baylin, 2007; Jaenisch 
and Young, 2008). Gene transcription is a remarkably intricate process that is tightly 
regulated at many genetic and epigenetic levels (Lemon and Tjian, 2000). It is 
becoming increasingly clear that epigenetic control of gene regulation is itself highly 
complex, with significant crosstalk between different epigenetic processes evident 
(Goldberg et al., 2007). Much of the research in the field of epigenetics has focused on 
two processes, namely DNA methylation and histone modifications, and how the 
interplay between them establishes a transcriptionally active euchromatic state or 
transcriptionally silent heterochromatic state (Jones and Baylin, 2002; Jaenisch and 
Bird, 2003; Jones and Baylin, 2007; Blackledge and Klose, 2011; Poetsch and Plass, 
2011). 
1.6.1 DNA methylation and CpG islands 
DNA methylation has been described as a “powerful mechanism for the suppression of 
gene activity” (Jones and Laird, 1999). In the human genome, the predominant form of 
DNA methylation occurs symmetrically at carbon 5 position of cytosine residues on 
both strands of CpG dinucleotides (Bird, 2002). DNA methylation at CpG dinucleotides 
acts as a stable and heritable epigenetic mark that is generally associated with repressed 
chromatin states and inhibition of transcriptional activation (Klose and Bird, 2006) (see 
section 1.6.2). While CpG methylation affects approximately 70-80% of CpG sites, both 
the CpG sites and their degrees of methylation are unevenly distributed in the genome 
(Bird et al., 1987). Of great significance is the presence of CpG islands which are 
unmethylated GC-rich regions that are predominantly found at the promoter region of 
many genes (Bird et al., 1987).  
A CpG island is formally defined as a region of at least 200 base-pairs with an average 
CG content greater than 50% and an observed-to-expected CpG ratio greater than 0.6 
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(Gardiner-Garden and Frommer, 1987). CpG islands are a feature of housekeeping 
genes as well as many genes with a tissue-restricted expression pattern (Gardiner-
Garden and Frommer, 1987). Approximately 70% of genes are associated with CpG 
islands, the great majority of which are unmethylated at all stages during development 
and in all tissue types (Bird, 2002). During normal development a small number of CpG 
islands become methylated and this methylated state is associated with long-term gene 
silencing (Bird, 2002). Developmentally programmed CpG island methylation is 
involved in fundamental biological processes such as genomic imprinting and X 
chromosome inactivation (Bird, 2002).  
Genomic imprinting, which describes the non-equivalence in allele expression for 
certain gene loci in a parent-of-origin specific manner (Reik et al., 2001) and X 
chromosome inactivation in females involve the silencing of one allele only (Bird, 
2002). The importance of DNA methylation in mediating this silencing has been 
demonstrated in mouse models in which DNA methyltransferase enzymes (DNMTs) are 
disrupted leading to reactivation of X-linked genes (Sado et al., 2000) and the 
disruption of the monoallelic expression of several imprinted genes (Li et al., 1993). In 
normal somatic cells, CpG island methylation is also a feature of some tissue-specific 
genes and is thought to be critical in regulating their cell-type specific expression 
patterns (Strathdee et al., 2004b). Examples include the maspin gene which is 
methylated and repressed in mesenchymal and haematopoietic cells (Futscher et al., 
2002) and MCJ which is methylated and repressed in epithelial cells (Strathdee et al., 
2004a). De novo methylation of CpG islands also occurs in certain tissues during aging 
and is a significant feature of cancer cells (Bird, 2002) (see section 1.6.4). 
Transcriptionally active genes are associated with a methylation-free CpG island, 
however, the exact mechanisms by which CpG islands remain methylation-free and the 
precise mechanisms by which they contribute to gene regulation are not yet fully 
understood (Blackledge and Klose, 2011). As some tissue-specific genes have CpG 
islands that remain unmethylated in all tissues regardless of expression, an 
unmethylated CpG island is not indicative of active gene transcription but rather 
establishes a ‘permissive’ state of gene transcription (Bird, 2002). Early evidence 
suggests that a methylation-free CpG island may be created by gene promoters that are 
active in early development and that this may be as a result of a transcriptionally active 
 64 
 
chromatin state excluding the DNA methylation machinery (Bird, 2002). These findings 
suggest that unmethylated CpG islands represent footprints of embryonic promoter 
activity (Bird, 2002). The unmethylated state of promoter CpG islands has been shown 
to be strongly influenced by transcription factor binding with CpG islands acquiring 
methylation if they are depleted of transcription factor binding sites (Brandeis et al., 
1994; Macleod et al., 1994). Recent studies have identified a new family of DNA 
binding proteins (ZF-CxxC proteins) that are specifically recruited to unmethylated 
CpG dinucleotides and participate in establishing a transcriptionally active chromatin 
state and in gene activation (Blackledge et al., 2010; Thomson et al., 2010). These 
studies demonstrated that the ZF-CxxC domain of this protein family specifically 
targets unmethylated CpG islands, providing the first evidence that CpG islands are 
directly interpreted through recognition of non-methylated DNA (Blackledge et al., 
2010; Thomson et al., 2010; Blackledge and Klose, 2011).  
Outside of the predominantly unmethylated CpG islands, the remaining CpG sites in the 
genome are largely methylated (Bird, 2002). Activation of transposable element-derived 
promoters is a well-documented consequence of loss of this DNA methylation (Bird, 
2002). Transposable element (TE)-derived repetitive DNA sequences, such as LINES 
(long interspersed nuclear elements) and SINES (short interspersed nuclear elements) 
retrotransposons, comprise almost half of the human genome and are mobile DNA 
sequences that can migrate to different regions of the genome (Smit, 1996). TE 
sequences are heavily methylated and it is thought that this methylation contributes to 
the suppression of transposition and TE-mediated changes in gene expression and the 
overall maintenance of genomic stability (Morgan et al., 1999; Slotkin and Martienssen, 
2007). 
1.6.2 DNA methylation, histone modifications and chromatin structure 
Genomic DNA is packaged with histone proteins to form protein/DNA complexes 
known as chromatin. The basic unit of chromatin is the nucleosome which is composed 
of ~146bp of DNA wrapped around an octamer of the four core histone proteins (H2A, 
H2B, H3 and H4) (Luger et al., 1997). The amino terminal tails of the core histone 
proteins are subject to several post-translational modifications by histone modifying 
enzymes. These modifications include acetylation, methylation, phosphorylation, 
ubiquitination and sumoylation and are critical for regulating chromatin structure and 
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function, and influence many DNA processes including gene transcription (Koch et al., 
2007). 
Acetylation and methylation of histone lysine residues are the two most common post-
translational modifications that interact with DNA methylation to establish 
transcriptionally active euchromatic states and transcriptionally inactive 
heterochromatic states (Jones and Baylin, 2002; Jones and Baylin, 2007; Blackledge 
and Klose, 2011; Poetsch and Plass, 2011). Euchromatin is a region where the DNA is 
accessible to the transcription machinery and other DNA binding proteins, representing 
an open conformation due to the relaxed state of well-spaced nucleosomes. In contrast, 
heterochromatic regions are areas where DNA is packaged into tightly compacted 
nucleosomes rendering it inaccessible to transcription factors and other chromatin-
associated proteins (Jones and Baylin, 2002) (Figure 1.11). The balance between 
euchromatin and heterochromatin in a given cell type ensures that the gene expression 
pattern is stably inherited in daughter cells (Bird, 2002). 
Unmethylated CpG islands, especially those that are associated with active gene 
promoters, reside in regions of euchromatin composed of widely and irregularly spaced 
nucleosomes (Jones and Baylin, 2002). Active gene promoters are characterised by 
nucleosome depleted regions (NDRs) immediately upstream from their transcription 
start site, while flanking nucleosomes carry the histone modification H3 trimethylated 
on lysine 4 (H3K4me3) as well as highly acetylated histone H3 and H4 lysine residues 
(Jenuwein and Allis, 2001; Baylin and Jones, 2011) (Figure 1.11). These flanking 
nucleosomes are also associated with the histone variant H2A.Z which dynamically 
regulates chromatin conformation by creating domains that are poised for transcriptional 
activation through its ability to destabilise nucleosomes to facilitate access to DNA and 
gene transcription (Fan et al., 2002; Baylin and Jones, 2011).  
In contrast, methylated DNA resides in regions of transcriptionally silent 
heterochromatin composed of tightly packed nucleosomes (Lin et al., 2007; Baylin and 
Jones, 2011) and where it occurs at gene promoters, they lack the H2A.Z histone variant 
and are accompanied by repressive histone modifications, such as H3K27me3 and 
H3K9me3 (Jones and Baylin, 2002; Lin et al., 2007) (Figure 1.11). Polycomb group 
(PcG) proteins are transcriptional repressors that play a central role in gene regulation 
during differentiation and development through their histone modification activities, in 
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particular applying the repressive H3K27me3 inhibitory mark and conferring repressive 
chromatin structure at gene promoters (Bracken and Helin, 2009) (Figure 1.11). The 
PcG proteins form multiprotein repressive complexes, known as Polycomb repressive 
complexes (PRCs), and they have been shown to co-occur with the active histone mark, 
H3K4me3, around the TSS of key developmental and lineage-specific genes in 
embryonic stem cells (ESCs) (Mikkelsen et al., 2007). This dynamic bivalent chromatin 
state is thought to confer regulatory flexibility by maintaining ESC pluripotency 
through their quiescence while allowing for their rapid transcriptional activation during 
differentiation (Mikkelsen et al., 2007). Bivalent gene promoters are prone to de novo 
DNA methylation in cancer and pre-cancerous cells (Ohm et al., 2007; Widschwendter 
et al., 2007). 
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Figure 1.11. Model of the overall structure of the epigenome in normal human cells. Diagram shows the 
balanced state of chromatin in the genome, which maintains the packaging state of DNA; DNA methylation, histone 
modifications and nucleosome positioning associated with the different states of euchromatin and heterochromatin 
are shown. The top of the figure shows a silenced gene (indicated by a red X over the transcription start site); its 
promoter CpG island is occupied by a repressive Polycomb group (PcG) complex (indicated by the red shaded area) 
that mediates chromatin changes, including the repressive histone modification trimethylation of lysine 27 on histone 
3 (H3K27me3). CpG dinucleotides within this region are unmethylated (blue circles) (unmethylated DNA is not 
indicative of gene transcription), and nucleosomes are postioned over the transcriptional start sites. Sites upstream 
from the gene promoter are heavily methylated (red circles). The gene promoter beneath the silenced gene has 
adopted a fully active transcriptional state, associated with the active H3K4me3 marks and acetylation of key H3 and 
H4 lysines. Nucleosomes are absent from the transcription start site. Towards the bottom of the figure the packaging 
of the majority of DNA into a transcriptionally repressed heterochromatin state is shown; nucleosomes are densely 
packed, repressive H3K9me2 and H3K9me3 marks are present and DNA is heavily methylated. Figure taken from 
Baylin and Jones, 2011. 
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1.6.2.1 DNA methylation and transcriptional repression 
The exact mechanisms by which DNA methylation mediates transcriptional silencing 
are not yet completely understood however insights have been gained from an increased 
understanding of the DNA methylation machinery.  
There are three active DNA methyltransferase enzymes (DNMT1, DNMT3A and 
DNMT3B) that catalyse the transfer of a methyl group from S-adenosyl-L-methionine 
to cytosine residues; DNMT1 is the major maintenance methyltransferase that has a 
preference for hemimethylated CpG sites and is responsible for copying pre-existing 
methylation patterns onto the new strand during DNA replication. DNMT3A and 
DNMT3B are de novo methyltransferases that are active on unmethylated DNA and are 
responsible for establishing methylation patterns during early development (Klose and 
Bird, 2006). The importance of DNMT3A and DNMT3B enzymes during development 
is evident by the fact that knock-out mice lacking either of them show different defects 
and die at different developmental stages (Okano et al., 1999). De novo methylation is 
active in germ cells and in the early embryo; de novo methylation in developing germ 
cells gives rise to substantially methylated genomes which then undergo a wave of 
genome-wide demethylation in the early embryo pre-implantation stage, followed 
shortly afterwards by large-scale de novo methylation in somatic cell lineages (Strachan 
and Read, 2004a).  
Studies have suggested that de novo methylation by DNMT3 may be targeted to 
specific genomic regions either through recognition of specific histone modifications 
such as unmethylated H3K4, or through their direct recruitment by histone 
methyltransferases such as those responsible for writing the repressive histone mark 
H3K9me3 (Chen and Riggs, 2011). Further strengthening their role as transcriptional 
repressors, all three DNMTs have been shown to interact with histone deacetylase 
enzymes which are central to many gene silencing protein complexes, to establish a 
transcriptionally silent chromatin state (Fuks et al., 2000; Robertson et al., 2000; 
Rountree et al., 2000). 
It is thought that DNA methylation can repress gene transcription through two broad 
mechanisms. The first mechanism involves direct repression by inhibiting the binding 
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of sequence-specific transcription factors whose binding sites contain CpG sites such as 
MYC and MYCN (Tate and Bird, 1993).  
The second mechanism of methylation-dependent gene repression is mediated by 
methyl-CpG binding proteins (MBPs) that specifically bind methylated DNA. The first 
MBP identified was the methyl-CpG binding protein 2 (MeCP2) (Lewis et al., 1992), 
and this was followed by methyl-CpG binding domain proteins (MBD1, MBD2 and 
MBD4) which all bind methylated DNA with a higher affinity than unmethylated DNA 
via their conserved MBD homology domain (Hendrich and Bird, 1998). The MBPs may 
compete with transcription factors for their DNA binding sites but a major breakthrough 
in understanding methylation-mediated repression came with the finding that MeCP2 
interacts with a co-repressor complex containing histone deacetylase enzymes (HDACs) 
(Jones et al., 1998; Nan et al., 1998). Further studies reported similar findings with 
other MBPs (Ng et al., 1999; Feng and Zhang, 2001), strongly supporting their role as 
transcriptional repressors through the recruitment of histone deacetylation to methylated 
DNA in regions of transcriptional silencing (Jones and Baylin, 2002) (Figure 1.12). 
Additionally MBPs have been shown to participate in chromatin remodelling 
complexes, which are large multi-protein complexes that regulate gene expression 
through nucleosome restructuring (Saha et al., 2006); MBPs have been identified in 
complexes that contain transcriptional co-repressors, such as Sin3A as well as histone 
deacetylases, and are recruited to methylated genomic regions where they establish a 
transcriptionally inactive chromatin state (Wade et al., 1999; Zhang et al., 1999; Feng 
and Zhang, 2001). 
For many years the causal role of DNA methylation in initiating gene silencing versus 
maintaining a silent state induced by another mechanism has been the topic of intense 
debate. Early studies investigating de novo methylation during embryonic development 
support DNA methylation as a secondary event that affects genes that have already been 
silenced by other mechanisms, effectively stabilising their inactivation (Bird, 2002). 
Recent studies that have been carried out using a novel Nucleosome occupancy 
methylome sequencing (NOMe-Seq) approach have strongly supported this notion that 
promoter DNA methylation occurs secondary to other inactivating events and acts to 
effectively stabilise or “lock” the transcriptionally inactive state (Han et al., 2011; Kelly 
et al., 2012). 
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NOMe-Seq is a single molecule, high resolution nucleosome positioning assay based on 
enzyme accessibility to GpC sites that also retains endogenous DNA methylation 
information from CpG sites. This novel approach allowed the investigators to study 
both DNA methylation and nucleosome positioning on the same individual DNA 
molecule (Han et al., 2011; Kelly et al., 2012). Using NOMe-Seq to look at individual 
DNA strands they found that promoter DNA methylation occurred secondary to the 
DNA becoming inaccessible by nucleosome occupancy, with DNA methylation 
requiring the nucleosomes to be present (Han et al., 2011; Kelly et al., 2012). Of further 
interest the investigators also reported that the chromatin architecture of non-CpG island 
promoters was almost identical to that of CpG island promoters and reported gene 
silencing directly associated with methylated non-CpG island gene promoters (Han et 
al., 2011; Kelly et al., 2012). Their findings suggest that epigenetic mechanisms of gene 
regulation are shared between CpG island promoters and non-CpG island promoters. 
These findings will have important implications in the study of cancer epigenetics, and 
studies of aberrant DNA methylation in cancer should include non-CpG island promoter 
methylation as this may also contribute to tumourigenesis in a similar manner to 
established CpG island promoter hypermethylation (Han et al., 2011) (see section 
1.6.4). 
While DNA methylation interacts with other epigenetic events, including histone 
modifications and nucleosome positioning (relationships are summarised in Table 1.7), 
experimental evidence suggests that DNA methylation is the dominant event and acts to 
seal in transcriptional repression (Jones and Baylin, 2002). This evidence comes from 
the use of HDAC inhibitors such as trichostatin that alone do not reactivate aberrantly 
methylated and silenced genes in tumour cells. Reactivation of many aberrantly 
methylated and silenced genes in tumour cells can only be achieved by using agents that 
block DNMT activity, such as 5-aza-2’-deoxycytidine, either alone or in combination 
with HDAC inhibitors (Cameron et al., 1999). 
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Figure 1.12. A CpG-rich promoter in transcriptionally active and transcriptionally repressed states. A. A 
typical actively transcribed promoter that contains a CpG island; CpG island is unmethylated; nucleosomes are 
widely spaced and contain the active acetylated histone marks, mediated by histone acetyltransferase (HAT) and the 
active H3K4me3 mark, mediated by lysine 4 methyltransferase (HMT). The open chromatin structure allows entry of 
the transcription activator complex which consists of a co-activator protein (CA), transcription factor and HAT. 
DNMTs are excluded from the promoter and directed toward flanking repressed chromatin, associated with 
deacetylated histones that contain H3K9 methylation marks, dense DNA methylation, methyl binding protein (MBP)- 
and histone deacetylase (HDAC)-complexes and tightly packed nucleosomes. B. The transcriptionally repressed 
promoter is associated with dense CpG island methylation. MBPs bind to the DNA and recruit complexes containing 
HMT and HDAC complexes, which deacetylate the nucleosomes alongside methylation of H3K9 to generate a tightly 
compacted chromatin structure that is inaccessible to the transcriptional machinery. Figure taken from Jones and 
Baylin, 2002. 
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 Active chromatin Repressive chromatin 
Structure Less condensed, open, 
accessible; wide and 
irregular spaced 
nucleosomes 
Condensed, closed, 
inaccessible; densely packed 
nucleosomes 
Activity Active, expressed Silent, repressed 
DNA methylation Hypomethylation Hypermethylation 
Histone acetylation Hyperacetylation of histone 
H3 and H4 
Hypoacetylation of histone 
H3 and H4 
Histone methylation H3K4me2, H3K4me3 H3K27me2, H3K27me3, 
H3K9me2, H3K9me3 
Table 1.7. Summary of DNA methylation and histone modifications associated with transcriptionally active 
and transcriptionally repressed chromatin states. 
 
1.6.3 DNA methylation in cancer 
The disruption of epigenetic mechanisms is now established as a hallmark of cancer 
(Wong et al., 2007), and genetic and epigenetic processes are believed to co-operate at 
all stages of cancer development (Jones and Baylin, 2007; Baylin and Jones, 2011). It 
has been recognised for many years that DNA methylation patterns are widely disrupted 
in tumour cells; global loss of methylation across the genome is accompanied by gene-
specific promoter hypermethylation (Feinberg and Tycko, 2004; Esteller, 2005). It is 
clear that genetic aberrations alone cannot account for all the molecular events that 
drive tumourigenesis, and genetic and epigenetic processes are inextricably linked in the 
regulation of gene transcription (Lemon and Tjian, 2000). Understanding the functional 
role of aberrant DNA methylation events in cancer is fundamental to our understanding 
of the molecular pathogenesis of cancer types. The significant technological advances in 
DNA methylation analysis that have been made over the years mean that entire cancer 
methylomes can now be interrogated at single base-pair resolution (Laird, 2010). Such 
advances have facilitated the molecular characterisation of many tumour types as well 
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as the identification of methylation markers that predict patient outcome and represent 
novel therapeutic targets (Laird, 2003) (see section 1.6.3.4). 
1.6.3.1 Promoter hypermethylation and transcriptional silencing 
The most widely studied alteration of DNA methylation in tumours is the silencing of 
tumour suppressor genes by CpG island hypermethylation (Jones and Baylin, 2002; 
Jones and Baylin, 2007; Esteller, 2008) and this plays a key tumourigenic role 
contributing to all the typical hallmarks of a cancer cell that result from tumour 
suppressor inactivation (Hanahan and Weinberg, 2011) (see section 1.2.4). Promoter 
methylation is now established, alongside genetic mutations and loss of heterozygosity 
(LOH), as a potential contributor of one hit, according to Knudson’s two-hit hypothesis, 
for loss of function of a tumour suppressor gene (Jones and Laird, 1999).  
It is thought that between 5-10% of all promoter CpG islands that are normally 
unmethylated become aberrantly methylated in cancer, affecting hundreds of genes 
across almost all cancer types (Jones and Baylin, 2002; Jones and Baylin, 2007). The 
functional significance of CpG island promoter hypermethylation is appreciated by the 
many genes affected that are involved in processes such as cell cycle regulation, tumour 
cell invasion, chromatin remodelling, transcription and apoptosis, emphasising the 
importance of methylation-mediated gene silencing as a major driver for cancer 
initiation and progression (Robertson, 2005) (Table 1.8). For many of these genes 
promoter hypermethylation is the only mechanism for their loss of function (Jones and 
Baylin, 2002). 
Evidence from familial cancer syndromes suggests that aberrant promoter 
hypermethylation can be an early event in tumourigenesis and provide a selective 
advantage to tumour cells (Jones and Baylin, 2002). Germ-line mutations in VHL (von 
Hippel-Lindau), BRCA1 (breast cancer 1, early onset) and STK11 (serine/threonine 
kinase 11) genes cause familial forms of renal, breast and colon cancer, respectively; 
these genes are often silenced by promoter DNA methylation in sporadic cases of these 
cancers (Jones and Baylin, 2002). Further evidence of DNA hypermethylation being an 
early driver event comes from the identification of genes which are involved in key 
developmental pathways and are hypermethylated and silenced in different tumour 
types (Baylin and Ohm, 2006). In colon cancer (Suzuki et al., 2004) and also in 
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medulloblastoma (Kongkham et al., 2010a), the SFRP (secreted frizzled related protein) 
family of WNT pathway inhibitors are known to be silenced by DNA methylation. This 
shows how epigenetic inactivation can complement single driver mutations, such as 
those in the WNT pathway genes, APC and β-catenin, and aberrantly activate pathway 
signalling (Baylin and Jones, 2011). 
Tumour suppressor genes that are frequently mutated or epigenetically inactivated in 
cancers often reside in genomic regions characterised by LOH (loss of heterozygosity) 
caused by chromosomal deletions (Jones and Baylin, 2002). The tumour suppressor 
genes, RASSF1A (located at 3p21) and HIC1 (located at 17p13.3) are in chromosomal 
regions that are characterised by frequent LOH in several tumour types, and both genes 
are frequently silenced by promoter hypermethylation in many cancer types. 
Interestingly, gene mutations have not been consistently found in these regions, and 
RASSF1A and HIC1 constitute the principal tumour suppressor genes in these regions 
and are defined solely by epigenetic events (Jones and Baylin, 2002). 
The importance of methylation-mediated gene silencing in cancer is also recognised by 
the occurrence of changes that predispose to mutational events during tumour 
progression. This was first shown for the mismatch-repair gene MLH1 (mutL 
homologue 1, colon cancer, non-polyposis type 2) which is hypermethylated and 
silenced in sporadic tumours that have microsatellite instability (MSI) (Jones and 
Baylin, 2002). MGMT (O-6-methylguanine-DNA methyltransferase) is another DNA 
repair gene that is silenced by promoter hypermethylation in several different tumour 
types, leading to a failure to repair DNA and a predisposition to mutations in key genes 
such as TP53 and K-RAS (Esteller et al., 2000b; Esteller et al., 2001). These findings 
show how CpG methylation can directly cause genetic changes in cancer and emphasise 
the interaction between genetics and epigenetics in tumourigenesis (Baylin and Jones, 
2011). Mutational events have also been identified that are associated with epigenomic 
events in cancers, for example, mutations of the IDH1 (isocitrate dehydrogenase 1) gene 
in gliomas have been found to correlate significantly with a DNA CpG island 
hypermethylated phenotype (Noushmehr et al., 2010). The TET family proteins have 
recently been identified as enzyme systems that actively remove DNA methylation, 
forming 5-hydroxylmethyl cytosine from methylated cytosine. These proteins have been 
discovered to be crucially important during development and tumourigenesis 
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(Kriaucionis and Heintz, 2009; Sharma et al., 2010). Mutations in the TET2 gene have 
been identified in gliomas and leukaemias (Figueroa et al., 2010; Noushmehr et al., 
2010). In leukaemias, TET2 mutations were associated with increased numbers of 
hypermethylated genes (Figueroa et al., 2010). Furthermore, recent whole-exome 
sequencing studies have identified frequent mutations in genes that are known to play 
roles in epigenome organisation (Ernst et al., 2010; Jiao et al., 2011; Yap et al., 2011), 
suggesting that many abnormal epigenetic events may lie downstream of genetic events 
(Baylin and Jones, 2011). An emerging important role for promoter hypermethylation is 
the transcriptional repression of multiple microRNAs (miRNAs) (Baylin and Jones, 
2011). MicroRNAs are small non-coding RNAs that target mRNA transcripts for 
cleavage or translational repression and can, therefore, influence the output of many 
protein coding genes (Bartel, 2004). Their repression can lead to pathway disruption 
and upregulation of their oncogenic targets (Saito et al., 2006) and has been shown to 
produce a metastatic phenotype (Lujambio et al., 2008). 
Important roles for DNA methylation outside of gene promoters and CpG islands are 
emerging. From their genome-wide study of DNA methylation patterns in colon cancer, 
Irizarry et al. reported that most DNA methylation alterations in colon cancer did not 
occur in promoters or in CpG islands but occurred in regions up to 2kb distant from the 
promoter CpG island, which they termed ‘CpG island shores’(Irizarry et al., 2009). 
CpG island shore methylation was strongly associated with gene expression and with 
tissue of origin, consistent with the notion that epigenetic changes cause cancer largely 
through the disruption of differentiation processes (Irizarry et al., 2009). In their 
findings, Irizarry et al. reported hypermethylation events enriched closer to associated 
CpG islands, while hypomethylation events were enriched further from the CpG island. 
This is consistent with the DNA methylation ‘spreading theory’ which describes that de 
novo DNA methylation may begin at flanking CpG sites and progressively invade into 
the core of the CpG island (Stirzaker et al., 2004). The exact mechanism of how ‘shore’ 
methylation regulates gene transcription is not yet fully understood and one suggestion 
is that it may do so through the control of enhancer elements (Tsai and Baylin, 2011).  
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Gene function Gene Cancer type 
Cell-cycle regulation 
RB1 Retinoblastoma 
CDKN2A Colon, lung and many more 
Tumour-cell invasion 
CDH1 Breast, gastric, thyroid, leukaemia, 
liver 
CDH13 Lung, ovarian, pancreatic 
TIMP3 Brain ,kidney 
VHL Kidney 
DNA 
repair/detoxification 
MLH1 Colon, endometrial, gastric 
MGMT Colon, brain, lung, breast 
BRCA1 Breast, ovarian 
GSTP1 Prostate, liver, colon, breast, 
kidney 
Chromatin 
remodelling 
SMARCA3 Colon, gastric 
Cell signalling 
RASSF1A Lung, liver, brain (incl. 
medulloblastoma) 
SOCS1 Colon, liver, multiple myeloma 
SFRP Colon, medulloblastoma 
Transcription ESR1 Colon, breast, lung, leukaemia 
Apoptosis 
DAPK1 Lymphoma 
CASP8 Medulloblastoma 
Table 1.8. Examples of genes silenced by aberrant promoter DNA methylation in cancer. Gene function and 
cancers in which the methylation-dependent gene silencing is observed are listed for each gene. Table adapted from 
Robertson, 2005. 
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1.6.3.2 DNA hypomethylation in cancer 
In 1983, DNA methylation was first linked to cancer when it was shown that the 
genomes of cancer cells were largely hypomethylated compared to their normal 
counterparts (Feinberg and Vogelstein, 1983a). This global DNA hypomethylation 
occurs primarily in satellite and pericentromeric repetitive DNA sequences, regions that 
are heavily methylated and associated with a heterochromatic state in normal cells (De 
Smet and Loriot, 2010). Genomic instability is a hallmark of cancer cells, and it is 
thought that global DNA hypomethylation contributes to tumourigenesis through the 
reactivation of transposable elements (see section 1.6.1), causing genomic instability 
and the disruption of gene structure (Robertson, 2005; De Smet and Loriot, 2010). 
Reactivation of transposon promoters following demethylation may also lead to 
aberrant gene regulation by interfering with transcription or by generating antisense 
transcripts (Robertson and Wolffe, 2000). Loss of methylation has been identified as an 
early event in cancer and has been associated with a severe and metastatic phenotype in 
many cancers (Widschwendter et al., 2004). 
Gene-specific DNA hypomethylation can lead to gene activation, and although not as 
frequently reported as tumour suppressor gene silencing by promoter hypermethylation, 
a small number of genes have been identified that are reactivated following loss of 
methylation from their promoter region. The HRAS oncogene has been shown to be 
reactivated in colorectal and small cell lung carcinomas following hypomethylation of 
its normally methylated CpG island promoter (Feinberg and Vogelstein, 1983b). The 
MAGE (melanoma antigen) family of cancer-testis genes (expressed normally in the 
testis and aberrantly in tumours) encode tumour antigens and are frequently 
demethylated and overexpressed in cancers (De Smet et al., 1999). Other genes reported 
to be affected by promoter CpG demethylation accompanied by overexpression include 
the S100A4 (S100 calcium binding protein A4) gene in colon cancer (Nakamura and 
Takenaga, 1998), cyclin D2 (Oshimo et al., 2003) and maspin (Akiyama et al., 2003) in 
gastric tumours and the HPV16 (human papillomavirus 16) gene in cervical cancer 
(Badal et al., 2003). DNA hypomethylation can also lead to loss of imprinting (LOI) 
and this can drive tumourigenesis. This is best characterised by the abnormal activation 
of the maternally inherited allele of the IGF2 (insulin-like growth factor II) gene which 
is observed in approximately 40% of colorectal cancers (Wong et al., 2007).  
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1.6.3.3 Genome-wide analysis of DNA methylation patterns in tumours 
Over the last decade, significant advances have been made in the technologies used to 
analyse DNA methylation. As a result of these advances, cancer epigenetic studies have 
progressed from assessing the methylation status of specific regions in a small number 
of genes to an unbiased, genome-wide interrogation of DNA methylation. 
DNA methylation information is erased by standard molecular biology techniques, 
including cloning in bacteria and PCR. As a result, almost all sequence-specific DNA 
methylation analysis techniques rely on a methylation-dependent pre-treatment of the 
DNA, which can be carried out using one of three main approaches: endonuclease 
digestion, affinity enrichment and bisulfite conversion (Laird, 2010). Following 
methylation-dependent treatment of genomic DNA, array-based hybridisation and 
sequencing technologies are commonly employed to investigate methylation at CpG 
dinucleotides on a genome-wide scale (Laird, 2010). The development of DNA 
methylation microarray hybridisation techniques made a significant impact on the study 
of cancer epigenomics, allowing the study of DNA methylation on a genome-wide scale 
for a large number of samples (Laird, 2010). As a result of the advances that have been 
made in sequencing technologies in recent years, it is likely that array-based analyses 
will shift to analysis by next-generation sequencing technologies such as whole genome 
shotgun bisulfite sequencing (WGSBS) (Lister et al., 2009), which is considered the 
ultimate comprehensive single base-pair resolution DNA methylation analysis 
technique (Laird, 2010). 
The first locus-specific DNA methylation analyses used methylation-sensitive 
restriction endonucleases to fragment DNA in a methylation-dependent manner which 
could then be identified using gel electrophoresis and Southern blotting (Kaput and 
Sneider, 1979). Methylation-sensitive restriction digestion followed by PCR across the 
restriction site is a very sensitive technique that is still currently in use, however, these 
methods are prone to false positive results due to incomplete digestion for reasons other 
than DNA methylation (Laird, 2010). 
Restriction landmark genome scanning (RLGS) was the first genome-wide technique 
for studying DNA methylation patterns (Hayashizaki et al., 1993). This endonuclease-
dependent method uses two-dimensional gel electrophoresis to investigate differences in 
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methylation which are detected as differences in the pattern of restriction fragments 
generated, however, the process is labour-intensive and has largely been replaced by 
methods that do not rely on gel electrophoresis (Laird, 2010). Comprehensive high-
throughput array-based relative methylation (CHARM) analysis is a genome-wide 
array-based method that uses the methylation-dependent endonuclease McrBC, which 
provides greater sensitivity to densely methylated regions compared with a methylation-
sensitive enzyme (Irizarry et al., 2008). It was using this method, to assess genome-
wide DNA methylation in colon cancers, that led Irizarry et al. to report the presence of 
CpG hypermethylation in ‘CpG island shores’ (Irizarry et al., 2009) (see section 
1.6.3.1).  
MeDIP (methylated DNA immunoprecipitation) is an array-based analysis that utilises 
affinity enrichment of methylated regions by immunoprecipitation of denatured 
genomic DNA with an antibody specific for methylated cytosine, followed by 
hybridisation to an array (Weber et al., 2005; Weber et al., 2007). Affinity-based 
methods, such as MeDIP, allow for rapid and efficient genome-wide assessment of 
DNA methylation, however, they do not provide information on individual CpG 
residues and require adjustment for varying CpG density across the genome (Laird, 
2010). As with other array-based methods, affinity enrichment techniques are being 
adapted for analysis by next generation sequencing (Down et al., 2008). 
Bisulfite conversion of DNA followed by sequencing is considered to be the gold-
standard approach for characterising DNA methylation patterns at base-pair resolution 
(Clark et al., 1994). The method of sequencing bisulfite-converted DNA to map 5-
methylcytosine was first developed by Frommer et al. (Frommer et al., 1992). Briefly, 
sodium bisulfite treatment converts non-methylated cytosines to uracil while methylated 
cytosines remain unchanged. Converted uracil residues are subsequently read as 
thymine following PCR amplification and sequencing and the only cytosines that 
remain in the sequence are methylated. Bisulfite-converted genomic DNA can be 
assayed both on microarrays and by next generation sequencing to investigate genome-
wide DNA methylation patterns. The methylation array platforms utilise amplified 
bisulfite-converted genomic DNA, hybridised to microarrays containing methylation-
specific oligonucleotides (MSO) to determine a quantitative measure of methylation at 
CpG sites (Gitan et al., 2002). Illumina have developed three generations of methylation 
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microarrays with increasing genomic coverage; the first generation GoldenGate Cancer 
Panel I microarray targets 1,505 CpG sites across a targeted panel of 807 known cancer 
genes (Bibikova et al., 2006). Subsequently the Infinium (27,000 CpG sites) (Bibikova 
et al., 2009) and the Infinium 450K (450,000CpG sites) (Bibikova et al., 2011) were 
released that achieve unprecedented coverage to allow a truly genome-wide 
characterisation of DNA methylation. Both the GoldenGate Cancer Panel I and the 
Infinuim 450K microarrays were used in this project and are discussed further in section 
2.7.  
Unlike other methylation analysis methods, whole-genome shotgun bisulfite sequencing 
(WGSBS) generates quantitative genome-wide methylation profiles at single nucleotide 
resolution (Laird, 2010). The first human methylomes published using this technique 
were in 2009 (Lister et al., 2009) and it is likely that this gold standard approach will 
supersede all other techniques in the near future. While bisulfite-based methods are 
accurate and reproducible (Laird, 2010), the major sources of bias and error are 
incomplete bisulfite conversion and differential PCR efficiencies for methylated 
compared with unmethylated versions of the same sequence (Warnecke et al., 1997). 
Nanopore sequencing is a novel sequencing approach that is currently in development. 
It offers the potential for direct sequencing of methylated cytosines without the need for 
prior bisulfite treatment of DNA (Branton et al., 2008; Clarke et al., 2009), and may be 
the next major advance in high-throughput DNA methylation analysis. 
As the number of epigenomic studies carried out using unbiased, genome-wide 
approaches increases, new and interesting findings are being made about the functional 
significance of DNA methylation outside of gene promoters and CpG islands, which 
have been the focus of many conventional approaches. For example, the discovery by 
Irizarry et al. that functionally relevant hypermethylation occurs outside of gene 
promoters and CpG islands, at CpG sites located in regions up to 2kb distant from CpG 
islands, termed ‘CpG island shores’(Irizarry et al., 2009). Also, potential roles for 
intragenic DNA methylation in controlling alternative promoter usage (Maunakea et al., 
2010) and in alternative splicing have been reported (Shukla et al., 2011; Brown et al., 
2012). The ability to assess DNA methylation genome-wide, at single nucleotide 
resolution, presents exciting new opportunities to more fully explore the role of DNA 
methylation in gene regulation both in normal cells and in cancer. 
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Another genome-wide approach used in DNA methylation analysis involves expression 
profiling of cells treated with DNA methyltransferase inhibitors, such as 5’-aza-2’-
deoxycytidine, to discover genes that are epigenetically dysregulated by DNA 
methylation in cancer cells. This approach was used in this project for investigations 
reported in Chapter 4, where it is discussed in further detail. 
1.6.3.4 The clinical and therapeutic role of DNA methylation biomarkers in 
cancer 
Aberrant DNA methylation in cancer has long held promise as a potential biomarker 
strategy (Laird, 2003), and as epigenome-wide investigations gather pace, methylation 
patterns are being recognised that are biomarkers for tumour type, early detection, 
assessment of prognosis and predicted response to therapy (Baylin and Jones, 2011). 
Commercial assays are currently awaiting approval for the detection of hypermethylated 
genes in stool and blood DNA as markers for colon cancer risk and detection (Lofton-
Day et al., 2008; Glockner et al., 2009), as well as the detection of GSTP1 (glutathione 
S-transferase PI) hypermethylation in tumour biopsy and urine samples for prostate 
cancer (Cairns et al., 2001; Rosenbaum et al., 2005).  
Prognostic DNA methylation biomarkers have been identified that can identify patients 
with Stage I non-small-cell lung cancer who are considered high-risk and would 
therefore benefit from intensified adjuvant therapeutic strategies (Brock et al., 2008). In 
patients with glioma, hypermethylation and subsequent silencing of the DNA repair 
gene MGMT can predict response to the chemotherapeutic agent, temozolamide 
(Esteller et al., 2000a). 
An increasing number of studies are recognising that DNA methylation patterns may 
reflect cellular origins; Fernandez et al. profiled 1054 cancers on the GoldenGate Caner 
Panel I array and reported that patterns of methylation could identify tumour type origin 
of cancers of unknown primary site (Fernandez et al., 2012). In another study conducted 
across 7 different cancer types, the authors reported that differential methylation profiles 
reflected the developmental history and transcriptional state of the different cells of 
origin (Sproul et al., 2012). Thus characterisation of cancer methylomes may provide 
clues into the precise cell of origin of the cancer type and subtypes.  
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The DNA methylation mark is reversible and therefore presents an exciting and 
attractive therapeutic target (Issa and Kantarjian, 2005).The azanucleosides, 5’-
azacytidine and 5’-aza-2’-deoxycytidine (decitabine) were developed over 40 years ago 
as cytostatic agents (Sorm et al., 1964). They have long been known to cause global 
demethylation in human cell line model systems (Jones and Taylor, 1980) and do so 
through the inhibition of all DNA methyltransferases (DNMTs) (Stresemann and Lyko, 
2008). This finding led to their development as epigenetic drugs and following 
substantial refinements in their clinical dosing schedules to minimise drug-related 
toxicities, they have showed significant clinical benefits in the treatment of 
myelodysplastic syndrome (MDS), a proleukaemic bone marrow disorder (Silverman et 
al., 2002; Kantarjian et al., 2006). Subsequently, 5’-azacytidine (Vidaza) and decitabine 
(Dacogen) received approval by the FDA for the treatment of MDS and it is hoped that 
they will show similar therapeutic benefit in other haematological malignancies and in 
solid tumours. 
While it is clear that the azanucleosides have cytotoxic effects and it has been shown 
that they cause DNA demethylation in patients (Mund et al., 2005; Soriano et al., 2007), 
their precise mode of action in inducing the clinical responses observed are still not 
fully understood. The rationale behind their use is in their ability to re-activate genes 
that have been aberrantly silenced by hypermethylation; many aberrantly methylated 
and silenced genes in tumour cells are reactivated following demethylation using 
DNMT inhibitors (Cameron et al., 1999). The identification of robust associations 
between critical epigenetic reactivation events and patient responses will be an 
important area of research in azanucleoside-based therapies. While treatment with 
azanucleosides is effective and improves overall survival rates (Fenaux et al., 2009), 
most patients eventually develop resistance (Tuma, 2009). Furthermore, treatment with 
azanucleosides results in non-specific overall DNA demethylation and multiple 
regulatory pathways may be affected (Komashko and Farnham, 2010). Significant 
efforts are therefore being made to develop more selective DNMT inhibitors (Chik and 
Szyf, 2011). 
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1.7 The role of DNA methylation in medulloblastoma 
The vast majority of DNA methylation studies in medulloblastoma to-date have focused 
on hypermethylation of gene promoter regions and subsequent gene silencing. These 
studies have led to the identification of a number of genes that are epigenetically 
silenced by promoter hypermethylation in medulloblastoma (Table 1.9), many of them 
emerging from classical candidate gene approaches. Utilising DNA methylation 
microarray technologies, two recent independent studies have revealed the presence of 
discrete methylomic subgroups of medulloblastoma, and demonstrated that genome-
wide DNA methylation profiles can reliably and reproducibly classify tumours into the 
four core molecular subgroups (SHH, WNT, Group 3 and Group 4). Alongside 
epigenetic classification, the value of DNA methylation biomarkers in disease 
prognostication is being recognised as the number of epigenome-wide studies in 
medulloblastoma increases.  
1.7.1 Gene silencing by promoter hypermethylation in medulloblastoma 
The disruption of DNA methylation at the whole-genome level was first alluded to in 
medulloblastoma by an early study that used restriction landmark genomic scanning 
(RLGS) and reported up to 1% of all CpG islands in primary medulloblastomas and 6% 
in medulloblastoma cell lines to be aberrantly methylated (Fruhwald et al., 2001). This 
was followed by a series of candidate gene-specific investigations to look for evidence 
of methylation-dependent expression in medulloblastoma; individual genes were 
selected for analysis either because they were known to be inactivated by genetic 
mechanisms in medulloblastoma or because they were known to be epigenetically 
inactivated in other cancers (Lindsey et al., 2005). 
Initial methods for interrogating promoter methylation status relied on bisulfite 
conversion of genomic DNA followed by PCR amplification using primers specific for 
either the methylated or unmethylated template (methylation-specific PCR). These 
methods have proved useful to confirm the presence of promoter hypermethylation in a 
number of genes in medulloblastoma, of which HIC1 (Rood et al., 2002), RASSF1A 
(Lusher et al., 2002) and CASP8 (Zuzak et al., 2002) were consistently found to be 
hypermethylated and silenced in primary tumours, and represent the most frequent 
epigenetically inactivated genes in medulloblastoma (Lindsey et al., 2005). While the 
functional significance of their silencing has not been fully investigated in 
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medulloblastoma, studies in other tumour types have provided insights into the 
tumourigenic effect of their loss and HIC1, RASSF1A and CASP8 represent strong 
candidates for tumour suppressor genes in medulloblastoma pathogenesis (Lindsey et 
al., 2005). 
A genome-wide approach based on expression profiling of cells that have been treated 
with the DNA methyltransferase inhibitor, 5’-aza-2’-deoxycytidine (5-azaCdR), has 
been useful in identifying further candidate tumour suppressor genes in 
medulloblastoma. Coupled with 5-azaCdR-induced expression changes, methylation-
specific PCR has identified aberrant promoter methylation and subsequent epigenetic 
inactivation of COL1A2 (Anderton et al., 2008), SPINT2 (Kongkham et al., 2008) and 
the SFRP gene family (SFRP1, SFRP2, SFRP3) (Kongkham et al., 2010a) in primary 
tumours. 
Epigenetic inactivation of COL1A2 has previously been reported in other cancers 
(Sengupta et al., 2003; Chiba et al., 2005). COL1A2 encodes collagen type 1 which is a 
major component of the extracellular matrix, the disruption of which is a frequent event 
in promoting tumour growth and progression (Kalluri and Zeisberg, 2006). Anderton et 
al. identified CpG island promoter hypermethylation associated with COL1A2 silencing 
in the majority (77%) of primary tumours. Interestingly, they identified a subset of 
tumours that were unmethylated at the COL1A2 promoter; these tumours represented 
infant desmoplastic/nodular cases and suggest a disease subgroup-specific role for 
COL1A2 epigenetic regulation in medulloblastoma (Anderton et al., 2008). 
SPINT2 promoter methylation was detected in ~35% of primary medulloblastomas and 
was associated with transcriptional silencing (Kongkham et al., 2008). SPINT2 is a 
negative regulator of HGF/MET signalling, which is known to be dysregulated in 
medulloblastomas (Binning et al., 2008). HGF/MET signalling is disrupted in many 
different cancer types, contributing to tumourigenesis and metastasis through its 
programme of invasive growth signalling (Comoglio et al., 2008). Kongkham et al. 
showed that re-expression of SPINT2 in medulloblastoma cell lines reduced 
proliferation and motility and demonstrated improved survival times in vivo following 
its re-rexpression (Kongkham et al., 2008). Their findings strongly support SPINT2 as a 
putative tumour suppressor gene in medulloblastoma and further implicate 
dysregulation of the HGF/MET signalling pathway in medulloblastoma. 
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The SFRP gene family (SFRP1, SFRP2 and SFRP3) are inhibitors of WNT signalling 
and have been identified as putative tumour suppressor genes silenced by DNA 
methylation (Kongkham et al., 2010a). These findings suggest that epigenetic 
dysregulation of the WNT pathway may complement driver mutations in key pathway 
genes, such as β-catenin, to aberrantly activate WNT signalling. Additional evidence for 
epigenetic dysregulation of key developmental pathways in medulloblastoma comes 
from the PTCH1 gene which is a negative regulator of the SHH pathway. Based on 5-
azaCdR-induced expression changes and assessment of CpG island promoter 
methylation using a denaturation of methylation differences (DAMD) assay (genome-
wide assay based on increased melting temperature of methylated DNA), epigenetic 
silencing of PTCH1 by promoter DNA methylation was demonstrated in 
medulloblastoma (Diede et al., 2010). 
Epigenetic regulation of the S100 gene family has also been investigated in 
medulloblastoma. The S100 family of calcium binding proteins are multifunctional 
proteins involved in a variety of cellular processes including cell growth and cell cycle 
regulation (Lindsey et al., 2007). By assessing 5-azaCdR-induced expression changes, 
Lindsey et al. screened 16 S100 genes for evidence of epigenetic regulation in 
medulloblastoma. Two members, S100A6 and S100A10, demonstrated 
hypermethylation of their CpG island promoter associated with their transcriptional 
silencing in medulloblastoma. For one member, S100A4, a tumour-specific 
hypomethylated pattern was observed which was associated with elevated expression. 
S100A4 does not contain a promoter-associated CpG island, and epigenetic regulation 
of S100A4 in medulloblastoma was associated with hypomethylation of 2 critical 
intragenic CpG sites located within the 1
st
 intron. S100A4 hypomethylation has been 
detected in other cancers (Nakamura and Takenaga, 1998; Rosty et al., 2002), and high 
levels of S100A4 expression have been associated with metastatic progression (Hernan 
et al., 2003). Alongside tumour suppressor gene silencing by promoter 
hypermethylation, aberrant hypomethylation events leading to oncogene activation may 
play a significant role in medulloblastoma pathogenesis. 
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Gene Gene function References 
CDKN2A Cell cycle regulator (Fruhwald et al., 2001) 
RASSF1A Interacts with DNA repair protein 
XPA, inhibits accumulation of 
cyclin D1 and induces cell cycle 
arrest 
(Lusher et al., 2002) 
CASP8 Central role in execution of 
apoptosis 
(Zuzak et al., 2002) 
HIC1 Growth regulator (Rood et al., 2002) 
MCJ (DNAJD1) Hypermethylated in many types 
of cancer, loss of expression 
correlates with increased 
resistance to antineoplastic drugs 
(Lindsey et al., 2006) 
ZIC2 Transcriptional repressor (Pfister et al., 2007) 
S100 family 
(S100A6, S100A10) 
Encodes multifunctional calcium 
binding protein family, involved 
in variety of cellular processes 
including cell growth and cell 
cycle regulation 
(Lindsey et al., 2007) 
SPINT2 Inhibitor of HGF/MET signalling (Kongkham et al., 2008) 
COL1A2 Encodes pro-alpha2 chain of type 
I collagen 
(Anderton et al., 2008) 
SFRP family 
(SFRP 1,2,3) 
Inhibitors of WNT pathway (Kongkham et al., 2010a) 
KLF4 Transcription factor, key 
regulator in embryonic 
development 
(Nakahara et al., 2010) 
PTCH1 Negative regulator of SHH 
pathway 
(Diede et al., 2010) 
Table 1.9. Examples of genes silenced by promoter hypermethylation in medulloblastoma. Gene function and 
reference to the studies in which they were first identified are listed for each gene. Table adapted from Batora et al., 
2013. 
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1.7.2 Genome-wide characterisation of the medulloblastoma methylome 
1.7.2.1 Medulloblastoma comprises four discrete methylomic subgroups 
The current gold standard assay for establishing medulloblastoma subgroup status is 
expression profiling by microarray (Taylor et al., 2012) (see section 1.5.8). 
Recent studies have demonstrated independently that DNA methylation assayed on 
DNA methylation microarrays can accurately and reliably subgroup medulloblastomas 
into the four core molecular subgroups (SHH, WNT, Group 3, Group 4) (Schwalbe et 
al., 2013) (Hovestadt et al., 2013). 
In the first study, a large series of 230 medulloblastomas were profiled on the Illumina 
GoldenGate Cancer Panel I array (see section 1.6.3.3) (Schwalbe et al., 2013). The 
cohort was demographically representative of the disease and all histopathological 
variants were included. Using a non-negative matrix factorization (NMF) (Brunet et al., 
2004) consensus clustering approach, Schwalbe et al. demonstrated the presence of four 
robust DNA methylation subgroups; findings were cross-validated in a training set 
comprised of fresh-frozen tumour extracts, and a test set comprised of DNA extracted 
from formalin-fixed paraffin embedded (FFPE) tissue (Schwalbe et al., 2013). Overall 
216/230 (94%) tumours could be reliably and reproducibly assigned to a subgroup. The 
DNA methylation subgroups showed significant associations with established 
expression subgroup markers, demonstrating that the DNA methylation subgroups and 
gene expression subgroups were closely related (Schwalbe et al., 2013). The DNA 
methylation subgroups were also significantly associated with distinct clinical, 
pathological and genomic features, consistent with those observed for their 
transcriptomic counterparts (Schwalbe et al., 2013).  
In the second study, Hovestadt et al. generated genome-wide methylation profiles of a 
large series of 276 medulloblastomas, comprising both frozen and FFPE samples, on the 
Illumina Infinium 450K array (see section 1.6.3.3) (Hovestadt et al., 2013). Similar to 
the study by Schwalbe et al., this study showed that DNA methylation profiling allows 
robust molecular subgrouping of medulloblastomas from both frozen and FFPE 
samples; four methylomic subgroups were identified that correlated strongly with 
previously defined transcriptomic subgroups of medulloblastoma (Hovestadt et al., 
2013). 
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It is firmly recognised that the four distinct molecular subgroups of medulloblastoma 
will require different therapeutic approaches (Kool et al., 2012; Northcott et al., 2012a). 
Accurate tumour classification in the clinic will therefore be paramount to implement 
future risk stratification models based on molecular features, and for the design and 
implementation of prospective clinical trials assessing personalised and molecularly 
targeted therapies. The DNA methylation profiling studies described here demonstrate 
the clinical utility of DNA methylation to accurately subclassify medulloblastomas 
(Hovestadt et al., 2013; Schwalbe et al., 2013). A DNA-based platform has clear 
advantages over an RNA based platform due to the superior stability of DNA, and also 
performs well on either frozen or FFPE tumour material and small amounts of starting 
material (Hovestadt et al., 2013; Schwalbe et al., 2013). An additional advantage of the 
Infinium 450K array is the ability to generate genome-wide copy-number profiles using 
the intensity measures of the methylation probes, facilitating a more refined molecular 
classification in the clinical setting (Hovestadt et al., 2013).  
1.7.2.2 DNA methylation biomarkers in medulloblastoma 
It is anticipated that, with increasing DNA methylation profiling of well-defined clinical 
trial cohorts of medulloblastomas, an increasing number of methylation biomarkers will 
be identified that will significantly improve and refine disease risk stratification both 
between and within the molecular subgroups.  
In their DNA methylation profiling study, Schwalbe et al. identified two novel 
independent high-risk methylation biomarkers in medulloblastoma (Schwalbe et al., 
2013). Survival analysis was carried out on a cohort of 191 patients that were included 
in the PNET3 clinical trial (see section 1.5.5). Owing to the very good prognosis of the 
WNT subgroup of tumours (see section 1.5.8.2), the prognostic potential of methylation 
events was tested across the non-WNT tumours. MXI1 and IL8 promoter methylation 
were both significantly associated with a worse prognosis in the non-WNT tumours, and 
the addition of these two methylation markers to current stratification models based on 
known clinical and molecular risk variables significantly improved survival prediction 
of favourable-risk and high-risk medulloblastomas (Schwalbe et al., 2013). This 
improved risk stratification model incorporating methylation biomarkers offers the 
potential to more accurately identify favourable-risk patients in the clinic who may 
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benefit from de-escalated treatment regions, while targeting intensified regimens to 
those with high-risk disease. 
Promoter methylation of the hTERT (human telomerase) gene has been identified as a 
clinically useful biomarker for leptomeningeal metastasis detection in cerebrospinal 
fluid (Bougel et al., 2013). Telomerase, the enzyme that maintains telomeres, is active 
in 90% of advanced cancers but not in normal tissues, and promoter hypermethylation 
associated with increased hTERT expression in cancers is well described (Bougel et al., 
2013; Castelo-Branco et al., 2013). Approximately 30% of children show evidence of 
metastatic spread of medulloblastoma at diagnosis (Bailey et al., 1995), with spread 
occurring mainly via the cerebrospinal fluid and leading to a high incidence of spinal 
and of diffuse leptomeningeal seeding (Sure et al., 1995). Early detection of metastastic 
spread is critical to accurate therapeutic stratification (see section 1.5.4). hTERT 
promoter hypermethylation has been detected in medulloblastomas (Castelo-Branco et 
al., 2013). Its detection in the CSF provides an attractive method, as an adjunct to 
routine cytology, for the non-invasive diagnosis of leptomeningeal metastasis at an 
early stage of diagnosis (Bougel et al., 2013). Furthermore, hTERT promoter 
hypermethylation has been shown to correlate with high-grade paediatric brain tumours 
and with tumour progression and poor prognosis (Castelo-Branco et al., 2013). 
As well as the identification of prognostic methylation markers, genome-wide DNA 
methylation profiling of large series of primary medulloblastomas holds significant 
promise for the discovery of novel epigenetically regulated genes that may play key 
roles in driving tumour initiation and progression. The identification of critical 
functional DNA methylation events could help further understanding of tumour 
pathogenesis as well as identify potential epigenetic therapeutic targets. Methylomic 
subclassification of medulloblastoma could enable a refined discovery of critical 
methylation events that are specific to the development of distinct subgroups of the 
disease.  
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1.8 Summary and aims 
Medulloblastoma is the most common malignant brain tumour of childhood and 
accounts for approximately 10% of all childhood cancer deaths. While 5-year survival 
rates of ~80% have been achieved using current clinical risk stratification models, there 
remains a proportion of high-risk cases for which prognosis is very poor. Furthermore, 
survivors of medulloblastoma suffer considerable long-term adverse effects associated 
with their treatment. Significant advances have been made in understanding 
medulloblastoma genomics, and have led to the recognition of medulloblastoma as a 
disease that comprises four core transcriptomic subgroups (SHH, WNT, Group 3 and 
Group 4). The subgroups of medulloblastoma are associated with distinct clinical 
behaviours and genetic features and will, therefore, require different therapeutic 
strategies in the clinic. 
While molecular subclassification is beginning to inform treatment of medulloblastoma, 
more insights need to be gained from the underlying molecular pathology of the 
different disease subgroups, to identify critical driver events that could potentially be 
targeted therapeutically. Group 3 and Group 4 medulloblastomas are less well-defined 
molecularly compared with the SHH and WNT subgroups. Group 3 and Group 4 
tumours have not been found to be associated with specific signalling pathways and 
whole exome and whole genome sequencing studies have not identified high frequency 
driver mutational events. Group 3 tumours carry a dismal prognosis and Group 4, the 
largest subgroup, comprises subsets of tumours with poor clinical outcome. There is an 
urgent need to understand the molecular defects that are driving these particularly 
aggressive phenotypes and to develop better therapies to improve survival. 
The role of the epigenome in medulloblastoma is increasingly being recognised, and the 
diversity of genetic/epigenetic interactions is beginning to be more fully understood. 
Recent whole exome and whole genome sequencing studies have estimated that at least 
one third of all medulloblastomas are affected by mutations in genes that regulate 
chromatin structure and function. Such events have the potential to widely alter the 
transcriptome of medulloblastomas. Furthermore, dysregulation of chromatin modifiers 
was found to be subgroup-specific and was a significant feature of Group 3 and Group 4 
tumours, suggesting that epigenetic processes may be crucial in their development. 
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DNA methylation plays a key role in epigenetic transcriptional regulation. Tumour 
suppressor genes that are silenced by promoter DNA methylation in medulloblastoma 
have been known for quite some time. Many of these genes were identified using classic 
candidate gene approaches and did not recognise the distinct subgroups of 
medulloblastoma. 
Significant advances have been made in the technologies used to study DNA 
methylation, and it is now possible to interrogate this epigenetic mark at single base-
pair resolution and on a genome-wide scale. Profiling primary medulloblastomas on 
DNA methylation microarrays has revealed the existence of four methylomic subgroups 
of the disease that are strongly associated with their transcriptomic counterparts (SHH, 
WNT, Group 3 and Group 4). The methylomic subgroups of medulloblastoma hold 
considerable promise for the refined discovery of DNA methylation events that are 
associated with gene expression, and that may play a critical role in the development of 
distinct disease subgroups and may potentially be targeted therapeutically. 
The genome-wide role of DNA methylation in medulloblastoma subgroups has not been 
widely investigated. Furthermore, the majority of studies to date have focused on 
promoter-associated CpG island methylation. As an increasing number of cancer 
methylomes are being characterised, roles for DNA methylation outside of the gene 
promoter and outside of CpG islands are being recognised. An unbiased assessment of 
CpG methylation in distinct medulloblastoma subgroups must be undertaken to fully 
comprehend the gene-wide role of DNA methylation in medulloblastoma development. 
1.8.1 Aims 
This project aimed to investigate the role of DNA methylation in distinct subgroups of 
medulloblastoma, using two high-throughput screening approaches: 
1.  In the first approach, detailed in Chapter 3, the specific aims were: 
 to identify Group 3 and/or Group 4-specific DNA methylation 
events using methylation profiles generated for a large cohort of 
primary medulloblastomas on the Illumina GoldenGate Cancer 
Panel I methylation microarray, and  
 to investigate their association with gene expression in Group 3 
and/or Group 4 tumours and in medulloblastoma cell lines treated 
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with the demethylating agent 5’-aza-2’-deoxycytidine (5-
azaCdR). 
2. In the second approach, detailed in Chapter 4, the specific aims were: 
 to identify candidate epigenetically regulated genes using a 
functional epigenomics analysis of gene expression alterations in cell 
lines following 5-azaCdR treatment, combined with a genome-wide 
assessment of DNA methylation, and  
 to investigate them further for evidence of subgroup-specific 
differential methylation concordant with differential gene expression 
and epigenetic gene regulation in primary tumours. 
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Chapter 2 Materials and methods 
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2.1 Primary tumour cohorts 
2.1.1 Primary medulloblastoma cohort 1 
Cohort 1, a representative cohort of 216 primary medulloblastomas (Table 2.1), was 
used for investigations reported in Chapter 3. The cohort comprised 75 (35%) 
medulloblastomas collected in Newcastle, UK (designated with the prefix NMB); 12 
(5%) medulloblastomas kindly provided by Dr. Richard Gilbertson (Department of 
Developmental Neurobiology, St. Jude Children’s Research Hospital, Memphis, TN, 
USA) (prefixed RJG) and 129 (60%) medulloblastomas from the PNET3 clinical trials 
cohort (prefixed PNET3). The SIOP/UKCCSG PNET3 (Primitive neuro-ectodermal 
tumour 3) clinical trial took place from March 1992 to January 2000 and recruited 
patients from across Europe aged from 3 to 16 years and defined as standard-risk. 
Patients were placed into one of two treatment arms (radiotherapy alone versus 
application of chemotherapy prior to radiotherapy). The study reported no statistically 
significant difference in overall survival for standard-risk patients treated with pre-
radiation chemotherapy compared with those treated with radiotherapy alone (Taylor et 
al., 2003b). 
The histological subtypes of cohort 1, according to the current WHO classification 
(Louis et al., 2007) (see section 1.5.1), comprised 169 (78%) classic, 21 (10%) LCA, 1 
(0.5%) MBEN and 25 (12%) DN tumours. Histological variants were confirmed on 
review by Professor David Ellison (Chair of Pathology, St. Jude Children’s Research 
Hospital, Memphis, TN, USA). There were 14 (6.5%) infant cases (< 3 years at 
diagnosis), 195 (90.5%) children (3-15 years) and 7 (3%) adults (≥16 years). The 
median age at diagnosis was 8.4 years. The cohort comprised 131 (61%) male and 85 
(39%) female cases, with a male: female ratio of 1.5:1. M stage classification, as 
defined by the Chang staging system (Chang et al., 1969) (see section 1.5.3) was 
available for most cases; M0 and M1 cases were assigned M negative status, while M2 
and M3 cases were assigned M positive status. There were no M4 cases identified in the 
cohort. The majority of tumours were M-negative (167/207 (81%)), while 40 cases 
(19%) were M-positive. Patient age, sex and M stage data were kindly collated and 
provided by Professor Simon Bailey (Newcastle University Paediatric Brain Tumour 
Research Group).  
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DNA methylation profiles of the primary tumours in cohort 1 were assessed on the 
high-throughput Illumina GoldenGate Cancer panel I methylation microarray platform 
(see section 2.7.2). The 216 primary medulloblastomas were reliably subclassified 
according to their methylation profiles by Dr. Ed Schwalbe (Newcastle University 
Paediatric Brain Tumour Research Group). Dr. Schwalbe demonstrated by cross-
validation in training and test cohorts that medulloblastoma comprises four robust DNA 
methylation subgroups (SHH, WNT, Group 3 and Group 4) that are strongly associated 
with the four principal transcriptomic subgroups of the same nomenclature and which 
have distinct molecular, clinical and pathological disease features (Schwalbe et al., 
2013). The proportion of tumours classified in each methylomic subgroup was 
comparable to those described for their transcriptomic counterparts (Kool et al., 2012). 
Group 4 tumours formed the largest group (44% [94 tumours]), followed by SHH (23% 
[50 tumours]) and Group 3 (20% [44 tumours]). WNT tumours represented the smallest 
group (13% [28 tumours]) (Schwalbe et al., 2013) (Table 2.1). 
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NMB112 43.0 F CLAS 0 SHH 
NMB138 3.3 M CLAS 0 SHH 
NMB141 11.7 F CLAS 0 SHH 
NMB143 2.8 M LCA 0 SHH 
NMB148 1.6 M CLAS 0 SHH 
NMB154 4.7 M CLAS 0 SHH 
NMB156 7.3 M DN 0 SHH 
NMB159 22.8 M DN NA SHH 
NMB181 8.4 M DN 0 SHH 
NMB200 1.3 F DN 0 SHH 
NMB202 40.0 F DN 0 SHH 
NMB253 0.4 M DN 0 SHH 
NMB33 1.5 F DN 0 SHH 
NMB64 1.5 F MBEN 0 SHH 
NMB79 3.5 F CLAS 1 SHH 
NMB81 14.2 F DN 0 SHH 
RJG112 0.7 F DN 0 SHH 
RJG116 19.0 M DN 0 SHH 
RJG126 2.6 M DN 1 SHH 
RJG127 4.8 F DN 0 SHH 
RJG142 1.0 F DN 0 SHH 
PNET30113 4.1 F CLAS 0 SHH 
PNET30124 6.2 F LCA 0 SHH 
PNET30160 8.8 F DN 0 SHH 
PNET30165 12.4 M CLAS 0 SHH 
PNET30175 5.4 F CLAS 0 SHH 
PNET30179 3.5 F CLAS 0 SHH 
PNET30185 10.3 M CLAS 0 SHH 
PNET30019 15.4 M CLAS 0 SHH 
PNET30193 7.3 F LCA 0 SHH 
PNET30195 6 F DN 0 SHH 
PNET30199 15.5 F DN 0 SHH 
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PNET30201 6.6 M LCA 0 SHH 
PNET30030 14.6 M DN 0 SHH 
PNET30035 11 M CLAS 0 SHH 
PNET30038 10.8 F LCA 0 SHH 
PNET30044 9.2 M DN 0 SHH 
PNET30047 7.3 M DN 0 SHH 
PNET350011 13.4 M CLAS 0 SHH 
PNET350019 15.4 M CLAS 0 SHH 
PNET350021 14 M CLAS 1 SHH 
PNET350063 5.3 F CLAS 0 SHH 
PNET350091 4.4 M CLAS 1 SHH 
PNET350104 5.4 M LCA 1 SHH 
PNET350116 3.8 F CLAS 0 SHH 
PNET350165 14 F CLAS 0 SHH 
PNET350176 7.8 F DN 0 SHH 
PNET350218 3.4 M DN 0 SHH 
PNET350290 9.7 F CLAS 0 SHH 
PNET350075 8 F CLAS 0 SHH 
NMB131 10.3 M CLAS 0 WNT 
NMB135 11.2 F CLAS 0 WNT 
NMB139 12.7 M CLAS 0 WNT 
NMB93 10 M CLAS 0 WNT 
NMB94 9.0 F CLAS 0 WNT 
PNET30119 15.8 M CLAS 0 WNT 
PNET30131 5.4 F LCA 0 WNT 
PNET30139 7.6 F CLAS 0 WNT 
PNET30147 10.8 F CLAS 0 WNT 
PNET350129 9.9 M CLAS 0 WNT 
PNET30112 7.1 F CLAS 0 WNT 
PNET30137 13.4 M LCA 0 WNT 
PNET30152 10.2 F CLAS 0 WNT 
PNET30172 8.4 M CLAS 0 WNT 
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PNET30180 9.9 M CLAS 0 WNT 
PNET30002 12.8 F CLAS 0 WNT 
PNET30202 9.7 F CLAS 0 WNT 
PNET30028 7.2 F CLAS 1 WNT 
PNET30039 8.5 F CLAS 0 WNT 
PNET350045 6.8 M CLAS 0 WNT 
PNET350056 10.8 M CLAS 0 WNT 
PNET350075 8 F CLAS 0 WNT 
PNET350080 10.3 M CLAS 0 WNT 
PNET350090 10.3 F CLAS 0 WNT 
PNET350170 10.9 F CLAS 1 WNT 
PNET30051 7.5 F CLAS 0 WNT 
PNET30052 9.4 M CLAS 0 WNT 
PNET30009 6.3 F CLAS 0 WNT 
NMB136 10.5 M CLAS 1 Group 3 
NMB147 19.6 M CLAS 0 Group 3 
NMB153 3.3 M CLAS NA Group 3 
NMB157 5.4 M DN 1 Group 3 
NMB164 7.1 F LCA 0 Group 3 
NMB168 9.8 F LCA 0 Group 3 
NMB169 8.9 M LCA 0 Group 3 
NMB17 4.0 M CLAS 0 Group 3 
NMB171 7.7 M CLAS NA Group 3 
NMB188 8.6 F CLAS NA Group 3 
NMB227 4.0 M CLAS 1 Group 3 
NMB60 5.0 M CLAS 0 Group 3 
NMB65 9.3 M CLAS 0 Group 3 
NMB89 4.6 F CLAS 0 Group 3 
RJG113 2.5 M LCA 1 Group 3 
RJG121 4.1 M LCA 0 Group 3 
RJG122 2.5 M LCA 0 Group 3 
RJG131 5.7 F DN 1 Group 3 
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RJG135 3.6 F CLAS 0 Group 3 
PNET30105 8.3 M CLAS 0 Group 3 
PNET30106 6.4 M CLAS 0 Group 3 
PNET30116 9.5 M CLAS 0 Group 3 
PNET30012 4.7 M CLAS 0 Group 3 
PNET30120 6.3 M CLAS 0 Group 3 
PNET30129 7.9 M LCA 1 Group 3 
PNET30018 3.4 M CLAS 0 Group 3 
PNET30210 4.6 M CLAS 0 Group 3 
PNET30031 7.2 M CLAS 0 Group 3 
PNET30048 14.4 M CLAS 0 Group 3 
PNET350010 5.9 M CLAS 0 Group 3 
PNET350034 14.3 M CLAS 0 Group 3 
PNET350049 13.1 F LCA 1 Group 3 
PNET350106 7.9 F CLAS 1 Group 3 
PNET350124 7.1 M CLAS 1 Group 3 
PNET350137 6 F CLAS 0 Group 3 
PNET350150 5.1 M CLAS 1 Group 3 
PNET350166 10.6 M CLAS 0 Group 3 
PNET350169 3.1 M LCA 1 Group 3 
PNET350172 5.4 M CLAS 0 Group 3 
PNET350174 12.5 M CLAS 1 Group 3 
PNET350184 11.8 M CLAS 0 Group 3 
PNET350248 3.9 M CLAS 0 Group 3 
PNET350256 4.2 M CLAS 1 Group 3 
PNET350259 9.1 M CLAS 1 Group 3 
NMB109 8.0 M CLAS 0 Group 4 
NMB110 10.0 F CLAS 0 Group 4 
NMB111 10.0 M CLAS 0 Group 4 
NMB125 6.0 F CLAS NA Group 4 
NMB126 8.4 F CLAS NA Group 4 
NMB129 5.7 M LCA NA Group 4 
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NMB134 4.9 M CLAS 1 Group 4 
NMB140 9.4 M CLAS 0 Group 4 
NMB142 12.1 M CLAS 1 Group 4 
NMB144 5.1 M CLAS 1 Group 4 
NMB149 6.3 M LCA NA Group 4 
NMB151 9.8 M CLAS 1 Group 4 
NMB152 0.5 M CLAS 0 Group 4 
NMB155 19.8 M CLAS NA Group 4 
NMB16 0.1 M CLAS 0 Group 4 
NMB162 5.1 M CLAS 0 Group 4 
NMB165 12.7 M CLAS 0 Group 4 
NMB166 9.7 F CLAS 0 Group 4 
NMB167 6.5 F CLAS 0 Group 4 
NMB180 10.7 M CLAS 0 Group 4 
NMB184 8.6 M CLAS 0 Group 4 
NMB185 14.0 M CLAS 1 Group 4 
NMB186 8.0 M CLAS 0 Group 4 
NMB187 3.7 M CLAS 0 Group 4 
NMB189 8.6 M CLAS 0 Group 4 
NMB190 11.7 M CLAS 1 Group 4 
NMB199 9.8 M CLAS 1 Group 4 
NMB203 6.2 M CLAS 0 Group 4 
NMB252 13.1 F CLAS 0 Group 4 
NMB254 1.5 F DN 0 Group 4 
NMB43 9.0 M CLAS 0 Group 4 
NMB45 12.6 M CLAS 0 Group 4 
NMB51 6.8 M CLAS 0 Group 4 
NMB52 8.6 F CLAS 0 Group 4 
NMB76 7.5 M CLAS 0 Group 4 
NMB77 8.5 F CLAS 0 Group 4 
NMB78 5.5 M CLAS 1 Group 4 
NMB80 10.2 F CLAS 0 Group 4 
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NMB82 5.4 M CLAS 0 Group 4 
NMB88 17.0 F CLAS 0 Group 4 
PNET30146 9.1 F CLAS 0 Group 4 
RJG124 6.3 M DN 1 Group 4 
RJG141 9.8 F CLAS 0 Group 4 
PNET30107 5.9 F CLAS 0 Group 4 
PNET30121 13.2 M CLAS 0 Group 4 
PNET30126 8.4 M CLAS 0 Group 4 
PNET30013 9.9 M CLAS 0 Group 4 
PNET30132 5.1 F CLAS 0 Group 4 
PNET30134 8.4 M LCA 0 Group 4 
PNET30145 5.0 M CLAS 0 Group 4 
PNET30015 12.9 M CLAS 0 Group 4 
PNET30161 8.1 M CLAS 0 Group 4 
PNET30164 8.3 F CLAS 0 Group 4 
PNET30166 8.6 M CLAS 0 Group 4 
PNET30186 11.6 F CLAS 0 Group 4 
PNET30191 7.8 M LCA 0 Group 4 
PNET30033 8.8 F CLAS 0 Group 4 
PNET350015 4.6 F CLAS 1 Group 4 
PNET350035 9.9 F CLAS 0 Group 4 
PNET350040 15.6 M CLAS 0 Group 4 
PNET350044 8.1 M CLAS 0 Group 4 
PNET350057 14.0 M CLAS 0 Group 4 
PNET350058 11.6 M CLAS 1 Group 4 
PNET350068 6.3 F CLAS 1 Group 4 
PNET350088 15.2 F CLAS 0 Group 4 
PNET350099 13.0 F CLAS 0 Group 4 
PNET350132 14.1 M CLAS 0 Group 4 
PNET350133 9.5 F CLAS 0 Group 4 
PNET350136 12.1 M CLAS 0 Group 4 
PNET350142 9.4 F CLAS 1 Group 4 
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PNET350147 5.3 M CLAS 0 Group 4 
PNET350161 6.8 F CLAS 0 Group 4 
PNET350163 6.8 F CLAS 0 Group 4 
PNET350167 6.9 F CLAS 0 Group 4 
PNET350189 14.3 M CLAS 0 Group 4 
PNET350193 14.1 F CLAS 0 Group 4 
PNET350198 9.5 M CLAS 1 Group 4 
PNET350208 9.7 F CLAS 1 Group 4 
PNET350209 9.1 M CLAS 0 Group 4 
PNET350212 10.8 M CLAS 1 Group 4 
PNET350217 9.5 M CLAS 1 Group 4 
PNET350224 14.9 M CLAS 0 Group 4 
PNET350241 13.1 M CLAS 1 Group 4 
PNET350244 14.1 M CLAS 0 Group 4 
PNET350253 9.6 M CLAS 0 Group 4 
PNET350254 5.6 F CLAS 0 Group 4 
PNET350284 11.2 M CLAS 0 Group 4 
PNET350292 3.3 M CLAS 1 Group 4 
PNET30054 6.2 M CLAS 0 Group 4 
PNET30062 6.6 M CLAS 0 Group 4 
PNET30065 5.7 F CLAS 0 Group 4 
PNET30066 5.9 M CLAS 0 Group 4 
PNET30072 7.6 F CLAS 0 Group 4 
PNET30083 4.5 F CLAS 0 Group4 
Table 2.1. Primary medulloblastoma cohort 1 clinical data. Patient ID, age in years at diagnosis and sex are 
shown. Histological subtype is coded as follows: CLAS- classic; LCA- large cell/anaplastic; DN- 
desmoplastic/nodular; MBEN- MB with extensive nodularity. M stage is coded as follows: (0)– M-negative status 
(Chang stage M0/M1); (1) – M- positive status (Chang stage M2/M3). Tumours were subclassified into 4 principal 
methylomic subgroups (SHH, WNT, Group 3, Group 4) according to their Illumina GoldenGate methylation profiles. 
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2.1.2 Primary medulloblastoma cohort 2 
Primary medulloblastoma cohort 2, detailed in Table 2.2, was used for investigations 
reported in Chapter 4. It was a representative cohort comprising 109 primary 
medulloblastomas. With the exception of one PNET3 case (PNET30200), the cohort 
comprised NMB tumours collected in Newcastle, UK. The histological subtypes of 
cohort 2, according to the current WHO classification (Louis et al., 2007) (see section 
1.5.1), comprised 76 (70%) classic, 17 (15.5%) LCA, 3 (3%) MBEN and 9 (8%) DN 
tumours. There were 4 (3.5%) medulloblastoma tumours whose histology was 
ambiguous and they could not be classified according to the WHO criteria. These 
tumours were classified MB-NOS (medulloblastoma- not otherwise specified). The 
histological variant for 88 tumours (81%) was centrally reviewed and confirmed by a 
panel of 3 expert neuropathologists. The remaining cases (19%) had their histology 
determined locally at their treatment centre. There were 19 (17.5%) infant cases (< 3 
years at diagnosis), 82 (75%) children (3-15 years) and 8 (7.5%) adults (≥16 years). The 
median age at diagnosis was 6 years. The cohort comprised 67(61.5%) male and 42 
(38.5%) female cases, with a male: female ratio of 1.6:1. M stage classification, as 
defined by the Chang staging system (Chang et al., 1969) (see section 1.5.3) was 
available for most cases; M-negative status was assigned to 69/104 tumours (66%) , 
while 35 cases (34%) were M-positive. Patient age, sex and M stage data were again 
kindly collated and provided by Professor Simon Bailey (Newcastle University 
Paediatric Brain Tumour Research Group).  
DNA methylation profiles of the primary tumours in cohort 2 were assessed on the 
genome-wide Illumina 450K methylation microarray platform (see section 2.7.3). Using 
the same methodologies previously described for the GoldenGate methylation 
microarray (Schwalbe et al., 2013), the 109 primary tumours were reliably subclassified 
into the 4 principal molecular subgroups (SHH, WNT, Group 3, Group 4) according to 
their 450K methylation profiles by Dr. Ed Schwalbe (Newcastle University Paediatric 
Brain Tumour Research Group). The proportion of tumours classified in each 
methylomic subgroup was comparable to those described for their transcriptomic 
counterparts (Kool et al., 2012). Group 4 formed the largest group (34% [37 tumours]), 
followed by SHH (27% [29 tumours]) and Group 3 (27% [30 tumours]). WNT tumours 
represented the smallest group (12% [13 tumours]) (Table 2.2). 
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NMB138 3.3 M CLAS 0 SHH 
NMB168 9.8 F LCA 0 SHH 
NMB254 1.4 F DN 0 SHH 
NMB324 0.7 M CLAS NA SHH 
NMB460 3.9 M DN 0 SHH 
NMB465 1.5 F MBEN 1 SHH 
NMB471 0.9 F MBEN 1 SHH 
NMB483 1 M MBEN 1 SHH 
NMB555 0.3 F MB-NOS 1 SHH 
NMB612 2.5 F DN 0 SHH 
NMB625 0.3 F CLAS 0 SHH 
NMB670 1 M CLAS 1 SHH 
NMB674 2.6 F DN 0 SHH 
NMB690 2.6 M DN 1 SHH 
NMB108 35 F CLAS 1 SHH 
NMB112 43 F CLAS 0 SHH 
NMB147 19.6 M CLAS 0 SHH 
NMB156 7.3 M DN 0 SHH 
NMB18 20.3 M DN NA SHH 
NMB347 9.7 M CLA 0 SHH 
NMB370 6.4 F CLA 0 SHH 
NMB408 17.6 M LCA 1 SHH 
NMB435 14.8 M DN 1 SHH 
NMB437 14.2 F CLA 1 SHH 
NMB548 14.5 M LCA 0 SHH 
NMB549 5.6 F LCA 0 SHH 
NMB645 12.3 M MB-NOS 0 SHH 
NMB719 7.4 M LCA 1 SHH 
NMB738 9.82 F CLA 1 SHH 
NMB131 10.4 M CLAS 0 WNT 
NMB139 12.7 M CLAS 0 WNT 
NMB191 14.4 M CLAS 0 WNT 
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NMB264 5.1 F CLAS 1 WNT 
NMB380 7.8 M CLAS 1 WNT 
NMB389 16.6 F CLAS 0 WNT 
NMB390 16.6 M CLAS 0 WNT 
NMB409 8.8 F LCA 0 WNT 
NMB417 8.6 M CLAS 0 WNT 
NMB436 4.9 M CLAS 0 WNT 
NMB458 16 F LCA 0 WNT 
NMB649 6 F CLAS 0 WNT 
NMB94 9.4 F CLAS 0 WNT 
NMB127 13.6 M LCA 0 Group 3 
NMB169 8.9 M LCA 0 Group 3 
NMB17 4.7 M CLAS 0 Group 3 
NMB176 4.3 F CLAS 0 Group 3 
NMB184 8.5 M CLAS 0 Group 3 
NMB188 8.6 F CLAS NA Group 3 
NMB277 15.1 F CLAS 1 Group 3 
NMB329 3.3 M CLAS 1 Group 3 
NMB330 4.7 M CLAS 0 Group 3 
NMB335 4.2 M LCA 0 Group 3 
NMB344 5 M CLAS 1 Group 3 
NMB374 0.6 F CLAS 0 Group 3 
NMB381 4.6 M CLAS 1 Group 3 
NMB384 4.5 M MB-NOS 0 Group 3 
NMB411 15.8 M CLAS 1 Group 3 
NMB440 5.6 M LCA 1 Group 3 
NMB459 4.4 M CLAS 1 Group 3 
NMB484 1.2 M CLAS 0 Group 3 
NMB490 1.9 F LCA 1 Group 3 
NMB519 4.2 M LCA 0 Group 3 
NMB535 2 M MB-NOS 1 Group 3 
NMB536 8.4 M CLAS 0 Group 3 
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NMB60 5 M CLAS 0 Group 3 
NMB610 8.8 M CLAS 0 Group 3 
NMB633 4.5 F CLAS 0 Group 3 
NMB666 2.2 M CLAS 1 Group 3 
NMB684 2.6 F CLAS 1 Group 3 
NMB762 0.8 M CLAS 1 Group 3 
NMB783 3.4 F CLAS NA Group 3 
PNET30200 5.2 M LCA 0 Group 3 
NMB109 8 M CLAS 0 Group 4 
NMB110 10 F CLAS 0 Group 4 
NMB125 6 F CLAS 0 Group 4 
NMB126 8.4 F CLAS NA Group 4 
NMB132 9.3 M CLAS 0 Group 4 
NMB134 4.9 M CLAS 1 Group 4 
NMB142 12.1 M CLAS 1 Group 4 
NMB151 9.8 M CLAS 1 Group 4 
NMB166 9.7 F CLAS 0 Group 4 
NMB173 9.1 M CLAS 0 Group 4 
NMB178 5 M CLAS 1 Group 4 
NMB189 11.4 M CLAS 0 Group 4 
NMB203 6.2 M CLAS 0 Group 4 
NMB250 4.7 M CLAS 0 Group 4 
NMB260 11.3 F CLAS 0 Group 4 
NMB262 13.3 F CLAS 0 Group 4 
NMB266 7.9 M LCA 0 Group 4 
NMB283 7.5 M LCA 0 Group 4 
NMB360 11 M CLAS 1 Group 4 
NMB365 4.6 M CLAS 0 Group 4 
NMB368 11.8 M CLAS 0 Group 4 
NMB373 5.2 M CLAS 1 Group 4 
NMB401 5.7 M CLAS 1 Group 4 
NMB403 5.9 M CLAS 1 Group 4 
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NMB410 15.6 M CLAS 0 Group 4 
NMB416 4.6 F CLAS 0 Group 4 
NMB438 5 M CLAS 0 Group 4 
NMB445 7.8 M DN 0 Group 4 
NMB457 4.7 F CLAS 0 Group 4 
NMB529 8 F LCA 0 Group 4 
NMB531 2.7 F CLAS 0 Group 4 
NMB632 4.8 M CLAS 0 Group 4 
NMB713 4.9 F CLAS 0 Group 4 
NMB715 4.6 F CLAS 0 Group 4 
NMB716 3 F CLAS 0 Group 4 
NMB77 8.5 F CLAS 1 Group 4 
NMB82 5.4 M CLAS 0 Group 4 
Table 2.2. Primary medulloblastoma cohort 2 clinical data. Patient ID, age in years at diagnosis and sex are 
shown. Histological subtype is coded as follows: CLAS- classic; LCA- large cell/anaplastic; DN- 
desmoplastic/nodular; MBEN- MB with extensive nodularity; MB-NOS-MB-not otherwise specified. M stage is 
coded as follows: (0)– M-negative status (Chang stage M0/M1); (1) – M- positive status (Chang stage M2/M3). 
Tumours were subclassified into 4 principal methylomic subgroups (SHH, WNT, Group 3, Group 4) according to 
their Illumina 450K methylation profiles. 
 
2.2 Medulloblastoma cell lines 
The origins and karyotypes of the medulloblastoma cell lines used in this project are 
provided in Table 2.3.  
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Cell line Reference Cell line derived from Karyotypes Probable molecular 
subgroup 
Med1 (MHH-
Med-1) 
(Pietsch et al., 
1994) 
Male, 10 years;  establishd from cells recovered from CSF of patient 
with relapsed cerebellar PNET 
Near diploid stem line karyotypes with clonal structural abnormalities. Partial trisomy of 1q; 46, XY; +del(1)(p22), add(4)(p160, -
9, t(10;13)(q24-26;q14) 
Group3/SHH 
Med8A No reference Male; no other data Incomplete karyotype only. Near triploid chromosome number with multiple structural abnormalities; i17q, dmin Group 3 
DAOY (Jacobsen et al., 
1985) 
Male, 4 years; established from a biopsy of a solid mass tumour 
removed from the posterior fossa. Diagnosed as desmoplastic 
medulloblastoma. 
89 to 196 chromosomes. 95% of cells were tetraploid, remainder near octoploid. Del(1)(q32) with inv(1)(q23q32); del(1)(p13); 
del(3)(p21); t(1q5q); del(6)(q15q25); del(7)(q32); t(1;7)(q32;q36), t(5p8q), t(3;9)(p21;q34), i(13q); 15p+; del(20)(q12q13); i(21q). 
Absence of Y (90%), monosomy of 22, 2 copies of 4, trisomy of 10, duplicate X, small number of dmin 
Group 3/SHH 
D283 (D283 
Med) 
(Friedman et al., 
1985) 
Male, 6 years; derived from the peritoneal implant and malignant 
ascitic fluid of patient with metastatic medulloblastoma. 
47 chromosomes, including 3 marker chromosomes, 8q+, 17p+, 20q+ Group 3 
D341 (Friedman et al., 
1988) 
3.5 years; derived from large cerebellar midline mass at 
craniectomy,interpreted histologically as medullblastoma. Patient 
subsequently developed metastatic lesions (4 months post diagnosis) 
47, XY; +del(1)(p13), +8, i(17)(q10), -22, dmin Group 3 
D384 (D384 
Med) 
(He et al., 1991) Male, 18 months; taken from the posterior fossa and massive 
leptomeningeal metastases. Large cell, anaplastic tumour. 
45, X; -Y, -8, +der(8)t(1;8)(p11;q24), dmin Group 3 
D556 (Aldosari et al., 
2002b) 
Female, 7 years; Large cell, anaplastic tumour. 46, XX;  +1, dic(1;13)(p11.1;q34), i(17)(q10), dmin Group 3 
D425 (D425 
Med) 
(He et al., 1991) Male, 6 years; taken from posterior fossa 46, XY;  del(10)(q22), i(17)(q10), dmin, cells contained 76-78 chromosomes Group 3 
D458 (D458 
Med) 
(He et al., 1991) Male, 6 years; obtained from tumour cells that had spread to the CSF 
of the D425 Med patient, 6 months postdiagnosis, after radiation and 
chemotherapy had failed. 
46, XY; del(3)(p11), del(6)(q21q25), del(10)(q22), i(17)(q10), dmin,  cells contained 76-78 chromosomes Group 3 
UW228-2 (Keles et al., 1995) Female, 9 years; midline posterior fossa mass involving cerebellar 
vermis. Histological examination revealed hallmarks of 
medulloblastoma. 
59, XX; +1,+7, +9, +15, +17, +19, +20, +21, +4mar Group 3/SHH 
UW228-3 (Keles et al., 1995) Female, 9 years; midline posterior fossa mass involving cerebellar 
vermis. Histological examination revealed hallmarks of 
medulloblastoma. 
58, XX; +1, +7, +9, +15, +19, +20, +21, +4mar Not profiled on 450K 
methylation array 
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Table 2.3. Medulloblastoma cell line origins and karyotypes. Abbreviations: CSF, cerebrospinal fluid; del, deletion; add, additional; -, chromosome absent; I, isochromosome; t, translocation; amp, 
amplification; mar, marker chromosome; dmin, double minute. MHH-Med-1 and MEB-Med8A were kind gifts from Professor T. Pietsch, University of Bonn Medical Centre, Germany. D458 Med, 
D384 Med and D556 Med were kindly provided by Dr. D. Bigner, Duke University, USA. UW228-2 and UW228-3 were kind gifts from Dr. J. R. Silber, University of Washington, USA. DAOY, D283 
Med, D341 Med were obtained from the American Type Culture Collection. Medulloblastoma cell line origins and karyotypes adapted from (Langdon et al., 2006). DNA methylation profiles for 10 cell 
lines were assessed on the genome-wide Illumina 450K methylation microarray. Probable molecular subgroup based on DNA methylation patterns is shown. For 7 cell lines their DNA methylation 
patterns clustered with medulloblastoma Group 3 primary tumours. DNA methylation patterns for Med1, DAOY and UW228-2 clustered between Group 3 and SHH tumour subgroups (Ed Schwalbe, 
Newcastle Paediatric Brain Tumour Group; unpublished data). 
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2.3 Non-neoplastic cerebellar samples 
The methylation profiles of 21 non-neoplastic cerebellar samples were assessed on the 
GoldenGate methylation microarray platform (see section 2.7.2) and used for 
investigations reported in Chapter 3. The cohort comprised 4 foetal, 12 infant 
(newborn–25 months) and 4 adult (43 years-68 years) samples, with the age of 1 patient 
sample unknown. The methylation profiles of 17 non-neoplastic cerebellar samples 
were assessed on the 450K methylation microarray platform (see section 2.7.3) and 
used for investigations reported in Chapter 4. The cohort comprised 3 foetal, 10 infant 
(newborn–25 months) and 3 adult (43 years–67 years) samples, with the age of 1 
sample unknown. All samples consisted of post-mortem material from patients who 
died of non-neoplastic conditions. 
2.4 Primary medulloblastoma transcriptomic datasets 
Gene expression microarray data was available for 4 independent primary 
medulloblastoma cohorts: 
 Kool dataset; comprised 62 primary tumours assayed on the Affymetrix 
U133+2 microarray platform (Kool et al., 2008).  
 Fattet dataset; comprised 40 primary tumours assayed on the 
Affymetrix U133+2 microarray platform (Fattet et al., 2009). 
 Cho dataset; comprised 204 primary tumours assayed on the Affymetrix 
U133A platform (Cho et al., 2011). 
 Northcott dataset; comprised 103 primary tumours assayed on the 
Affymetrix Exon 1.0ST array (Northcott et al., 2011b). 
The Kool, Fattet and Northcott datasets were available from Gene Expression Omnibus 
(GEO) (www.ncbi.nlm.nih.gov/geo; GSE10327, GSE12992 and GSE21140, 
respectively) and were downloaded into the statistical computing program R (v 2.12) (R 
foundation) using the GEOquery package available from the Bioconductor website 
(www.bioconductor.org). The Cho dataset was kindly provided by Dr. Dan Williamson 
(Newcastle University Paediatric Brain Tumour Group). Raw data (.CEL files) for the 
Kool and Fattet datasets, both analysed on the U133+2 platform, were downloaded from 
GEO and normalised together (hereafter referred to as the Kool/Fattet dataset) using  the 
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Robust Multi-array Average (RMA) normalisation approach for raw Affymetrix data 
(Irizarry et al., 2003). Supporting annotation packages for the Affymetrix U133+2 
(hgu133plus2.db) and the U133A (hgu133a.db) platforms were downloaded into R (v 
2.12) from the Bioconductor website. The annotation data file for the gene-level 
transcript cluster identifiers in the Affymetrix exon array was downloaded from the 
Affymetrix website (www.affymetrix.com/). The annotation files contained functional 
annotation data assigned by Affymetrix and facilitated the mapping of Affymetrix probe 
identifiers to important information such as chromosomal location and gene 
identification. In each dataset probes that mapped to an Entrez Gene ID were selected 
for analysis and all data was log2 transformed. 
2.4.1 Medulloblastoma subgroup designation using a four metagene 
classifier 
Original transcriptomic profiling results for 3 of the available datasets reported a 
variable number of molecular disease subgroups; Cho et al. reported 6 medulloblastoma 
subgroups, while Kool et al. reported 5 and Northcott et al. reported 4 discrete 
subgroups. All studies identified a WNT-pathway activated and SHH-pathway activated 
subgroup with a variable number of pathway- independent groups (see section 1.5.8.1). 
Following an international meta-analysis of available data there is now a consensus that 
medulloblastoma comprises 4 principal subgroups (SHH, WNT, Group 3 and Group 4) 
(see section 1.5.8.2). Through the application of NMF (non-negative matrix 
factorisation) to training and test cohorts, Dr. Dan Williamson (Newcastle University 
Paediatric Brain Tumour Group) identified and validated a 4 expression metagene 
classifier that reliably subclassifies medulloblastomas into the 4 principal molecular 
subgroups. Briefly, NMF is a method for reducing the complexity in high-dimensional 
data and is widely used for class discovery in biological research (Brunet et al., 2004). 
Through the identification of expression patterns, NMF describes the variation within a 
dataset by reducing it to a small number of relevant metagenes (aggregate patterns of 
gene expression) that provide a robust clustering of samples to reveal class 
memberships.  
Dr. Williamson applied the 4 metagene classifier to the Kool/Fattet, Cho and Northcott 
datasets and reliably subclassified ~90% of the tumours in each dataset into the 4 
subgroups (Table 2.4). These 3 transcriptomic datasets, subgrouped according to the 
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universal metagene classifier, were used for investigations reported in Chapter 3 and 
Chapter 4. 
 Transcriptomic dataset 
Consensus Subgroup Kool/Fattet Northcott Cho 
SHH 21 31 48 
WNT 14 8 16 
Group3 17 20 46 
Group4 42 35 59 
Not classified 8 9 25 
Table 2.4. Subclassification of independent transcriptomic datasets using a universal four metagene classifier. 
The number of tumours reliably subclassified into each consensus medulloblastoma subgroup are shown for each 
dataset. Approximately 90% of tumours in each dataset were reliably subclassified using the universal 4 metagene 
classifier. 
 
2.5 Culture of medulloblastoma cell lines 
Ten medulloblastoma cell lines (DAOY, D283 Med, D425 Med, D458 Med, D341 
Med, D384 Med, D556 Med, MHH-MED-1, MEB-MED-8A, UW228-2) (see section 
2.2) were cultured in the presence and absence of the demethylating agent 5’-aza-2’-
deoxycytidine (5-azaCdR) and used for investigations reported in Chapter 4. 
2.5.1 Reviving cell lines stored in liquid nitrogen 
All work with cell line cultures was carried out in a Class II tissue culture hood using 
sterilised pipettes and sterile techniques. Cryotube vials (Nunc
®
, Thermo Scientific, 
Loughborough, UK) containing 1ml of frozen cells (5x10
6 
cells) (see section 2.5.4) 
were defrosted rapidly by placing in a water bath pre-warmed to 37
0
C. The thawed cells 
were added drop-wise and slowly to 5ml of complete growth medium (see section 2.5.2) 
in a 15ml centrifuge tube (VWR International Ltd, Lutterworth, UK). Complete growth 
media had been pre-warmed to 37
0
C in a water bath. The cells and medium were gently 
mixed by pipetting up and down and then centrifuged at 250 x g (relative centrifugal 
force, RCF) for 5 minutes in a Thermo Scientific Multifuge 3S+ centrifuge (Thermo 
Scientific, Loughborough, UK) to remove the cryoprotectant agent dimethylsulfoxide 
(DMSO) (Sigma-Aldrich Ltd, Gillingham, UK) (see section 2.5.4). The supernatant was 
aspirated and discarded and cells were resuspended in 5mls of fresh complete growth 
 113 
 
medium and transferred to a sterile 25cm
2
 cell culture flask (Corning
®
, Sigma Aldrich 
Ltd, Gillingham, UK). Cultures were incubated at 37
0
C in a humidified incubator with 
5% CO2 (Sanyo Ltd, Loughborough, UK). 
2.5.2 Maintaining cell line cultures 
In order for cells to grow and proliferate in culture, they require a source of nutrients, 
hormones and growth factors. To prepare complete growth media, each 500ml of 
appropriate medium (Table 2.5) was supplemented with 10% (v/v) fetal calf serum 
(FCS) (Sigma-Aldrich Ltd, Gillingham, UK), 1% (v/v) L-glutamine solution 200mM 
(Sigma-Aldrich Ltd, Gillingham, UK) and 1% (v/v) sodium pyruvate solution 100mM 
(Sigma-Aldrich Ltd, Gillingham, UK). To control bacterial contamination 1% (v/v) 
penicillin/streptomycin mixture (10,000I.U/10,000µg/ml) (Sigma-Aldrich Ltd, 
Gillingham, UK) was added to media.  
Cell cultures were regularly examined by microscopy to assess growth characteristics 
(Table 2.5), to observe the morphology and viability of cells and to check for microbial 
contamination. The contamination of cell cultures by mycoplasmas is a major problem. 
Mycoplasmas are resistant to the antibiotics used, they are difficult to detect and 
contamination can mediate a wide variety of negative effects on cultures (Sung et al., 
2006). Actively growing cell cultures were routinely tested for mycoplasma infection 
every 2 months and prior to freezing stocks (see section 2.5.4) and were uniformly 
negative. 
The cell lines have infinite replicative capacity and following an initial recovery period 
immediately after seeding, will grow exponentially until they reach confluency in the 
flask or exhaust the nutrient supply. The media in which the cells were cultured was 
changed every 2-3 doublings (Table 2.5) to replenish nutrients and remove waste as the 
cell concentration increased. For cells growing adherently (Table 2.5), media was 
aspirated and replaced with fresh media that had been pre-warmed to 37
0
C in a water 
bath. For non-adherent cell lines (Table 2.5), the cell suspension was transferred to a 
centrifuge tube and centrifuged at 250 x g (RCF) for 5 minutes in a Thermo Scientific 
Multifuge 3S+ centrifuge (Thermo Scientific, Loughborough, UK), the supernatant was 
aspirated and the cell pellet was resuspended in the appropriate volume of pre-warmed 
media. 
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Cell Line Growth characteristics Approximate 
doubling time 
(hrs) 
Media 
DAOY Adherent 24 DMEM + 10% FCS 
D283 Med 40% adherent 36 DMEM + 10% FCS 
D425 Med Non-adherent 24-36 DMEM + 10% FCS 
D458 Med 60-70% adherent 36+ DMEM + 10% FCS 
D341 Med Non-adherent 36-48 DMEM + 10% FCS 
D384 Med 80% non-adherent 48 DMEM + 10% FCS 
D556 Med 95% non-adherent 48+ DMEM + 10% FCS 
MHH-MED-1 40% adherent 36-48 DMEM + 10% FCS 
MHH-MED-8A Adherent 36-48 DMEM + 10% FCS 
UW228-2 Adherent 24 DMEM/Ham's F12 +10% FCS 
Table 2.5. Growth characteristics, approximate doubling times and media for medulloblastoma cell line 
cultures. Media was either Dulbecco’s Modified Eagle’s Medium (DMEM) or a 1:1 mixture of DMEM and Ham’s 
Nutrient Mixture F12 (DMEM/Ham’s F12). Media was supplied by Sigma Aldrich LTD, Gillingham, UK. 
Cell lines must be subcultured on a regular basis to maintain them in the exponential 
phase of growth and ensure viability. Confluency of cells was examined 
microscopically and once cells reached approximately 70-80% confluence they were 
subcultured to reduce cell density. Cells were subcultured usually once or twice weekly 
and were generally subcultured at a 1:2 to 1:4 ratio depending on the growth 
characteristics of the individual cell line. Adherent cells were trypsinised first to form a 
cell suspension for subculture. Trypsin is a proteolytic enzyme that detaches adherent 
cells from the surface of the culture flask. A 1x trypsin/EDTA solution was prepared 
from 10 x trypsin/EDTA (Sigma-Aldrich Ltd, Gillingham, UK) using sterile phosphate 
buffered saline (PBS) (Sigma-Aldrich Ltd, Gillingham, UK). After aspirating the media 
cells were washed twice with sterile PBS (pre-warmed to 37
o
C) to remove traces of 
media as trypsin is inactivated by FCS. Enough 1 x trypsin/EDTA solution (pre-warmed 
to 37
o
C) was added to the culture flask to cover the layer of cells and the flask was 
incubated at 37
0
C for approximately 2 minutes. The flask was gently tapped to aid 
detachment and suspension of cells which was confirmed microscopically. Complete 
medium with serum was added to inhibit further trypsin activity and the trypsinised 
cells were transferred to a centrifuge tube and centrifuged at 250 x g (RCF) for 5 
minutes. For non-adherent cells the cell suspension was transferred directly to a  
 115 
 
centrifuge tube and centrifuged with no trypsinisation step. Following centrifugation the 
supernatant was aspirated and the cell pellet was resuspended in fresh complete media 
pre-warmed to 37
0
C and transferred to sterile culture flasks. 
2.5.3 Cell counting 
Cell counts were performed prior to freezing stocks of cells and at regular intervals 
during subculture to monitor growth rates and to check viability. After resuspending 
pellets in fresh media as described above, a 1:1 mixture of cell suspension and 1 x 
trypan blue stain (Sigma-Aldrich Ltd, Gillingham, UK) was prepared in a 1.5ml 
microcentrifuge tube (Starlab UK LTD, Milton Keynes, UK). Trypan blue stain is not 
absorbed by healthy viable cells but enters dead or damaged cells, allowing them to be 
counted. 10µl of the cell/trypan blue mixture was loaded onto a dual chamber counting 
slide (Bio-Rad Laboratories Ltd, Hemel Hempstead, UK) and cell counts were 
performed using a Bio-Rad TC10 Automated cell counter (Bio-Rad). The automated 
counter calculated a total cell count and a live cell count. 
2.5.4 Cryopreservation of cell lines 
Cell cultures are suitable for long-term storage in a liquid nitrogen freezer at 
temperatures below -130
0
C. Prior to freezing, cell pellets were produced in the same 
way as during subculture (see section 2.5.2) and counted as described in section 2.5.3. 
Frozen stocks of cells were prepared at a concentration of 5 x 10
6
 cells / ml. Cell pellets 
were resuspended in an appropriate volume of chilled FCS and placed on ice for 10 
minutes. Freeze medium was prepared containing 20% DMSO and 80% FCS chilled on 
ice. An equal volume of freeze medium was added drop-wise to the chilled cell 
suspension and the suspension was left on ice for 10 minutes to allow the DMSO to 
permeate the cells. Addition of the cryoprotectant agent DMSO prevents the formation 
of intracellular ice crystals and prevents cell lysis during thawing. 1ml aliquots of cell 
suspension were transferred to cryotube vials (Nunc
®
, Thermo Scientific, 
Loughborough, UK) and stored overnight at -80
0
C in a Nalgene® Mr Frosty freezing 
container (Sigma-Aldrich Ltd, Gillingham, UK). The container facilitates a slow 
cooling rate, generally 1
0
C per minute and minimises intracellular ice formation during 
freezing. Frozen cells were transferred to liquid nitrogen freezer tanks the following day 
for long term storage. 
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2.5.5 5’-aza-2’-deoxycytidine treatment 
5’-aza-2’-deoxycytidine (5-azaCdR) is a potent DNA demethylating agent. It is an 
azanucleoside that is incorporated into replicating DNA, replacing cytosine residues. 
Once incorporated it forms a covalent bond with DNA methyltransferase enzymes, 
inhibiting methyltransferase function (Stresemann and Lyko, 2008). Treatment of 
medulloblastoma cells in vitro with 5-azaCdR has been found to reactivate 
epigenetically silenced tumour suppressor genes (see section 1.7.1). 
A 500µM stock solution of 5-azaCdR was prepared by dissolving 5-azaCdR powder 
(Sigma-Aldrich Ltd, Gillingham, UK) in DMEM. 0.5ml aliquots of stock solution were 
stored in sterile universal containers (Fisher Scientific UK Ltd, Loughborough, UK) at -
20
0
C. Cell cultures were treated with 5µM 5-azaCdR for 72 hours. Media and 5-azaCdR 
were renewed every 24 hours as 5-azaCdR is unstable at 37
0
C. Media replenishment 
was carried out as described in section 2.5.2. 5-azaCdR is incorporated into newly 
synthesised DNA over several cell doublings and cells were initially seeded at an 
appropriate density that avoided the need to subculture over the 72 hours and ensured 
cells were approximately 80% confluent at the end of the treatment period. Following 
treatment with 5-azaCdR, cells were harvested for RNA and DNA extraction as 
described below. At high doses 5-azaCdR is toxic to cells (Stresemann and Lyko, 
2008). The optimum concentration of 5-azaCdR and the optimum time for cell line 
DNA demethylation and gene reactivation had previously been assessed and determined 
by Dr. Jennifer Anderton (Anderton J.A. PhD Thesis, Newcastle University).  
2.5.6 Harvesting cells for RNA extraction 
Cells need to be harvested for RNA extraction when they are still actively proliferating 
in the exponential phase and pellets need to be frozen rapidly to prevent degradation of 
RNA. Cells were harvested when they were approximately 80% confluent. Immediately 
prior to harvesting the culture flasks were placed on ice. For adherent cell cultures the 
media was discarded and the surface of cells washed with sufficient chilled sterile PBS 
for 1-2 minutes. The PBS was aspirated and replaced with 5mls of fresh chilled PBS. 
Cell scrapers (VWR International Ltd, Lutterworth, UK) were used to lift cells adhering 
to the flask surface. The surface was washed with chilled PBS and the cell suspension 
transferred to a centrifuge tube and centrifuged at 750 x g (RCF) for 5 minutes at 4
0
C in 
a Thermo Scientific Multifuge 3SR+ centrifuge (Thermo Scientific, Loughborough,  
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UK). A small volume of suspension was retained to perform cell counts as described in 
section 2.5.3. Following centrifugation the supernatant was discarded, the pellet re-
suspended in an appropriate volume of chilled PBS and 1ml aliquots containing 5 x 10
6
 
cells transferred to 1.5ml microcentrifuge tubes. The tubes were centrifuged at 450 x g 
(RCF) for 1 minute at 4
0
C in an Eppendorf centrifuge 5415R (Eppendorf Inc., New 
York, USA) to remove PBS and the pellets were immediately snap frozen in dry ice and 
stored at -80
0
C. For non-adherent cells the media was transferred to a centrifuge tube 
and centrifuged at 450 x g (RCF) for 5 minutes at 4
0
C. The cell pellet was washed in 
chilled PBS and centrifuged as before. The washed pellet was re-suspended in PBS, 
aliquoted and frozen as described for adherent cells. 
2.5.7 Harvesting cells for DNA extraction 
The procedure used for harvesting cells for DNA extraction was the same as that for 
RNA described above in section 2.5.6, with the exception that cells were not kept on ice 
as DNA is less susceptible to degradation by exogenous exonucleases. 
2.6 Extraction and assessment of nucleic acids 
2.6.1 RNA extraction from cells 
Total RNA was extracted from harvested cells (see section 2.5.6) using phenol-
chloroform extraction and alcohol precipitation methods. TRIzol
®
 Reagent (Invitrogen 
Ltd, Paisley, UK) is a monophasic solution of phenol and guanidine isothiocyanate that 
lyses cells and dissolves cellular components producing a homogenate. Addition of 
chloroform to the homogenate causes the separation of a colourless upper aqueous 
layer, an interphase layer and a lower red phenol-chloroform organic layer. RNA is 
precipitated from the upper aqueous phase with isopropanol. After washing with ethanol 
the RNA pellet was re-suspended in RNase free water. The procedure was carried out 
according to manufacturer’s instructions and purified RNA was stored at -800C. 
2.6.2 DNA extraction from cells 
Total DNA was extracted from harvested cells (see section 2.5.7) using the DNeasy
®
 
Blood and Tissue kit (Qiagen Ltd, Manchester, UK) according to the manufacturer’s 
instructions. The procedure uses proteinase K to lyse cells and the lysate is passed 
through a silica-based membrane column that selectively binds DNA. The DNA is 
washed to remove contaminants and eluted from the membrane in elution buffer (AE). 
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Purified DNA was stored at -20
0
C. The DNeasy
®
 procedure will produce DNA yields 
from samples as small as 100 cells up to samples as large as 5x10
6
 cells. The procedure 
will recover DNA fragments between 100bp and 50kb in size. 
DNA was extracted from frozen primary tumour samples using TRIzol
®
 Reagent 
(Invitrogen Ltd, Paisley, UK) (see section 2.6.1). DNA was extracted from the 
interphase and phenol-chloroform organic layer with ethanol according to 
manufacturer’s instructions. After washing, DNA was resuspended in 10mM Tris-Cl, 
pH8.5 and stored at -20
0
C. 
2.6.3 Qualitative and quantitative assessment of nucleic acids 
2.6.3.1 Spectrophotometry 
UV spectrophotometry can be used to determine the concentration of RNA or DNA in a 
sample. Both RNA and DNA absorb UV light very efficiently and have a maximum 
absorption at 260nm. In contrast to the nucleic acids, proteins have an absorption 
maximum of 280nm. The NanoDrop 1000 spectrophotometer (Thermo Scientific, 
Loughborough, UK) was used to measure the concentration and assess the purity of 
DNA and RNA samples. The machine measures the optical density (OD) of a 1µl 
sample at wavelengths of 260 and 280nm and calculates the concentration of nucleic 
acid as well as the OD260/OD280 ratio. Pure DNA has an OD260/OD280 ratio ~ 1.7-1.9 and 
pure RNA has a ratio ~2.0. Obtaining lower ratio values can be indicative of protein 
contamination. NanoDrop spectrophotometry measurements are prone to overestimation 
as the presence of DNA, RNA and phenol contaminants in a sample will also be 
detected. The NanoDrop spectrophotometer produces an absorbance scan with a 
symmetric peak at 260nm confirming high nucleic acid purity. 
2.6.3.2 Fluorometry 
Fluorescence-based assays for the quantitation of nucleic acids are more sensitive and 
selective then spectrophotometric analysis. The Qubit
®
 dsDNA BR Assay kit 
(Invitrogen Ltd, Paisley, UK) along with the Qubit
®
 2.0 fluorometer (Invitrogen) were 
used to determine the concentration of DNA in a sample. The assay uses advanced 
molecular probe fluorophores that fluoresce upon binding to double-stranded DNA 
(dsDNA). In contrast to UV-absorbance analysis, the Qubit
®
 assay selectively measures 
the concentration of dsDNA and is tolerant to the presence of common contaminants. 
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The assay provides no measurement of the purity of DNA in a sample and can 
accurately calculate concentrations from 100pg/µl to 1000ng/µl. The Qubit
®
 dsDNA 
BR Assay was performed according to manufacturer’s instructions. 
2.6.3.3 Bioanalyzer 
Gene expression microarrays require high quality RNA. Prior to biotin RNA labelling 
(see section 2.6.4) for subsequent microarray analysis (see section 2.8), a more sensitive 
and accurate method for determining the quality and quantity of RNA was employed. 
The Agilent 2100 Bioanalyzer (Agilent Technologies UK Ltd, Wokingham, UK) is a 
chip-based platform that utilises capillary electrophoresis to determine quality control 
metrics for DNA, RNA and protein. The Agilent RNA 6000 Nano Kit (Agilent 
Technologies UK Ltd) was used to prepare the chip and samples according to the 
manufacturer’s instructions. The Bioanalyzer can assess a total RNA concentration from 
5-500ng/µl from a 1µl sample. The Agilent 2100 software (Agilent Technologies UK 
Ltd) calculates a total RNA concentration, the 28S:18S rRNA ratio and the RNA 
Integrity number (RIN) which assesses total RNA quality in terms of extent of 
degradation. High quality RNA will produce a Bioanalyzer electropherogram and gel-
like image output showing 2 distinct ribosomal peaks and bands, respectively (Figure 
2.1(A)). High quality RNA will have a RIN greater than 9 and a 28S:18S ratio of 2 or 
more. For microarray analysis a RIN higher than 8 is generally required for cultured 
cells. Degraded RNA will produce a RIN closer to 1 and a 28S:18S ratio less than 2, 
with degradation products appearing between the ribosomal peaks and bands of the 
electropherogram and gel-like image respectively (Figure 2.1(B)). 
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Figure 2.1. Analysis of total RNA integrity using the Agilent 2100 Bioanalyzer. (A) Upper electropherogram and 
gel-like image show high quality total RNA with the 18S and 28S subunit as 2 distinct peaks and bands. (B) 
Degradation products from partially degraded total RNA will produce peaks between the 2 ribosomal peaks in the 
electropherogram and between the ribosomal bands on the gel-like image. Figure taken from Agilent 2100 
Bioanalyzer Application Compendium (Agilent Technologies UK Ltd, Wokingham, UK). 
2.6.4 RNA amplification and biotinylation 
Total RNA extracted from the 10 medulloblastoma cell lines cultured in the presence 
and absence of 5-azaCdR (see section 2.5.5) was amplified and biotinylated prior to 
hybridisation with the Illumina HumanHT-12 v4.0 BeadChip (see section 2.8.1). Direct 
biotin labelling of target RNA transcripts is commonly employed in microarray analysis 
and Cy3 fluorescent conjugates are used to generate a fluorescent signal and detect 
transcript levels following hybridisation to complementary probe sequences. For each 
cell line sample, 200ng of total RNA, determined by Bioanalyzer assessment (see 
section 2.6.3.3), was amplified and biotin-labelled using the Illumina
®
 TotalPrep RNA 
Amplification Kit (Illumina, San Diego, CA,USA), according to the manufacturer’s 
instructions. The procedure consisted of an initial reverse transcription step using an 
oligo (dT) primer and ArrayScript reverse transcriptase to generate first strand 
complementary DNA (cDNA). This was followed by second strand cDNA synthesis 
using DNA polymerase and RNase H to generate double-stranded DNA (dsDNA). 
Following purification the dsDNA template underwent in vitro transcription using T7 
RNA polymerase and biotin-NTP mix during a 14 hour incubation step to generate 
multiple copies of biotinylated complementary RNA (cRNA). Purified cRNA was 
eluted in 200µl of nuclease-free water and the yield was assessed by NanoDrop (see 
section 2.6.3.1). cRNA samples were stored at -80
0
C prior to being sent for expression 
microarray analysis (see section 2.8). 
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2.7 DNA methylation profiling 
2.7.1 Introduction to high-throughput array-based DNA methylation profiling 
DNA methylation microarray technologies allow for the interrogation of cytosine 
methylation at CpG dinucleotides on a genome–scale and at base-pair resolution. 
Advances in the technology in recent years have led to the development of high density 
arrays providing coverage of more than 450,000 CpG sites representing in excess of 
20,000 genes. 
The assays used in this project are based on genotyping bisulfite-converted genomic 
DNA (gDNA). The method of sequencing bisulfite-converted DNA to map 5-
methylcytosine was first developed by Frommer et al. (Frommer et al., 1992). Briefly, 
sodium bisulfite treatment converts non-methylated cytosines to uracil while methylated 
cytosines remain unchanged. Converted uracil residues are subsequently read as 
thymine following PCR amplification and sequencing and the only cytosines that 
remain in the sequence are methylated. DNA methylation profiling methodologies 
based on bisulfite conversion pre-treatment cannot discriminate between 5-
methylcytosine and 5-hydroxymethylcytosine, which is a key intermediate in active 
demethylation pathways mediated by the TET family of proteins (Baylin and Jones, 
2011). The methylation array platforms described below utilise amplified bisulfite-
converted gDNA, hybridised to microarrays containing methylation-specific 
oligonucleotides (MSO) to determine a quantitative measure of methylation at CpG 
sites (Gitan et al., 2002). 
2.7.2 GoldenGate Methylation Cancer Panel I platform 
The GoldenGate Methylation Cancer Panel I microarray interrogates the methylation 
status of 1,505 CpG sites selected from a target panel of 807 genes. The selected genes 
represent tumour suppressor genes, oncogenes, imprinted genes, genes involved in 
DNA repair, cell cycle control, differentiation and apoptosis, as well as previously 
reported differentially methylated genes (Bibikova et al., 2006). Assay probes have 
been designed around the promoter and first exon of genes and are annotated according 
to the number of base pairs upstream or downstream from the transcription start site 
(TSS) they occur. Probes located upstream of the TSS are labelled with P (promoter) 
while those located downstream of the TSS are labelled with E (exon). Therefore, the 
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probe ASCL2_E76_R, is measuring methylation at the ASCL2 gene, 76 base pairs 
downstream of the TSS, with the reverse strand being assayed. Probes are situated both 
within (n=1044) and outside (n=461) of CpG islands (CpG islands were defined by 
Illumina). The number of sites per gene assayed on the array ranges from one CpG site 
(28.6% genes) to three or more sites (14.1% genes). The assumption is made that CpG 
residues adjacent to the target site have the same methylation status. This assumption 
has been validated using bisulfite sequencing (Bibikova et al., 2006; Schwalbe et al., 
2013). 
2.7.2.1 GoldenGate methylation microarray assay 
Microarray analysis was performed on the Illumina GoldenGate Cancer Panel I 
methylation array at the Wellcome Trust Centre for Human Genetics, Oxford, UK 
according to the manufacturer’s protocols (Illumina, San Diego, CA,USA).  
The GoldenGate methylation microarray assay is a bead array assay based on Illumina’s 
BeadArray Technology. The assay uses 3-micron silica beads randomly assembled in 
microwells. Each bead is covered with hundreds of thousands of copies of a specific 
oligonucleotide that captures its complementary target sequence and produces a 
fluorescent signal, the intensity of which is read by the Bead Array reader. There are 
approximately 30 beads per target sequence on the array platform. A decoding 
algorithm is applied to determine the location and identity of each bead due to their 
random assembly, allowing for high density packing on a miniaturised platform 
(Gunderson et al., 2004).  
Two pairs of probes have been designed for each CpG site being interrogated on the 
GoldenGate methylation platform; one pair of allele-specific (ASO) and locus-specific 
(LSO) oligonucleotides for the methylated state and a corresponding pair for the 
unmethylated state. Pooled query oligos anneal to bisulfite converted gDNA with 
subsequent extension and ligation occurring from the ASO to the matched LSO creating 
PCR templates. The methylated and unmethylated templates are selectively amplified 
by PCR using fluorescently labelled universal PCR primers and hybridised to the bead 
array bearing the complementary address sequences (Figure 2.2). Ninety-six well arrays 
were scanned in the Bead Array reader and the intensity of fluorescent signals of both 
the methylated and unmethylated alleles measured. 
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Figure 2.2. Principles of the Illumina GoldenGate methylation array technology. (A) Bisulfite 
treatment of gDNA converts unmethylated cytosine (C) residues to uracil (U), while methylated cytosines 
remain unchanged. (B) Two pairs of probes per CpG site are hybridized to target bisulfite-converted gDNA, 
with one probe pair specific to a methylated state and the other specific to an unmethylated state (recognised 
as a C/T polymorphism). Probe pairs comprise an allele-specific oligonucleotide (ASO) that discriminates the 
C/T polymorphism and a locus-specific oligonucleotide (LSO) that discriminates the CpG site. ASO/LSO probe 
pairs bind in this discriminatory manner to the converted uracil and methylated cytosine residues, with an 
initial ASO extension phase followed by ligation to corresponding LSO creating a template which is PCR-
amplified using fluorescently labelled universal primers that are associated with the “T” (unmethylated) allele 
or the “C” (methylated) allele respectively.  The fluorescently labelled PCR products are hybridized to the 
BeadArray platform based on complementary address sequences. The methylation status of each CpG site is 
determined by measuring the ratio of the fluorescent signal from the methylated allele to the sum of the 
signals of both methylated and unmethylated alleles. This is defined as the β-value and provides a continuous 
measure of DNA methylation levels ranging from 0 (completely unmethylated) to 1 (completely methylated). 
Figure taken from Bibikova et al., 2006. 
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BeadStudio is a general purpose program for the analysis of all Illumina array data. Raw 
data was exported and processed by Dr. Ed Schwalbe (Newcastle University Paediatric 
Brain Tumour Research Group) in BeadStudio v3.2 (Illumina, San Diego, CA, USA). 
The methylation status of each interrogated CpG locus was recorded as a β-value, 
calculated according to the following equation: 
 
 
where ymeth and yunmeth are the intensities measured by the methylated and unmethylated 
probes, respectively. A constant bias of 100 is added to the denominator to regularise β 
when both methylated and unmethylated probe intensities are low (Bibikova et al., 
2006). The β-value provides a continuous measure of DNA methylation levels ranging 
from 0 (completely unmethylated) to 1 (completely methylated). Array quality control 
measures and normalisation processes were carried out by Dr. Ed Schwalbe in 
BeadStudio v3.2 (Schwalbe et al., 2013). The GoldenGate methylation array was used 
for investigations reported in Chapter 3. 
Initial evaluation of the GoldenGate methylation array technology by Bibikova et al. 
found it to be specific and highly sensitive, capable of detecting a change in β-value ≥ 
0.2 with 95% confidence. The high reproducibility of the assay was determined using 
technical replicates (average R
2 ≥ 0.98). The accuracy of the array was validated by 
methylation-specific PCR (MSP) which is able to sensitively determine methylation 
levels of individual genes (Bibikova et al., 2006). Bisulfite sequencing studies have also 
validated the accuracy of the GoldenGate methylation array (Bibikova et al., 2006; 
Schwalbe et al., 2013). 
2.7.3 Infinium Methylation 450K platform 
The 450K DNA Methylation microarray is the most recent methylation array developed 
by Illumina and follows the success of the GoldenGate platform described above and its 
successor the Infinium 27K platform.  
The 450K array interrogates the methylation status of approximately 475,000 CpG sites, 
providing coverage of a total of 21,231 UCSC RefGenes. The content of the 450K array 
was selected with the guidance of a consortium of DNA methylation experts and 
                 max (ymeth, 0) 
max (yunmeth, 0) + max (ymeth, 0) + 100 
 
 
β= 
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provides comprehensive coverage across the complete gene and CpG island regions 
(Bibikova et al., 2011). Probes have been designed covering multiple gene sub-regions 
as defined by Illumina; probes target promoter regions at 200bp and 1500bp blocks 
upstream of the transcription start site (annotated TSS200 and TSS1500, respectively) 
as well as the 5’ and 3’ UTR, first exon and gene body regions. Ninety-six per cent of 
CpG islands are represented on the array as well as CpG island shores (regions 0-2kb 
from CpG islands) and CpG island shelves (regions 2-4kb from CpG islands). Shore 
and shelf regions located upstream of their associated CpG island are annotated “north” 
(N_Shore and N_shelf), while regions located downstream of their associated island are 
annotated “south” (S_Shore and S_shelf). CpG islands, island shores and island shelves 
were defined by Illumina and they also include an “Open Sea” annotation, defining 
isolated CpGs in the genome. In addition to coding RNA transcripts probes have been 
designed that target non-coding RNAs and intergenic regions previously shown to be 
biologically significant or informative (Bibikova et al., 2011). 
2.7.3.1 Infinium 450K methylation microarray assay 
Microarray analysis was performed on the Illumina Infinium HumanMethylation450 
BeadChip at the Wellcome Trust Clinical Research Facility, Edinburgh, UK according 
to the manufacturer’s protocols (Illumina, San Diego, CA,USA).  
As for the GoldenGate platform, the 450K methylation array is a bead array assay (see 
section 2.7.2.1). It differs from the GoldenGate assay in that it utilises Illumina’s 
Infinium technology, employing both Infinium I and Infinium II assays to achieve high 
density coverage (Figure 2.3). 
The Infinium beads have long target-specific probes designed for individual CpG sites. 
The Infinium I methylation-specific assay uses two bead types per CpG locus, one 
designed against the unmethylated site and one against the methylated site. The 
3’terminus of the probe is designed to match either the protected cytosine (methylated) 
or the thymine resulting from bisulfite conversion (unmethylated) and incorporates a 
fluorescent label for detection (Figure 2.3(A)). The Infinium I assay has been designed 
based on the assumption that CpG sites adjacent to the target locus have the same 
methylation status (Bibikova et al., 2011).The Infinium II assay uses one bead type per  
locus for CpG sites located in regions of low CpG density. The underlying CpG sites 
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are represented by a degenerate R-base, allowing the methylation status of the target 
locus to be assessed independently of assumptions on the status of neighbouring sites. 
The 3’ terminus of the probe matches the base directly upstream of the target site and a 
single base extension adds either a labelled G or A base depending on the methylation 
status of the cytosine residue in the targeted CpG site (Figure 2.3(B)). 
 
 
Figure 2.3. Principles of the Illumina Infinium 450K methylation array technology. (A) Infinium I 
assay: two bead types correspond to each CpG locus on the target bisulfite-converted gDNA- one to the 
methylated state(C) and the other to the unmethylated state (recognised as a C/T polymorphism). 
Following complementary recognition of the methylated or unmethylated state the probe incorporates a 
fluorescently labelled nucleotide. Probe design assumes the same methylation status for adjacent sites. (B) 
Infinium II assay: one bead type corresponds to each target CpG site and the probe can contain up to 3 
underlying CpG sites, represented by a degenerate R base corresponding to “C” in the CpG site. 
Methylation state is detected by single base extension with labelled “A” base incorporated at an 
unmethylated site and labelled “G” at a methylated site. Infinium II assay allows target loci to be assessed 
independently of neighbouring CpG site status and is used in regions of low CpG density. Methylation 
status is measured using two methods: the β-value method provides a continuous measure of methylation 
ranging from 0 (completely unmethylated) to 1 (completely methylated); the M-value method calculates 
the log2 ratio of intensities of methylated probe versus unmethylated probe and also provides a 
continuous measure with positive M-values reflecting increasing methylation and negative M-values 
representing decreasing methylation. The M-value method is advantageous in microarray analysis 
because, unlike the β-value, it is statistically valid for many of the existing microarray statistical 
frameworks. Figure taken from Bibikova et al., 2011. 
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The performance of the 450K methylation array has been validated by whole genome 
bisulfite sequencing (WGBS) and has been found to be highly reproducible for 
technical replicates (average R
2
=0.99). The array can reliably detect a change in beta 
value of 0.2 with 99% confidence (Bibikova et al., 2011). Within the Newcastle 
University Paediatric Brain Tumour Group, Dr. Ed Schwalbe has carried out extensive 
array validation experiments, including assessments of intra- and inter-replicate 
reproducibility, alongside quality control measures. Independent bisulfite sequencing 
studies carried out within the group have validated the accuracy of the array.  
There are currently two methods for measuring and reporting on the methylation levels 
determined by the Infinium 450K array. The first one is the β-value which is the ratio of 
the fluorescent signal from the methylated allele to the sum of the fluorescent signals of 
both methylated and unmethylated alleles and provides a continuous measure of 
methylation levels ranging from 0 (completely unmethylated) to 1 (completely 
methylated) (see section 2.7.2.1). The second method is the M-value which is calculated 
as the log2 ratio of the intensities of methylated probe versus unmethylated probe as in 
the following equation: 
 
 
 
A constant bias of 1 is added to the intensity values to prevent large changes in M-value 
that may occur due to small intensity estimation errors. M-values close to zero indicate 
a hemi-methylated state, while positive M-values reflect increasing methylation and 
negative values reflect decreasing methylation. The M-value is widely used in mRNA 
expression microarray analysis and, therefore, the benefits of using this method in 
methylation analysis are that many of the existing microarray statistical frameworks can 
be applied to methylation data analysis (Du et al., 2010). 
Twelve samples were processed in parallel on Infinium HumanMethylation450 
BeadChips. GenomeStudio is the successor to the BeadStudio software for the analysis 
of Illumina array data. Raw data was exported and processed by Dr. Ed Schwalbe 
(Newcastle University Paediatric Brain Tumour Research Group) in GenomeStudio 
max(ymeth, 0) + 1 
max(yunmeth, 0) + 1 
M = log2 
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(Illumina, San Diego, CA, USA). Array quality control measures and normalisation 
processes were carried out by Dr. Ed Schwalbe in GenomeStudio. The 450K 
methylation array was used for investigations reported in Chapter 4. 
2.8 Gene expression microarray analysis 
2.8.1  HumanHT-12 v4.0 Expression BeadChip 
Expression alterations in medulloblastoma cell lines following treatment with the 
demethylating agent 5-azaCdR (see section 2.5.5) were assessed by gene expression 
microarray analysis using the Illumina HumanHT-12 v4.0 BeadChip and used for 
investigations reported in Chapter 4. The HumanHT-12 Expression BeadChip (Illumina, 
San Diego, CA, USA) provides whole genome gene expression profiling. The chip 
contains a total of 47,231 probes covering 31,335 genes. Probes were designed to cover 
NCBI RefSeq content, as well as supplemental UniGene content. The platform utilises 
Illumina’s bead array direct hybridisation assay. Similar to the methylation microarray 
platforms described above, the expression BeadChip comprises arrays of randomly 
positioned 3-micron diameter silica beads. A specific 50-mer oligonucleotide probe 
sequence is assigned to each bead type and with approximately 700,000 copies of the 
same probe sequence attached to each bead and an average of 30 beads per bead type 
this high level of redundancy supports high quality reproducible data. Every bead on the 
array is identified by a 29-mer address sequence using a series of decoding 
hybridisations (Gunderson et al., 2004). 
2.8.2 Expression microarray assay 
Microarray analysis was performed on the Illumina HumanHT-12 BeadChip at the 
Wellcome Trust Clinical Research Facility, Edinburgh, UK according to the 
manufacturer’s protocols (Illumina, San Diego, CA, USA). Amplified biotinylated RNA 
(cRNA) (see section 2.6.4) was sent for array analysis at a concentration of 150ng/µl as 
measured by NanoDrop (see section 2.6.3.1). Prior to microarray analysis, the quality 
and quantity of cRNA were evaluated at the Wellcome Trust Facility using the Agilent 
2100 Bioanalyzer (Agilent Technologies UK Ltd, Wokingham, UK). Cell line pairs (5-
azaCdR treated and untreated) were processed on the same BeadChip (12 samples/chip) 
and all samples were processed in a single batch using 2 chips to minimise batch effect. 
Reproducibility of the assay had previously been demonstrated by Illumina with high 
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concordance between technical replicates. The assay can detect a statistically significant 
fold change ≤ 1.35, depending on the number of replicates included, and this is 
detectable over a dynamic range ≥ 3logs, making it highly sensitive and precise 
(Illumina, 2011). 
Arrays were scanned in the Bead Array reader and the intensity of fluorescent signal for 
target and control probes measured. Quality assessment and processing of the raw bead 
level data was carried out by the Wellcome Trust Facility in Edinburgh using the 
Illumina GenomeStudio Gene Expression Module (Illumina, San Diego, CA, USA). 
There were 7 control categories built into the assay controlling for sample, labelling, 
hybridisation and signal generation. The performance of the controls was evaluated by 
the Wellcome Trust Facility alongside the assessment of systematic differences between 
arrays and spatial artefacts to identify problematic or outlier arrays.  
The Wellcome Trust Facility exported the GenomeStudio output for all target and 
control probes and provided the non-normalised, non-transformed bead summary data 
in text files. Bead summary data was created using Illumina’s default method of 
removing outliers greater than 3 median absolute deviations (MADs) from the median 
and calculating the mean and variance of the remaining beads for each probe type. 
Alongside bead summary probe profiles, summarised gene profiles were also provided 
which were calculated by averaging the intensity values from all the probe types in a 
gene probe set. For the investigations reported in Chapter 4 the individual summarised 
probe intensities were used. The detection p-value was included in the summarised 
probe profiles characterising the chance that the target probe sequence signal was 
distinguishable from the negative controls. Bead summary data was analysed using the 
R package beadarray (Dunning et al., 2007) as described in Chapter 4, section 4.3.3.2. 
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2.9 Reverse transcriptase polymerase chain reaction 
2.9.1 Introduction to PCR and reverse trancriptase PCR 
Polymerase chain reaction (PCR) is a powerful DNA amplification technique that is 
fundamental to many molecular biology laboratory protocols. The modern PCR 
technique was initially developed by Dr. Kary Mullis in 1983 (Bartlett and Stirling, 
2003). The technique is based on amplification of specific target DNA sequences using 
single-stranded oligonucleotides (primers) which are complementary to opposite strands 
of the target DNA. As PCR progresses under specific thermal cycling conditions, the 
multiple copies of double-stranded DNA generated are used as template for further 
replication in a chain reaction in which the DNA template is exponentially amplified. 
PCR-based assays are used for a variety of biological applications, including DNA 
cloning for sequencing and the quantification of expression of target genes 
There are 3 amplification phases during a PCR reaction; an initial exponential phase 
doubles the amount of PCR product at every cycle assuming the reaction is 100% 
efficient, a linear phase when the reaction is slowing due to consumption of reagents 
and a final plateau or end-point phase when the reaction has stopped due to exhaustion 
of reagents. Endpoint or traditional PCR (see section 2.9.3) uses agarose gel to detect 
PCR amplification products from the end point of the reaction and results are semi-
quantitative and based on nucleotide size discrimination (see section 2.9.3.1). Real-
Time quantitative PCR (qPCR) (see section 2.9.4) detects amplification during the 
entirety of the reaction as it progresses and measures product accumulation in the 
exponential phase, making it a more sensitive and precise method for quantifying DNA 
and gene expression. 
Reverse transcriptase PCR (RT-PCR) amplifies complementary DNA (cDNA) that has 
been reverse transcribed from messenger RNA (mRNA), permitting the determination 
of target gene expression levels. One-step RT-PCR includes the reverse transcriptase 
step in the same tube as the PCR reaction. For all RT-PCR experiments reported in this 
project a two-step RT-PCR method was employed which involves an initial reverse 
transcriptase step to synthesise cDNA (see section 2.9.2) followed by PCR of cDNA 
amplicons in a separate reaction.  
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2.9.2 cDNA synthesis 
Prior to performing PCR, cell line RNA was reverse transcribed using the iScript cDNA 
synthesis kit (Bio-Rad Laboratories Ltd, Hemel Hempstead, UK), according to the 
manufacturer’s instructions. The reverse transcriptase enzyme RNase H+ in the iScript 
kit can synthesise cDNA from RNA input ranging from 100fg to 1µg of total RNA. A 
blend of oligo dT and random hexamer primers which anneal to the poly(A) tail of 
mRNA and random complementary sites on mRNA respectively, optimise cDNA 
synthesis. For all RT-PCR experiments described in this project, 1µg of cell line total 
RNA was initially reverse transcribed using the iScript kit and the reaction was 
incubated in a GeneAmp
® 
9700 Thermocycler (Applied Biosystems, Foster City, USA) 
as per protocol. 
2.9.3 RT-PCR to assess re-expression of RASSF1A in medulloblastoma cell lines 
following 5-azaCdR treatment 
Expression of the RASSF1A transcript in medulloblastoma cell lines before and after 5-
azaCdR treatment (see section 2.5.5) was examined by endpoint RT-PCR for 
investigations reported in Chapter 4. RASSF1A was used as a positive control for the 
demethylating treatment of cell lines due to the robust evidence for its methylation-
mediated transcriptional silencing and reactivation following 5-azaCdR treatment in 
multiple medulloblastoma cell lines (Lusher et al., 2002). 
The PCR process involves multiple thermal cycles, with each cycle comprising 3 
successive reactions of DNA denaturation at 93-95
0
C, primer annealing at temperatures 
usually ranging from 50-70
0
C and DNA synthesis/extension typically at 72
0
C. Correct 
primer design is essential for selective target amplification. The desired characteristics 
of PCR primers include a length of 18-25 base pairs, a GC content of 40-60%, a similar 
melting temperature between primer pairs, and no stretches of sequence complementary 
within or between primers at the 3’ end. The selectivity of target amplification is 
dependent on using an optimised annealing temperature which is typically 3-5 
0
C below 
the melting temperature of the primers. The DNA synthesis/extension step employs a 
thermostable taq DNA polymerase (Applied Biosystems, Foster City, USA), which is 
isolated and purified from the bacterium Thermophilus aquaticus, and incorporates 
deoxynucleoside triphosphates (dNTPs) into a newly synthesised DNA strand 
complementary to the template in the 5’ to 3’ direction.  
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For this project, a previously published RASSF1A primer pair was used (Dammann et 
al., 2000). Primer sequences for RASSF1A were as follows: 
 5’ CAGATTGCAAGTTCACCTGCCACTA 3’ (forward)  
 5’ GATGAAGCCTGTGTAAAGAACCGTCCT 3’ (reverse)  
RASSF1A PCR product size was 242bp. The β-actin housekeeping gene was used to 
control for any differences in starting cDNA quantites between samples. β-actin is a 
commonly used endogenous control gene in PCR applications as it is constitutively 
expressed in all cells. A previously published β-actin primer pair was used (Horikoshi et 
al., 1992). Primer sequences for β-actin were as follows:  
 5’GAGCGGGAAATCGTGCGTGACATT 3’ (forward) 
 5’ GATGGAGTTGAAGGTAGTTTCGTG 3’ (reverse) 
β-actin PCR product size was 232bp. Primers were custom synthesised by Sigma 
Aldrich (Sigma Aldrich Ltd, Gillingham, UK) and supplied as lyophilised pellets. 
Primers were reconstituted in nuclease-free water (Qiagen Ltd, Manchester, UK) at a 
concentration of 100µM, and stored at -20
0
C alongside 10µM working stock aliquots. 
20µl PCR reactions were set up using the reagents listed in Table 2.6. Reagents were 
kept on ice and added to 0.2ml PCR tubes (Starlab UK LTD, Milton Keynes, UK) in the 
order listed in Table 2.6. Reactions were set up in a LabCaire PCR clean air cabinet 
(Scientific Laboratory Supplies Ltd, Nottingham, UK), and cDNA template was added 
last at the bench. Cell line RNA was initially reverse transcribed to cDNA as described 
in section 2.9.2, and 3µl of cDNA template were added to the PCR reagents. 
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Reagent Volume (µl) for 20µl 
reaction 
Final concentration 
Nuclease-free water 8.8 - 
10X PCR Buffer II 2 1X PCR Buffer II 
Forward primer (10µM) 2 1µM 
Reverse primer (10µM) 2 1µM 
Magnesium chloride 
(25mM) 
1.2 1.5mM 
dNTPs(5mM) 0.8 0.2mM 
AmpliTaq Gold (5U/µl) 0.2 0.05U/µl 
Table 2.6. PCR reaction reagents and concentrations for amplification of RASSF1A and β-actin cDNA. 
Reagents were obtained from Applied Biosystems (Applied Biosystems Foster City, USA). Nuclease-free water was 
obtained from Qiagen (Qiagen Ltd, Manchester, UK). Magnesium chloride is added to the reaction becauseTaq 
polymerase is a magnesium-dependent enzyme. 
 
PCR reactions were performed in GeneAmp
® 
9700 Thermocyclers (Applied 
Biosystems, Foster City, USA), according to the thermal cycling conditions listed in 
Table 2.7. 
Stage Step Process Temperature 
(
0
C) 
Time No. of cycles 
Stage 1 Step1 Incubation 95
0
C 10 minutes 1 cycle 
Stage 2 Step 1 Denaturation 94
0
C 50 seconds  
 Step 2 Primer annealing  60
0C (RASSF1A) 
560C (β-actin) 
50 seconds 35cycles(RASSF1A) 
25cycles(β-actin) 
 Step 3 Synthesis/extension 72
0
C 50 seconds  
Stage 3 Step 1 Extension 72
0
C 7 minutes 1 cycle 
Table 2.7. PCR thermal cycling conditions for amplification of RASSF1A and β-actin cDNA. An initial 
incubation step (Hot Start) ensures that active polymerase enzyme is generated at temperatures where the DNA is 
fully denatured. Optimum primer annealing temperature and cycling conditions for RASSF1A had previously been 
determined by Lusher et al. (Lusher et al., 2002). 
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2.9.3.1 Agarose gel electrophoresis 
Agarose gel electrophoresis is commonly used to separate DNA molecules on the basis 
of size. By applying an electric field, the negatively charged DNA molecules migrate 
through the agarose matrix towards the positively charged cathode. Smaller molecules 
migrate faster than larger molecules. The concentration of agarose influences product 
separation, and larger molecules are resolved better using a low concentration gel while 
smaller molecules separate better at high concentration gel. The RASSF1A and β-actin 
PCR amplification products were small fragment sizes (242bp and 232bp, respectively), 
and 2% agarose gels were used to detect them from the end point of the PCR reaction. 
Agarose gel results are semi-quantitative. GelRed Nucleic Acid Gel Stain (Biotium, 
Hayward, California, USA) was added to the agarose gel matrix in order to visualise the 
PCR products under UV light. GelRed is an intercalating nucleic acid stain and when 
exposed to UV light it fluoresces in a manner which intensifies after binding to DNA. A 
100bp DNA ladder (Promega, Madison, WI, USA) was used to allow estimation of 
product size for the bands detected. 
To prepare the gels, agarose powder (Invitrogen Ltd, Paisley, UK) was dissolved in 1 x 
TBE (Tris-Borate-EDTA) by heating in a microwave on medium power for 2-3 
minutes. TBE is an electrophoresis buffer and when mixed with agarose it produces a 
gelatinous conductive medium. The agarose/TBE solution was allowed to cool slightly 
to ~50
0
C before adding the GelRed stain; 1µl of a 10,000X stock solution of GelRed 
was added per 10ml agarose/TBE solution. After allowing the gel to set at room 
temperature in a gel cast, it was placed in a gel rig (Life Technologies Ltd, Carlsbad, 
CA, USA) and immersed in 1 x TBE buffer solution. PCR samples and 100bp DNA 
ladder were prepared for loading on the gel by diluting 5:1 in 6X Blue/Orange Loading 
Dye (Promega, Madison, WI, USA). Gels were run at 100 volts using a Powerpac (Bio-
Rad Laboratories Ltd, Hemel Hempstead, UK) and PCR cDNA amplification products 
were visualised under UV light using a transilluminator (Syngene, Cambridge, UK). 
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2.9.4 Real-time quantitative reverse transcriptase PCR 
Real-time RT-PCR (qRT-PCR) measures amplicon accumulation during the highly 
reproducible and precise exponential phase of the PCR reaction allowing for accurate 
and sensitive quantification of gene expression. qRT-PCR was used to quantify target 
gene expression levels in medulloblastoma cell lines for investigations reported in 
Chapter 3. 
SYBR Green I Dye (Invitrogen Ltd, Paisley, UK) was used to detect and quantify 
cDNA amplification for all qRT-PCR reactions described in Chapter 3. SYBR Green 
dye fluoresces upon binding the minor groove of double stranded DNA (dsDNA) and 
the emitted fluorescence is proportional to the amount of amplified dsDNA detected in 
every cycle  
A real-time PCR reaction is characterised by the cycle number when target 
amplification is first detected, known as the CT (threshold cycle). SYBR Green 
fluorescence is normalised to the internal passive reference dye ROX and produces a 
normalised reporter signal (Rn). The magnitude of target signal is determined by 
subtracting the Rn produced during the early cycles of PCR and is defined as the ΔRn. 
The qPCR instrument produces an amplification plot of ΔRn versus cycle number and 
sets a threshold level of fluorescence that is within the early stage of the exponential 
phase. The CT is thus defined as the cycle number at which fluorescence passes this 
threshold and is a relative measure of the concentration of target sequence in the PCR 
reaction. 
qRT-PCR reactions were carried out using Platinum
®
 SYBR
®
 Green qPCR SuperMix-
UDG with ROX (Invitrogen Ltd, Paisley, UK). This is a ready-to-use mix containing all 
the reagents required for qPCR, including taq polymerase, dNTPs and magnesium 
chloride along with SYBR Green I dye and the passive ROX reference dye. Cell line 
RNA was first reverse transcribed to cDNA as described in section 2.9.2. Full details 
describing how qRT-PCR reactions for target genes were set up are provided in Chapter 
3, section 3.3.10. Reactions were set up in 384-well plates (Applied Biosystems, Foster 
City, USA) and run on the ABI PRISM 7900 HT Detection System (Applied 
Biosystems, Foster City, USA).  
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Unlike traditional PCR (see section 2.9.3), qPCR instruments employ a 2 step thermal 
cycling process. The initial denaturation step occurs at 95
0
C with primer annealing and 
subsequent extension both occurring at 60
0
C. Amplicon size is smaller in qRT-PCR 
reactions (~150bp) compared with traditional RT-PCR (~300bp), permitting higher 
reaction efficiencies in the exponential phase. Primer Express
®
 software (Applied 
Biosystems, Foster City, USA) was used to design primers compatible with the thermal 
cycling conditions described above. Full details of primer design using Primer Express 
2.0 software are provided in Chapter 3, section 3.3.10.  
SYBR Green I dye binds to any double-stranded DNA and, therefore, a well optimised 
qRT-PCR reaction is essential to minimise non-specific binding and the generation of 
false positive signals. Full details on reaction optimisation for target genes, including 
optimisation of primer concentration and validation of primer specificity using melting 
curve analysis are provided in Chapter 3, section 3.3.10. 
2.9.4.1 Relative quantification using the delta-delta CT method 
There are two methods of quantification of cDNA from qRT-PCR assays; absolute 
quantification interpolates unknown quantities from a standard curve produced under 
the same reaction conditions, while relative quantification, also known as the delta delta 
CT (ΔΔCT) method, measures changes in gene expression relative to a reference sample 
(calibrator).  
For all qRT-PCR experiments performed in Chapter 3, the ΔΔCT method was used to 
calculate relative expression levels of target genes. The ΔΔCT method measures the 
difference in threshold cycles for the target sample and the designated reference sample, 
which have both been normalised to the same endogenous control, and calculates the 
amount of target according to the following formula: 
2
- ΔΔC
T
 
The ΔΔCT calculation is only valid if the efficiencies of the target and endogenous 
control amplifications are approximately equal. This requires a validation experiment to 
assess how the ΔCT (CT target- CT endogenous control) varies with template dilution. 
For amplification efficiencies that are approximately equal the ΔCT will not vary 
considerably over a range of concentrations. Full details of validation experiments for 
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each target gene and the calculation of relative target gene expression levels using the 
ΔΔCT calculation are provided in Chapter 3, section 3.3.11. 
2.10 Statistical methods 
Statistical analyses were performed using the R Statistical Computing Program, 
versions 2.12 and 2.15 (R foundation; www.R-project.org). R packages required for 
particular analyses were downloaded from the Bioconductor website 
(www.bioconductor.org). Statistical significance was tested using Mann-Whitney U 
tests and t-tests for investigations reported in Chapter 3. For investigations reported in 
Chapter 4 the R package limma (Smyth, 2004) was used. Limma uses a linear models 
approach to the analysis of microarray experiments and uses a different method of 
variance estimation compared to conventional t-tests, computing a moderated t-statistic. 
P-values were used to assess significance. Where necessary raw p-values were corrected 
for multiple hypothesis testing using the Benjamini-Hochberg false discovery rate 
(FDR) correction (Benjamini and Hochberg, 1995) and a FDR-adjusted p-value < 0.05 
was considered statistically significant. Pearson’s product-moment correlation 
coefficient (r) was calculated to assess the direction and strength of the linear 
association between CpG site methylation and the level of gene expression. A 
correlation coefficient r value < (-0.7) was indicative of a strong inverse relationship 
between methylation and gene expression. Further details of specific analyses are shown 
where appropriate. 
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Chapter 3  
Global investigation into DNA methylation-dependent 
gene regulation in Group 3 and Group 4 
medulloblastomas 
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3.1 Introduction 
Aberrant DNA methylation has an established role in driving tumourigenesis (Jones and 
Laird, 1999). In particular, CpG island promoter hypermethylation of tumour suppressor 
genes has been recognised as the most frequent mechanism for gene inactivation in 
cancers (Esteller, 2002; Baylin and Ohm, 2006; Tsai and Baylin, 2011), and, although 
not as frequently reported, an association between hypomethylation and increased gene 
expression has been found for several oncogenes (Feinberg and Vogelstein, 1983a; 
Hanada et al., 1993; Feinberg and Tycko, 2004). An investigation into DNA 
methylation-dependent gene regulation in medulloblastoma offers the potential for the 
identification of disease biomarkers and novel therapeutic targets. 
There are approximately 30 genes known to be aberrantly silenced by DNA methylation 
in medulloblastoma (Dubuc et al., 2012). Many of these, including the most frequently 
reported RASSF1A, CASP8 and HIC1 (Lindsey et al., 2005) have been identified from 
candidate gene small scale approaches. More recently, genome-wide methods, based on 
microarray gene expression profiling of cell lines before and after treatment with a 
demethylating agent, have identified COL1A2 (Anderton et al., 2008), SPINT2 
(Kongkham et al., 2008) and SFRP (Kongkham et al., 2010a) as novel tumour 
suppressor genes in medulloblastoma.  
The investigations reported in this chapter are based on results generated from a newer 
DNA methylation microarray technology (see section 2.7). Tumour profiling on the 
GoldenGate methylation platform has provided the opportunity to assess methylation 
patterns in medulloblastoma more widely, focusing on the promoter region of hundreds 
of cancer related genes (see section 2.7.2). Methylation profiling of a large cohort of 
primary medulloblastomas using the Illumina GoldenGate array has revealed the 
existence of four discrete methylomic subgroups of the disease that are strongly 
associated with their previously defined transcriptomic counterparts (SHH, WNT, 
Group 3 and Group 4) (Schwalbe et al., 2013) (see section 1.7.2.1). 
Medulloblastoma is thus a highly heterogenous tumour and is no longer considered a 
single disease. These 4 principal subgroups of medulloblastoma are associated with 
distinct molecular, clinical and pathological features and survival outcome, and will 
likely require different therapeutic strategies in the clinic (Kool et al., 2012; Taylor et 
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al., 2012). The WNT and SHH subgroups of medulloblastoma are molecularly well-
defined by key aberrations in their respective signalling pathways (see section 1.5.7), 
and the WNT subgroup is associated with a favourable prognosis compared to the other 
tumour groups (Ellison et al., 2005; Clifford et al., 2006; Kool et al., 2012). Different 
cellular origins have been identified for the WNT and SHH subgroups (Schuller et al., 
2008; Gibson et al., 2010). In contrast, very little is known about the underlying 
molecular pathology of the generically named Group 3 and Group 4 tumours. These two 
tumour subgroups make up approximately 60% of medulloblastomas. Group 3 
medulloblastomas currently have the worst outcome of the 4 subgroups; MYC 
amplification is enriched in Group 3 tumours, they are associated with LCA histology 
and are frequently metastatic at diagnosis (Kool et al., 2012) (see section 1.5.8.2). 
Group 4 is the largest tumour subgroup and carries an intermediate prognosis similar to 
SHH tumours. They are mainly classic tumours but can be of the LCA histological type 
and metastases are found in this subgroup. It is the Group 4 tumours whose molecular 
pathology remains the most elusive of all the subgroups (Kool et al., 2012) (see section 
1.5.8.2). While advances in the treatment of medulloblastoma have improved survival, 
the aggressive therapeutic regimens currently employed are associated with significant 
long-term adverse effects in the majority of survivors and for high-risk patients the 
prognosis remains poor (Pizer and Clifford, 2009). 
Previously, epigenetic regulation of COL1A2 was found to be significantly associated 
with distinct tumour-types of medulloblastoma, discriminating infant DN tumours from 
non-infant DN cases/non-desmoplastic tumours (Anderton et al., 2008). The presence of 
distinct methylomic subgroups offers the potential to further our understanding of the 
underlying molecular pathogenesis of the distinct subgroups of medulloblastoma. 
Paediatric medulloblastoma is characterised by relatively few mutational events 
(Parsons et al., 2011; Jones et al., 2012) and, therefore, the potential role of subgroup-
specific DNA methylation events must be investigated if we are to identify additional 
critical genes and novel pathways that may be driving tumourigenesis and that may be 
targeted therapeutically. 
To date, there have been no detailed studies into the role of DNA methylation in the 
pathogenesis of Group 3 and Group 4 medulloblastomas. Using high-throughput DNA 
methylation microarrays, this chapter reports a global investigation into DNA 
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methylation-dependent gene regulation and its potential role in Group 3 and Group 4 
medulloblastoma tumourigenesis. Unravelling the molecular biology of Group 3 and 
Group 4 medulloblastomas is vital if we are to deliver better and more personalised 
therapies to these patients, with the primary goal of improving survival and minimising 
the long-term adverse outcomes associated with aggressive treatment. 
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3.2 Aims 
The work reported in this chapter aimed to: 
 Identify significantly differentially methylated CpG sites that distinguish the 
Group 3 and the Group 4 medulloblastomas from other tumour subgroups. 
 
 Identify those differentially methylated genes that also exhibit significant 
differential expression in Group 3 and Group 4 tumours compared to other 
tumour subgroups across multiple independent primary tumour cohorts. 
 
 Evaluate the relationship between the patterns of differential methylation and 
gene expression observed across tumour subgroups, and identify putative 
candidate Group 3- and Group 4-specific epigenetically regulated genes. 
 
 For the selected list of candidate genes, investigate the relationship between 
DNA methylation and gene expression in a panel of medulloblastoma cell lines 
treated with the demethylating agent 5-azaCdR. 
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3.3 Materials and Methods 
3.3.1 GoldenGate Cancer Panel I Methylation Microarray 
The Illumina GoldenGate Cancer Panel I methylation microarray (see section 2.7.2) was 
used to assess patterns of methylation in a defined cohort of primary medulloblastomas, 
medulloblastoma cell lines and non-neoplastic cerebellar samples. The array 
interrogates the methylation status of 1,505 CpG sites located in the promoter region of 
over 800 genes. The methylation microarray analysis was performed at the Wellcome 
Trust Centre for Human Genetics, Oxford, UK, according to manufacturer’s protocols 
(Illumina, San Diego, CA, USA). All raw data processing and normalisation were 
carried out by Dr. Ed Schwalbe (Schwalbe et al., 2013), and final methylation β-value 
scores were kindly provided by Dr. Schwalbe. The β-value measures methylation status 
on a continuous scale, ranging from 0 (completely unmethylated) to 1 (completely 
methylated) (see section 2.7.2.1). The Illumina annotation data file for the GoldenGate 
methylation array was kindly provided by Dr. Ed Schwalbe and facilitated the mapping 
of probes to their official gene symbol, chromosome location and CpG island status. 
3.3.1.1 Primary medulloblastoma cohort 
A representative cohort of 216 primary medulloblastomas (see section 2.1.1) was 
analysed on the GoldenGate methylation array and used for investigations reported in 
this chapter. The cohort included all known medulloblastoma histopathological 
subtypes and patient ages ranged from 1.2 months to 43 years old. The 4 principal 
molecular subgroups of medulloblastoma (SHH, WNT, Group 3 and Group 4) were 
represented in the cohort. Newcastle Research Ethics Committee approval had been 
obtained for the collection, storage and biological study of all material. 
3.3.1.2 Medulloblastoma cell lines 
Eleven medulloblastoma cell lines (Med1, Med8A, DAOY, D283, D341, D384, D556, 
D425, D458, UW228-2, UW228-3) (see section 2.2) were analysed on the GoldenGate 
methylation array. 
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3.3.1.3 Non-neoplastic cerebellar samples 
The methylation profiles of 13 non-neoplastic cerebellar samples assayed on the 
GoldenGate methylation array were kindly provided by Dr. Christine Ladd-Acosta 
(Johns Hopkins University School of Medicine, Baltimore, USA). The cohort 
comprised 10 infant and 2 adult samples with the patient age of 1 sample unknown. 
Eight further non-neoplastic cerebellar samples were collected in Newcastle, UK and 
comprised 4 foetal, 2 newborn and 2 adult samples. Samples consisted of post-mortem 
material from patients who died from non-neoplastic conditions. 
3.3.1.4 Extraction and preparation of DNA 
DNA extractions for samples analysed on the GoldenGate methylation array were 
carried out by Dr. Meryl Lusher, Dr. Janet Lindsey and Mr. Kieran O’Toole (Newcastle 
University Paediatric Brain Tumour Research Group). The primary cohort comprised 
samples extracted from both frozen tumour tissue and formalin-fixed paraffin embedded 
(FFPE) tissue. DNA was extracted from FFPE samples using a Qiamp DNA FFPE 
tissue kit (Qiagen Ltd, Manchester, UK) and from cell lines using a Qiagen DNeasy kit 
(Qiagen Ltd, Manchester, UK), according to manufacturer’s instructions (see section 
2.6.2). DNA was extracted from frozen tumour samples using TRIzol
®
 Reagent 
(Invitrogen Ltd, Paisley, UK), according to manufacturer’s instructions (see section 
2.6.2). Aliquots of 1µg of DNA at 100ng/µl, as measured by NanoDrop (see section 
2.6.3.1), were sent for methylation array profiling. 
3.3.2 Medulloblastoma methylomic subgroups 
The 216 primary medulloblastomas were reliably subclassified according to their 
GoldenGate methylation profiles by Dr. Ed Schwalbe (Newcastle University Paediatric 
Brain Tumour Research Group). Dr. Schwalbe demonstrated by cross-validation in 
training and test cohorts that medulloblastoma comprises four robust DNA methylation 
subgroups (SHH, WNT, Group 3 and Group 4) that are strongly associated with the four 
principal transcriptomic subgroups of the same nomenclature and that have distinct 
molecular, clinical and pathological disease features (Schwalbe et al., 2013). 
The proportion of tumours classified in each methylomic subgroup was comparable to 
those described for their transcriptomic counterparts (Kool et al., 2012). Group 4 
tumours formed the largest group (44% [94 tumours]), followed by SHH (23% [50 
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tumours]) and Group 3 (20% [44 tumours]). WNT tumours represented the smallest 
group (13% [28 tumours]) (Table 2.1). 
3.3.3 Medulloblastoma gene expression profiles 
3.3.3.1 Primary tumour transcriptomic datasets 
Three independent in silico transcriptomic datasets (Kool/Fattet, Cho and Northcott; see 
section 2.4) were used for investigations reported in this chapter. Expression profiles 
and supporting annotation data files were accessed as described in section 2.4. The 
primary tumours in each dataset were reliably subclassified into the four principal 
subgroups of medulloblastoma (SHH, WNT, Group 3 and Group 4) by Dr. Dan 
Williamson (Newcastle University Paediatric Brain Tumour Research Group) using a 4 
metagene classifier as described in section 2.4.1.  
3.3.3.2 Cell line transcriptomic dataset  
Microarray gene expression profiling of 3 medulloblastoma cell lines, cultured in the 
presence and absence of the demethylating agent 5-azaCdR, had previously been carried 
out within the Newcastle University Paediatric Brain Tumour Research Group 
(Anderton et al., 2008). The Affymetrix U133A gene expression microarray platform 
was used to analyse expression changes following demethylation of the MED8A, D283 
and D425 cell lines (see section 2.2). This in silico cell line transcriptomic dataset was 
used to facilitate selection of candidate epigenetically regulated genes for further 
investigation. 
3.3.4 Differential methylation analysis  
3.3.4.1 Identification of Group 3 and Group 4 DNA methylation markers 
The Goldengate methylation β-value (see section 2.7.2.1) has a bounded range from 0 
(completely unmethylated) to 1 (completely methylated). The distribution of β-values is 
bimodal with the majority of samples being either fully methylated or fully 
unmethylated (Figure 3.1). Due to this non-normal distribution the non-parametric 
Mann-Whitney U test was used to identify CpG sites with significantly different 
methylation profiles in the Group 3 and the Group 4 medulloblastomas compared to the 
other tumour subgroups.  
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Figure 3.1. Density distribution of methylation β-values in primary medulloblastoma cohort. Kernel density 
plot illustrates the bimodal distribution of methylation β-values for the 216 primary tumours analysed on the 
GoldenGate methylation microarray.  
Applying the Mann-Whitney U test, pair-wise comparisons of the methylation status of 
the 1,505 CpG sites on the array were tested as follows: 
 Group 3 tumours were tested against the combined SHH, WNT and 
Group 4 tumours [G3 vs Other] 
 Group 4 tumours were tested against the combined SHH, WNT and 
Group 3 tumours [G4 vs Other] 
 The combined Group 3 and Group 4 tumours were tested against the 
combined SHH and WNT tumours [(G3+G4) vs (SHH+WNT)] 
The latter comparison was tested because, although Group 3 and Group 4 are distinct 
medulloblastoma subgroups, studies suggest they are likely more similar to each other 
than to SHH or WNT tumours (Taylor et al., 2012). Investigating the role of the Group 
(3+4) methylation markers in gene regulation offers the potential to identify underlying 
molecular pathology common to both Group 3 and Group 4 tumours. 
The Mann-Whitney U significance tests were conducted using the R Statistical 
Computing Program (v. 2.12). Raw p-values were corrected for multiple hypothesis 
testing using the Benjamini-Hochberg false discovery rate (FDR) correction (Benjamini 
and Hochberg, 1995). A FDR-adjusted p-value < 0.05 was considered statistically 
significant. To increase the sensitivity of the significance test and ensure that only 
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biologically relevant probes were selected an additional filter of an absolute difference 
in mean β-value (∆β) greater than 0.34 was applied. This value was chosen as it is 
double the limit of detection of the GoldenGate assay and is detectable by bisulfite 
sequencing (Illumina, 2007).  
Heatmaps, representing the methylation β-values as colours, were produced to visualise 
subgroup-specific methylation profiles. Principle component analysis (PCA), a 
statistical procedure that reveals the covariance structure of a complex dataset by 
reducing it to a smaller number of dimensions (principal components) was a useful tool 
for the visualisation and interpretation of differential methylation observed between 
medulloblastoma subgroups. The principal components of a complex dataset account 
for as much of the variation in the data as possible. Combined boxplots and strip-plots, 
depicting the distribution of β-values through quartiles, provided a visual representation 
of the distribution of methylation values within and between subgroups for individual 
CpG sites and facilitated the selection of candidate epigenetically regulated genes for 
further investigation (see section 3.3.6). Heatmaps, PCA plots and combined boxplots 
and strip-plots were constructed using R (v.2.12).  
3.3.4.2 Tumour specificity of Group 3 and Group 4 methylation markers 
The Group 3 and Group 4 methylation markers identified in section 3.3.4.1 were tested 
in their respective subgroup against the non-neoplastic cerebellar samples. The Mann-
Whitney U test was used to assess the tumour specificity of the subgroup-specific 
methylation markers. As described above, a FDR-adjusted p-value < 0.05 was 
considered statistically significant and an additional filter of an absolute difference in 
mean β value greater than 0.34 was applied. Heatmaps were constructed to visualise the 
results. 
3.3.5 Differential gene expression analysis 
Genes, corresponding to the significant differentially methylated CpG sites identified in 
section 3.3.4.1, were investigated for evidence of differential gene expression in 3 
independent primary tumour transcriptomic datasets (see section 3.3.3.1). 
Methylation and expression probes were paired on the basis of their official gene 
symbol identifiers as annotated by Illumina and Affymetrix respectively. For the 
Affymetrix U133A (Cho dataset) and U133plus 2.0 (Kool/Fattet dataset) expression 
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array platforms, probes annotated with the “_at” suffix were preferentially selected over 
those suffixed with “_a_at”, “_s_at” or “_x_at”, as they belong to unique probe sets that 
do not cross-hybridise to any other sequences (Leong et al., 2005). One probe per gene 
was selected for differential expression analysis. For the Affymetrix Exon 1.0ST array 
platform (Northcott dataset) the corresponding transcript cluster identifier was selected. 
Transcript clusters comprised all probes targeting individual exons of a given gene and 
provided gene-level expression estimates.  
Assuming normality, the parametric unpaired t-test was used to identify differentially 
expressed genes. The same pair-wise comparisons were tested as described in section 
3.3.4.1; genes corresponding to the Group 3-specific methylation markers were tested in 
a [G3 vs Other] comparison, Group 4-specific markers in a [G4 vs Other] and the Group 
(3+4) markers in a [(G3+G4) vs (SHH+WNT)] comparison.  
Unpaired t-tests were conducted using the R Statistical Computing Program (v. 2.12). 
Raw p-values were corrected for multiple hypothesis testing using a Benjamini-
Hochberg false discovery rate (FDR) correction (Benjamini and Hochberg, 1995). A 
FDR-adjusted p-value < 0.05 was considered statistically significant. To increase the 
sensitivity of the significance test and ensure the biological relevance of differential 
gene expression observed an absolute difference in mean log2 signal intensity (mean log 
ratio) threshold was applied. For each dataset, the average absolute difference in mean 
log2 intensities for all probes in all pair-wise comparisons was calculated and applied as 
the difference threshold. A mean log ratio threshold of 0.3 was applied to the 
Kool/Fattet and Northcott datasets and a threshold of 0.4 was applied to the Cho dataset 
(see Appendix B). Genes with a FDR-adjusted p-value < 0.05 and a mean log ratio > 
threshold in at least 2 out of 3 transcriptomic datasets were considered significantly 
differentially expressed. 
Combined boxplots and strip-plots illustrating the patterns of differential gene 
expression across the tumour subgroups were constructed in R (v.2.12). Assessment of 
the boxplots was performed to facilitate the selection of candidate epigenetically 
regulated genes for further investigation (see section 3.3.6). 
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3.3.6 Identification of methylation events with a putative effect on gene 
expression 
The patterns of significant differential methylation and gene expression observed across 
the tumour subgroups were assessed using the combined boxplots and strip-plots. 
Methylation of the corresponding CpG site was considered to have a putative effect on 
gene expression if a significantly higher subgroup-specific mean methylation status was 
associated with a significantly lower equivalent subgroup-specific mean gene 
expression level, and conversely if a significantly lower mean methylation status was 
associated with a significantly higher mean gene expression level (inverse relationship). 
Genes were considered to show evidence of potential epigenetic gene regulation by 
DNA methylation if an inverse subgroup-specific methylation-expression relationship 
was observed in 2 or more transcriptomic datasets. 
3.3.7 Correlating DNA methylation to gene expression using Pearson 
correlation 
Tumour-matched CpG methylation and gene expression data was only available for 9 
primary tumour samples. The primary tumours were Newcastle medulloblastoma 
samples (NMB111, NMB125, NMB131, NMB134, NMB135, NMB139, NMB143, 
NMB82, NMB93) and had been expression profiled by Kool et al. (Kool et al., 2008). 
The 9 samples comprised four WNT subgroup tumours, one SHH and four Group 4 
tumours (Table 2.1). 
The association between CpG methylation and the level of gene expression was 
assessed by calculating Pearson’s product-moment correlation coefficient (r) The level 
of gene expression was considered to be inversely correlated with CpG methylation if 
the coefficient r value obtained was less than (–0.7). 
3.3.8 In silico analysis of gene expression changes following demethylating 
treatment in medulloblastoma cell lines 
The in silico cell line transcriptomic dataset, described in section 3.3.3.2, was used to 
assess microarray gene expression changes following 5-azaCdR treatment of 3 
medulloblastoma cell lines.  
Based on the magnitude of mean log ratios observed for significant differentially 
expressed genes in primary tumours (see section 3.3.5 and Appendix B), probes 
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detecting an expression increase >1.5 fold following 5-azaCdR were considered 
upregulated by 5-azaCdR. To determine whether transcriptional silencing and 
upregulation following 5-azaCdR treatment was associated with DNA methylation, the 
GoldenGate methylation β-values of the corresponding CpG sites were considered; sites 
with a β value ≥0.7 were classed as methylated (M), those with a β value <0.3 were 
classed as unmethylated (U) and those with values between 0.3 and 0.7 were classed as 
part-methylated (PM). Genes which were upregulated by 5-azaCdR treatment consistent 
with their CpG methylation were considered to show evidence of methylation-
dependent gene regulation in cell lines. 
3.3.9 Identification of subgroup-specific candidate epigenetically regulated 
genes 
Putative subgroup-specific candidate epigenetically regulated genes were identified as 
those that: 
 were significantly differentially methylated at one or more CpG sites in Group 3 
and/or Group 4 tumours, and patterns of differential methylation showed an 
inverse association with equivalent subgroup-specific differential gene 
expression in at least 2 transcriptomic datasets (see section 3.3.6) 
And either 
 showed a strong inverse correlation between methylation and gene expression, 
as measured by Pearson’s correlation coefficient r (r<  -0.7) (see section 3.3.7) 
Or 
 showed >1.5-fold increase in expression following 5-azaCdR treatment in at 
least one methylated cell line, as determined by in silico analysis of 5-azaCdR-
induced gene expression changes (see section 3.3.8)  
It was decided not to require the Group 3 and Group 4 methylation markers to also be 
tumour-specific (see section 3.3.4.2) in the candidate gene selection criteria. It was 
recognised that this could lead to some candidate genes having an aberrant methylation 
status that would potentially be functionally significant in SHH or WNT tumours. 
However, as it is likely that Group 3 and Group 4 tumours have different cellular 
origins to each other and to SHH and WNT tumours (Kool et al., 2012) (see section 
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1.5.9), and in the absence of appropriate cell-type specific controls to allow an accurate 
comparison of tumour versus normal, tumour specificity was not a requirement. The 
tumour-specific nature of Group 3- and/or Group 4-specific methylation markers was, 
however, used as a reference to appraise the potential functional significance of 
subgroup-specific DNA methylation events. Candidate genes were selected for further 
investigation of a direct relationship between CpG methylation and gene expression by 
qRT-PCR assessment of expression changes in medulloblastoma cell lines treated with 
5-azaCdR (see section 3.3.10). 
3.3.10 Real-time quantitative RT-PCR 
Real-time quantitative reverse transcriptase PCR (qRT-PCR) (see section 2.9.4) was 
performed in a panel of medulloblastoma cell lines to assess candidate gene expression 
levels before and after treatment with the demethylating agent 5-azaCdR. Relative gene 
expression levels before and after 5-azaCdR treatment were determined using the delta 
delta CT method (see section 2.9.4.1). 
3.3.10.1 Medulloblastoma cell lines 
A panel of 6 medulloblastoma cell lines (D283, D384, D425, D556, DAOY and MED1) 
(see section 2.2) had previously been cultured in the presence of 5µM 5-azaCdR for 72 
hours. RNA extracted from the untreated and 5-azaCdR-treated cell line pairs was 
kindly provided by Dr. Janet Lindsey (Newcastle University Paediatric Brain Tumour 
Group). 
3.3.10.2 cDNA synthesis 
The concentration of RNA in the cell line samples was determined by NanoDrop (see 
section 2.6.3.1) and 1µg of cell line total RNA was reverse transcribed to cDNA using 
the iScript cDNA synthesis kit (Bio-Rad Laboratories Ltd, Hemel Hempstead, UK) (see 
section 2.9.2), according to the manufacturer’s instructions. 
3.3.10.3 Primer design 
qRT-PCR primers were designed using transcript information obtained from the 
EMBL-EBI Ensembl Genome Browser (www.ensembl.org). To prevent genomic DNA 
detection and amplification during the PCR reaction primers were designed to span an 
exon-exon junction. In circumstances where genes had more than one transcript the 
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UCSC Genome Browser (http://genome.ucsc.edu/) was used to identify exons common 
to multiple isoforms. 
The sequences for gene-specific forward and reverse primers (Table 3.1) were designed 
using the Primer Express 2.0 software (Applied Biosystems, Foster City, USA). The 
software automates primer design and was designed specifically for Applied 
Biosystems real-time PCR instruments. Primer Express facilitates the design of primers 
for applications using SYBR Green I dye detection (see section 2.9.4); the designed 
primers required minimal optimisation (see section 3.3.10.4) and were compatible with 
the thermal cycling conditions (see section 3.3.10.5). All primers were designed to 
anneal at 60
0
C and to generate amplicons with a maximum length of 150bp to facilitate 
optimum reaction efficiencies. To ensure that primers spanned an exon-exon junction 
and that no SNPs were present in the sequence, the primer pairs were assessed using the 
in-silico PCR function on the UCSC Genome Bioinformatics website 
(http://genome.ucsc.edu/). The NCBI BLAST tool was used to ensure target specificity 
of primer sets (http://blast.ncbi.nlm.nih.giv/). BLAST aligns and compares query DNA 
sequences against gene sequence databases and facilitates the identification of non-
specific amplification. 
The isoform A transcript of the RASSF1 gene was used as a positive control for the 
demethylating treatment of the cell lines with 5-azaCdR. RASSF1A was used due to the 
robust evidence for its methylation-dependent transcriptional silencing and re-activation 
following 5-azaCdR treatment in multiple medulloblastoma cell lines (Lusher et al., 
2002). A previously published RASSF1A primer set was used (Palakurthy et al., 2009) 
(Table 3.1). Primer sequences for the endogenous control genes, TBP and GAPDH, 
were kindly provided by Dr. Sarra Ryan and Dr. Lisa Russell, respectively (Newcastle 
University Leukaemia Research Cytogenetics Group) (Table 3.1). TBP and GAPDH are 
common endogenous control genes in PCR applications. They are housekeeping genes 
essential for the maintenance of basic cellular functions and are constitutively expressed 
in all cells. Endogenous controls were necessary to normalise any differences in starting 
cDNA quantities between samples.  
Primers were custom synthesised by Sigma Aldrich (Sigma Aldrich Ltd, Gillingham, 
UK) and supplied as lyophilised pellets. Upon delivery primers were reconstituted in 
 153 
 
nuclease-free water (Qiagen Ltd, Manchester, UK) at a concentration of 100µM and 
stored at -20
0
C alongside 10µM working stock aliquots. 
Gene Name F primer (5’-3’) R primer (5’-3’) Amplicon 
size (bp) 
Exons 
spanned 
DDR2 CAGCTTCCAGTCAGTGGTCAGA CCAGCCTTCCATATTTGGCA 51 5&6 
HDAC1 GCCATCCTGGAACTGCTAAAGT AATGTCAATGTACAGCACCCTCTG 51 5&6 
MET GCTACACACTGGTTATCACTGGGA CATTCAATGGGATCTTCGTGATC 51 4&5 
RHOH CCAGTTGAAGACTAGGCTTTGGAG CATCCAAGCACCGTCTGCTT 51 2&3 
RASSF1A ACCTCTGTGGCGACTTCATC CGGTAGTGGCAGGTGAACTT 51 1&2 
GAPDH CAAGGTCATCCATGACAACTTTG GTCCACCACCCTGTTGCTGTAG 51 7&8 
TBP TGTATTAACAGGTGCTAAAGTCAG TTTTCAAATGCTTCATAAATTTCTGC 51 7&8 
Table 3.1. Primer sequences for qRT-PCR. Forward and reverse primer sequences, amplicon size and exons 
spanned during primer design are shown for target and control genes. 
 
3.3.10.4 Primer validation and optimisation  
A melt curve analysis was performed immediately after each real-time PCR run to 
confirm target specificity of primers. The Primer Express software sets a default 
maximum melting temperature (Tm) of 85
0
C for amplicons generated during the PCR 
reaction, with most falling between 75
0
C and 85
0
C. The melt curve analysis was applied 
between 60-95
0
C at 10
0
C intervals and produced a plot of change in fluorescence 
against temperature. For each primer set the melt curve should have one peak occurring 
at the appropriate Tm for the amplicons generated and this should be consistent across 
all samples tested. A melt curve will identify any non-specific amplification, including 
primer-dimer formation (see Figure 3.2). Primer-dimers occur when primers anneal to 
each other creating short sequence by-products of the PCR reaction that can adversely 
affect the quality of PCR results. 
The formation of primer-dimers can be minimised by optimising the concentration of 
primers being added to the reaction. The minimum primer concentration was chosen 
that produced sufficient early detection (lowest CT/ highest fluorescent signal) while 
minimising primer-dimer formation (see Table 3.2). All primer sets were validated 
using melt curves and, at the primer concentrations detailed in Table 3.2, non-specific 
amplification was not evident. 
 154 
 
PCR reaction efficiencies for the target and endogenous control genes were validated as 
described in section 3.3.11.1. Inspection of CT values and signal intensities produced 
from these validation experiments facilitated the optimisation of input cDNA 
concentration. The optimum CT values for gene quantification are generally between 15 
and 30. For genes whose initial CT values fell outside this range (highly and lowly 
expressed) the concentration of input cDNA was optimised (Table 3.2). 
 
Figure 3.2. Melt curve analysis to detect non-specific PCR amplification. The melt curve represents a plot of the 
first derivative of rate of change in fluorescence as a function of temperature and shows typical primer-dimer 
formation. Primer-dimers are short sequence PCR by-products caused by primers annealing to each other. Primer-
dimers have a characteristically lower Tm compared to that of the larger specific target PCR product. Figure taken 
from the Applied Biosystems SYBR® GreenPCR Master Mix User Guide (Applied Biosystems, Foster City, USA). 
3.3.10.5 Protocol for qRT-PCR 
qRT-PCR reactions were carried out using Platinum SYBR
®
 Green qPCR SuperMix-
UDG with ROX (Invitrogen Ltd, Paisley, UK). 10µl reactions were set up as follows: 
5.1µl SYBR Green superMix, 0.5µl nuclease-free water, 0.2µl forward primer and 0.2µl 
reverse primer. 6µl of reaction mix and 4µl of cDNA template were added to wells on a 
384 well-plate. Each reaction was performed in triplicate with no-template controls. 
Reactions were set up in a LabCaire PCR clean air cabinet (Scientific Laboratory 
Supplies Ltd, Nottingham, UK) and the cDNA template was added at the bench. Table 
3.2 details the primer concentration and the input cDNA concentration used for each 
target gene reaction.  
Real-time PCR amplification was carried out using the ABI PRISM 7900 HT Detection 
System (Applied Biosystems, Foster City, USA) according to the following protocol: 10 
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minutes at 95
0
C (incubation), followed by 40 cycles of 15 seconds at 95
0
C 
(denaturation) and 60 seconds at 60
0
C (annealing/extension). The qRT-PCR results 
presented in section 3.4.9 are representative of triplicate PCR runs carried out on 
different days. 
Amplicon Primer conc. in 10µl reaction cDNA conc. in 10µl reaction 
DDR2 0.2µM 0.2ng/µl 
HDAC1 0.2µM 0.2ng/µl 
MET 0.05µM 2ng/µl 
RHOH 0.05µM 2ng/µl 
RASSF1A 0.2µM 7ng/µl 
GAPDH 0.2µM 0.2ng/µl 
TBP 0.2µM 0.2ng/µl 
Table 3.2. Optimised primer concentration and cDNA template concentration for target and control genes. 
Concentration of primers and cDNA template added to each 10µl PCR reaction are shown for target and control 
genes tested by qRT-PCR. 
3.3.11 Relative quantification using the delta delta CT method 
The delta delta CT (∆∆CT) method (see section 2.9.4.1) was used to determine the 
relative gene expression levels in medulloblastoma cell lines before and after treatment 
with 5-azaCdR. A validation experiment was first performed to determine if the reaction 
efficiencies of the target and endogenous control genes were approximately equal, 
ensuring the validity of the ∆∆CT calculation.  
3.3.11.1 Validation of PCR reaction efficiencies 
PCR reaction efficiencies for the target and endogenous control genes were assessed by 
carrying out reactions using two- and three-fold serial dilutions of a pooled 
medulloblastoma cell line cDNA sample. The concentration of cDNA in the pooled 
sample was determined by NanoDrop (see section 2.6.3.1) and dilutions were prepared 
spanning 5-6 input cDNA concentrations. Reactions were performed in triplicate as 
described in section 3.3.10.5. CT values were exported from the instrument software to 
Microsoft Excel 2007 and the ∆CT (CT target – CT endogenous control) was calculated 
for each serial dilution of cDNA template. A plot of log input cDNA amount versus 
∆CT was produced in Microsoft Excel. The efficiencies of target and endogenous 
control genes were considered equal if the absolute value of the slope was ≤0.2. 
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3.3.11.2 Relative quantification of candidate gene expression before and after 
5-azaCdR treatment 
The ∆∆CT method measures changes in gene expression relative to a reference sample 
(calibrator sample). For investigations reported in this chapter the sample with the 
lowest expressed levels (highest CT values) was designated the calibrator sample. 
Following each PCR run CT values were exported to Microsoft Excel 2007 and the 
mean CT and standard deviation values of the replicate sample results were calculated. 
The mean CT was used to determine relative target gene expression as follows: 
 ∆CT was calculated by: CT target – CT endogenous control. 
 ∆∆CT was calculated by: ∆CT test sample - ∆CT calibrator sample. 
 Relative gene expression in the treated and untreated cell line pairs was 
calculated using the formula 2
-∆∆CT
. 
For each candidate gene, the fold-change in expression following 5-azaCdR treatment 
was calculated by normalising the relative mean expression in the treated cell line to the 
relative mean expression in the untreated cell line in Excel 2007. Graphs illustrating 
relative mean expression and mean fold-change in expression from triplicate PCR runs 
were produced in GraphPad Prism (v.4.03). 
Genes that showed an expression increase > 2-fold following 5-azaCdR treatment were 
classed as being significantly upregulated. To determine whether the transcriptional 
silencing and gene upregulation following 5-azaCdR treatment observed was associated 
with DNA methylation, the methylation status of the corresponding GoldenGate CpG 
probe (see section 3.3.6) was considered. Using the GoldenGate methylation β-value 
scores, loci with a β value ≥0.7 were classed as methylated (M), those with a β value 
<0.3 were classed as unmethylated (U) and those with values between 0.3 and 0.7 were 
classed as part-methylated (PM). Genes that were silenced and upregulated by 5-
azaCdR in methylated cell lines but not in unmethylated cell lines had a methylation 
status consistent with their epigenetic regulation and showed strong evidence of 
methylation-dependent transcriptional regulation in medulloblastoma cell lines. 
Candidate gene CpG methylation was considered to be functionally significant in 
medulloblastoma cell lines if evidence of epigenetic gene regulation was seen in 4 or 
more cell lines. 
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3.4 Results 
This chapter aimed to investigate the role of gene promoter DNA methylation in the 
regulation of gene expression in the Group 3 and Group 4 medulloblastoma subgroups. 
Using the high-throughput GoldenGate methylation microarray a panel of 807 genes 
were assessed for potential epigenetic regulation in a representative cohort of 216 
primary medulloblastomas.  
3.4.1 Novel methylation markers of Group 3 and Group 4 medulloblastomas 
Using the Mann-Whitney U test, novel methylation markers of Group 3, Group 4 and of 
Group (3+4) medulloblastomas were identified as described in section 3.3.4.1. 
There were 23 significant differentially methylated CpG sites in Group 3 tumours 
(Table 3.3 and Figure 3.3(A)); 31 CpG sites were Group 4-specific (Table 3.4 and 
Figure 3.3(B)) and 48 CpG sites significantly discriminated Group (3+4) from both 
SHH and WNT tumours (Table 3.5 and Figure 3.4)  
Three Group 3-specific events (13%) were also specific to Group (3+4) (Table 3.3). In 
the larger Group 4 there were 26 events (84%) that were also significant for Group 
(3+4) (Table 3.4). Significance testing was carried out by combining distinct subgroups 
of medulloblastoma together to facilitate a 2 group comparison (see section 3.3.4.1). 
The high proportion of Group 4 events that are also Group (3+4) events highlights the 
potential limitations of the experimental design and significance test applied in 
accommodating the unequal variances and sample sizes across the 4 distinct subgroups 
of medulloblastoma. The results do, however, strongly support the current view that 
while Group 3 and Group 4 are distinct molecular entities in medulloblastoma they are 
more similar to each other than to SHH and WNT tumours (Taylor et al., 2012). 
A total of 73 CpG sites (encompassing 63 genes) were identified that significantly 
distinguish the Group 3 and/or Group 4 medulloblastomas and represent novel 
methylation markers of these poorly characterised subgroups (Figure 3.5).
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Table 3.3. Medulloblastoma Group 3-specific DNA methylation events. Results of the Mann-Whitney U tests 
assessing methylation in Group 3 tumours against methylation in all other tumour subgroups are detailed. 
Methylation probe ID and presence of a CpG island, as defined by Illumina, are shown. 23 CpG sites were 
significantly differentially methylated with a FDR-adjusted p-value <0.05 and a ∆β value >0.34. 61% (14/23) of sites 
were located in a CpG island. One gene (FES) had 2 CpG sites both located in a CpG island that had significantly 
different methylation levels in Group 3 tumours compared to all other subgroups. * Probes were also significantly 
differentially methylated in Group (3+4) tumours compared to (SHH+WNT) tumours. 
 
Group 3 vs Other 
Methylation CpG 
probe 
CpG 
Island 
Mean β value 
(Group 3) 
Mean β value 
(Other) 
Absolute Difference in mean 
β value (∆β) 
Corrected p-
value 
BCAP31_P1072_F Y 0.39 0.86 0.47 5.47E-10 
BCR_P422_F Y 0.64 0.28 0.36 5.06E-09 
BLK_P668_R * N 0.26 0.82 0.56 1.28E-13 
CCL3_E53_R N 0.50 0.87 0.36 8.93E-11 
CHI3L2_P226_F * N 0.27 0.66 0.39 2.05E-10 
FES_E34_R Y 0.58 0.10 0.48 7.79E-13 
FES_P223_R Y 0.60 0.13 0.47 2.14E-11 
FGF1_P357_R N 0.61 0.22 0.39 2.12E-10 
FRZB_E186_R Y 0.52 0.08 0.43 1.08E-08 
HFE_E273_R * Y 0.88 0.41 0.48 6.35E-10 
HLA-DOB_P357_R N 0.42 0.79 0.37 9.25E-11 
IL1RN_P93_R Y 0.58 0.13 0.45 1.42E-13 
KRT1_P798_R N 0.54 0.93 0.39 5.31E-14 
MMP14_P13_F Y 0.53 0.09 0.46 1.04E-12 
PLA2G2A_E268_F N 0.47 0.88 0.41 7.22E-12 
RARRES1_P426_R Y 0.63 0.21 0.41 8.93E-11 
SERPINA5_E69_F N 0.54 0.88 0.34 5.54E-12 
TGFB2_E226_R Y 0.50 0.09 0.41 7.31E-06 
THBS2_P605_R N 0.46 0.88 0.43 1.04E-12 
TP73_P945_F Y 0.56 0.19 0.37 6.79E-07 
TRIP6_E33_F Y 0.59 0.18 0.41 2.64E-11 
WRN_P969_F Y 0.65 0.173 0.49 1.37E-12 
ZNFN1A1_E102_F Y 0.41 0.90 0.49 5.31E-14 
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Group 4 vs Other 
Methylation CpG 
probe 
CpG 
Island 
Mean β value 
(Group 4) 
Mean β value 
(Other) 
Absolute Difference in mean 
β value (∆β) 
Corrected p-
value 
ASCL2_P609_R ** Y 0.12 0.49 0.37 2.34E-10 
CCKAR_E79_F ** N 0.08 0.58 0.50 2.30E-15 
CCKAR_P270_F ** N 0.10 0.59 0.49 3.86E-14 
CSF3R_P472_F N 0.36 0.71 0.36 4.63E-17 
DDR2_E331_F ** N 1.0 0.64 0.35 2.66E-10 
FZD9_E458_F ** Y 0.13 0.47 0.34 6.71E-09 
HDAC1_P414_R ** Y 0.85 0.44 0.41 9.42E-17 
HIC_seq_48_S103_R 
** 
Y 0.33 0.83 0.50 4.25E-16 
HLA-DPA1_P28_R N 0.85 0.50 0.35 1.59E-15 
IFNGR2_P377_R ** Y 0.09 0.52 0.43 1.05E-17 
IGF1_E394_F N 0.78 0.40 0.38 1.35E-13 
IL16_P93_R ** N 0.21 0.56 0.35 1.11E-10 
L1CAM_P19_F ** Y 0.89 0.36 0.53 4.10E-16 
LEFTY2_P719_F ** N 0.86 0.49 0.37 1.15E-17 
MEST_E150_F ** Y 0.29 0.64 0.35 1.39E-09 
MEST_P4_F ** Y 0.39 0.73 0.34 4.65E-10 
MEST_P62_R ** Y 0.32 0.70 0.38 1.88E-11 
MET_E333_F ** Y 0.66 0.28 0.38 3.52E-10 
MMP10_E136_R ** N 0.82 0.42 0.40 9.40E-14 
NOTCH4_P938_F N 0.73 0.38 0.35 3.02E-12 
PADI4_P1158_R ** N 0.75 0.41 0.35 5.08E-12 
PIK3R1_P307_F ** N 0.08 0.60 0.52 6.39E-22 
PLG_E406_F ** N 0.29 0.68 0.39 1.95E-15 
RAN_P581_R Y 0.21 0.64 0.43 4.69E-16 
RHOH_P121_F ** N 0.41 0.82 0.41 9.63E-14 
SPP1_E140_R ** N 0.75 0.37 0.38 3.92E-14 
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Group 4 vs Other 
Methylation CpG 
probe 
CpG 
Island 
Mean β value 
(Group 4) 
Mean β value 
(Other) 
Absolute Difference in mean 
β value (∆β) 
Corrected p 
value 
TM7SF3_P1068_R N 0.53 0.88 0.35 1.59E-15 
TRIM29_E189_F ** Y 0.74 0.33 0.41 2.71E-16 
WNT10B_P993_F ** Y 0.76 0.33 0.42 8.03E-17 
ZIM3_P718_R ** N 0.42 0.77 0.35 1.46E-12 
ZNF264_P397_F ** Y 0.09 0.46 0.36 1.53E-09 
Table 3.4. Medulloblastoma Group 4-specific DNA methylation events. Results of the Mann-Whitney U tests 
assessing methylation in Group 4 tumours against methylation in all other tumour subgroups are detailed. 
Methylation probe ID and presence of a CpG island, as defined by Illumina, are shown. 31 CpG sites were 
significantly differentially methylated with a FDR-adjusted p-value <0.05 and a ∆β value >0.34. 48% (15/31) of sites 
were located in a CpG island. Two genes, CCKAR and MEST, had 2 and 3 CpG sites, respectively, that had 
significantly different methylation levels in Group 4 tumours compared to all other subgroups. MEST CpG sites were 
located in a CpG island while CCKAR sites were not. ** Probes were also significantly differentially methylated in 
Group (3+4) tumours compared to (SHH+WNT) tumour 
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Group (3+4) vs (SHH+WNT) 
Methylation CpG 
probe 
CpG 
Island 
Mean β value 
(Group(3+4)) 
Mean β value 
(SHH+WNT) 
Absolute Difference in 
mean β value (∆β) 
Corrected p- 
value 
ASCL2_E76_R Y 0.03 0.46 0.43 3.67E-09 
ASCL2_P360_F Y 0.04 0.56 0.52 5.82E-14 
ASCL2_P609_R Y 0.14 0.67 0.53 1.81E-18 
AXIN1_P995_R Y 0.20 0.57 0.37 2.25E-08 
BGN_P333_R N 0.63 0.26 0.37 3.64E-16 
BLK_P668_R N 0.58 0.93 0.35 8.15E-13 
CAPG_E228_F N 0.95 0.57 0.38 4.89E-22 
CCKAR_E79_F N 0.12 0.80 0.68 9.83E-26 
CCKAR_P270_F N 0.11 0.85 0.74 3.33E-27 
CEACAM1_E57_R N 0.13 0.51 0.37 3.35E-16 
CHI3L2_P226_F N 0.46 0.80 0.34 3.95E-14 
CSF3R_P472_F N 0.44 0.77 0.34 4.74E-15 
CYP2E1_E53_R N 0.66 0.29 0.37 1.05E-12 
DDR2_E331_F N 0.98 0.45 0.53 2.92E-18 
FGF1_E5_F N 0.55 0.19 0.36 6.55E-16 
FZD9_E458_F Y 0.14 0.63 0.49 2.59E-17 
HDAC1_P414_R Y 0.74 0.40 0.34 1.00E-10 
HFE_E273_R N 0.75 0.08 0.67 1.13E-23 
HIC1_seq_48_S103_R Y 0.46 0.88 0.42 5.23E-12 
IFNGR2_P377_R Y 0.16 0.64 0.48 4.91E-20 
IL16_P226_F N 0.11 0.46 0.34 6.77E-11 
IL16_P93_R N 0.22 0.75 0.53 4.89E-22 
IL1RN_E42_F N 0.65 0.32 0.34 2.84E-15 
IL8_P83_F N 0.92 0.57 0.35 9.45E-14 
L1CAM_P19_F Y 0.78 0.25 0.54 1.66E-15 
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Group (3+4) vs (SHH+WNT) 
Methylation CpG 
probe 
CpG 
Island 
Mean β value 
(Group(3+4)) 
Mean β value 
(SHH+WNT) 
Absolute Difference in 
mean β value (∆β) 
Corrected p- 
value 
LCN2_P86_R N 0.86 0.52 0.34 5.07E-16 
LEFTY2_P719_F N 0.80 0.38 0.43 9.14E-20 
MEST_E150_F Y 0.33 0.78 0.45 4.98E-15 
MEST_P4_F Y 0.42 0.87 0.46 6.87E-16 
MEST_P62_R Y 0.36 0.84 0.48 2.68E-17 
MET_E333_F Y 0.66 0.06 0.59 3.16E-21 
MMP10_E136_R N 0.75 0.33 0.42 8.87E-15 
MSH2_P1008_F Y 0.13 0.64 0.51 3.64E-16 
PADI4_P1158_R N 0.68 0.33 0.35 5.45E-11 
PIK3R1_P307_F N 0.15 0.78 0.64 1.69E-25 
PLG_E406_F N 0.31 0.88 0.58 2.58E-29 
RHOH_P121_F N 0.50 0.90 0.40 1.05E-16 
SPARC_P195_F N 0.63 0.15 0.47 4.89E-22 
SPP1_E140_R N 0.73 0.21 0.52 5.84E-23 
STAT5A_E42_F N 0.90 0.47 0.42 4.17E-20 
TAL1_P594_F Y 0.13 0.54 0.42 8.10E-15 
TFPI2_P152_R Y 0.49 0.13 0.36 2.58E-18 
TRIM29_E189_F Y 0.69 0.20 0.50 1.06E-21 
VAV1_E9_F Y 0.96 0.51 0.45 1.31E-18 
VAV1_P317_F N 0.90 0.40 0.49 3.16E-21 
WNT10B_P993_F Y 0.68 0.22 0.46 2.23E-18 
ZIM3_P718_R N 0.48 0.86 0.38 8.49E-16 
ZNF264_P397_F Y 0.15 0.56 0.41 7.70E-11 
 163 
 
Table 3.5. Medulloblastoma Group (3+4)-specific DNA methylation events. Results of the Mann-Whitney U tests 
assessing methylation in Group (3+4) tumours against methylation in the SHH and WNT subgroups are detailed. 
Methylation probe ID and presence of a CpG island, as defined by Illumina, are shown. 48 CpG sites were 
significantly differentially methylated with a FDR-adjusted p-value <0.05 and a ∆β value >0.34. 44% (21/48) of sites 
were located in a CpG island. Five genes, ASCL2,CCKAR, IL16,MEST and VAV1, had 2 or more CpG sites that had 
significantly different methylation levels in Group (3+4) tumours compared to SHH and WNT tumours. CpG sites for 
ASCL2 and MEST were located within a CpG island. VAV1 had one CpG site (VAV1_E9_F) located within an island 
while the other (VAV1_P317_F) was outside an island. Sites for CCKAR and IL16 were not located within CpG 
islands. 
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Figure 3.3. Heatmaps illustrating differential methylation patterns for Group 3-specific and Group 4-specific 
methylation markers. Colour gradients represent the continuous β-values between 0: completely unmethylated 
(GREEN) and 1: completely methylated (RED). (A) Group 3-specific methylation events; the differential pattern of 
methylation for the 23 CpG sites clearly distinguishes Group3 tumours from all other subgroups. (B) Group 4-
specific methylation events; 26 of the 31 Group 4-specific CpG sites also significantly distinguish Group (3+4) from 
SHH and WNT tumours. The differential pattern of methylation for the Group 4 sites clearly illustrates the similarity 
to Group 3 tumours. Subgroups are represented on heatmaps by different colours: SHH, blue; WNT, red; Group 
3(G3), purple; Group 4 (G4), orange. 
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Figure 3.4 Heatmap illustrating differential methylation pattern for Group (3+4)-specific methylation 
markers. Colour gradients represent the continuous β-values between 0: completely unmethylated (GREEN) and 1: 
completely methylated (RED).The differential pattern of methylation for the 48 CpG sites clearly distinguishes Group 
(3+4) tumours from SHH and WNT tumours. Subgroups are represented on heatmaps by different colours: SHH, 
blue; WNT, red; Group 3(G3), purple; Group 4 (G4), orange. 
 
 
Figure 3.5. 3-D PCA plot of the Group 3 and Group 4 methylation markers. Plot illustrates how the 73 Group 3- 
and/or Group 4- specific CpG sites effectively distinguish Group 3 (purple) and Group 4 (orange) tumours from the 
SHH (blue) and WNT (red) tumours. The methylation markers identify Group 3 and Group 4 as distinct subgroups 
that are more similar to each other than to SHH and WNT. 
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3.4.2 Tumour specificity of Group 3 and Group 4 methylation markers 
The Mann-Whitney U test was next used to assess the tumour specificity of the Group 
3-, Group 4- and the Group (3+4)-specific methylation markers as described in section 
3.3.4.2.  
The majority of Group 3 methylation markers (21/23; 91%) were significantly 
differentially methylated between Group 3 tumours and non-neoplastic cerebella 
(Appendix A); 12 CpG sites were hypermethylated and 9 were hypomethylated in 
Group 3 (Figure 3.6(A)). Less than half of Group 4 methylation markers (13/31; 42%) 
were significantly differentially methylated between Group 4 and non-neoplastic 
cerebella (Appendix A); 5 CpG sites were hypermethylated and 8 were hypomethylated 
in Group 4 (Figure 3.6(B)). Similarly, 42% (20/48) of Group (3+4) methylation markers 
had significantly different methylation levels in the Group (3+4) tumours compared to 
the non-neoplastic cerebella (Appendix A); 9 CpG sites were hypermethylated and 11 
were hypomethylated in Group (3+4) tumours (Figure 3.6(C)). The tumour-specific 
markers showed more variable patterns of methylation in the Group 3 and Group 4 
primary tumour samples compared with the non-neoplastic cerebellar samples, which 
showed greater consistency in their methylated and unmethylated states (Figure 3.6). 
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Figure 3.6. Heatmaps illustrating differential methylation patterns for the tumour-specific Group 3 and Group 4 methylation markers. Colour gradients represent the continuous β-values 
between 0: completely unmethylated (GREEN) and 1: completely methylated (RED). Heatmaps demonstrate the significant differential patterns of methylation observed between primary tumour 
subgroup and non-neoplastic cerebella (cbl). (A) 21/23 Group 3-specific CpG sites are also tumour-specific, encompassing 12 hypermethylated and 9 hypomethylated events. (B) 13/31 Group 4-specific 
CpG sites are also tumour-specific, encompassing 5 hypermethylated and 8 hypomethylated events. (C) 20/48 Group (3+4)-specific CpG sites are also tumour-specific, encompassing 9 hypermethylated 
and 11 hypomethylated events. Tumour-specific markers show less variable methylation patterns in non-neoplastic cerebella (cbl) compared with Group 3 and Group 4 primary tumours. Primary tumour 
subgroups and non-neoplastic cerebella are represented on heatmaps by different colours: Group 3(G3), purple; Group 4 (G4), orange; non-neoplastic cerebella (cbl), pink.  
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3.4.3 Differential gene expression across multiple primary cohorts 
The 63 genes containing Group 3-, Group 4- and Group (3+4)-specific CpG sites (see 
section 3.4.1) were next investigated for evidence of equivalent subgroup-specific 
differential gene expression in 3 independent primary medulloblastoma cohorts, using 
unpaired t-tests as described in section 3.3.5. 
In general, across the 3 transcriptomic datasets, the absolute difference in mean log2 
expression levels (mean log ratio) observed for all pair-wise comparisons were small 
(see Appendix B). A total of 15 out of the 63 genes were significantly differentially 
expressed in a subgroup-specific manner (Table 3.6). The results can be summarised as 
follows: 
 Group 3-specific events:- of the 22 genes differentially methylated at 1 
or more CpG sites, 3 (14%) were differentially expressed in Group 3 
tumours. 
 Group 4-specific events:- of the 28 genes differentially methylated at 1 
or more CpG sites, 8 (29%) were differentially expressed in Group 4 
tumours. 
 Group (3+4)-specific events:- of the 41 genes differentially methylated at 
1 or more CpG sites, 7 (17%) were differentially expressed in Group 
(3+4) tumours. 
3.4.4 Methylation events with a putative effect on gene expression 
The patterns of differential methylation and gene expression across the tumour 
subgroups were assessed using combined boxplots and strip-plots for the 15 genes 
identified in section 3.4.3. Subgroup-specific methylation-expression relationships were 
evaluated as described in section 3.3.6 to evaluate potential epigenetic gene regulation 
by DNA methylation. 
There was no evidence of an inverse methylation-expression relationship for the three 
Group 3-specific genes (Table 3.6). Three Group 4-specific genes, HDAC1, IGF1 and 
RHOH, showed evidence of potential methylation-dependent gene regulation in primary 
tumours by demonstrating an inverse methylation-expression relationship in 2 or more 
transcriptomic datasets (Table 3.6). Similarly, three Group (3+4)-specific genes (BGN, 
DDR2, MET) showed evidence of a direct relationship between CpG methylation and 
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gene expression (Table 3.6). The patterns of differential methylation and gene 
expression observed were diverse and gene-specific. The strongest evidence of putative 
subgroup-specific epigenetic regulation was seen for HDAC1, DDR2 and MET. These 
genes showed >2-fold changes in expression across the 3 transcriptomic datasets 
consistent with their methylation profiles as described below. 
Differential methylation analysis identified the HDAC1 CpG probe, HDAC1_P414_R, 
as a Group 4- and a Group (3+4)-specific marker. The magnitude of methylation change 
(∆β) and corresponding expression change (mean log ratio) observed were greater for 
Group 4 versus all other groups (Tables 3.4, 3.5 and 3.6). From this point forward 
HDAC1 was considered a Group 4-specific gene. The significantly higher methylation 
of the HDAC1_P414_R probe in the Group 4 tumours correlated with significantly 
lower gene expression levels in Group 4 (Figure 3.7(A)). 
The DDR2 CpG probe, DDR2_E331_F, was identified as a Group 4-and Group (3+4)-
specific marker. The magnitude of methylation change (∆β) and corresponding 
expression change (mean log ratio) observed were greater for Group (3+4) versus 
(SHH+WNT) (Tables 3.4, 3.5 and 3.6). From this point forward DDR2 was considered 
a Group (3+4)-specific gene. This was reinforced by the strong differential methylation 
patterns observed across the 4 tumour subgroups (Figure 3.7(B)). The significantly 
higher methylation status of the DDR2_E331_F probe in the Group (3+4) tumours 
correlated with significantly lower gene expression in Group (3+4) compared to the 
(SHH + WNT) tumours (Figure 3.7(B)). The differential pattern of methylation seen 
across the 4 tumour subgroups was consistent with the differential pattern of gene 
expression and epigenetic gene regulation, with the greatest corresponding differences 
observed between the Group (3+4) tumours and the WNT subgroup, while the SHH 
subgroup of tumours had an intermediate expression and methylation profile (Figure 
3.7(B)).  
The MET CpG probe, MET_E333_F, was a Group 4- and a Group (3+4)-specific 
methylation marker. The magnitude of methylation change (∆β) observed was greater 
for Group (3+4) versus (SHH+WNT) (Tables 3.4 and 3.5). Methylation of 
MET_E333_F showed a strong differential pattern across the 4 tumour subgroups, 
clearly distinguishing Group (3+4) tumours from (SHH+WNT) tumours (Figure 
3.7(C)). Differential expression analysis identified MET as significantly differentially 
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expressed between Group (3+4) and (SHH+WNT) tumours and between Group 4 and 
all other subgroups (Table 3.6). Assessment of the boxplots, however, showed a strong 
SHH-specific differential expression profile (Figure 3.7(C)). This result highlights the 
potential limitations of combining discrete disease subgroups of unequal size and 
variance together to facilitate a 2 group comparison for differential expression analysis 
using t-tests (see section 3.3.5). The subgroup-specific methylation profile of 
MET_E333_F was consistent with potential epigenetic transcriptional regulation in the 
SHH, Group 3 and Group 4 medulloblastomas (Figure3.7 (C)); upregulated expression 
was observed in SHH tumours consistent with an unmethylated state while Group 3 and 
Group 4 tumours had significantly higher methylation levels consistent with their 
transcriptional silencing. The methylation-expression relationship did not extend to 
WNT tumours. They were unmethylated in a manner similar to SHH tumours but had a 
silenced expression profile similar to Group 3 and Group 4 tumours, suggesting that 
methylation-independent mechanisms are responsible for repressing MET expression in 
this distinct subgroup of tumours. 
RHOH (Group 4-specific) and BGN (Group (3+4)-specific) were differentially 
expressed in 2 of the 3 transcriptomic datasets and both genes showed evidence of an 
inverse methylation-expression relationship in the 2 datasets (Table 3.6). The lower 
methylation of the RHOH CpG probe, RHOH_P121_F, in Group 4 tumours correlated 
with a higher gene expression. The differential gene expression observed for RHOH 
was most significant between Group 4 and (SHH+WNT) tumours consistent with the 
differential patterns of methylation (Figure 3.8(A)). Higher methylation of the BGN 
CpG probe, BGN_P333_R, in Group (3+4) tumours correlated with lower gene 
expression which was most significant between Group (3+4) and WNT tumours 
consistent with its methylation profile (Figure 3.8(B)). IGF1 (Group 4-specific) was 
differentially expressed in 3 transcriptomic datasets and showed an inverse methylation-
expression relationship in 2 (Table 3.6). Increased methylation of the IGF1 CpG probe, 
IGF1_E394_F, in Group 4 correlated with lower IGF1 expression (Figure 3.8(C)).The 
magnitude of subgroup-specific expression changes observed for RHOH, BGN and 
IGF1 were not as large as those observed for HDAC1, DDR2 and MET (Figures 3.7 and 
3.8). 
 171 
 
The remaining genes that were differentially methylated and differentially expressed in 
Group 3 and/or Group 4 tumours did not show evidence of an association between 
methylation and expression indicative of methylation-dependent gene regulation (Table 
3.6). Assessment of the differential patterns of CpG methylation and gene expression 
across the tumour subgroups thus identified 6 genes (HDAC1, DDR2, MET, RHOH, 
BGN and IGF1), that showed evidence of potential subgroup-specific epigenetic 
regulation by DNA methylation, for further analysis. 
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     Significant differential expression 
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methylated CpG 
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BCAP31_P1072_F Y X BCAP31 200837_at 
 
0.59 
 
0.002072 
 
N 4026669 
 
0.47 
 
0.001676 
 
N 200837_at 
 
0.76 
 
5.59E-09 
 
N 
CHI3L2_P226_F N 1 CHI3L2 213060_s_
at 
 
0.37 
 
0.022322 
 
N   NS - 213060_s_at 
 
0.64 
 
0.001476 
 
N 
FGF1_P357_R N 5 FGF1 205117_at 
 
0.79 
 
0.022322 
 
N   NS - 205117_at 
 
0.71 
 
0.003815 
 
N 
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DDR2_E331_F 
 
N 1 DDR2 205168_at 1.08 8.80E-06 Y  2364231 1.03 1.80E-06 Y  205168_at 0.92 2.55E-06 Y  
HDAC1_P414_R_ 
 
Y 1 HDAC1 201209_at 1.99 2.14E-18 Y  2328868 1.45 9.73E-14 Y  201209_at 2.75 8.22E-21 Y  
IGF1_E394_F 
 
N 12 IGF1 209540_at 1.04 0.000115 Y  3468345 0.30 0.001287 Y  209540_at 0.98 0.003876 N  
LEFTY2_P719_F 
 
N 1 LEFTY2 206012_at 0.58 0.001686 N 2458629 0.81 6.89E-07 Y 206012_at 0.79 4.47E-06 N 
MET_E333_F 
 
Y 7 MET 203510_at 1.19 0.000205 Y  3020343 1.29 2.63E-06 Y  203510_at 2.18 2.45E-09 Y  
RAN_P581_R 
 
Y 12 RAN 200750_s_
at 
0.69 3.70E-13 N 3438027 0.33 0.001247 N 200750_s_at 0.74 4.61E-11 N 
RHOH_P121_F 
 
N 4 RHOH 204951_at 0.40 0.035632 Y  2724671 0.27 0.00088 
 
N 204951_at 0.40 0.01436 Y  
TM7SF3_P1068_R 
 
N 12 TM7SF3 217974_at 0.42 0.006573 N 3448481 0.66 9.14E-07 N 217974_at 0.77 1.39E-07 N 
G
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u
p
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3
+
4
) 
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BGN_P333_R 
 
N X BGN 201262_s_
at 
0.57 0.001578 Y  3995633 0.58 0.001107 Y   NS - 
DDR2_E331_F 
 
N 1 DDR2 205168_at 1.36 8.80E-06 Y 2364231 1.34 7.33E-06 Y  205168_at 1.70 3.63E-10 Y 
HDAC1_P414_R 
 
Y 1 HDAC1 201209_at 1.28 3.25E-06 Y  2328868 1.0 3.39E-07 Y 201209_at 1.68 9.75E-11 Y 
MEST_E150_F * 
 
Y 7 MEST 202016_at 1.32 8.01E-05 N   NS - 202016_at 1.50 1.30E-09 N 
MET_E333_F 
 
Y 7 MET 203510_at 1.12 0.009999 Y*  3020343 1.75 2.66E-06 Y* 203510_at 3.13 9.75E-11 Y * 
MSH2_P1008_F 
 
Y 2 MSH2 209421_at 0.40 0.001876 N 2480992 0.34 0.006251 N 209421_at 0.59 1.30E-06 N 
STAT5A_E42_ N 17 STAT5A 203010_at 0.47 2.78E-05 N 3721658 0.51 1.09E-05 N 203010_at 0.67 7.48E-06 N 
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Table 3.6. Subgroup-specific differential CpG methylation and gene expression. Genes that contained 1 or more significant differentially methylated CpG sites and were also significantly 
differentially expressed are shown. Subgroup-specificity, significant GoldenGate CpG probe and presence of a CpG island, along with results of the differential expression analysis are detailed; genes 
with a FDR-adjusted p-value <0.05 and a mean log ratio > threshold in at least 2 out of 3 transcriptomic datasets were considered to be significantly differentially expressed. A mean log ratio threshold 
of 0.3 was applied to the Kool/Fattet and Northcott datasets and a threshold of 0.4 was applied to the Cho dataset. DDR2, HDAC1 and MET showed methylation and expression patterns that were 
specific to Group 4 tumours and to Group (3+4). Genes highlighted in yellow showed a direct inverse relationship (inverse reln) between CpG methylation and gene expression, and this relationship was 
observed in at least 2 transcriptomic datasets. * only one of three differentially methylated sites is shown. NS=not significant. 
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Figure 3.7. Combined boxplots and strip-plots showing differential patterns of CpG methylation and gene 
expression in primary tumours for HDAC1, DDR2 and MET. (A) HDAC1: significantly higher methylation of 
HDAC1_P414_R in Group 4 vs other (p=9.4E-17) correlates with significantly lower gene expression in Group 4 
(p=2.1E-18). (B) DDR2: significantly higher methylation of DDR2_E331_F in Group (3+4) vs other (p=2.9E-18) 
correlates with significantly lower gene expression in Group (3+4) (p=8.8E-06). (C) MET: significantly higher 
methylation of MET_E333_F in Group (3+4) vs other (p=3.2E-21) correlates with significantly lower gene 
expression in Group (3+4) vs other (p=0.01). Boxplots show that MET expression is lower in Group (3+4) compared 
to the SHH subgroup but not compared to the WNT subgroup. Expression profiles for all genes are representative of 
the Kool/Fattet dataset. Subgroups are represented on boxplots by different colours: SHH, blue (n=50); WNT, red 
(n=28); Group 3(Grp3), purple (n=44); Group 4 (Grp4), orange (n=94).  
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Figure 3.8. Combined boxplots and strip-plots showing differential patterns of CpG methylation and gene 
expression in primary tumours for RHOH, BGN and IGF1. (A) RHOH significantly lower methylation of 
RHOH_P121_F in Group 4 vs other (p=9.6E-14) correlates with significantly higher gene expression in Group 4 
(p=0.04). Consistent with the methylation profile, gene expression difference is most distinguishable between Group 
4 and (SHH+WNT) tumours, with patterns closely related in Group 3 and Group 4. (B) BGN: significantly higher 
methylation of BGN_P333_R in Group (3+4) vs other (p=3.6E-16) correlates with significantly lower gene 
expression in Group (3+4) (p=0.002). Consistent with the methylation profile, gene expression difference is most 
distinguishable between Group (3+4) and WNT tumours. (C) IGF1: significantly higher methylation of 
IGF1_E394_F in Group 4 vs other (p=1.4E-13) correlates with significantly lower gene expression in Group 4 
(p=1.2E-04). Expression profiles for all genes are representative of the Kool/Fattet dataset. Subgroups are represented 
on boxplots by different colours: SHH, blue (n=50); WNT, red (n=28); Group 3(Grp3), purple (n=44); Group 4 
(Grp4), orange (n=94). 
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3.4.5 Correlation between CpG methylation and gene expression in primary 
tumours 
Methylation and gene expression data were available for 9 matched primary tumour 
samples. To support the subgroup-specific inverse methylation-expression relationships 
observed for the 6 genes identified in section 3.4.4, and to determine the strength of the 
association between CpG methylation and gene expression, Pearson’s correlation 
coefficient (r) was calculated.  
HDAC1 and DDR2 showed strong inverse correlations (r < (-0.7)) between the level of 
gene expression and CpG methylation (Figure 3.9 (A) and (B)) providing further 
supportive evidence for their methylation-dependent regulation in primary 
medulloblastomas. IGF1, BGN and RHOH did not show the same strong inverse 
correlation between CpG methylation and gene expression (data not shown). Pearson 
correlation r values were (-0.4), (-0.5) and (-0.5) for IGF1, BGN and RHOH, 
respectively. 
The weakest correlation between CpG methylation and gene expression was seen for 
MET (r= (-0.2)) (data not shown). Based on the subgroup-specific methylation-
expression relationships observed for MET (Figure 3.7(C)), a strong inverse correlation 
would not be expected. MET showed evidence of potential epigenetic regulation in 
SHH, Group 3 and Group 4 tumours but not in WNT tumours. In the WNT subgroup, 
an unmethylated state did not correlate with upregulated expression as it did in the SHH 
group (Figure 3.7(C)), suggesting that other methylation-independent gene regulatory 
mechanisms are repressing transcription in the WNT subgroup of tumours. 
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Figure 3.9. Linear correlation between CpG methylation and gene expression for HDAC1 and DDR2. (A) 
HDAC1 and (B) DDR2 show strong inverse correlation between CpG methylation β-values and level of gene 
expression. Pearson correlation r values measuring the strength of the inverse relationship are shown. 
 180 
 
3.4.6 In silico gene expression analysis in cell lines treated with 5-azaCdR 
The six genes identified in section 3.4.4 were next investigated for evidence of 
methylation-dependent transcriptional silencing and upregulation by 5-azaCdR in 3 
medulloblastoma cell lines (see section 3.3.8). Affymetrix U133A microarray probe 
signal intensities before and after 5-azaCdR (see section 3.3.3.2) are detailed in Table 
3.7. 
Genes which showed an increase in expression >1.5-fold following 5-azaCdR treatment 
were considered upregulated. DDR2, MET and RHOH showed evidence of upregulated 
gene expression following treatment with 5-azaCdR consistent with a methylated status 
in at least one cell line. DDR2 and MET were part-methylated/methylated in the 3 cell 
lines and both genes showed > 1.5-fold increases in expression following 5-azaCdR 
treatment of D283 (Table 3.7). RHOH was methylated in the 3 cell lines and expressed 
at low levels. RHOH showed increased expression in 2 out of 3 methylated cell lines 
following treatment, and was considered upregulated in D425, where it showed a 5.2-
fold increase in expression after 5-azaCdR treatment (Table 3.7).  
HDAC1 showed reduced endogenous expression in the methylated D283 cell line 
compared to the 2 unmethylated cell lines, but this was not accompanied by upregulated 
HDAC1 expression following 5-azaCdR treatment of D283. IGF1 was unmethylated in 
D283 and D425 and showed 1.6-fold and 7.1-fold increases in expression following 5-
azaCdR treatment, respectively, suggesting that methylation-independent mechanisms 
were responsible for the expression changes observed. There was no evidence of 
methylation-dependent re-expression of BGN in the cell lines following 5-azaCdR 
treatment (Table 3.7). 
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 MED8A  D283  D425 
Gene 
Symbol 
Affy U133A 
probe ID 
5-
azaCdR 
treated 
signal 
Untreated 
signal 
Fold-
change in 
expression 
after 
treatment 
Methylation 
status in 
MED8A 
 5-
azaCdR 
treated 
signal 
Untreated 
signal 
Fold-
change in 
expression 
after 
treatment 
Methylation 
status in D283 
 5-
azaCdR 
treated 
signal 
Untreated 
signal 
Fold-
change  in 
expression 
after 
treatment 
Methylation 
status in D425 
HDAC1 201209_at 642 602 1.1 U  443 544 0.8 M  927 946 1 U 
DDR2 205168_at 602 545 1.1 PM  43 20 2.2 M  92 98 1 M 
MET 203510- 16 13 1.2 M  105 66 1.6 M  177 142 1.2 M 
RHOH 204951_at 18 14 1.3 M  8 29 0.3 M  31 6 5.2 M 
BGN 201262_s_at 82 91 0.9 U  9 16 0.6 PM  17 20 0.9 U 
IGF1 209540_at 6 42 0.1 U  47 29 1.6 U  50 7 7.1 U 
Table 3.7. Gene expression changes from microarray data following 5-azaCdR treatment of 3 medulloblastoma cell lines. Gene symbol and corresponding Affymetrix U133A microarray probe 
identifier are shown. For each of the 3 cell lines (MED8A, D283 and D425) the 5-azaCdR treated signal intensity, untreated signal intensity, fold-change in expression signal and methylation status are 
shown for the 6 genes. Fold-change in expression after 5-azaCdR treatment was calculated by normalising the treated signal to the corresponding untreated signal. Genes with fold-change > 1.5 were 
considered upregulated by 5-azaCdR. Methylation status describes the GoldenGate β-value scores for the CpG sites identified in section 3.4.4 that have a putative effect on gene expression; U 
(unmethylated): β<0.3, PM (part-methylated): 0.3≥β<0.7, M (methylated): β≥0.7. 
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3.4.7 Subgroup-specific candidate epigenetically regulated genes 
Subgroup-specific candidate epigenetically regulated genes were identified according to 
the criteria defined in section 3.3.9. Based on the strength of evidence for their potential 
epigenetic regulation, four candidate genes (HDAC1, DDR2, MET and RHOH) were 
identified (Table 3.8). Candidate genes were investigated for evidence of a direct 
relationship between CpG methylation and gene expression by qRT-PCR assessment of 
expression changes in medulloblastoma cell lines treated with 5-azaCdR (see section 
3.4.8).  
BGN and IGF1 both contained a CpG residue that showed evidence of a subgroup-
specific methylation-expression relationship following visual inspection of the boxplots 
(Figure 3.8). However, neither gene showed a strong inverse linear correlation between 
CpG methylation and gene expression (see section 3.4.5), or in silico evidence of 
methylation-dependent re-expression by 5-azaCdR treatment in medulloblastoma cell 
lines (see section 3.4.6). These genes were not considered further (Table 3.8). 
Gene Subgroup-specific 
(Group 3 and/or 
Group 4) methylation 
pattern 
Subgroup-specific 
inverse methylation-
expression relationship 
Inverse correlation 
between CpG 
methylation and gene 
expression for 9 
matched primary 
tumour samples 
Pearson correlation             
r < (-0.7) 
Methylation-dependent 
re-expression in ≥ 1 
cell line after 5-
azaCdR 
(in silico microarray 
data) 
Subgroup-specific 
candidate 
epigenetically 
regulated gene 
BGN Group (3+4) Y N N N 
DDR2 Group (3+4) Y Y N Y 
HDAC1 Group 4 Y Y N Y 
IGF1 Group 4 Y N N N 
MET Group (3+4) Y N Y Y 
RHOH Group 4 Y N Y Y 
Table 3.8. Identification of subgroup-specific candidate epigenetically regulated genes. To be selected as 
candidates for further investigation, genes were required to demonstrate a subgroup-specific inverse methylation-
expression relationship and either a strong inverse correlation (r<(-0.7)) between CpG methylation and gene 
expression for 9 primary tumour samples for which methylation and expression data were both available, or evidence 
of methylation-dependent re-expression in at least 1 cell line following 5-azaCdR, from in silico analysis of 
microarray data. Subgroup-specificity of differential methylation event(s) is shown for each gene in table. 
 
 183 
 
3.4.8 qRT-PCR assessment of candidate gene expression changes in 
medulloblastoma cell lines following 5-azaCdR treatment 
qRT-PCR was performed for the candidate genes to investigate methylation-dependent 
expression in medulloblastoma cell lines. Relative gene expression levels were 
measured before and after treatment with the demethylating agent 5-azaCdR using the 
delta delta CT method as described in section 3.3.11.2.  
3.4.8.1 Validation of PCR reaction efficiencies 
To ensure the validity of the delta delta CT method, PCR reaction efficiencies for the 
target and endogenous control genes were assessed as described in section 3.3.11.1. 
Target and control gene amplification efficiencies were successfully validated. Absolute 
slope values for the ∆CT versus log cDNA input plots ranged from 0.02-0.2, 
demonstrating approximately equal amplification efficiencies for the targets and the 
endogenous control genes. Figure 3.10 shows the results of the validation experiment 
for the target gene MET and the endogenous control gene GAPDH. 
The performance of the endogenous control genes was equivalent and consistent in the 
untreated and 5-azaCdR treated cell lines in all experimental runs. Figure 3.11 shows 
the equivalent performance of the control genes in the 12 cell line samples for one 
experimental run. All results presented in section 3.4.9 have been normalised to the 
GAPDH endogenous control gene. 
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Figure 3.10. Validation of the delta delta CT method of relative quantification. Difference in CT value (delta CT) 
between target gene MET and endogenous control gene GAPDH over a range of pooled medulloblastoma cell line 
cDNA concentrations are shown. Plot shows a consistent delta CT across cDNA input range producing an absolute 
slope value of 0.02, demonstrating equal reaction efficiencies of target and control gene and validating delta delta CT 
method of gene quantification. All target genes were validated with an absolute slope value ≤0.2. 
 
 
Figure 3.11. Equivalent performance of endogenous control genes in qRT-PCR reactions. Mean CT values for 
TBP show strong correlation with mean CT values for GAPDH in 12 cell line samples, demonstrating high 
equivalence in performance of the 2 endogenous control genes in the cell lines. This result was consistently produced 
in all experimental runs. 
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3.4.9  qRT-PCR results 
Genes were considered upregulated by 5-azaCdR if they showed an expression increase 
> 2-fold following treatment. Genes that demonstrated evidence of methylation-
dependent transcriptional regulation in 4 or more cell lines (≥67%) were considered to 
show strong evidence of epigenetic regulation by DNA methylation. 
3.4.9.1 RASSF1A 
The isoform A transcript of the RASSF1 gene was used as a positive control for the 
demethylating treatment of the cell lines with 5-azaCdr (see section 3.3.10.3). 
Increased RASSF1A expression ≥ 100-fold was observed across the 6 cell lines 
following 5-azaCdR treatment (Figure 3.12). Hypermethylation of the RASSF1A CpG 
island-associated promoter has previously been established in all medulloblastoma cell 
lines tested (Lusher et al., 2002). The methylation of RASSF1A was consistent with the 
epigenetic transcriptional regulation seen in cell lines. This result demonstrated the 
success of the 5-azaCdR treatment in demethylating the cell lines and proved the 
technical validity and robustness of this method to assess methylation-dependent gene 
regulation in medulloblastoma cell lines for the selected candidate genes. 
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Figure 3.12. Methylation dependent re-expression of RASSF1A in medulloblastoma cell lines. RASSF1A was re-
expressed by 5-azaCdR in the 6 cell lines tested. Greater than 100-fold increase in expression was observed in all cell 
lines following treatment. RASSF1A promoter-associated CpG island is hypermethylated in medulloblastoma cell 
lines (Lusher et al.,2002), consistent with its epigenetic transcriptional regulation observed. Presence or absence of 5-
azaCdR is shown as follows: (-) untreated cell line; (+) 5-azaCdR treated cell line. Mean fold change in expression 
following treatment was calculated by normalising relative mean expression in the treated cell line (+) to relative 
mean expression in its untreated pair (-). 
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3.4.9.2 DDR2 
DDR2 did not show strong evidence of methylation-dependent re-expression by 5-
azaCdR in medulloblastoma cell lines (Figure 3.13). The DDR2_E331_F CpG probe 
was constitutively methylated (β ≥ 0.7) in the cell lines. With the exception of D283, 
which showed a 2.2-fold increase in expression following 5-azaCdR treatment, 
expression remained relatively unchanged after treatment. D425 showed a small 
decrease in expression following treatment.  
 
Figure 3.13. DDR2 expression is relatively unchanged following demethylation of cell lines. The DDR2_E331_F 
probe was constitutively methylated in cell lines. Upregulated DDR2 expression was observed in one cell line 
(D283) consistent with a methylated status, while expression remained relatively unchanged in the remaining cell 
lines. Presence or absence of 5-azaCdR is shown as follows: (-) untreated cell line; (+) 5-azaCdR treated cell line. 
Mean fold change in expression following treatment was calculated by normalising relative mean expression in the 
treated cell line (+) to relative mean expression in its untreated pair (-). Methylation status describes the GoldenGate 
β-value scores for the DDR2_E331_F CpG probe; M (methylated): β≥0.7. 
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3.4.9.3 HDAC1 
No evidence of methylation-dependent transcriptional regulation was found for 
HDAC1. Expression levels remained relatively constant before and after 5-azaCdR 
irrespective of the methylation status of the HDAC1_P414_R CpG probe (Figure 
3.14(A)). The methylated cell line D283 did show an increased expression following 
treatment but it was not significantly upregulated (>2-fold increase) by 5-azaCdR. 
There was no strong evidence of transcriptional silencing in methylated cell lines 
compared with unmethylated cell lines (Figure 3.14(B)). HDAC1 expression in the 
methylated D283 and DAOY cell lines was considerably reduced compared with the 
unmethylated D425 but not compared with other unmethylated cell lines (D556, D384 
and MED1) (Figure 3.14(B)). 
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Figure 3.14. HDAC1 does not show evidence of methylation-dependent transcriptional regulation in 
medulloblastoma cell lines. (A) HDAC1 expression levels were largely unchanged following 5-azaCdR treatment 
irrespective of methylation status of the HDAC1_P414_R CpG probe in cell lines. Presence or absence of 5-azaCdR 
is shown as follows: (-) untreated cell line; (+) 5-azaCdR treated cell line. Mean fold change in expression following 
treatment was calculated by normalising relative mean expression in the treated cell line (+) to relative mean 
expression in its untreated pair (-). (B) Relative mean HDAC1 expression levels in the untreated cell lines do not 
show evidence of transcriptional silencing associated with HDAC1 methylation. Expression was reduced in HDAC1 
methylated cell lines compared with unmethylated D425 but not compared to the 3 other unmethylated lines. 
Methylation status describes the GoldenGate β-value scores for the HDAC1_P414_R  CpG probe; U (unmethylated): 
β<0.3, M (methylated): β≥0.7. 
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3.4.9.4 MET 
MET showed strong evidence of methylation-dependent transcriptional regulation in 
medulloblastoma cell lines. The MET_E333_F CpG probe was methylated/part-
methylated in 5 out of 6 cell lines. Three out of five MET methylated cell lines (D556, 
D384 and MED1) were transcriptionally silenced compared to the unmethylated DAOY 
cell line (Figure 3.15(B)) and were upregulated following 5-azaCdR treatment (Figure 
3.15 (A)). The unmethylated DAOY cell line showed significantly higher endogenous 
expression levels compared to methylated lines (Figure 3.15(B)), and did not show 
upregulation following 5-azaCdR (Figure 3.15(A)). The methylated D283 and D425 
cell lines did not show re-expression of MET following 5-azaCdR treatment (Figure 
3.15(A)), suggesting that methylation-independent mechanisms are involved in MET 
regulation in these cell lines. 
The methylation status of the MET CpG probe (MET_E333_F) was consistent with its 
epigenetic transcriptional regulation in 4 out of 6 medulloblastoma cell lines (D556, 
D384, MED1 and DAOY), providing strong evidence of methylation-dependent 
expression of the MET oncogene in medulloblastoma.  
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Figure 3.15. MET shows evidence of epigenetic regulation by DNA methylation in medulloblastoma cell lines. 
(A) Three out of five MET methylated/part-methylated cell lines (D556, D384 and MED1) show upregulated MET 
expression following 5-azaCdR treatment. DAOY did not show upregulated expression consistent with its 
unmethylated status. Presence or absence of 5-azaCdR is shown as follows: (-) untreated cell line; (+) 5-azaCdR 
treated cell line. Mean fold change in expression following treatment was calculated by normalising relative mean 
expression in the treated cell line (+) to relative mean expression in its untreated pair (-).(B) MET is transcriptionally 
silenced in the methylated cell lines, D556, D384 and MED1, compared to the unmethylated DAOY cell line, which 
shows significantly higher endogenous MET expression. Endogenous expression of MET is reduced in the methylated 
D283 cell line but does not undergo significant upregulation by 5-azaCdR. Methylation-dependent re-expression is 
not observed in the methylated D425 cell line. Methylation status describes the GoldenGate β-value scores for the 
MET_E333_F CpG probe; PM (part-methylated): 0.3≥β<0.7, M (methylated): β≥0.7. 
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3.4.9.5 RHOH 
The RHOH_P121_F CpG probe was constitutively methylated (β ≥ 0.7) in the cell lines. 
Methylation-dependent re-expression following 5-azaCdR was observed in 4 out of the 
6 cell lines (Figure 3.16). MED1 showed a 1.9-fold increase in expression after 5-
azaCdR, falling just below the threshold (2-fold) to be considered upregulated. RHOH 
expression was reduced in D384 after 5-azaCdR, suggesting that gene expression is not 
regulated by DNA methylation in this cell line.  
Four out of six medulloblastoma cell lines (D556, D283, D425 and DAOY) showed 
upregulation of RHOH following 5-azaCdR treatment consistent with methylation of 
the RHOH_P121_F CpG probe, and thus providing strong evidence of epigenetic 
regulation of RHOH by DNA methylation in medulloblastoma. 
 
Figure 3.16. RHOH shows evidence of epigenetic regulation by DNA methylation in medulloblastoma cell lines. 
RHOH is constitutively methylated in the cell lines. Four cell lines (D556, D283, D425and DAOY) show significant 
re-expression of RHOH by 5-azaCdR, providing strong evidence of methylation-dependent transcriptional regulation. 
Increased expression following 5-azaCdR treatment is observed in MED1, while D384 shows downregulation of 
RHOH following 5-azaCdR treatment. Presence or absence of 5-azaCdR is shown as follows: (-) untreated cell line; 
(+) 5-azaCdR treated cell line. Mean fold change in expression following treatment was calculated by normalising 
relative mean expression in the treated cell line (+) to relative mean expression in its untreated pair (-). Methylation 
status describes the GoldenGate β-value scores for the RHOH_P121_F CpG probe; M (methylated): β≥0.7. 
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3.5 Discussion 
3.5.1 Novel methylation markers of Group 3 and Group 4 medulloblastomas 
The four principal subgroups of medulloblastoma are associated with distinct DNA 
methylomic profiles (Schwalbe et al., 2013). This study has identified novel CpG 
methylation biomarkers of the poorly characterised Group 3 and Group 4 tumours. 
There were 23 Group 3, 31 Group 4 and 48 Group (3+4) methylation biomarkers 
identified. The results reported in this study strongly support the current opinion that 
Group 3 and Group 4 tumours are molecularly more similar to each other than they are 
to SHH and WNT tumours (Taylor et al., 2012) with 13% of Group 3 and 84% of 
Group 4 markers also discriminating Group (3+4) tumours. 
The number of medulloblastomas within each molecular subgroup is not equal (see 
section 3.3.2) and assessment of boxplots illustrating the subgroup-specific patterns of 
methylation for the markers identified showed unequal variances between groups. The 
non-parametric Mann-Whitney U test was applied to identify subgroup-specific 
methylation markers, and while this test is assumed to be relatively insensitive to 
unequal sample sizes, the large proportion of Group 4 events that were also Group 
(3+4)-specific suggest that it was potentially limited in accommodating the unequal 
sizes and variances that exist between the subgroups, particularly after combining 
distinct groups together to facilitate a two group comparison. A Kruskal-Wallis test 
comparing the 4 subgroups, followed by post hoc Mann-Whitney U tests comparing 
individual pair-wise comparisons may have improved sensitivity to identify more Group 
4 events that do not also discriminate Group (3+4). Applying a difference threshold to 
the significance test, in the form of an absolute difference in mean methylation scores, 
increased the sensitivity of the test to identify true positive subgroup-specific events and 
the methylation markers identified clearly distinguished the Group 3 and Group 4 
tumours from each other and from the SHH and WNT tumours, while also recognising 
Group 3 and Group 4 as being more similar to each other than to SHH and WNT 
tumours (Figure 3.5). 
The methylation markers were variably located within and outside of CpG islands 
within gene promoter regions, and for a small number of genes (n=6) two or three CpG 
sites were concordantly differentially methylated in a subgroup-specific manner. The 
majority of Group 3-markers (91%) were also tumour-specific and, therefore, any 
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subsequent functional gene regulatory effect identified would signify a significantly 
aberrant event in this subgroup of tumours. In contrast, less than 50% of Group 4- and 
Group (3+4)-markers were tumour-specific. The tumour-specific events identified were 
hypermethylated and hypomethylated in equal numbers compared to normal cerebella. 
It was important to exercise caution interpreting the results of tumour-specificity 
because the cellular origin of Group 3 and Group 4 tumours is still unknown and it is 
likely they have different cellular origins to each other and to SHH and WNT tumours 
(Kool et al., 2012). It has already been shown that the SHH and WNT subgroups have 
different cellular origins, with SHH tumours most likely arising from GNP cells of the 
developing cerebellum (Schuller et al., 2008), while WNT tumours are believed to arise 
outside the cerebellum from progenitor cells of the dorsal brainstem (Gibson et al., 
2010). Until cell of origin can be identified we must consider with caution the utility of 
non-matched cerebellar samples as controls for a disease that comprises four distinct 
subgroups with different cellular origins. The control cerebellar samples will include a 
mix of different cell types and the methylation β value will reflect the average 
methylation of these mixed cell populations. In this study non-neoplastic cerebellar 
samples were used as a useful control reference to evaluate potentially aberrant 
methylation in specific subgroups. 
3.5.2 Differential methylation and gene expression in Group 3 and Group 4 
medulloblastomas 
Sixty-three genes were differentially methylated at one or more CpG sites in Group 3 
and Group 4 tumours. Fifteen genes (24%) were also differentially expressed in Group 
3 and Group 4. Upon assessment of the differential patterns of methylation and 
expression, three Group 4-specific genes showed an inverse methylation-expression 
relationship consistent with epigenetic regulation, three Group (3+4)-specific genes 
showed a relationship consistent with epigenetic regulation while there were no Group 3 
genes that showed patterns consistent with epigenetic regulation. These results suggest 
that the majority of discriminatory methylation markers do not have an effect on gene 
expression in Group 3 and Group 4 and that the association between DNA methylation 
and gene expression is weak. 
In general, the differential patterns of gene expression were not as strong as the 
differential patterns of CpG methylation and the differences in gene expression 
 195 
 
observed between subgroups were small for many genes. It is important to remember 
that these genes are not representative of the most differentially expressed genes in 
medulloblastoma subgroups, but rather they were pre-selected for differential analysis 
based on them having one or more differentially methylated CpG sites. The small 
magnitude of expression change does not negate its biological importance, particularly 
if it is associated with dysregulation of a normal regulatory mechanism, such as DNA 
methylation, that is known to drive tumourigenesis in its aberrant form. 
The patterns of differential methylation and gene expression observed across the tumour 
subgroups were diverse and gene-specific. The inverse methylation-expression 
relationships ranged from strong subgroup-specific correlations for HDAC1 and DDR2 
(Figure 3.7(A) and (B)) to more subtle expression changes inversely correlating with 
CpG methylation of RHOH, BGN and IGF1 (Figure 3.8(A), (B) and (C)). Contributing 
to the complexity of methylation and gene expression relationships is an unmethylated 
promoter state that correlates with transcriptional competence but is not indicative of it 
(Bird, 2002). MET was transcriptionally silenced in Group 3 and Group 4 tumours 
correlating with a methylated state and while an unmethylated state correlated with 
upregulated expression in SHH tumours this was not true for WNT tumours which were 
unmethylated and transcriptionally repressed (Figure 3.7(C)). The patterns of 
methylation and expression observed were consistent with epigenetic regulation in the 
SHH, Group 3 and Group 4 tumours. Interestingly the lack of a relationship in WNT 
tumours suggests that different gene regulatory mechanisms may be employed by 
subgroups of a disease with distinct molecular biology. 
BGN is located on the X chromosome and showed an inverse methylation-expression 
relationship consistent with epigenetic regulation in medulloblastoma subgroups. It is 
important to consider the sex chromosomes because females who are diploid X carry a 
methylated silenced X chromosome (Wutz and Gribnau, 2007) while the single X 
chromosome of males is largely unmethylated. Differential methylation of X-
chromosome probes may reflect gender-specific differences rather than a true biological 
effect and their potential to confound a differential analysis should not be ignored. It is 
important to note also the loss of one copy of the X chromosome that is found in 80% of 
females with Group 4 tumours (Taylor et al., 2012) resulting in the loss of methylation 
in female tumours which can further confound results. Aberrant methylation of X-
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linked genes has previously been reported in medulloblastoma and may contribute to 
tumourigenesis, particularly in male patients (Anderton et al., 2008). 
For those genes that were differentially methylated and differentially expressed in 
Group 3 and Group 4 tumours but showed no evidence of a methylation-expression 
relationship consistent with epigenetic gene regulation, the patterns of methylation and 
expression were varied; some genes showed higher levels of methylation correlating 
with higher levels of expression while for others the patterns were more complex and 
not consistent across multiple tumour subgroups.  
3.5.3 Majority of DNA methylation markers do not show a clear association 
with gene expression 
The results of this study show that the majority of DNA methylation markers specific to 
Group 3 and Group 4 medulloblastomas do not show a clear association with gene 
expression. There are a number of possible reasons for this observed weak association 
between methylation and expression. In model systems DNA methylation has been 
found to repress transcription in a manner that depends on the location and density of 
CpGs relative to the gene promoter (Bird, 2002). It is possible that differentially 
methylated sites identified in this study are too distant from the transcription start site to 
influence expression or that their methylation status is not representative of the 
neighbouring region Although bisulfite sequencing has confirmed methylation status 
consistent with adjacent CpG sites for probes on the GoldenGate array (Bibikova et al., 
2006), this may not hold true for all probes. It is also possible that the changes in 
methylation observed across the tumour subgroups are secondary or ‘passenger’ events 
that are not directly involved in driving tumourigenesis but rather accompany it. As 
previously discussed it is highly probable that the four distinct subgroups of 
medulloblastoma arise from different cells of origin. Another explanation for the lack of 
functional relationship observed between DNA methylation and gene expression is that 
the distinct methylation patterns associated with the disease subgroups may reflect their 
different cell of origin and developmental stage. A study in breast cancer found that 
aberrant promoter hypermethylation targeted genes that were already repressed in the 
normal tissue in a cell lineage-specific manner and concluded that the hypermethylation 
event did not cause gene silencing with which it was associated but rather marked the 
cell lineage from which the tumour developed (Sproul et al., 2011). The authors 
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extended this study further across 7 different cancer types and concluded the same 
finding that differential methylation profiles reflect the developmental history and 
transcriptional state of the different cells of origin (Sproul et al., 2012). 
Gene transcription is a remarkably intricate process that is tightly regulated at many 
genetic and epigenetic levels (Lemon and Tjian, 2000). Epigenetic transcriptional 
regulation relies on the interplay between different mechanisms that control chromatin 
organisation, including DNA methylation, histone modifications and nucleosome 
remodelling (Jones and Baylin, 2007; Blackledge and Klose, 2011; Tsai and Baylin, 
2011). While there are many reports in the literature of a direct association between 
DNA methylation and gene expression this does not appear to be true for the majority of 
DNA methylation markers of Group 3 and Group 4 medulloblastomas. Given the 
established complexity of epigenetic regulation it would be prudent to investigate 
epigenetic regulation within the wider context of nucleosome structure and chromatin 
organisation. Several chromatin modifiers have recently been identified as frequently 
mutated in medulloblastomas (Parsons et al., 2011; Robinson et al., 2012). Whole 
genome sequencing of primary tumours identified mutations that were enriched in 
specific subgroups and found mutations in genes controlling histone methylation 
targeting Group 3 and Group 4 tumours exclusively (Robinson et al., 2012).  
Investigations into the deregulation of wider epigenetic mechanisms may yield a greater 
understanding of any functional role of aberrant DNA methylation in gene regulation 
and in driving medulloblastoma tumourigenesis. 
3.5.4 Identification of subgroup-specific candidate epigenetically regulated 
genes in medulloblastoma  
Four genes (HDAC1, DDR2, MET and RHOH) were identified as candidate 
epigenetically regulated genes in primary medulloblastomas. Genes were selected based 
on the strength of evidence for epigenetic regulation from the data that was available 
(see Table 3.8). This study was limited by not having gene expression data for all the 
samples for which there was GoldenGate methylation data. Associations between 
subgroup-specific patterns of differential methylation and gene expression had to be 
determined, in large part, by a comparison of means based on the results of the 
differential methylation and expression analyses of microarray data. Methylation-
expression relationships were evaluated from visual inspection of boxplots illustrating 
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the differential patterns across the tumour subgroups and this was supported by 
Pearson’s correlation analysis of a small sample of 9 tumours for which methylation and 
expression data were available. Based on the limited tumour-matched data available, in 
silico analysis of microarray gene expression changes by 5-azaCdR in medulloblastoma 
cell lines was carried out, to further support evidence of a potential functional 
relationship between methylation and gene expression in medulloblastoma subgroups. 
Tumour-specificity of the Group 3 and Group 4 methylation markers was considered to 
assess potential aberrant methylation and the potential oncogenic or tumour suppressor 
role of candidate genes in medulloblastoma development. Gene expression data for 
normal cerebellar samples was not available to confirm aberrant gene expression 
patterns.  
HDAC1 showed strong evidence of methylation-dependent transcriptional regulation in 
primary tumours. Due to the strength of the differential patterns of methylation and 
expression observed across the tumour subgroups and the strong inverse correlation 
between methylation and expression, consistent with epigenetic gene regulation, 
HDAC1 was selected as a candidate gene. The HDAC1 CpG site (HDAC1_P414_R) is 
located in a CpG island-associated promoter and is methylated in Group 4 tumours, 
correlating with a lower gene expression in this subgroup (Figure 3.7(A)). The 
methylation status of HDAC1_P414_R in Group 4 tumours was not significantly 
different to non-neoplastic cerebella (p=0.19, ∆β<0.34; Appendix A) and was therefore 
not tumour-specific for Group 4 tumours, suggesting that hypomethylation of HDAC1 
in SHH, WNT and Group 3 tumours effects upregulated gene expression in these 
tumour subgroups (Figure 3.7(A)). A literature search did not identify any previously 
published reports of epigenetic HDAC1 regulation in cancers. 
DDR2 showed a strong methylation-expression relationship in primary tumours and 
showed evidence of methylation-dependent re-expression following 5-azaCdR in the 
D283 cell line. The DDR2 CpG site (DDR2_E331_F) is located in a non-CpG island 
promoter region and had a significantly higher methylation status in Group (3+4) 
tumours, correlating with a significantly lower gene expression (Figure 3.7(B)).The 
methylation status of the CpG site in Group (3+4) tumours was not tumour-specific 
(p=0.01, ∆β<0.34; Appendix A), suggesting that hypomethylation of DDR2 in SHH and 
WNT tumours effects upregulated gene expression in these tumour subgroups compared 
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to the methylated and silenced Group 3 and Group 4 tumours (Figure 3.7(B)). In order 
to be significantly tumour-specific, methylation markers had to satisfy p< 0.05 and ∆β 
>0.34. DDR2 has previously been reported to be hypomethylated in a subset of 
hepatocellular carcinomas and is thought to contribute to tumour progression 
(Hernandez-Vargas et al., 2010). 
MET showed evidence of potential epigenetic gene regulation in SHH, Group 3 and 
Group 4 tumours. It also showed evidence of methylation-dependent re-expression 
following 5-azaCdR in the D283 cell line. The MET_E333_F probe is located in a CpG 
island-associated promoter and was differentially methylated in Group (3+4) tumours 
compared with (SHH+WNT) tumours (Figure 3.7(C)). The methylation status of 
MET_E333_F in Group (3+4) tumours was significantly different to non-neoplastic 
cerebella (p=2.3E-10, ∆β>0.34; Appendix A), suggesting that it is aberrantly methylated 
in Group 3 and Group 4 tumours. Expression of MET in SHH tumours was significantly 
higher compared to Group 3 and Group 4 and this was consistent with a significantly 
lower methylation in SHH.(Figure 3.7(C)). The methylation-expression relationship did 
not extend to WNT tumours which were unmethylated and silenced for MET. It is 
important to remember that while an unmethylated state permits gene transcription it is 
not indicative of it (Bird, 2002) and these results would suggest that methylation-
independent mechanisms are responsible for MET silencing in WNT tumours.  
The proto-oncogene MET encodes the tyrosine kinase receptor for the hepatocyte 
growth factor (HGF) ligand and HGF/MET signalling has been implicated in a variety 
of cancer types, contributing to tumourigenesis, disease progression and metastasis 
through its programme of invasive growth signalling (Comoglio et al., 2008). Aberrant 
MET signalling in medulloblastoma is well documented and it was not surprising to 
find upregulated MET expression specifically in SHH tumours. The role of MET 
signalling in normal cerebellar development directing the proliferation, migration and 
invasion of GNP cells (cell of origin of SHH medulloblastomas) has been well 
established (Ieraci et al., 2002). In mouse models with activated SHH signalling, 
overexpression of the MET receptor ligand HGF in GNP cells increased new 
medulloblastoma formation compared with SHH activation alone (Binning et al., 2008) 
and this apparent co-operation between SHH and MET signalling suggests a selective 
advantage for MET overexpression in SHH medulloblastoma formation and 
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progression. MET dysregulation in tumours is most frequently caused by 
overexpression of MET or its ligand HGF (Comoglio et al., 2008) and there are a 
number of mechanisms reported to cause overexpression of MET in medulloblastomas. 
MET amplifications have been identified in a significant proportion of primary 
medulloblastomas (Kongkham et al., 2010b). Silencing of MET pathway inhibitors has 
also been implicated in medulloblastoma pathogenesis (Kongkham et al., 2008). While 
mutations in MET pathway genes have been identified in several cancer types 
(Comoglio et al., 2008), a recent study found that mutations played a minor role in 
pathway dysregulation in medulloblastomas (Onvani et al., 2012).  
The strong patterns of differential methylation and expression, consistent with 
epigenetic regulation of MET in SHH, Group 3 and Group 4 tumours suggest that the 
MET promoter may potentially be controlled by DNA methylation in these tumour 
subgroups and that absence of promoter DNA methylation in SHH tumours may cause 
upregulated MET expression independent of amplification and mutation. WNT 
medulloblastomas arise from a different cell of origin to SHH tumours (Gibson et al., 
2010) and it is most likely that Group 3 and Group 4 tumours have different cellular 
origins (Kool et al., 2012). There may therefore not be the same selective advantage for 
MET overexpression in these tumour subgroups as for SHH tumours. If this is the case 
the differential pattern of methylation between Group (3+4) tumours and WNT tumours 
would suggest that biologically distinct subgroups may use different mechanisms to 
regulate key signalling pathways and gene regulation may be highly subgroup-specific. 
MET was selected as a candidate gene due to its established oncogenic role in 
medulloblastoma and the strength of evidence for methylation-dependent transcriptional 
regulation in SHH, Group 3 and Group 4 medulloblastomas. 
The RHOH CpG site (RhoH_P121_F) is located in a non-CpG island promoter. The 
significantly lower methylation of RHOH_P121_F in Group 4 tumours correlated with 
significantly higher gene expression (Figure 3.8(A)). RHOH expression profiles for 
Group 3 and Group 4 tumours were more similar to each other than to SHH and WNT 
and this was consistent with their methylation profiles and epigenetic regulation. The 
difference in gene expression observed between the tumour subgroups was more subtle 
than that observed for HDAC1, DDR2 and MET, however, small changes in expression 
can be biologically important, particularly for low expressed genes. In silico analysis of 
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gene expression microarray data showed > 5-fold increase in RHOH expression in the 
methylated D425 cell line following 5-azaCdR treatment, providing further evidence for 
epigenetic regulation. The methylation status of the RHOH_P414_R probe in Group 4 
tumours was significantly different to non-neoplastic cerebella and the marker was, 
therefore, tumour-specific (p=7.6E-06, ∆β>0.34; Appendix A). The RHOH marker was 
hypomethylated in Group 4 tumours, suggesting a potential oncogenic role for this gene 
in this subgroup of medulloblastomas. RHOH belongs to the family of Rho GTPases 
that play key roles in intracellular signalling and regulate cellular morphology, motility 
and proliferation (Williams et al., 2008). RHOH is a hematopoietic-specific member of 
the protein family and overexpression of RHOH has been reported in lymphomas, 
myelomas and leukaemias (Sanchez-Aguilera et al., 2010). Upregulated expression of 
RHOH has been reported to contribute to the initiation and progression of B-cell chronic 
lymphocytic leukaemia (CLL) and to be associated with an unfavourable prognosis 
(Sanchez-Aguilera et al., 2010; Troeger et al., 2012). 
Most studies have reported on tumour suppressor gene silencing by DNA 
hypermethylation of CpG island-associated promoters and so it was interesting to note 
that for 3 of the candidate genes the potential functional relationship was associated 
with hypomethylation of their respective CpG sites, suggesting a potential oncogenic 
role in tumour development. One candidate gene, RHOH, showed aberrant 
hypomethylation with potential functional significance in Group 4 tumours. 
Hypomethylation leading to activation of oncogenes has previously been reported 
(Feinberg and Vogelstein, 1983a; Hanada et al., 1993). Recently OCT4, a transcription 
factor involved in maintaining self-renewal of embryonic stem cells, has been identified 
to be upregulated by DNA hypomethylation in gliomas (Shi et al., 2013). The 
differentially methylated CpG sites identified in this study for HDAC1 and MET were 
located in CpG island-associated promoters, while the DDR2 and RHOH CpG sites 
were located in non-CpG island promoters. Evidence suggests that non-CpG island 
promoters behave in a manner similar to CpG island-associated promoters (Marx et al., 
2013; Oster et al., 2013). 
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3.5.5 MET and RHOH show strong evidence of methylation-dependent 
expression which may be functionally relevant in subgroups of 
medulloblastoma 
qRT-PCR assessment of expression changes following 5-azaCdR treatment in 
medulloblastoma cell lines identified a direct relationship between promoter CpG 
methylation and gene expression for 2 out of the 4 candidate genes analysed (MET and 
RHOH), providing strong evidence of epigenetic regulation by DNA methylation for 
MET and RHOH in medulloblastoma (Table 3.9). There was no evidence of 
methylation-dependent expression of HDAC1 and DDR2 in medulloblastoma cell lines, 
suggesting that the subgroup-specific patterns of methylation and expression observed 
for these genes are not functionally related. 
The result for RHOH strongly supports its epigenetic regulation by hypomethylation in 
Group 4 medulloblastomas and identifies RHOH as a novel candidate oncogene in 
Group 4 medulloblastoma pathogenesis (see section 3.5.6). 
The result for MET strongly supports DNA methylation-dependent gene regulation as a 
candidate mechanism of MET pathway regulation/dysregulation in distinct subgroups of 
medulloblastoma. The functional significance of upregulated MET expression in driving 
medulloblastoma tumourigenesis , progression and metastasis has been demonstrated in 
vitro and in vivo (Li et al., 2005; Binning et al., 2008; Kongkham et al., 2008; 
Provencal et al., 2009). MET is an attractive drug target in many cancers and there are a 
number of mechanisms by which the MET signalling pathway and its downstream 
effectors can be targeted therapeutically using small molecule inhibitors and blocking 
antibodies (Gherardi et al., 2012). Medulloblastoma cells have previously shown 
sensitivity to small molecule inhibitors of MET (Kongkham et al., 2010b). The method 
of targeting MET signalling will depend on the mechanism of pathway activation. The 
findings reported here suggest an alternative mechanism of MET pathway activation in 
SHH medulloblastomas that could act independent of gene amplification and mutation 
and could help guide choice of targeted therapy. Perhaps the most interesting 
observation is that the Group 3 and Group 4 tumours appear to require promoter DNA 
methylation to repress MET expression while this is not the case for WNT tumours 
which are unmethylated and repressed, suggesting that distinct biological disease 
subgroups potentially use different gene regulatory mechanisms to control gene 
expression programmes. This may be explained in part by different cells of origin and 
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different selective pressures acting in concert with different tumour biology to drive 
tumourigenesis, as observed with MET and SHH signalling in SHH medulloblastoma 
formation (Binning et al., 2008). 
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Gene Subgroup-
specific 
(Group 3 
and/or 
Group 4) 
methylation 
pattern 
Subgroup-
specific 
inverse 
methylation-
expression 
relationship 
Tumour-
specific 
methylation 
event 
Aberrant 
methylation 
state 
Methylation-
dependent 
expression 
in ≥ 4/6 cell 
lines 
(qRT-PCR; 
-/+ 
5azaCdR) 
DDR2 Group (3+4) Y N Hypomethylatd 
in SHH + WNT  
N 
HDAC1 Group 4 Y N Hypomethylated 
in SHH, WNT 
and Group 3 
N 
MET Group (3+4) In SHH, 
Group 3 and 
Group 4 but 
not WNT 
Y Hypermethylated 
in Group (3+4) 
Y 
RHOH Group 4 Y Y Hypomethylated 
in Group 4 
Y 
Table 3.9. Summary table of Group 3 and/or Group 4–specific candidate epigenetically regulated genes. 
Candidate genes showed evidence of an inverse methylation/expression relationship in Group 3 and/or Group 4 
tumours. For two candidate genes, MET and RHOH, their subgroup-specific methylation was also tumour-specific, 
indicating an aberrant event in Group 3and/or Group 4. Candidate genes were investigated further for evidence of 
methylation-dependent gene expression in medulloblastoma cell lines by qRT-PCR. Expression was assessed in cell 
lines before and after treatment with the demethylating agent 5-azaCdR. MET and RHOH show strong evidence of a 
direct relationship between CpG methylation and gene expression in cell lines, which may be functionally relevant in 
the development of distinct subgroups of medulloblastoma. 
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3.5.6 RHOH – a novel candidate oncogene in Group 4 medulloblastomas  
This work has identified a potential functional relationship between DNA methylation 
and gene expression for the RHOH gene in Group 4 medulloblastomas. RHOH was 
found to be hypomethylated in Group 4 tumours consistent with upregulated expression, 
and suggestive of a potential oncogenic role in Group 4 tumourigenesis (Figure 3.17). 
The promoter-associated RHOH CpG site was unmethylated (β≤ 0.3) in 51% (48/94) of 
Group 4 tumours. There were no unmethylated control cerebellar samples (0/21). 
Aberrant hypomethylation (β≤ 0.3) was also observed in 21% (9/44) of Group 3 
tumours and in 18% (5/28) of WNT tumours, while 100% (50/50) of SHH tumours 
were methylated (β≥ 0.7) at this residue (Figure 3.17). 
RHOH is located on chromosome 4p13 and is a member of the Rho GTPase family of 
proteins that function in intracellular signalling and regulate cell proliferation and 
motility (Williams et al., 2008). Unlike other Rho GTPases, RHOH is GTPase-deficient 
and is dependent on interactions with other GTPases, post-translational modifications 
and expression levels for cellular activity (Li et al., 2002). RHOH is expressed in 
haematopoietic cells and has been identified to be dysregulated in lymphomas and 
leukaemias (Sanchez-Aguilera et al., 2010). Upregulated RHOH expression has been 
reported to promote migration of B cells in CLL suggesting a critical role in disease 
progression (Sanchez-Aguilera et al., 2010; Troeger et al., 2012). 
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Figure 3.17. Patterns of CpG methylation and gene expression for RHOH. Combined boxplots and strip-plots 
illustrate the differential patterns of CpG methylation and gene expression for the RHOH promoter-associated CpG 
residue RHOH_P121_F. Methylation of RHOH_P121_F in control cerebellar samples (CB) is also shown. The CpG 
residue is hypomethylated in Group 4 medulloblastomas and hypomethylation is associated with significantly higher 
expression in Group 4 compared with the other tumour subgroups. Primary tumour subgroups and control cerebella 
(CB) are represented on boxplots by different colours: SHH, blue; WNT, red; Group 3(Grp3), purple; Group 4 
(Grp4), orange; control cerebella (CB), green. Expression profiles are representative of the Kool/Fattet transcriptomic 
dataset. Expression profiles for control cerebella were not available for this study. 
 
3.6 Further work 
Investigations reported in this chapter have identified novel DNA methylation markers 
of the poorly characterised Group 3 and Group 4 medulloblastomas. While the majority 
of these markers did not show a clear association with gene expression, this work has 
identified a potential novel candidate oncogene in Group 4 tumours, which may be 
upregulated by DNA hypomethylation in this tumour subgroup. It will now be essential 
to validate these findings in vitro and in vivo and to elucidate any functional role for 
RHOH in Group 4 medulloblastoma pathogenesis. The results reported in this study for 
RHOH are based on the methylation status of a single CpG residue located within the 
non-CpG island gene promoter. It will be necessary to validate the methylation status of 
the wider promoter region in primary tumours and in normal cerebella by bisulfite 
sequencing (see section 1.6.3.3). qRT-PCR will need to be performed in primary 
tumours and normal cerebella to assess the subgroup-specific expression changes and to 
validate a functional methylation-expression relationship in primary medulloblastomas, 
and the upregulated expression consistent with hypomethylation in Group 4 tumours. It 
will be important to determine whether the increased RHOH mRNA levels translate to 
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elevated protein levels in Group 4 tumours by western blot analysis. To determine any 
functional role for RHOH and perhaps for wider Rho signalling pathways in Group 4 
medulloblastomas, proliferation, apoptosis and migration assays will need to be 
conducted in vitro and in vivo following modulation of RHOH expression. Results from 
functional assays will reveal any involvement of RHOH in the initiation and progression 
of Group 4 medulloblastomas and identify its potential as a therapeutic drug target 
within these tumours. There are currently no mouse models of Group 4 
medulloblastomas reported. While RHOH represents a Group 4-specific gene, the 
patterns of differential methylation and expression observed are more similar in Group 
3 and Group 4 tumours compared to SHH and WNT tumours. Aberrant 
hypomethylation is also observed in 21% (9/44) of Group 3 tumours (Figure 3.17). 
Recently mouse models of Group 3 medulloblastomas that express c-MYC have been 
generated (Kawauchi et al., 2012; Pei et al., 2012). A potential functional role for 
RHOH in medulloblastoma tumourigenesis could be investigated using these models of 
Group 3 tumours. 
Further work will be required to validate the methylation status of the wider promoter 
CpG island of MET in primary tumours and in normal cerebella by bisulfite sequencing, 
and qRT-PCR will be required to validate a functional relationship between methylation 
and expression in tumour subgroups. It may also be interesting to investigate expression 
of other MET pathway components in WNT, Group 3 and Group 4 tumours to possibly 
gain an understanding of why methylation may be required for MET silencing in Group 
3 and Group 4 tumours but not in the WNT subgroup. 
The work in this study did not extend to an investigation into the prognostic relevance 
of the Group 3 and Group 4 methylation markers identified. Prognostically significant 
methylation biomarkers have recently been identified in medulloblastoma, which offer 
the potential for improved disease risk stratification owing to their high clinical utility 
(Castelo-Branco et al., 2013; Schwalbe et al., 2013) (see section 1.7.2.2). It will be 
important to assess the independent prognostic relevance of the Group 3 and Group 4 
methylation markers across all primary tumours and tumour subgroups. For those 
markers whose methylation is variable within the subgroup(s), their intra-group 
prognostic relevance will need to be investigated. Prognostication within a subgroup 
may identify subsets of tumours which behave differently, and which may benefit from 
 208 
 
either less intensive or more aggressive therapies depending on the prognosis conferred. 
It will be particularly important to investigate the prognostic value of the Group 4-
specific RHOH methylation marker, as it could potentially represent a prognostic 
marker with functional relevance.  
Alongside an investigation into the potential role of Group 3 and Group 4 methylation 
events as independent prognostic biomarkers, it will be important to assess their ability 
to improve the accuracy of survival prediction alongside established prognostic features. 
Group 3 medulloblastomas are enriched for MYC amplification and LCA histology and 
are frequently metastatic. Metastases and LCA histology are also reported in Group 4 
tumours (Kool et al., 2012). These are established prognostic features in 
medulloblastoma (Ellison et al., 2011b). It will be important to assess the ability of the 
methylation markers to improve the accuracy and significance of current survival 
prediction by adding them to a multivariate Cox regression model (Cox, 1972) 
containing the known risk variables. Developing a more accurate and refined disease 
risk stratification is essential to improve survival and minimise late adverse treatment 
effects through the delivery of more personalised therapies (Pizer and Clifford, 2009).  
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3.7 Summary 
This study has identified 2 genes, MET and RHOH, which show strong evidence for a 
direct role of DNA methylation in transcriptional regulation within distinct subgroups of 
medulloblastoma. RHOH has been identified as a potential novel oncogene 
epigenetically regulated by promoter DNA hypomethylation in Group 4 
medulloblastomas. Further work must now be carried out to validate epigenetic 
regulation of RHOH in medulloblastoma and to determine any functional role in Group 
4 tumourigenesis. This study has also identified a potential candidate mechanism of 
MET regulation and dysregulation by DNA methylation in distinct medulloblastoma 
subgroups that requires further validation. 
This study has been limited by the lack of tumour-matched methylation and expression 
data available, and methylation-expression associations have had to be determined 
largely by a comparison of means based on subgroup-specific differential analysis. 
Tumour-matched data would permit a more accurate statistical correlation on a tumour 
by tumour basis. Using the methods described in this chapter, the results suggest that 
DNA methylation may directly regulate relatively few genes in Group 3 and Group 4 
medulloblastomas. While a simplistic relationship between DNA methylation and gene 
expression may not exist for the majority of methylation events identified, 
transcriptional regulation is highly complex and DNA methylation status alone may not 
be sufficient to explain gene expression differences.  
Investigations in this chapter have focused on a role for promoter DNA methylation of a 
targeted panel of cancer-related genes. Epigenome-wide studies in cancer are beginning 
to reveal roles for DNA methylation outside of the gene promoter and outside of CpG 
islands (Irizarry et al., 2009; Kulis et al., 2013). Using genome-wide approaches, an 
unbiased assessment of gene-wide DNA methylation offers the potential to gain greater 
insights into the role of DNA methylation in medulloblastoma development and to 
identify further epigenetically regulated genes within the subgroups. The genome-wide 
role of DNA methylation in medulloblastoma has not been widely investigated. Using a 
functional epigenomics approach, investigations reported in Chapter 4 sought to identify 
genes whose expression was upregulated in cell lines following demethylating 
treatment, and to undertake a comprehensive characterisation of DNA methylation 
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events that may be associated with expression changes, and that may play a key role in 
the development of distinct subgroups of medulloblastoma. 
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Chapter 4  
Functional epigenomics identifies novel candidate 
epigenetically regulated genes in distinct subgroups of 
medulloblastoma 
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4.1 Introduction 
Most studies of cancer DNA methylation have focused on defining aberrant gene 
promoter and, in particular, CpG island-associated events and their contribution to 
tumour development. Using the first generation Illumina GoldenGate methylation 
microarray (Bibikova et al., 2006), investigations reported in Chapter 3 provided a 
detailed study into the role of promoter DNA methylation in gene regulation for 807 
cancer-related genes in the distinct Group 3 and Group 4 subgroups of 
medulloblastoma. The coverage offered by DNA methylation analysis methods has 
increased substantially in recent years and it is now possible to study DNA methylation 
at significantly higher resolution and on a genome-wide scale. Using the latest 
generation Illumina Infinium 450K methylation array (Bibikova et al., 2011), the 
investigations reported in this chapter sought to undertake a more comprehensive 
characterisation of DNA methylation events that may regulate gene expression and that 
may play a role in the development of distinct subgroups of medulloblastoma. 
The Illumina Infinium 450K methylation array provides genome-wide coverage of over 
450,000 CpG sites (see section 2.7.3). This high density array interrogates sites located 
across the complete gene and CpG island regions (Bibikova et al., 2011), permitting an 
unbiased study into the role of gene-wide DNA methylation in gene regulation. The 
450K methylation array targets CpG sites in gene promoters in 200 base pair and 1500 
base pair blocks upstream of the transcription start site (designated TSS200 and 
TSS1500, respectively). The 5’UTR and 3’UTR, first exon and gene body regions are 
also targeted independently (Bibikova et al., 2011). As the number of epigenome-wide 
studies increases potential roles for intragenic gene body DNA methylation in gene 
regulation processes are being recognised. It has been confirmed in human brain 
samples that intragenic DNA methylation plays a role in controlling alternative 
promoter usage (Maunakea et al., 2010) and roles in alternative splicing have also been 
reported (Shukla et al., 2011; Brown et al., 2012). Studies have also demonstrated that a 
large number of enhancer regions show an inverse correlation between DNA 
methylation and gene expression levels or enhancer activity (Schmidl et al., 2009; 
Hoivik et al., 2011; Aran et al., 2013), and of particular interest was the finding that 
enhancer methylation changes were associated with gene expression alterations while 
promoter methylation remained unaffected (Aran et al., 2013). In one study in a large 
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cohort of CLL patients, the strongest correlation between gene expression and DNA 
methylation was found for intragenic CpGs rather than for those located at 5’ regions, 
and the negative correlation was frequently related to enhancer regions, suggesting that 
in some cases the methylation status of distal regulatory regions might be more 
predictive of expression levels than promoter methylation (Kulis et al., 2012). 
The 450K methylation array provides enhanced coverage of CpG island regions; 96% 
of CpG islands are represented on the array as well as CpG island shores and CpG 
island shelves (Bibikova et al., 2011). It has recently been suggested that many CpG 
islands are flanked by CpG island shores, which have been defined as regions 
immediately outside of CpG islands and located within 2kb of the island, where the 
density of CpG sites has fallen to approximately one tenth the density in the island itself 
(Irizarry et al., 2009). CpG island shelves are 2kb regions immediately outside of CpG 
island shores with further reduced CpG density (Bibikova et al., 2011). The importance 
of DNA methylation in these regions adjacent to CpG islands was first recognised in the 
colon cancer methylome (Irizarry et al., 2009). Using an epigenome-wide approach, 
Irizarry et al. reported that most methylation changes in colon cancer occurred not in 
promoters and not in CpG islands but rather in the CpG island shore regions, and were 
strongly related to gene expression (see section 1.6.3.1). 
The azanucleoside 5’-aza-2’-deoxycytidine (5-azaCdR) is a demethylating drug that 
incorporates into the genome of actively replicating cells, where it establishes an 
irreversible covalent bond with DNA methyltransferase enzymes (DNMTs), blocking 
their methyltransferase function and promoting their subsequent degradation 
(Stresemann and Lyko, 2008). As a result, DNA methylation marks are lost during 
DNA replication (Stresemann and Lyko, 2008). Studies have shown that 5-azaCdR 
induces significant demethylation in human cell lines (Jones and Taylor, 1980). 
Investigations reported in this chapter utilised a genome-wide microarray-based analysis 
of gene expression changes induced by the demethylating agent 5-azaCdR to discover 
candidate epigenetically silenced genes in cancer cell lines that were further 
investigated for evidence of methylation-dependent regulation in primary tumours. This 
pharmacological-based approach relies on the functional criterion of transcriptional 
activation following demethylation and has proved an effective screening method to 
discover epigenetically regulated genes in cancer cells (Suzuki et al., 2002). Using this 
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genome-wide functional screening approach several genes have been identified that are 
silenced by promoter hypermethylation in primary medulloblastomas, including 
COL1A2 (Anderton et al., 2008), SPINT2 (Kongkham et al., 2008) and the SFRP family 
of WNT inhibitors (Kongkham et al., 2010a). 
Medulloblastoma comprises four core methylomic subgroups (SHH, WNT, Group 3 
and Group 4) that are strongly associated with their transcriptomic counterparts 
(Schwalbe et al., 2013). It is recognised that these subgroups are distinct molecular 
entities and thus future clinical trials and treatments should take subgroup status into 
account (Northcott et al., 2012b; Taylor et al., 2012). It is believed that most human 
cancers are associated with aberrant gene expression that can be attributed in part to 
epigenetic alterations (Sadikovic et al., 2008). There are currently approximately 30 
genes known to be aberrantly silenced by DNA methylation in the medulloblastoma 
epigenome (Dubuc et al., 2012). DNA methylation studies in medulloblastoma have 
previously been restricted to specific promoter-associated loci in a limited number of 
genes and the functional significance of gene-wide DNA methylation in the 
pathogenesis of distinct subgroups of medulloblastoma has not been widely 
investigated. The identification of subgroup-specific functionally important DNA 
methylation events offers the potential for the development of novel therapeutic targets 
and disease biomarkers that will facilitate the delivery of more personalised and targeted 
therapies, with the primary aim of improving survival and reducing the late adverse 
effects associated with current aggressive radiotherapy and chemotherapy regimens. 
The genome-wide role of DNA methylation in the distinct subgroups of 
medulloblastoma has not been widely investigated. Using a functional epigenomics 
analysis of methylation-dependent gene expression alterations by 5-azaCdR, combined 
with a genome-wide analysis of DNA methylation, investigations reported in the 
chapter sought to undertake a comprehensive characterisation of CpG methylation 
events that are associated with expression alterations and that may play a role in the 
pathogenesis of distinct subgroups of medulloblastoma. 
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4.2 Aims 
Using genome-wide expression and methylation microarray technologies, the work 
reported in this chapter aimed to: 
 Identify genes that undergo methylation-dependent transcriptional silencing and 
re-expression following 5-azaCdR treatment in medulloblastoma cell lines. 
 
 Identify critical CpG residues whose methylation status is consistent with 
methylation-dependent gene regulation in cell lines 
 
 Assess differential CpG methylation and gene expression in primary 
medulloblastomas, in a subgroup-specific context. 
 
 Identify subgroup-specific candidate epigenetically regulated genes, defined by 
those genes which show consistent methylation-dependent gene regulation in 
cell lines, alongside differential CpG methylation inversely correlated with gene 
expression in distinct subgroups of primary tumours. 
 
 For candidate genes assess patterns of CpG methylation across genomic regions 
and evaluate the potential effect of region-wide DNA methylation on gene 
expression. 
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4.3 Materials and methods 
4.3.1 5’-Aza-2’-deoxycytidine treatment of medulloblastoma cell lines and 
RNA extraction. 
Ten medulloblastoma cell lines (DAOY, D283 Med, D425 Med, D458 Med, D341 
Med, D384 Med, D556 Med, MHH-MED-1, MEB-MED-8A and UW228-2) (see 
section 2.2) were cultured in the presence and absence of the demethylating agent 5’-
aza-2’-deoxycytidine (5-azaCdR) as described in section 2.5.5, followed by RNA 
extraction as described in section 2.6.1. The quality and quantity of RNA were assessed 
by Bioanalyzer (see section 2.6.3.3).  
4.3.2 Re-expression of RASSF1A in medulloblastoma cell lines following 5-
azaCdR treatment 
To test the effectiveness of 5-azaCdR treatment in cell lines, and prior to sending 
samples for expression microarray analysis, RASSF1A expression was assessed by RT-
PCR, using cDNA synthesised from extracted RNA (see section 2.9.3). RASSF1A was 
used as a positive control for the demethylating treatment of the 10 cell lines due to the 
robust evidence for its methylation-dependent transcriptional silencing and re-
expression following 5-azaCdR treatment in multiple cell lines (Lusher et al., 2002). 
Agarose gel electrophoresis was used to determine the presence and size of PCR 
products (see section 2.9.3.1). 
4.3.3 Whole genome gene expression profiling 
4.3.3.1 HumanHT-12 microarray assay 
Whole genome gene expression profiles for the 10 untreated and 5-azaCdR-treated cell 
line pairs were generated on the Human HT12-v4.0 microarray platform (see section 
2.8). Extracted cell line RNA was amplified and biotinylated as described in section 
2.6.4, and aliquots of 750ng of cRNA at 150ng/µl were sent for microarray gene 
expression profiling. Microarray analysis was performed at the Wellcome Trust Clinical 
Research Facility, Edinburgh, UK, according to manufacturer’s protocols (Illumina, San 
Diego, CA, USA). Cell line pairs were processed on the same BeadChip and all samples 
were processed in a single batch using 2 chips to minimise batch effect. Quality 
assessment and processing of raw bead level data was carried out by the Wellcome 
Trust Facility in Edinburgh using the Illumina GenomeStudio Gene Expression Module 
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(Illumina, San Diego, CA, USA). All categories of Illumina controls performed as 
expected and no samples failed internal quality control measures. The number of 
detected genes (p<0.05) ranged from 10,000 to 14,000 across the cell line samples. The 
bead summary data output from GenomeStudio (see section 2.8.2) for target and control 
probes was kindly provided by the Wellcome Trust Facility. The bead summary data 
provided the average signal intensity and the detection p-value for each probe. The 
average standard error associated with bead to bead variability and the average number 
of beads per probe on each array was also provided. 
4.3.3.2 Quality control, array normalisation and data filtering 
Bead summary data was analysed in R (v 2.15) using the beadarray package (Dunning 
et al., 2007). The supporting annotation package for the HT12-v4.0 platform 
(illuminaHumanv4.db) was downloaded into R (v 2.15) from the Bioconductor website 
(www.bioconductor.org), and facilitated the mapping of Illumina probe sequences to 
important functional information including chromosome location and gene 
identification. 
Prior to normalisation the data was log2 transformed to stabilise variance. Boxplots of 
the average probe signal intensity levels and the average number of beads per probe 
type were constructed to assess any obvious differences in sample performance within 
and between BeadChips. Normalisation of high-throughput microarray data is important 
to correct for variation of non-biological origin across a chip and between chips so that 
all samples in an experiment are comparable, and it is important to select an appropriate 
normalisation method to avoid removing important biological effects. The method of 
quantile normalisation has previously been found to demonstrate favourable 
performance for high density microarray data (Bolstad et al., 2003). The goal of the 
quantile method is to make the distribution of intensities for each array in a set the same 
and given that genes do not change between arrays and intensity distribution between 
arrays should be the same this method is deemed appropriate (Bolstad et al., 2003). The 
log2 summarised data were quantile normalised in R (v 2.15). 
Transcript probe filtering measures were carried out to improve the power to detect 
differential gene expression. There were four probe quality categories (‘Perfect’, 
‘Good’, ‘Bad’ and ‘No match’) defined within the Illumina annotation package that 
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have been shown to correlate with expression level (Dunning et al., 2007). ‘Bad’ and 
‘No match’ probes were considered non-responding probes and were filtered from the 
data. This filtering step is reported to be equivalent to removing lowly-expressed probes 
as well as removing those with high expression caused by non-specific hybridisation 
(Dunning et al., 2007). It is also common practice in microarray data analysis to remove 
probes not detected in a proportion of samples. In this study, to account for genes being 
transcriptionally silenced by DNA methylation and subsequently re-activated following 
demethylation, probes not detected with a p-value <0.05 in at least 1 cell line were 
filtered out. It was important to consider probes that mapped to the sex chromosomes 
because females who are diploid X carry a methylated silenced X chromosome (Wutz 
and Gribnau, 2007), while the single X chromosome of males is largely unmethylated. 
Probes that mapped to the sex chromosomes were removed to eliminate the potential for 
gender-specific differences to confound differential analysis. Finally, probes that did not 
map to an official gene symbol or chromosome location according to Illumina’s 
annotation were removed as they were considered uninformative for downstream 
analysis. 
4.3.4 Genome-wide DNA methylation profiling 
4.3.4.1 Infinium 450K methylation microarray 
For investigations reported in this chapter the Infinium 450K methylation platform 
(Bibikova et al., 2011) (see section 2.7.3) was used to assess patterns of CpG 
methylation in a defined cohort of primary medulloblastomas, in cell lines and in non-
neoplastic cerebellar samples. The 450K microarray interrogates the methylation status 
of over 450,000 CpG sites corresponding to 21,231 genes. The array provides 
comprehensive CpG coverage across the complete genome with probes distributed 
across the gene promoter, 5’ UTR, 1st exon, gene body and the 3’UTR. The array 
provides coverage of CpG islands, CpG island shores and island shelves as well as 
isolated genomic sites. The 450K methylation microarray analysis was performed at the 
Wellcome Trust Clinical Research facility, Edinburgh, UK, according to manufacturer’s 
protocols (Illumina, San Diego, CA, USA). Raw data processing and normalisation 
measures were carried out by Dr. Ed. Schwalbe (Newcastle University Paediatric Brain 
Tumour Group) and final methylation M-value scores were kindly provided by Dr. 
Schwalbe. The M-value provides a continuous measure of DNA methylation and is 
 219 
 
calculated as the log2 ratio of the intensities of methylated probe versus unmethylated 
probe (see section 2.7.3.1); M-values close to zero indicate a hemi-methylated state, 
while positive M-values reflect increasing methylation and negative values reflect 
decreasing methylation. M-values can be transformed to their corresponding β-values 
using the “m2beta()” function within the lumi package in R. Compared with 
methylation β-values, M-values have greater homoscedasticity and this allows DNA 
methylation data to be appropriately analysed by robust statistical methods that are 
commonly employed for expression microarray analysis (Du et al., 2010).  
4.3.4.2 Primary medulloblastoma cohort 2 
A representative cohort of 109 primary medulloblastomas (see section 2.1.2) was 
analysed on the Infinium 450K methylation array and used for investigations reported in 
this chapter. The cohort included all known medulloblastoma histopathological 
subtypes and patient ages ranged from 3.6 months to 43 years old. The 4 principal 
molecular subgroups of medulloblastoma (SHH, WNT, Group 3 and Group 4) were 
represented in the cohort. Newcastle Research Ethics Committee approval had been 
obtained for the collection, storage and biological study of all material.  
4.3.4.3 Medulloblastoma cell lines 
The methylation profiles of 10 medulloblastoma cell lines (DAOY, D283 Med, D425 
Med, D458 Med, D341 Med, D384 Med, D556 Med, MHH-MED-1, MEB-MED-8A 
and UW228-2) (see section 2.2) were assessed on the 450K methylation array. Cell 
lines were cultured as described in section 2.5. 
4.3.4.4 Non-neoplastic cerebellar samples 
The methylation profiles of 17 non-neoplastic cerebellar samples (see section 2.3) were 
assessed on the 450K methylation array. Samples consisted of post-mortem material 
from patients who died from non-neoplastic conditions and included foetal, infant and 
adult patient samples.  
4.3.4.5 DNA extraction 
DNA was extracted from cell lines using a Qiagen DNeasy kit (Qiagen Ltd, 
Manchester, UK) (section 2.6.2), according to manufacturer’s instructions. DNA 
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extractions from primary tumours and non-neoplastic cerebellar samples were carried 
out by Dr. Janet Lindsey, Dr. Rebecca Hill and Dr. Chris Howell (Newcastle University 
Paediatric Brain Tumour Research Group) using TRIzol Reagent (Invitrogen Ltd, 
Paisley, UK) (see section 2.6.2), according to manufacturer’s instructions. Aliquots of 
1µg of DNA at 50ng/µl, as measured by Qubit fluorometry (see section 2.6.3.2) were 
sent for methylation array profiling. 
4.3.5 Medulloblastoma methylomic subgroups 
The 109 primary tumours were reliably subclassified into the four principal molecular 
subgroups (SHH, WNT, Group 3 and Group 4) according to their 450K methylation 
profiles by Dr. Ed Schwalbe (Newcastle University Paediatric Brain Tumour Research 
Group). Using the same methodologies described for the GoldenGate methylation 
microarray (Schwalbe et al., 2013), Dr. Schwalbe identified four robust methylomic 
subgroups that were strongly associated with their transcriptomic counterparts. 
The proportion of tumours classified in each methylomic subgroup was comparable to 
those described for their transcriptomic counterparts (Kool et al., 2012); Group 4 
formed the largest group (34% [37 tumours]), followed by SHH (27% [29 tumours]) 
and Group 3 (27% [30 tumours]). WNT tumours represented the smallest group (12% 
[13 tumours]) (Table 2.2).  
4.3.6 Primary medulloblastoma transcriptomic datasets 
The three transcriptomic datasets (Kool/Fattet, Cho and Northcott; see section 2.4) that 
were used for investigations reported in Chapter 3 were also used for investigations 
reported in this chapter. Expression profiles and supporting annotation data files were 
accessed as described in section 2.4. The primary tumours in each dataset were reliably 
subclassified into the four principal subgroups of medulloblastoma (SHH, WNT, Group 
3 and Group 4) by Dr. Dan Williamson (Newcastle University Paediatric Brain Tumour 
Research Group) using a 4 metagene classifier as described in section 2.4.1. 
4.3.7 Gene upregulation following 5-azaCdR treatment of medulloblastoma 
cell lines 
A fold change (FC) estimation approach was used to identify genes whose expression 
was upregulated following 5-azaCdR treatment of cell lines. Cell lines were treated 
independently. For each cell line pair the average probe signal intensity (non-log scale) 
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for the treated cell line was normalised to its untreated counterpart to determine the FC 
in expression after 5-azaCdR. The mean FC and the standard deviation of the mean 
were calculated for each cell line and a FC threshold of [meanFC + 3SD] was applied. 
Genes were considered upregulated by 5-azaCdR treatment and thus showed evidence 
of potential methylation-dependent transcriptional regulation in cell lines if the FC in 
expression exceeded the threshold in 2 or more cell lines. 
Gene ontology (GO) analysis of the upregulated genes was performed using the open 
access DAVID Bioinformatics Resource (http://david.abcc.ncifcrf.gov/). The DAVID 
Functional Annotation Clustering algorithm was applied to the list of Illumina probe 
identifiers. This algorithm measures the relationships between GO annotation terms and 
groups them into GO annotation groups, facilitating a more focused biological 
interpretation of the data (Huang da et al., 2007). 
4.3.8 Identification of critical CpG sites associated with methylation-
dependent expression alterations in cell lines 
Genes which were upregulated by 5-azaCdR treatment in medulloblastoma cell lines 
(see section 4.3.7) were selected for assessment of their methylation status in order to 
identify CpG sites whose methylation was consistent with methylation-dependent 
expression alterations observed following 5-azaCdR treatment. Methylation status was 
assessed using the Infinium 450K methylation array (see section 4.3.4.1). The 450K 
annotation package (IlluminaHumanMethylation450k.db) was downloaded from the 
Bioconductor website (www.bioconductor.org) into R (v 2.15). The package contained 
functional annotation data assigned by Illumina for all probes on the 450K array and 
facilitated the mapping of probes to important information including chromosome 
location and gene identification as well as genomic location (promoter, body, UTRs) 
and CpG density of neighbouring region (island, shore, isolated site). 
Methylation and expression probes were paired on the basis of their official gene 
symbol identifiers as annotated by Illumina in the relevant annotation packages. 
Methylation M-values were converted to their corresponding β-values using the lumi 
package which was downloaded from the Bioconductor website into R. All CpG 
methylation probes for each upregulated gene were initially extracted from the cell line 
450K methylation data. Probes with β-values ≤ 0.3 were considered unmethylated and 
those with β-values >0.3 were considered methylated. Probes that were unmethylated in 
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all 10 cell lines (constitutively unmethylated) were removed from the analysis as these 
were deemed uninformative and would not be associated with any upregulated 
expression observed in the cell lines following 5-azaCdR treatment. The remaining CpG 
probes were investigated further for evidence of a critical role in epigenetic gene 
regulation. 
4.3.8.1 Methylation-dependent re-expression in cell lines 
Following the removal of constitutively unmethylated probes the remaining CpG probes 
were considered constitutively methylated or variably methylated as follows: 
 Constitutively methylated: β-value >0.3 in all 10 cell lines. 
 Variably methylated: variable β-values ranging from 0 (completely 
unmethylated) to 1 (completely methylated) across the 10 cell lines. 
To determine whether methylation status was consistent with methylation-dependent re-
expression in cell lines following 5-azaCdR treatment, the fold changes in expression 
observed across the 10 cell lines for the upregulated genes were converted into a matrix 
of 0’s and 1’s in R. Fold changes greater than the cell line threshold were assigned the 
nominal value 1 (upregulated), while those not exceeding the threshold were assigned 
the nominal value 0 (not upregulated). Similarly, the methylation β-values for the 
corresponding CpG probes in the 10 cell lines were converted into a matrix of 0’s 
(unmethylated; β ≤0.3) and 1’s (methylated, β>0.3). The corresponding gene-specific 
rows and cell line-specific columns of the 2 matrices were added together to give a 
results matrix containing the values 0, 1 and 2 which were interpreted as a “consistent 
relationship” or “inconsistent relationship” as follows: 
 Results value 0: “consistent relationship”; CpG site was unmethylated 
and gene not upregulated by 5azaCdR. 
 Results value 2: “consistent relationship”; CpG site was methylated and 
gene upregulated by 5azaCdR. 
 Results value 1: “inconsistent relationship”; CpG site was unmethylated 
and gene was upregulated OR CpG site was methylated and gene was 
not upregulated by 5azaCdR. 
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CpG sites were considered to have a methylation status consistent with methylation-
dependent gene re-expression following 5-azaCdR treatment if the following criteria 
were met: 
 Constitutively methylated probes: a “consistent relationship” (results 
value 2) was observed in ≥ 60% cell lines 
 Variably methylated probes: a “consistent relationship” (results value 0 
or 2) was observed in ≥ 60% cell lines AND ≥ 60% methylated cell lines 
were upregulated (results value 2). 
Bar graphs were constructed in R (v 2.15) to illustrate methylation-dependent gene re-
expression following 5-azaCdR treatment in cell lines. 
4.3.8.2 Correlation between CpG methylation and gene expression in cell lines 
The variably methylated CpG sites whose methylation status was consistent with 
methylation-dependent re-expression observed in cell lines (see section 4.3.8.1) were 
further investigated for evidence of a significant inverse methylation-expression 
relationship. The association between CpG methylation and endogenous gene 
expression in the 10 untreated cell lines was assessed by calculating Pearson’s product-
moment correlation coefficient r and associated p-value. In order to control for the large 
number of correlation tests being performed raw p-values were corrected using the 
Benjamini-Hochberg false discovery rate (FDR) correction (Benjamini and Hochberg, 
1995). The level of endogenous gene expression was considered to be significantly 
inversely correlated with CpG methylation if the coefficient r value was < (-0.7) and the 
adjusted p-value was <0.05. Linear regression plots were constructed in R (v 2.15) to 
illustrate significant inverse methylation-expression relationships in cell lines. 
4.3.9 Identification of candidate epigenetically regulated genes in 
medulloblastoma cell lines 
Genes that corresponded to the constitutively methylated probes whose methylation was 
consistent with methylation-dependent re-expression in at least 60% of cell lines 
following 5-azaCdR treatment (see section 4.3.8.1) were selected as candidate 
epigenetically regulated genes. Similarly, genes that corresponded to the variably 
methylated probes whose methylation status was consistent with expression alterations 
as described in section 4.3.8.1 and whose methylation showed a significant inverse 
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correlation with endogenous gene expression in cell lines (see section 4.3.8.2) were 
selected as candidate epigenetically regulated genes.  
4.3.10 Linear models for microarray data: limma 
The candidate epigenetically regulated genes which were identified in cell lines (see 
section 4.3.9) were investigated for evidence of significant differential CpG methylation 
and associated differential gene expression in primary medulloblastoma subgroups 
using the R package limma (Smyth, 2004). The output statistics for significance analysis 
using limma are the moderated t-statistic and the moderated F-statistic, which have the 
same interpretation as the ordinary t-statistic and F-statistic in conventional t-tests and 
ANOVA, except that limma uses a different method of variance estimation (Smyth, 
2004). Limma uses a linear models approach to the analysis of microarray experiments 
and after fitting a linear model to each probe in the data it uses an empirical Bayes 
method to shrink probe-wise sample variances towards a common value and increase 
degrees of freedom for individual variances (Smyth, 2004). The effectiveness of limma 
in differential expression analysis has previously been demonstrated (Irizarry, 2005), 
and it has been found to be superior to the t-test and ANOVA, providing an increase in 
power and improvement in the false-positive rate (Jeanmougin et al., 2010).  
A further advantage of limma is its capability to assess differences in a multifactorial 
designed experiment where multiple contrasts between targets can be analysed 
simultaneously. For investigations reported in this chapter all pair-wise comparisons 
(SHHvWNT, SHHvGrp3, SHHvGrp4, WNTvGrp3, WNTvGrp4, Grp3vGrp4) could be 
tested simultaneously and subsequent subgroup-specificity determined (see sections 
4.3.11 and 4.3.12). Limma required 2 matrices to be specified; a design matrix that 
identified the subgroup of each sample in the data (SHH, WNT, Grp3 or Grp4) and a 
contrast matrix that specified the pair-wise comparisons to be made. Limma provided 
two functions that performed the significance tests and adjusted p-values for multiple 
testing. The “topTable()” function computed the moderated t-statistic for each probe and 
contrast, testing each individual contrast to 0, alongside a moderated F-statistic testing 
whether all the contrasts were 0. P-values were adjusted for multiple testing using the 
Benjamini-Hochberg false discovery rate correction (Benjamini and Hochberg, 1995). 
P-values were adjusted for the number of probes tested as well as the number of 
contrasts and all tests were treated as equivalent regardless of which probe or contrast 
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they related to, facilitating a comparison of the number of differential events between 
contrasts to be made. The “topTable()” output also included a log2 fold change (logFC) 
value. The logFC represented the value of the contrast. LogFC thresholds (difference 
thresholds) were applied to the differential methylation analysis (see section 4.3.11) and 
to the differential expression analysis (see section 4.3.12). The “decideTests()” function 
produced a numeric matrix with the elements -1, 0 or 1 depending on whether each t-
statistic was classified as significantly negative, not significant or significantly positive, 
respectively, according to the adjusted p-value and logFC thresholds imposed. 
4.3.10.1 Differential methylation in primary tumours using linear models 
Limma is a parametric statistical model that was designed for gene expression 
microarray data analysis, where the assumption of homoscedasticity used by this model 
is appropriately made (Jeanmougin et al., 2010). The M-value method of measuring 
methylation with Infinium arrays (see section 4.3.4.1) has been recommended for 
differential methylation analysis due to its approximate homoscedasticity, making it 
statistically valid to use methods such as limma (Du et al., 2010). In comparison, the β-
value measure of methylation (see section 2.7.3.1) has a finite range from 0 to 1 and 
shows severe heteroscedasticity at high and low levels of methylation due to the 
compressed nature of the data, making it inappropriate to use limma for differential 
analysis using β-values (Du et al., 2010).  
4.3.11 Identification of subgroup-specific differentially methylated CpG sites 
Candidate genes with strong evidence of methylation-dependent transcriptional 
regulation in medulloblastoma cell lines (see section 4.3.9) were selected for differential 
methylation analysis in primary tumours and non-neoplastic cerebellar samples. The 
critical CpG sites corresponding to the candidate genes were investigated for evidence 
of subgroup-specific and tumour-specific differential methylation using limma. 
SHH, WNT, Group 3 and Group 4 tumours and non-neoplastic cerebellar samples were 
identified in the design matrix. The contrast matrix included all pair-wise contrasts. An 
example of the pair-wise contrasts tested to determine SHH-specific events were as 
follows: 
 SHH v WNT; SHH v Group 3; SHH v Group 4; SHH v cerebella 
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Alongside single group contrasts, paired group contrasts were tested as follows: 
 (SHH+WNT) v (G3+G4); (SHH+G3) v (WNT+G4); (WNT+G3) v 
(SHH+G4); (G3+G4) v cerebella 
These contrasts were tested to identify events specific to Group (3+4) tumours. As 
previously discussed in Chapter 3, although Group 3 and Group 4 are distinct subgroups 
they are likely more similar to each other than to SHH or WNT tumours (Taylor et al., 
2012).  
Contrasts were required to satisfy a FDR-adjusted p-value <0.05 and a logFC (absolute 
difference in mean M-value scores) > 0.9 to be judged significant. A mean M-value 
difference threshold within the range 0.4 and 1.4 is recommended for differential 
methylation analysis (Du et al., 2010). Du et al. demonstrated that thresholds within this 
range are optimum as they can increase the true positive rate without deteriorating the 
detection rate of the significance test. A threshold of 0.9 was selected as it is midway in 
the recommended range. 
The “decideTests()” function of limma (see section 4.3.10) was applied to classify 
results as significantly negative, not significant or significantly positive using the 
elements -1, 0 and 1 respectively. Individual subgroup-specificity was determined by 
overlapping the results for the appropriate individual contrasts and selecting only those 
events that were significant (-1 or 1) in all selected contrasts. This was carried out in R. 
As an example, SHH-specific events were identified as those events that were 
significant (-1 or 1) in the contrasts SHH v WNT, SHH v G3 and SHH v G4. Group 
(3+4)-specific events were identified as those events that were significant (-1 or 1) in 
the (SHH+WNT) v (G3+G4) contrast but were not significant (0) in the (SHH+G3) v 
(WNT+G4) and the (WNT+G3) v (SHH+G4) contrasts. 
To further increase the sensitivity of the significance test and to ensure that only 
biologically relevant probes were selected, an additional filter of an absolute difference 
in mean β-value (Δβ) greater than 0.2 was applied. This value was chosen as it is the 
limit of detection of the Infinium 450K assay (Bibikova et al., 2011). This final filter 
was applied after subgroup specificity was determined using limma. 
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As an example, SHH-specific events were required to satisfy the following Δβ filter: 
 |mean β-value (SHH) – mean β-value (WNT+G3+G4)| > 0.2 
Contrasts assessing tumour subgroup methylation against non-neoplastic cerebella 
methylation were tested in the contrast matrix. Similar to the investigations reported in 
Chapter 3, the difference in methylation between the subgroup-specific event and the 
non-neoplastic cerebella (tumour-specificity) was used as a reference to appraise the 
potential functional significance of DNA methylation of candidate genes in 
medulloblastoma subgroups. 
4.3.12 Identification of subgroup-specific differentially expressed genes 
Candidate genes with strong evidence of methylation-dependent transcriptional 
regulation in medulloblastoma cell lines (see section 4.3.9) were selected for differential 
expression analysis in three independent primary tumour datasets (see section 4.3.6) 
using limma. Transcript probe identifiers were selected as previously described in 
section 3.3.5. 
SHH, WNT, Group 3 and Group 4 tumours were identified in the design matrix. The 
contrast matrix was identical to the one used for differential methylation analysis (see 
section 4.3.11) with the exception that non-neoplastic cerebella were not included. 
Expression profiles for non-neoplastic cerebella were not available for this study. 
An individual logFC (absolute difference in mean log2 expression values) threshold was 
applied to each transcriptomic dataset. The threshold applied was the mean logFC for 
all the contrasts and probes tested in that dataset, and was calculated in R from the 
limma “topTable()” output (see section 4.3.10). The following logFC thresholds were 
applied: Kool/Fattet dataset, 0.5; Cho dataset, 0.7; Northcott dataset, 0.4. Contrasts were 
required to satisfy a FDR-adjusted p-value <0.05 and a logFC > threshold to be judged 
significant. The “decideTests()” function (see section 4.3.10) was applied to classify 
results as significantly negative, not significant or significantly positive using the 
elements -1, 0 and 1 respectively. Subgroup specificity was determined as described in 
section 4.3.11. 
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4.3.13 Identification of subgroup-specific candidate epigenetically regulated 
genes 
The significance results for genes that were differentially methylated and differentially 
expressed in the same primary tumour subgroup were compared for evidence of an 
inverse methylation-expression relationship. Genes were considered to show evidence 
of a relationship consistent with potential methylation-dependent regulation if a 
significantly negative (-1) subgroup-specific methylation profile correlated with a 
significantly positive (1) subgroup-specific expression profile or vice versa. The inverse 
methylation-expression relationship had to be observed in at least 2 transcriptomic 
datasets. Combined boxplots and strip-plots were constructed in R and provided a visual 
representation of the differential patterns of CpG methylation and gene expression for 
candidate genes. 
Subgroup-specific candidate epigenetically regulated genes were defined by those genes 
which showed consistent methylation-dependent gene regulation in cell lines, alongside 
differential CpG methylation inversely correlated with gene expression in distinct 
subgroups of primary tumours. Figure 4.1 summarises the steps involved in the 
selection of subgroup-specific candidate epigenetically regulated genes. 
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Genome-wide analysis of gene expression changes following 5-azaCdR treatment of 
medulloblastoma cell lines 
10 untreated and 5-azaCdR-treated cell line pairs 
Gene expression profiled on Illumina HT12v4.0 microarray 
Per cell line pair, fold change in expression following 5-azaCdRtreatment (FC) calculated along 
with mean FC and standard deviation (SD) of the mean 
FC > [(mean FC +3SD)] in ≥ 2 cell lines 
Genes whose expression is upregulated following 5-azaCdR 
 
Genome-wide assessment of CpG methylation associated with gene expression changes 
following 5-azaCdR treatment of medulloblastoma cell lines 
Illumina 450K cell line methylation data (10 cell lines) 
CpG sites corresponding to upregulated genes 
 
 
 
 
 
 
 
 
 
 
Critical CpG sites associated with methylation-dependent gene expression in cell lines 
Candidate epigenetically regulated genes in medulloblastoma cell lines 
Differential methylation and gene expression analysis in primary tumours 
Constitutively methylated CpG sites 
(β>0.3 in 10 cell lines) 
 
Methylation consistent with gene 
upregulation in ≥ 60% cell lines 
Variably methylated CpG sites (0≤β≤1 
across 10 cell lines) 
 Methylation status consistent with 
expression changes observed in ≥ 
60% cell lines AND  
 Methylation consistent with gene 
upregulation in ≥ 60% methylated 
cell lines AND  
 Significant inverse linear 
correlation between CpG 
methylation and endogenous gene 
expression (r<(-0.7); p<0.05) 
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Figure 4.1. Selection of subgroup-specific candidate epigenetically regulated genes in primary 
medulloblastomas. Flow diagram illustrates the steps followed to select candidate epigenetically regulated genes in 
distinct subgroups of medulloblastoma. Genes were selected from an initial functional epigenomics screen in cell 
lines. Candidate genes that showed methylation-dependent gene regulation in cell lines were investigated for 
evidence of differential methylation and gene expression in distinct subgroups of primary tumours. Full details of 
differential methylation and gene expression analyses are provided in sections 4.3.11 and 4.3.12 respectively. For 
differential methylation analysis, a logFC threshold (absolute difference in mean M-values) and a Δβ threshold 
(absolute difference in mean β-values) were applied as described in section 4.3.11 to increase the sensitivity of the 
significance test. For differential expression analysis, logFC thresholds (absolute difference in mean log2 expression) 
ranging from 0.4 to 0.7, were applied to the 3 independent transcriptomic datasets as described in section 4.3.12. 
Significant subgroup-specific differential gene expression was required in at least 2 out of the 3 datasets. Candidate 
subgroup-specific epigenetically regulated genes were defined by those genes which showed consistent methylation-
dependent gene regulation in cell lines, alongside differential CpG methylation inversely correlated with gene 
expression in distinct subgroups of primary tumours. 
Differential methylation and gene expression analysis in primary tumours 
 
 
 
 
 
 
 
 
 
 
Subgroup-specific differential CpG methylation inversely associated with differential gene 
expression 
Subgroup-specific candidate epigenetically regulated genes in primary tumours 
Differential CpG methylation 
Critical CpG sites identified in cell lines 
Illumina 450K methylation array; 109 
primary tumours: 4 subgroups (SHH, WNT, 
Grp3, Grp4) 
R package limma 
Subgroup-specific significant differential 
CpG methylation: p<0.05, logFC>0.9, 
Δβ>0.2 
Differential gene expression 
Candidate genes identified in cell lines 
3 independent transcriptomic datasets; 357 
primary tumours: 4 subgroups (SHH, 
WNT, Grp3, Grp4) 
R package limma 
Subgroup-specific significant differential 
gene expression: p<0.05, logFC > (0.4-
0.7), ≥ 2 independent datasets 
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4.3.13.1 Assessment of region-wide DNA methylation for candidate 
epigenetically regulated genes  
For subgroup-specific candidate genes identified (see section 4.3.13), the methylation 
status of CpG residues adjacent to the critical significantly differentially methylated 
sites on the Illumina 450K array, were analysed in primary medulloblastomas and in the 
normal cerebellum. Residues with 450K array β-value scores ≤0.3 were considered 
unmethylated (U); β-value scores >0.7 were considered methylated (M) and scores >0.3 
but ≤0.7 were considered part-methylated (PM). Data was represented as clock 
diagrams produced in Excel 2007 to visually determine whether the methylation status 
of the differentially methylated sites, which were associated with gene expression in 
primary tumours, was reflective of the wider genomic region in which they were 
located. 
4.3.13.2 RNA-Seq versus microarray expression profiling of candidate gene 
expression changes following 5-azaCdR treatment in cell lines 
RNA-Seq is a high-throughput deep sequencing technology that provides resolution at 
the single base level. It is a more sensitive method of quantification of transcripts and 
their isoforms and has a better dynamic range compared with microarray technologies 
(Wang et al., 2009). It can therefore provide a useful validation of microarray profiling 
results. Towards the end of this project RNA sequencing reads were available for 6 
untreated and 5-azaCdR-treated medulloblastoma cell line pairs (D283, D341, D425, 
D556, D458, MED1), and were kindly provided by Dr. Richard Birnie (Newcastle 
University Paediatric Brain Tumour Group) for the candidate genes of interest. The 
correlation between RNA-Seq reads and log2 expression levels generated on the 
Illumina HT12v4.0 microarray for candidate genes identified in section 4.3.13 was 
assessed by calculating Pearson’s product moment correlation coefficient (r). RNA-Seq 
transcript reads were considered to validate methylation-dependent expression 
alterations observed by microarray analysis if the coefficient r value obtained was 
greater than 0.7. 
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4.4 Results 
This chapter aimed to investigate the genome-wide role of DNA methylation in the 
regulation of gene expression in distinct subgroups of medulloblastoma. Using a 
functional epigenomics analysis of methylation-dependent gene expression alterations, 
combined with a genome-wide analysis of DNA methylation, the investigations 
reported in this chapter provide a comprehensive characterisation of methylation events 
that are associated with expression alterations and that may play a role in the 
development of distinct subgroups of medulloblastoma. 
4.4.1 Re-expression of RASSF1A in medulloblastoma cell lines following 
treatment with 5-azaCdR 
The isoform A transcript of the RASSF1 gene was used as a positive control for the 
demethylating treatment of cell lines with 5-azaCdR (see section 4.3.2). Re-expression 
of RASSF1A was observed in all 10 cell lines following 5-azaCdR treatment (Figure 
4.2(A)). Hypermethylation of the RASSF1A CpG island-associated promoter has 
previously been established in multiple medulloblastoma cell lines (Lusher et al., 2002), 
indicating that RASSF1A promoter hypermethylation is a common event in 
medulloblastoma cell lines, consistent with its observed epigenetic inactivation and re-
expression by 5-azaCdR. Equivalent expression levels were observed for the β-actin 
control transcript in the treated and untreated cell line pairs (Figure 4.2(B)). Subsequent 
studies which have assessed genome-wide patterns of DNA methylation in a subset of 
cell lines after 5-azaCdR have demonstrated global demethylation following treatment 
(Ed Schwalbe, Newcastle University Paediatric Brain Tumour Group; unpublished 
data). 
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Figure 4.2. Re-expression of RASSF1A following 5-azaCdR treatment of medulloblastoma cell lines. (A) 
Reverse transcription PCR analysis of RASSF1A gene expression levels in the 10 medulloblastoma cell lines with (+) 
and without (-) treatment with 5-azaCdR. Methylation-dependent re-expression of RASSF1A was observed in all 10 
cell lines following 5-azaCdR treatment. (B) Reverse transcription PCR analysis of the β-actin endogenous control 
gene in the 10 medulloblastoma cell lines with (+) and without (-) treatment with 5-azaCdR. β-actin was expressed at 
equivalent levels in the treated and untreated cell line pairs. PCR was assessed against a negative control reaction      
(-ve), which was set up identically to the experimental PCR but without template DNA. Results of negative control 
reaction show no PCR product demonstrating that there was no contamination of PCR reactions from non-sample 
DNA. 
 
4.4.2 Whole genome gene expression profiling 
The Illumina HT12-v4.0 microarray profiles the expression of 47,231 mRNA 
transcripts (encompassing over 30,000 genes) and was used to assess expression 
alterations in medulloblastoma cell lines following treatment with 5-azaCdR. 
4.4.2.1 Quality control and array normalisation 
The 10 untreated and 5-azaCdR-treated cell line pairs were processed in a single batch 
on two BeadChips. There were no obvious differences in the distribution of average 
probe signal intensities for samples within and between chips (Figure 4.3(A)), and the 
average number of beads per probe type represented on each array was approximately 
equal for all samples (Figure 4.3(B)). The distribution of average probe signal 
intensities was identical for all samples following quantile normalisation of data (Figure 
4.3 (C)). 
RASSF1A β-actin 
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4.4.2.2 Data filtering 
A total of 12,881 probes were assigned a ‘Bad’ or ‘No match’ quality score as defined 
by Illumina after normalisation. By their definition these probes are considered to have 
undesirable properties and have been shown to correlate with lowly expressed probes 
and with probes expressed at high levels due to non-specific hybridisation (Dunning et 
al., 2007). They were classed as non-responding probes and removed from the data.  
All samples showed high numbers of probes detected with p<0.05, with similar 
numbers within and between chips (mean=17,497 and SD=1,299). These levels were 
similar to other published reports using Illumina chips (Powell et al., 2012) and were 
indicative of a high overall sample expression quality. There were 13,111 (28%) probes 
that were not detected (p<0.05) in any cell line sample and were therefore filtered from 
the data, while 8,286 (18%) probes were detected in all samples. An additional 740 
probes were removed from the data. They represented probes that mapped to the sex 
chromosomes or that did not map to an official gene symbol or chromosome location 
according to Illumina’s annotation.  
Overall, data filtering measures removed 26,732 (57%) probes that were considered 
unreliable or uninformative. The remaining 20,499 (43%) probes were investigated for 
evidence of methylation-dependent gene expression alterations in medulloblastoma cell 
lines following 5-azaCdR treatment.  
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Figure 4.3. Quality control and normalisation of Illumina gene expression bead summary data. (A). Boxplots illustrating the distribution of average probe signal intensities before data 
normalisation for all samples processed across the 2 BeadChips. Distributions are similar for all samples and no arrays were identified as problematic or outliers. (B). Boxplots illustrating the similar 
average number of beads per probe type represented on each array across the 2 BeadChips. (C). Boxplots illustrating the identical distributions of average probe signal intensities following quantile 
normalisation of bead summary data for all samples. Twelve samples (6 cell line pairs) were processed on BeadChip1 and eight samples (4 cell line pairs) were processed on BeadChip2. BeadChips 
were processed in a single batch to minimise batch effects. 
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4.4.3 Upregulated gene expression following 5-azaCdR treatment of 
medulloblastoma cell lines 
FC thresholds were defined as described in section 4.3.7. The FC thresholds applied to 
the 10 cell lines ranged from 1.3 to 2.9. Analysis of individual cell lines showed that 
between 0.2% and 1.7% of probes detected an expression increase greater than the 
threshold following 5-azaCdR treatment (Table 4.1). 
 
Cell line meanFC+3SD FC threshold FC>threshold 
(no. probes) 
 
FC> 
threshold 
(% probes) 
D341 1.50 1.5 165 0.8 
D458 1.57 1.6 257 1.3 
D425 1.78 1.8 252 1.2 
DAOY 1.62 1.6 264 1.3 
D384 1.57 1.6 200 1.0 
D283 1.45 1.5 244 1.2 
MED1 1.34 1.3 357 1.7 
MED8A 1.81 1.8 148 0.7 
UW228-2 2.93 2.9 46 0.2 
D556 1.44 1.4 106 0.5 
Table 4.1. Fold change thresholds for upregulated gene expression in medulloblastoma cell lines following 5-
azaCdR treatment. The FC threshold applied to each cell line was the mean FC (fold change in expression after 5-
azaCdR) + 3SD of the mean. The number and percentage of transcript probes that exceeded the threshold in each cell 
line are shown. Probes were considered upregulated by 5-azaCdR if they detected an expression increase greater than 
the threshold in 2 or more cell lines following 5-azaCdR treatment. 
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A total of 307 probes (1.5%), encompassing 283 genes, detected an expression increase 
greater than the threshold in 2 or more cell lines and were considered upregulated by 5-
azaCdR treatment. 58% (179/307) of upregulated probes were observed in only 2 cell 
lines and 1% (3/307) were observed in 7 cell lines. Microarray analysis did not detect 
any upregulated probes following 5-azaCdR treatment in more than 7 out of the 10 cell 
lines (Table 4.2). 
 
Number of cell lines Number of probes upregulated (%) 
2 179 (58%) 
3 70 (23%) 
4 24 (8%) 
5 21 (7%) 
6 10 (3%) 
7 3 (1%) 
8 0 (0%) 
9 0 (0%) 
10 0 (0%) 
Table 4.2. Microarray analysis of gene upregulation in medulloblastoma cell lines. The number of probes 
upregulated by 5-azaCdR treatment and the number of cell lines in which upregulation was observed are shown.  
 
GO analysis of upregulated probes using the DAVID Bioinformatics Resource revealed 
enrichment for genes involved in the maintenance, structure and function of the 
intracellular cytoskeleton as well as genes involved in the regulation of apoptosis and 
stimulus response genes. There was no specific pathway enrichment identified among 
the upregulated genes (Figure 4.4).  
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Figure 4.4. Gene ontology of probes upregulated by 5-azaCdR The top 6 annotation clusters computed using the 
DAVID Functional Annotation Clustering Algorithmn are shown. For each cluster the group of enriched terms 
having similar biological meaning due to sharing similar gene members are detailed, along with the number of genes 
involved in each term, and the modified Fisher Exact p-value for gene enrichment.The overall Enrichment Score for 
the group was computed using the p-values of each term member; the higher the enrichment score, the more enriched 
the group of terms. 131 clusters were identified from the 307 upregulated Illumina probe IDs that were entered into 
the DAVID Bioinformatics Annotation Clustering Tool. The top 6 clusters had enrichment scores greater than 4. 
Functional Annotation Clustering Report down;loaded from the DAVID Bioinformatics website 
(http://david.abcc.ncifcrf.gov/). 
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4.4.4 Critical CpG sites associated with methylation-dependent gene 
regulation in cell lines 
The 283 genes upregulated by 5-azaCdR treatment in cell lines encompassed 5,251 CpG 
probes that were extracted from the cell line 450K methylation array data. Of these, 
1,013 (19%) were constitutively unmethylated in the cell lines and were removed from 
the data as they would not be associated with any methylation-dependent expression 
changes observed for their respective genes. There were 1,579 (30%) constitutively 
methylated probes (see section 4.3.8.1) and 2,659 (51%) variably methylated probes 
(see section 4.3.8.1) that were investigated for evidence of a critical role in epigenetic 
gene regulation. 
4.4.4.1 Constitutively methylated CpG sites 
Constitutively methylated CpG sites were considered to show strong evidence of a 
critical role in methylation-dependent gene regulation if re-expression was observed in 
≥ 60% of cell lines following 5-azaCdR treatment. A “consistent relationship” (see 
section 4.3.8.1) between CpG methylation and gene re-expression following 5-azaCdR 
was observed in ≥ 60% of cell lines for 71 (4%) constitutively methylated CpG sites. 
The 71 sites (encompassing 12 genes) were considered to show strong evidence of a 
critical role in epigenetic gene regulation. As an example of the constitutively 
methylated critical CpG sites identified, Figure 4.5 illustrates methylation-dependent re-
expression of the gene SYT11 in cell lines. 
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Figure 4.5. Methylation-dependent re-expression of SYT11 in medulloblastoma cell lines. Bar-graph illustrates 
the fold change (FC) in expression after 5-azaCdR treatment in 10 cell lines for the SYT11 transcript probe 
ILMN_171793. Dark blue bars represent a FC > threshold for that cell line, indicative of upregulated gene expression 
by 5-azaCdR; light blue bars represent a FC < threshold for that cell line, indicative of no upregulated expression by 
5-azaCdR. Methylation status M = methylated (β-values >0.3). Methylation of the SYT11 CpG site cg15727252 is 
consistent with methylation-dependent re-expression observed in 70% of cell lines. 
 
4.4.4.2 Variably methylated CpG sites 
There were 291 variably methylated CpG sites (11%) that showed a “consistent 
relationship” (see section 4.3.8.1) between CpG methylation status and gene expression 
alterations observed following 5-azaCdR treatment in ≥ 60% of cell lines. The 291 CpG 
sites corresponded to 66 genes. 
Of the 291 sites, 89 also showed a significant inverse correlation (r< -0.7; FDR adjusted 
p-value<0.05) between methylation and endogenous gene expression levels in 
medulloblastoma cell lines. Methylation of these 89 CpG sites (encompassing 17 genes) 
was considered to show strong evidence of an association with transcriptional silencing 
and re-expression by 5-azaCdR and thus a critical role in epigenetic gene regulation. As 
an example of the variably methylated critical CpG sites identified, Figure 4.6 illustrates 
the “consistent relationship” that was observed between the methylation status of the 
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TUBA1C CpG probe shown (cg27632435) and expression alterations in 80% of cell 
lines following 5-azaCdR treatment, with 67% of methylated cell lines showing 
upregulated expression after treatment. Figure 4.7 illustrates the significant inverse 
correlation between methylation of the same TUBA1C CpG site (cg27632435) and 
endogenous gene expression in cell lines. Together these results demonstrate that 
methylation of this CpG site was consistent with TUBA1C transcriptional silencing and 
upregulation by 5-azaCdR in cell lines.  
   
Figure 4.6. Methylation-dependent regulation of TUBA1C in medulloblastoma cell lines. Bar-graph illustrates 
the fold change (FC) in expression after 5-azaCdR treatment of 10 cell lines for the TUBA1C transcript probe 
ILMN_3251341. Dark blue bars represent a FC > threshold for that cell line, indicative of upregulated gene 
expression by 5-azaCdR; light blue bars represent a FC < threshold for that cell line, indicative of no upregulated 
expression by 5-azaCdR. Methylation status M = methylated (β-values >0.3). Methylation status U= unmethylated 
(β≤0.3). Methylation of the TUBA1C CpG probe cg27632435 is consistent with methylation-dependent re-expression 
observed in 67% (4/6) of methylated cell lines. Consistent with methylation-dependent expression, 100% (4/4) of 
unmethylated cell lines do not show re-expression after 5-azaCdR. Overall methylation status is consistent with 
epigenetic gene regulation in 80% of cell lines. 
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Figure 4.7. Inverse linear correlation between CpG methylation and gene expression for TUBA1C. Methylation 
status of the TUBA1C CpG probe cg27632435 is significantly inversely correlated with gene expression in 10 cell 
lines. Pearson correlation r value measuring the strength of the inverse relationship and the FDR-adjusted p-value of 
the correlation test are shown. Results show that methylation of the CpG site is associated with TUBA1C 
transcriptional silencing in cell lines. 
 
4.4.5 Candidate epigenetically regulated genes in medulloblastoma cell lines 
A total of 160 CpG sites (71 constitutively methylated and 89 variably methylated) were 
identified that showed strong evidence of a critical role in epigenetic gene regulation in 
medulloblastoma cell lines. The 160 CpG sites encompassed 21 genes. All genes were 
associated with DNA methylation events occurring at multiple residues, ranging from 
18 critical CpG sites in the gene SQSTM1 to 2 critical CpG sites in FABP5 and 
S100A10 (Table 4.3). 
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Gene Chromosome Number of critical CpG sites 
identified 
ACTC1 15 7 
ANXA2 15 6 
DAZL 3 16 
FABP5 8 2 
FAM46A 6 4 
HSPB1 7 7 
IER3 6 4 
MAP1LC3A 20 17 
MFGE8 15 5 
PRPH 12 4 
S100A10 1 2 
S100A4 1 5 
S100A6 1 8 
SAP25 7 6 
SQSTM1 5 18 
SYT11 1 3 
TAGLN 11 5 
TEAD2 19 4 
TGFBI 5 14 
TUBA1C 12 13 
UBB 17 10 
Table 4.3. Candidate epigenetically regulated genes in medulloblastoma cell lines. Twenty-one genes contained 
multiple CpG residues which had a methylation status consistent with their epigenetic transcriptional regulation in 
cell lines. Chromosome location and number of critical CpG sites associated with methylation-dependent gene 
regulation are shown for each gene.  
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50% (80/160) of the CpG sites identified were located in CpG islands and the majority 
of these were island-associated promoters (Figure 4.8). 32% (52/160) of sites were 
located in CpG island shores and island shelves and these were distributed equally 
between promoter regions and gene body/3’UTR regions. A further 18% (29/160) of 
residues were isolated sites distributed equally between promoter and gene body/3’UTR 
regions (Figure 4.8). 
 
Figure 4.8. Genomic distribution of CpG sites associated with methylation-dependent gene regulation in cell 
lines. Pie chart illustrates the percentage of critical CpG sites in the different genomic regions (as defined by 
Illumina) and in different regions of CpG density (as defined by Illumina). CpG sites were located in gene promoter, 
gene body and 3’UTR functional regions and were within CpG islands and island shores/shelves as well as isolated 
non-CpG island sites within the gene. 50% of sites were located in a CpG island while a further 32% were located in 
a CpG island shore/shelf. 62% of sites were located in gene promoter regions. Pie chart was produced in Excel 2007.  
 
4.4.6 Subgroup-specific differential CpG methylation 
Of the 160 critical CpG sites whose methylation was consistent with epigenetic gene 
regulation in cell lines, 32 (20%) were significantly differentially methylated in specific 
subgroups of primary medulloblastomas (see section 4.3.11). The 32 differentially 
methylated sites encompassed 10 of the 21 (48%) candidate genes (Table 4.4). Four 
genes (ANXA2, MAP1LC3A, MFGE8 and TUBA1C) were differentially methylated in 
more than 1 subgroup; differential methylation of MFGE8 occurred at different CpG 
sites in the different subgroups while for ANXA2, MAP1LC3A and TUBA1C differential 
methylation occurred at the same residues in different subgroups and could be explained 
by the variable methylation observed for these sites in some tumour subgroups 
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compared to others. Figure 4.9 illustrates the variable methylation observed for 
TUBA1C in the SHH and Group 3 tumours that led to the same CpG site being 
significantly differentially methylated in WNT tumours and in Group 4 tumours. There 
were 4 CpG sites (encompassing 2 genes) that were significantly differentially 
methylated between Group (3+4) and (SHH+WNT) tumours (Table 4.4). Interestingly, 
there were no sites that were differentially methylated between (SHH+Group 3) and 
(WNT+Group 4) or between (SHH+Group 4) and (WNT+Group 3), supporting the 
current opinion that Group 3 and Group 4 tumours are more similar to each other than 
they are to SHH or WNT tumours (Taylor et al., 2012). 
 
Subgroup Gene Number of differentially 
methylated CpG loci 
SHH 
FAM46A 3 
MFGE8 1 
WNT 
ANXA2 1 
MAP1LC3A 2 
MFGE8 1 
PRPH 1 
S100A4 2 
TUBA1C 13 
Group 3 
TAGLN 2 
MAP1LC3A 1 
Group 4 
ANXA2 1 
MAP1LC3A 1 
TUBA1C 13 
Group (3+4) 
SQSTM1 2 
ACTC1 2 
Table 4.4. Subgroup-specific differential CpG methylation in primary medulloblastomas. Ten candidate genes 
were differentially methylated at 1 or more CpG sites in specific subgroups of medulloblastoma. Subgroup specificity 
and number of differentially methylated CpG sites are shown for each gene. Four genes were differentially 
methylated in more than 1 subgroup; differential methylation of MFGE8 occurred at different CpG sites in different 
subgroups while for ANXA2, MAP1LC3A and TUBA1C differential methylation occurred at the same site(s) in the 
different subgroups. A total of 32 critical CpG sites were differentially methylated in a subgroup-specific manner in 
primary medulloblastomas. 
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Figure 4.9. Differential methylation of TUBA1C in WNT and in Group 4 tumours. Boxplots illustrate the 
differential patterns of methylation β-values of the TUBA1C CpG probe cg00507738 across the tumour subgroups. 
The same site is significantly differentially methylated in WNT tumours compared to (SHH+Grp3+Grp4) tumours 
and in Grp4 tumours compared to (SHH+WNT+Grp3) tumours. The methylation β-values are variable in the SHH 
and Group 3 tumours compared to the uniform WNT and Group 4 tumours explaining specificity in 2 distinct 
subgroups. The same differential patterns of methylation were observed for the 13 WNT-specific and Group 4-
specific TUBA1C CpG sites (see Table 4.4). 
4.4.7 Subgroup-specific differential gene expression 
Candidate genes were next investigated for evidence of subgroup-specific differential 
gene expression (see section 4.3.12). Of  the 21 candidate genes (encompassing the 160 
critical CpG sites) identified in cell lines (see section 4.4.5), 15 were significantly 
differentially expressed in specific subgroups of primary medulloblastomas in at least 1 
transcriptomic dataset and 11 genes (52%) were differentially expressed in the same 
subgroup in 2 or more datasets (Table 4.5). The following subgroup-specific 
differentially expressed genes were identified in 2 or more datasets: 
 SHH-specific: FAM46A, PRPH 
 WNT-specific: ANXA2, HSPB1, PRPH, S100A4, S100A6, TGFBI 
 Group 3-specific: HSPB1, SYT11 
 Group (3+4)-specific: ACTC1, MFG8A, SYT11, TEAD2 
No genes were identified that were differentially expressed in Group 4 tumours in 2 or 
more datasets. 
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  Significant differential gene expression 
Subgroup 
specificity 
Gene Kool/Fattet Cho Northcott 
SHH 
ACTC1   √ 
FAM46A √ √ √ 
PRPH √ √  
S100A6  √  
TEAD2 √   
WNT 
ACTC1 √   
ANXA2 √ √ √ 
HSPB1 √ √ √ 
PRPH √ √  
S100A4 √ √  
S100A6 √ √  
TEAD2 √   
TGFBI √ √ √ 
Group 3 
ANXA2 √   
HSPB1 √ √ √ 
IER3 √   
SYT11 √ √ √ 
TEAD2   √ 
Group 4 
ANXA2  √  
FAM46A  √  
SYT11  √  
TAGLN   √ 
TEAD2   √ 
Group (3+4) 
ACTC1  √ √ 
FABP5 √   
MFGE8  √ √ 
S100A6   √ 
SYT11  √ √ 
TEAD2 √  √ 
Table 4.5. Subgroup-specific differential gene expression in primary medulloblastomas. Significant subgroup-
specific differential gene expression (√) is shown for each transcriptomic dataset. A total of 15 genes were 
significantly differentially expressed in 1 or more subgroups in at least 1 dataset and 11 genes were significantly 
differentially expressed in the same subgroup in 2 or more datasets. Significant subgroup-specific differential 
expression was determined as described in section 4.3.12. 
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4.4.8 Subgroup-specific candidate epigenetically regulated genes in primary 
tumours 
Subgroup-specific candidate epigenetically regulated genes were defined by those genes 
which showed methylation-dependent gene regulation in cell lines, alongside 
differential CpG methylation inversely correlated with gene expression in distinct 
subgroups of primary tumours (Figure 4.1).  
The following 5 genes showed evidence of methylation-dependent regulation in cell 
lines, alongside differential CpG methylation inversely correlated with gene expression 
in distinct subgroups of primary tumours, consistent with their epigenetic regulation: 
 SHH-specific: FAM46A (Figure 4.10) 
 WNT-specific: ANXA2 (Figure 4.11), PRPH (Figure 4.12), S100A4 
(Figure 4.13) 
 Group (3+4)-specific: ACTC1 (Figure 4.14) 
To illustrate the identification of subgroup-specific candidate genes, Table 4.6 details 
the significant differentially methylated and significant differentially expressed events 
in SHH tumours compared to all other subgroups, and explains the identification of 
FAM46A as a candidate epigenetically regulated gene in SHH tumours.  
The 5 candidate genes encompassed 9 critical CpG sites that showed an association with 
gene expression in primary tumours. These represented 6% of the 160 critical sites that 
showed an association with expression in cell lines. Figure 4.15 summarises the number 
of genes and critical CpG sites identified at each step of the analysis, which led to the 
identification of the 5 candidate epigenetically regulated genes in primary tumours.  
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   Contrasts Absolute difference in mean β-values(Δβ) 
 450K methylation 
probe 
Gene WNTvSHH G3vSHH G4vSHH SHHvCerebella SHHv(WNT+G3+G4) SHHvCerebella 
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 cg04399083 FAM46A 1 1 1 0 0.323823 0.089449 
cg11075693 FAM46A 1 1 1 0 0.347132 0.077789 
cg22388948 FAM46A 1 1 1 0 0.595152 0.038517 
cg08896420 MFGE8 1 1 1 -1 0.466019 0.216803 
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KoolFattet dataset      
Transcript Probe ID Gene WNTvSHH G3vSHH G4vSHH 
224973_at FAM46A -1 -1 -1 
213847_at PRPH 1 -1 -1 
238323_at TEAD2 1 -1 -1 
Cho dataset     
Transcript Probe ID Gene WNTvSHH G3vSHH G4vSHH 
221766_s_at FAM46A -1 -1 -1 
213847_at PRPH 1 -1 -1 
217728_at S100A6 1 -1 -1 
Northcott dataset     
Transcript Probe ID Gene WNTvSHH G3vSHH G4vSHH 
3588303 ACTC1 1 1 1 
2962383 FAM46A -1 -1 -1 
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Table 4.6. Significant differential CpG methylation and gene expression in SHH medulloblastomas. Limma significance results are shown for significantly differentially methylated and 
significantly differentially expressed events specific to SHH tumours; 1= significantly positive event; 0= not significant; -1= significantly negative event. 450K CpG methylation probes, transcript 
probes from the 3 datasets (Kool/Fattet, Cho and Northcott) and the contrasts tested using limma are shown. The CpG methylation probes and the transcript probes shown are significantly different (1 or 
-1) in the 3 contrasts: WNTvSHH, Grp3vSHH and Grp4vSHH, making them SHH-specific events. CpG methylation was judged significantly different (1 or -1) only if the FDR-adjusted p-value was < 
0.05 and the absolute difference in mean M-value methylation scores was >0.9. An additional filter of absolute difference in mean β-values>0.2 also had to be satisfied (see section 4.3.12). Gene 
expression was judged significantly different (1 or -1) only if the FDR-adjusted p-value was <0.05 and the absolute difference in log2 expression levels was >0.5 for the Kool/Fattet dataset; >0.7 for the 
Cho datasset and >0.4 for the Northcott dataset (see section 4.3.13). FAM46A is the only gene differentially methylated and differentially expressed in SHH tumours; the significantly lower methylation 
status (1) in SHH tumours correlates with significantly higher expression (1) in the 3 transcriptomic datasets, identifying FAM46A as a strong candidate epigenetically regulated gene in SHH tumours. 
The 3 SHH-specific FAM46A CpG loci do not have a significantly different methylation profile in SHH tumours compared to non-neoplastic cerebella (limma result 0 and ∆β<0.34), suggesting that a 
hypermethylated status in WNT,Group3 and Group4 tumours is associated with transcriptional silencing in these tumour subgroups (see Figure 4.9). Expression data was not available for non-neoplastic 
cerebellar samples to assess aberrant gene expression. G3=Group 3 and G4=Group 4. 
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Figure 4.10. Epigenetic regulation of FAM46A in primary medulloblastomas. Boxplots illustrate the differential 
patterns of CpG methylation for the 3 critical FAM46A CpG probes (cg22388948, cg04399083 and cg11075693) and 
differential patterns of gene expression for the Kool/Fattet FAM46A transcript probe (224973_at). Significantly lower 
FAM46A methylation correlated with significantly higher gene expression in SHH tumours. The same pattern of 
significant differential gene expression was observed in Cho and Northcott datasets (not shown). Methylation profiles 
of critical FAM46A sites in SHH tumours were not significantly different to non-neoplastic cerebella (CB) 
(cg22388948, p=0.7, Δβ=0.04; cg11075693, p=0.5, Δβ=0.08; cg04399083, p=0.2, Δβ=0.09), and were therefore not 
tumour-specific. These results suggest that FAM46A is potentially silenced by hypermethylation of critical CpG sites 
in WNT, Grp 3 and Grp 4 medulloblastomas. 
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Figure 4.11. Epigenetic regulation of ANXA2 in primary medulloblastomas. Boxplots illustrate the differential 
patterns of CpG methylation for critical ANXA2 CpG probe (cg02072495) and differential patterns of gene expression 
for the Kool/Fattet ANXA2 transcript probe (213503_x_at). Significantly lower ANXA2 methylation correlated with 
significantly higher gene expression in WNT tumours. The same pattern of significant differential gene expression 
was observed in Cho and Northcott datasets (not shown). Methylation profile of critical ANXA2 CpG site in WNT 
tumours was significantly different to non-neoplastic cerebella (CB) (p<1x10-6, Δβ=0.7) and was therefore tumour-
specific. These results suggest that ANXA2 is potentially upregulated by hypomethylation of critical CpG site(s) in 
WNT medulloblastomas. 
 
Figure 4.12. Epigenetic regulation of PRPH in primary medulloblastomas. Boxplots illustrate the differential 
patterns of CpG methylation for critical PRPH CpG probe (cg25763520) and differential patterns of gene expression 
for the Kool/Fattet PRPH transcript probe (213847_at). Significantly lower PRPH methylation correlated with 
significantly higher gene expression in WNT tumours. The same pattern of significant differential gene expression 
was observed in Cho dataset (not shown). Methylation profile of critical PRPH CpG site in WNT tumours was 
significantly different to non-neoplastic cerebella (CB) (p<1x10-6, Δβ=0.4) and was therefore tumour-specific. These 
results suggest that PRPH is potentially upregulated by hypomethylation of critical CpG site(s) in WNT 
medulloblastomas. 
 
 254 
 
 
Figure 4.13. Epigenetic regulation of S100A4 in primary medulloblastomas. Boxplots illustrate the differential 
patterns of CpG methylation for the 2 critical S100A4 CpG probes (cg01411912 and cg23048494) and differential 
patterns of gene expression for the Cho S100A4 transcript probe (203186_s_at). Significantly lower S100A4 
methylation correlated with significantly higher gene expression in WNT tumours. The same pattern of significant 
differential gene expression was observed in Kool/Fattet dataset (not shown). Methylation profiles of critical S100A4 
CpG sites in WNT tumours were significantly different to non-neoplastic cerebella (CB)(cg01411912: p<1x10-6, 
Δβ=0.4; cg23048494: p<1x10-6, Δβ=0.4),  and were therefore tumour-specific. These results suggest that S100A4 is 
potentially upregulated by hypomethylation of critical CpG sites in WNT medulloblastomas. 
 
 
 255 
 
 
Figure 4.14. Epigenetic regulation of ACTC1 in primary medulloblastomas. Boxplots illustrate the differential 
patterns of CpG methylation for the 2 critical ACTC1 CpG probes (cg06048973 and cg08190298) and differential 
patterns of gene expression for the Cho ACTC1 transcript probe (205132_at). Significantly higher ACTC1 
methylation correlated with significantly lower gene expression in Group (3+4) tumours. The same pattern of 
significant differential gene expression was observed in Northcott dataset (not shown). Methylation profile of critical 
ACTC1 CpG probe cg08190298 in Group (3+4) tumours was significantly different to non-neoplastic cerebella (CB) 
(p=0.009, Δβ=0.2) and was therefore tumour-specific. Methylation profile of critical ACTC1 site cg06048973 in 
Group (3+4) tumours was not significantly different to non-neoplastic cerebella (CB) (p=0.5, Δβ=0.04) and was 
therefore not tumour-specific. Methylation profiles of both sites in (SHH+WNT) tumours were significantly different 
to non-neoplastic cerebella (CB) (cg06048973: p<1x10-6, Δβ=0.3; cg08190298: p=1x10-5, Δβ=0.3), and were 
therefore tumour-specific in (SHH+WNT) tumours. These results suggest that ACTC1 is potentially upregulated by 
hypomethylation of critical CpG sites in (SHH+WNT) medulloblastomas Non-neoplastic cerebellar samples have an 
intermediate methylation profile between Group (3+4) and (SHH+WNT) tumours and so potential silencing by 
hypermethylation of critical sites in Group (3+4) tumours cannot be excluded. 
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Genome-wide analysis of gene expression changes following 5-azaCdR treatment of 
medulloblastoma cell lines 
10 untreated and 5-azaCdR- treated cell line pairs / Gene expression profiled on Illumina HT12v4.0 
microarray 
307 transcript probes upregulated with FC > [(mean FC +3SD)] in ≥ 2 cell lines following 5-azaCdR 
treatment 
283 genes upregulated following 5-azaCdR treatment of cell lines 
Genome-wide assessment of CpG methylation associated with gene expression changes following 
5-azaCdR treatment of medulloblastoma cell lines 
Illumina 450K cell line methylation data (10 cell lines) 
4238 constitutively methylated and variably methylated CpG sites corresponding to upregulated genes 
160 critical CpG sites associated with methylation-dependent gene expression in cell lines 
21 candidate epigenetically regulated genes in medulloblastoma cell lines 
Differential methylation and gene expression analysis in primary tumours 
 
 
 
 
9 critical CpG sites were significantly differentially methylated in subgroups of primary 
medulloblastomas and showed an inverse relationship between subgroup-specific methylation and 
gene expression 
5 subgroup-specific candidate epigenetically regulated genes in primary medulloblastomas 
 FAM46A, ANXA2, PRPH, S100A4, ACTC1 
Differential CpG methylation 
32 out of 160 critical CpG sites (10 out of 21 
genes) significantly differentially methylated 
in distinct subgroups of medulloblastoma 
Differential gene expression 
15 out of 21 genes significantly differentially 
expressed in distinct subgroups of 
medulloblastoma 
Figure 4.15. Identification of subgroup-specific candidate epigenetically regulated genes in primary 
tumours. Flow diagram summarises the number of genes and critical CpG sites identified at each step of the 
analysis, which led to the identification of 9 critical CpG sites, encompassing 5 genes, which showed strong 
evidence of methylation-dependent gene expression in distinct subgroups of medulloblastoma. 
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4.4.9 Region-wide CpG methylation and candidate gene expression 
For the 5 candidate genes, patterns of CpG methylation across the gene were assessed 
using the 450K array. For each gene, adjacent CpG residues on the 450K array were 
selected encompassing the critical differentially methylated CpG site(s) that were 
associated with subgroup-specific gene expression. 
4.4.9.1 FAM46A 
The 3 critical CpG sites identified for FAM46A (Figure 4.10) were adjacent to each 
other on the 450K array and were located in a CpG island and CpG island shore within 
the gene body (Figure 4.16). In total, there were 4 gene body sites represented on the 
array and their methylation status was consistent with each other in primary tumours 
and in non-neoplastic cerebella (Figure 4.16), suggesting that their methylation may 
reflect wider gene body island and island shore methylation. This pattern was supported 
by the strength of the linear relationship (r=0.9) between the methylation β-value of the 
critical gene body site (cg04399083) and the mean methylation β-value of the 4 gene 
body CpG sites in primary tumours and non-neoplastic cerebella (Figure 4.17). The 
critical CpG site (cg04399083) was aberrantly methylated (β>0.3) in 72% of primary 
tumours and in 100% of these methylated tumours the wider gene body, as represented 
on the array, was also aberrantly methylated (β>0.3 in ≥75% gene body sites); the site 
was unmethylated (β≤0.3) in 28% of primary tumours and in 100% of normal cerebella 
and in 77% of unmethylated tumours and 88% of normal cerebella the wider gene body, 
as represented on the array, was also unmethylated (β≤0.3 in ≥75% gene body sites). 
Aberrant methylation of the critical FAM46A CpG sites was seen in WNT, Group 3 and 
Group 4 tumours (Figure 4.10). These results suggest that hypermethylation of the gene 
body may potentially effect FAM46A silencing in WNT, Group 3 and Group 4 tumours. 
The CpG island-associated promoter of FAM46A was consistently unmethylated in 
primary tumours and normal cerebella (Figure 4.16). FAM46A represents a strong 
candidate epigenetically regulated gene in primary medulloblastomas (Table 4.7). 
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Figure 4.16. Methylation status of FAM46A in primary tumours and non-neoplastic cerebella. The methylation 
status of nine adjacent CpG probes on the 450K methylation array , encompassing the 3 critical CpG sites identified 
for FAM46A (annotated in red) are shown in a representative sample of 30 primary tumours and in normal cerebellar 
samples. Genomic region and CpG density were defined by Illumina: TSS200: 200base pairs upstream of 
transcription start site; 5’UTR: 5’ untranslated region; Body: gene body; island: CpG island; N_shore: less dense 
CpG region located within 2kb upstream of the associated CpG island. Filled circles: β≥0.7; half-filled circles: 
0.3<β<0.7; empty circles: β≤0.3. Aberrant hypermethylation of the 4 gene body sites on the array can be seen in a 
subset of primary tumours. FAM46A CpG island-associated promoter was consistently unmethylated in primary 
tumours and non-neoplastic cerebella. Subgroup status of primary tumours is shown. An unmethylated state (β≤0.3) 
is observed exclusively in SHH tumours, while hypermethylation of the gene body region (β>0.3 in ≥75% gene body 
sites)  is observed in WNT, Group 3 (GRP3) and Group 4 (GRP4) tumours, consistent with the subgroup-specific 
patterns of methylation observed for the 3 individual critical CpG sites (see Figure 4.10). 
 
 
 cg04399083 
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Figure 4.17 FAM46A gene body methylation. Linear association between the methylation β-value of the FAM46A 
gene body CpG site (cg04399083) and the mean methylation β-value of the 4 gene body sites represented on the 
450K array is shown for the 109 primary tumours and 17 non-neoplastic cerebellar samples assayed on the Illumina 
Infinium 450K methylation array. Pearson correlation r value measuring the strength of the linear association is 
shown. 
 
4.4.9.2 ANXA2 
The critical CpG site identified for ANXA2 (cg02072495) (Figure 4.11) was located in a 
CpG island shore in the 5’UTR (Figure 4.18). The site was hypomethylated in the WNT 
subgroup of tumours and hypomethylation was associated with significantly increased 
expression in WNT tumours compared with the other tumour subgroups (Figure 4.11). 
A hypomethylated state (β≤0.3) was observed in 69% of WNT tumours in contrast to a 
methylated state (β>0.3) observed in 100% of non-neoplastic cerebella and in 93% of 
SHH, 90% of Group 3 and 100% of Group 4 tumours. The aberrant hypomethylated 
state of this site in the subset of primary tumours was not reflected across the wider 
island and island shore-associated 5’UTR as it was represented on the array (Figure 
4.18) (Table 4.7). 
r=0.9 
 260 
 
 
Figure 4.18. Methylation status of ANXA2 in primary tumours and non-neoplastic cerebella. The methylation 
status of nine adjacent CpG probes on the 450K methylation array , encompassing the critical CpG site identified for 
ANXA2(annotated in red) are shown in a representative sample of 30 primary tumours and in normal cerebellar 
samples. Genomic region and CpG density were defined by Illumina: TSS200: 200base pairs upstream of 
transcription start site; 5’UTR: 5’ untranslated region; island: CpG island; N_shore: less dense CpG region located 
within 2kb upstream of the associated CpG island; N_shelf: 2kb region upstream of the associated CpG island shore. 
Filled circles: β≥0.7; half-filled circles: 0.3<β<0.7; empty circles: β≤0.3. Aberrant hypomethylation of the critical site 
can be seen in a subset of primary tumours. The methylation status of the wider 5’UTR on the array was consistent in 
all primary tumours and non-neoplastic cerebella. Subgroup status of primary tumours is shown. The critical CpG site 
is hypomethylated (β≤0.3) in 69% of WNT tumours. A hypomethylated state is also observed in 10% of Group 3 
(GRP 3) tumours. Methylation (β>0.3) consistent with non-neoplastic cerebella is observed in the majority of SHH, 
Group 3 (GRP 3) and Group 4 (GRP 4) tumours (see Figure 4.11) 
 
cg02072495 
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4.4.9.3 PRPH 
The critical CpG site identified for PRPH (cg25763520) (Figure 4.12) was located in a 
CpG island shore in a 1500 base pair block upstream of the TSS in the gene promoter 
(Figure 4.19). The site was hypomethylated in the WNT subgroup of tumours and 
hypomethylation was associated with significantly increased expression in WNT 
tumours compared with the other tumour subgroups (Figure 4.12). A hypomethylated 
state (β≤0.3) was observed in 38% of WNT tumours in contrast to a methylated state 
(β>0.3) in 100% of non-neoplastic cerebella and in 97% of SHH, 100% of Group 3 and 
100% of Group 4 tumours. In the subset of tumours where this site was 
hypomethylated, aberrant hypomethylation of adjacent island shore-associated promoter 
sites was not observed on the array (Figure 4.19) (Table 4.7). The methylation status of 
adjacent promoter sites on the array was variable in the non-neoplastic cerebellar 
samples (Figure 4.19). Interestingly, in tumours that were hypomethylated at the critical 
promoter site there was dense aberrant methylation of the CpG island-associated gene 
body region on the array (Figure 4.19). 
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Figure 4.19.  Methylation status of PRPH in primary tumours and non-neoplastic cerebella. The methylation 
status of 14 adjacent CpG probes on the 450K methylation array , encompassing the critical CpG site identified for 
PRPH (annotated in red) are shown in a representative sample of 30 primary tumours and in normal cerebella 
samples. Genomic region and CpG density were defined by Illumina: TSS1500: 1500base pairs upstream of 
transcription start site; TSS200: 200base pairs upstream of transcription start site; 5’UTR: 5’ untranslated region; 
body: gene body; 3’UTR: 3’ untranslated region; island: CpG island; N_shore: less dense CpG region located within 
2kb upstream of the associated CpG island; S-shore: less dense CpG region located within 2kb downstream of the 
associated CpG island;. Filled circles: β≥0.7; half-filled circles: 0.3<β<0.7; empty circles: β≤0.3. Aberrant 
hypomethylation of the critical site can be seen in a subset of primary tumours. The methylation status of the wider 
gene promoter region represented on the array was variable in non-neoplastic cerebella. Tumours that were 
hypomethylated at the critical site demonstrated dense aberrant methylation of the CpG island-associated gene body 
region represented on the array. Subgroup status of primary tumours is shown. The critical CpG site is 
hypomethylated (β≤0.3) in 38% of WNT tumours. A hypomethylated state is also observed in 3% of SHH tumours. 
Methylation (β>0.3) consistent with non-neoplastic cerebella is observed in 97% of SHH and 100% of Group 3 
(GRP3) and Group 4 (GRP4) tumours (see Figure 4.12). 
 
cg25763520 
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4.4.9.4 S100A4 
There were 2 differentially methylated critical CpG probes identified for S100A4 
(Figure 4.13); 1 probe (cg23048494) was located in the 5’UTR and the other 
(cg01411912) was located in the gene body. S100A4 has a non CpG island-associated 
promoter and there were a total of 8 CpG sites represented on the 450K array and 
covering mainly the gene promoter (Figure 4.20). 
The 2 critical sites were hypomethylated in the WNT subgroup of tumours and 
hypomethylation was associated with significantly increased expression in WNT 
tumours compared with the other tumour subgroups (Figure 4.13). For the 5’UTR site, a 
hypomethylated state (β≤0.3) was observed in 56% of WNT tumours in contrast to a 
methylated state (β>0.3) in 100% of non-neoplastic cerebella and in 100% of SHH, 97% 
of Group 3 and 93% of Group 4 tumours. In tumours where this site was 
hypomethylated, aberrant hypomethylation of the wider 5’UTR and gene promoter 
region represented on the array was not observed (Figure 4.20) (Table 4.7). Methylation 
of the wider region was consistent in primary tumours and non-neoplastic cerebella 
(Figure 4.20). The aberrant hypomethylation of the critical gene body CpG site 
(cg0141191) was more subtle; this site was fully methylated (β≥0.7) in 100% of non-
neoplastic cerebella and in 97% of SHH, 80% of Group 3 and 87% of Group 4 tumours. 
In contrast, the site was fully methylated in only 8% of WNT tumours and was part-
methylated (0.3<β<0.7) in the remaining 92% of WNT tumours. This site was not 
unmethylated (β≤0.3) in any primary tumour or normal cerebellar samples. There were 
no other gene body CpG sites represented on the array. Aberrant hypomethylation of the 
5’UTR site (cg2304849) was observed in all WNT tumours that were aberrantly 
hypomethylated at the gene body site (cg0141191). 
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Figure 4.20. Methylation status of S100A4 in primary tumours and non-neoplastic cerebella. The methylation 
status of the 8 CpG probes on the 450K methylation array are shown in a representative sample of 30 primary 
tumours and in normal cerebellar samples. The critical CpG sites identified for S100A4 are annotated in red. Genomic 
region and CpG density were defined by Illumina: TSS1500: 1500base pairs upstream of transcription start site; 
TSS200: 200base pairs upstream of transcription start site; 5’UTR: 5’ untranslated region; body: gene body; NA: 
non-CpG island site. Filled circles: β≥0.7; half-filled circles: 0.3<β<0.7; empty circles: β≤0.3. Aberrant 
hypomethylation of the critical sites can be seen in a subset of primary tumours. All tumours that were 
hypomethylated at the cg014119 site were also hypomethylated at the cg2304849 site. The wider gene promoter 
region represented on the array was consistently methylated in primary tumours and in non-neoplastic cerebella. 
Subgroup status of primary tumours is shown. Hypomethylation of the 2 critical CpG sites was observed mainly in 
WNT tumours, while the majority of SHH, Group 3 (GRP3) and Group 4 (GRP4) tumours were methylated 
consistent with the non-neoplastic cerebella (see Figure 4.13). 
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4.4.9.5 ACTC1 
The 2 differentially methylated critical CpG sites identified for ACTC1 (Figure 4.14) 
were adjacent to each other on the 450K array and were located in the non-CpG island 
promoter region (Figure 4.21). The sites showed significantly higher methylation in the 
Group (3+4) tumours compared with (SHH+WNT) tumours and this was associated 
with significantly lower gene expression in Group (3+4) compared with (SHH+WNT) 
(Figure 4.14). Both sites showed variable methylation in the non-neoplastic cerebella 
(Figure 4.14 and Figure 4.21). For the cg06048973 probe, methylation (β>0.3) was 
observed in 51/109 primary tumours and in 80% of these methylated tumours the wider 
promoter region, as represented on the array (8 CpG sites), was also methylated (β>0.3 
in ≥75% promoter sites); the site was unmethylated (β≤0.3) in 58/109 primary tumours 
and in 79% of these unmethylated tumours the wider promoter region was similarly 
unmethylated (β≤0.3 in ≥75% promoter sites). Methylation (β>0.3) of the site was 
observed in 9/17 normal cerebellar samples but only 44% of these showed methylation 
of the wider region and for those that did, methylation was localised to the first 3 
promoter sites on the array and was not reflective of all promoter sites (Figure 4.21). 
These results suggest that potential methylation-dependent silencing of ACTC1 in the 
Group 3 and Group 4 tumours requires dense aberrant methylation of the gene promoter 
region. This is supported by the strong linear relationship (r=0.8) observed in the 
primary tumours and normal cerebella between the methylation β-value of the critical 
gene promoter site (cg06048973) and the mean methylation β-value of the 8 promoter 
sites represented on the array (Figure 4.22). ACTC1 represents a strong candidate 
epigenetically regulated gene in primary medulloblastomas (Tabl e 4.7). 
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Figure 4.21. Methylation status of ACTC1 in primary tumours and non-neoplastic cerebella. The methylation 
status of the 8 promoter-associated CpG sites represented on the array are shown in a representative sample of 30 
primary tumours and in normal cerebellar samples.. The 2 critical CpG sites identified for ACTC1 are annotated in 
red. Genomic region and CpG density were defined by Illumina: TSS1500: 1500base pairs upstream of transcription 
start site; TSS200: 200base pairs upstream of transcription start site; 5’UTR: 5’ untranslated region ; NA: non-CpG 
island site Filled circles: β≥0.7; half-filled circles: 0.3<β<0.7; empty circles: β≤0.3. Methylation of the 2 critical sites 
in primary tumours is strongly associated with aberrant hypermethylation of the wider gene promoter region as 
represented on the array. Subgroup status of primary tumours is shown. Dense methylation of the gene promoter 
(β>0.3 in ≥75% promoter sites) was observed mainly in Group 3 (GRP3) and Group 4 (GRP4) tumours consistent 
with the subgroup-specific patterns of methylation observed for the 2 critical sites (see Figure 4.13). 
 
 
cg06048973 cg08190298 
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Figure 4.22. ACTC1 promoter methylation. Linear association between the methylation β-value of the ACTC1 gene 
promoter CpG site (cg06048973) and the mean methylation β-value of the 8 gene promoter CpG sites represented on 
the 450K array is shown for the 109 primary tumours and 17 non-neoplastic cerebellar samples assayed on the 
Illumina Infinium 450K methylation array. Pearson correlation r value measuring the strength of the linear 
association is shown. 
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Gene Methylation-
dependent 
transcriptional 
silencing and 
upregulation  
by 5azaCdR 
treatment in 
cell lines 
Subgroup-
specific 
methylation 
pattern of 
critical 
CpG sites 
associated 
with 
expression 
alterations 
in cell lines 
Subgroup-
specific 
inverse 
methylation-
expression 
relationship 
Tumour-
specific 
methylation 
event(s) 
Aberrant 
methylation 
state 
Location 
of 
subgroup-
specific 
critical 
CpG 
site(s)  
Aberrant 
methylation 
patterns 
observed 
across 
multiple 
adjacent 
CpG sites 
FAM46A Y SHH Y N Hypermethylated 
in WNT, Group 
3 and Group 4 
Gene 
Body 
Y 
ACTC1 Y Group (3+4) Y Y Hypermethylated 
in Goup (3+4) 
Gene 
promoter 
Y 
PRPH Y WNT Y Y Hypomethylated 
in WNT 
subgroup 
Gene 
promoter 
N 
ANXA2 Y WNT Y Y Hypomethylated 
in WNT 
subgroup 
Gene 
promoter 
N 
S100A4 Y WNT Y Y Hypomethylated 
in WNT 
subgroup 
Gene 
promoter 
and Gene 
body 
N 
Table 4.7. Summary table of subgroup-specific candidate epigenetically regulated genes. FAM46A and ACTC1 
are the strongest candidate genes identified in this study as aberrant methylation of multiple adjacent CpG residues 
may regulate their transcription in primary medulloblastomas. CpG residues adjacent to the critical site(s) identified 
in PRPH, ANXA2 and S100A4 do not show similar aberrant methylation patterns. 
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4.4.10 RNA-Seq validates microarray expression alterations following 5-
azaCdR treatment in medulloblastoma cell lines 
Results from the more sensitive RNA-Seq method of gene quantification validated the 
methylation-dependent microarray expression alterations observed in 6 
medulloblastoma cell lines following 5-azaCdR treatment, for the 5 candidate 
epigenetically regulated genes identified in this chapter (Figure 4.23). Strong linear 
relationships (r>0.7) were observed between gene expression detected in the untreated 
and 5-azaCdR-treated cell lines by microarray profiling on the Illumina HT12 array and 
by RNA-Seq for the 5 candidate genes.  
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Figure 4.23. RNA-Seq versus microarray profiling of gene expression in medulloblastoma cell lines for candidate genes. Plots show the strong linear association between RNA-Seq and 
microarray profiling of gene expression in 6 medulloblastoma cell lines before and after treatment with 5-azaCdR. Results are shown for the 5 candidate genes. RNA-Seq transcript reads validate the 
methylation-dependent expression changes observed by microarray profiling for candidate genes. Pearson correlation r values measuring the strength of the linear association are shown.  
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4.5 Discussion  
4.5.1 Upregulated gene expression following 5-azaCdR treatment in cell lines 
A fold change (FC) estimation approach (see section 4.3.7) was used to identify genes 
whose expression was upregulated following 5-azaCdR treatment. A FC threshold 
(meanFC+3SD) was applied to each cell line and probes detecting an expression 
increase greater than the threshold following 5-azaCdR treatment in 2 or more cell lines 
were considered upregulated. This approach allowed cell lines to be treated 
independently. By doing so it broadened the scope of the analysis to facilitate the 
identification of both constitutive and variable methylation in cell lines that was 
associated with gene expression changes by 5-azaCdR consistent with potential 
epigenetic regulation (see section 4.4.4). 
The FC thresholds applied to the cell lines ranged from 1.3 to 2.9 (Table 4.1). The 
minimum detection threshold of 1.3 has previously been reported in the literature for 
differential gene expression with the Illumina HT12v4.0 microarray (Kibriya et al., 
2011). Microarrays tend to have a low dynamic range compared with the more sensitive 
methods of qRT-PCR and RNA-Seq and they can lead to small yet biologically 
significant fold changes in gene expression (Mutch et al., 2002). Expression microarray 
methods have demonstrated high accuracy to detect these small biologically important 
changes and results have been found to underestimate the fold change, implicating the 
importance of detecting small signal changes (Yao et al., 2004). Signal quenching is 
known to occur in expression microarray analysis and is a source of non-linearity 
between signal intensity and gene expression (Ramdas et al., 2001) and it was therefore 
considered important to select fold change thresholds that best described the data.  
There were 283 genes upregulated by 5-azaCdR in medulloblastoma cell lines. The 
upregulated genes were enriched for genes encoding components of the intracellular 
cytoskeleton and involved in processes relating to the intracellular cytoskeleton and 
muscle contraction (Figure 4.4). The cytoskeleton plays important roles in establishing 
cell shape and in cell division, motility and cell-matrix interactions. It is now 
understood that in response to the cellular microenvironment mechanical signalling 
through the intracellular cytoskeleton can regulate cancer cell proliferation and drive 
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cancer progression (Provenzano and Keely, 2011), illustrating potential key roles for 
their epigenetic dysregulation in medulloblastoma tumourigenesis. 
The upregulated genes were also enriched for stress response genes and genes involved 
in the regulation of apoptosis (Figure 4.4). The role of 5-azaCdR in demethylating cell 
lines and patient samples has been well established (Bender et al., 1998; Christman, 
2002; Stresemann and Lyko, 2008). It is also clear that 5-azaCdR has cytotoxic effects 
and as such it is a licensed epigenetic therapy for the treatment of myelodysplastic 
syndrome (MDS) (Stresemann and Lyko, 2008). At high doses 5-azaCdR can induce 
pronounced toxicities. The optimum concentration of 5-azaCdR (5µM) and the 
optimum time for cell line DNA demethylation and gene reactivation (72 hours) had 
previously been assessed and determined using the RASSF1A transcript by Dr. Jennifer 
Anderton (Anderton J.A. PhD Thesis, Newcastle University). For investigations 
reported in this chapter, RASSF1A expression in the untreated and treated cell line pairs 
was assessed by RT-PCR prior to microarray profiling. RASSF1A silencing and re-
expression by 5-azaCdR was evident in all 10 cell lines tested (Figure 4.2) serving as a 
positive control for the demethylation of cell lines by 5-azaCdR. At these doses adapted 
to optimise epigenetic effects it would still be expected to observe cellular stress 
responses and apoptosis owing to the cytotoxic effects of 5-azaCdR. With a 
pharmacological-based approach using 5-azaCdR it is important to be aware that some 
genes may be upregulated as an indirect consequence of exposure to the drug and not 
directly related to their methylation. Studies have shown that some changes in gene 
expression following 5-azaCdR are not the direct result of demethylation but rather the 
result of secondary effects (Komashko and Farnham, 2010). It is therefore necessary to 
analyse methylation patterns in cell lines and to assess upregulated expression 
associated with a methylated state and consistent with a direct association between 
DNA methylation and gene expression. 
4.5.2 Critical CpG sites associated with methylation-dependent gene 
regulation in cell lines 
Assessment of DNA methylation in accordance with transcriptional silencing and re-
expression by 5-azaCdR treatment in cell lines identified critical CpG sites that showed 
an association between their methylation and expression alterations seen for the 
upregulated genes, consistent with their potential epigenetic regulation (see section 
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4.4.4). The genome-wide 450K methylation array was used to assess the DNA 
methylation status of upregulated genes in cell lines and permitted an unbiased 
investigation into the potential role of gene-wide DNA methylation in gene regulation. 
There were over 5,251 CpG probes on the 450K array that corresponded to the 283 
upregulated genes and 4,238 (81%) of these were constitutively or variably methylated 
in the cell lines and, therefore, potentially associated with the observed upregulated 
expression by 5-azaCdR.  
In order for CpG sites to be considered to play a potential critical role in epigenetic gene 
regulation, an association between their DNA methylation status and expression 
alterations by 5-azaCdR treatment was required in at least 6 out of the 10 cell lines (see 
section 4.3.8.1). It was considered that by meeting this criterion, genes would 
demonstrate strong evidence of potential methylation-dependent regulation in cell lines 
while also recognising that different cell lines may utilise different mechanisms of gene 
regulation dependent on the varying selective pressures that may be acting to maintain 
their unlimited proliferation. A total of 160 (4%) constitutively and variably methylated 
CpG sites were found to have a strong association between their methylation and gene 
re-expression by 5azaCdR treatment in cell lines. These sites encompassed 21 of the 
283 upregulated genes (7%), suggesting that for the majority of upregulated genes the 
changes in expression observed due to 5-azaCdR treatment were not due to the relief of 
repression caused by methylation, as has previously been reported (Komashko and 
Farnham, 2010). These results reinforce the importance of assessing CpG methylation 
alongside re-expression by 5-azaCdR treatment and with the identification of 21 
candidate epigenetically regulated genes in medulloblastoma cell lines they highlight 
the utility of this functional epigenomics approach to screen for evidence of epigenetic 
gene regulation on a genome-wide scale. Of the 21 candidate genes identified in cell 
lines, 2 genes (S100A4 and DAZL) had previously been reported to undergo 
methylation-dependent re-expression by 5-azaCdR treatment in medulloblastoma cell 
lines (Anderton et al., 2008). 
The high resolution of the 450K methylation array facilitated the identification of 
multiple critical CpG sites for each candidate gene (Table 4.3). Overall the sites were 
located across all functional gene regions (promoter, gene body and 3’UTR), with equal 
numbers in promoter and non-promoter regions, and 82% were situated in CpG islands 
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and CpG island shores/shelves (Figure 4.8). While the role of CpG island-associated 
promoter methylation in gene regulation has been well established, these results suggest 
a strong potential role for CpG island and CpG island shore methylation in regions 
outside of the promoter, in the epigenetic regulation of genes in medulloblastoma. 
4.5.3 Differential CpG methylation associated with differential gene 
expression in distinct subgroups of medulloblastoma 
Candidate genes which showed strong evidence of methylation-dependent 
transcriptional regulation in medulloblastoma cell lines were investigated for evidence 
of a methylation-expression relationship in primary medulloblastoma subgroups. The R 
package limma was used to assess differential methylation of the critical CpG sites 
identified in cell lines and differential expression of candidate genes in primary 
medulloblastomas (see section 4.3.10). A major practical advantage of limma was its 
capability to assess multiple contrasts simultaneously and to select the overlapping 
significant contrasts that differentiated one subgroup from all others. This approach and 
the experimental design made the differential analyses more resistant to the effects of 
unequal group sizes and unequal variances that were observed in the differential 
analyses described in Chapter 3, where distinct groups were combined together to 
facilitate a single pair-wise comparison using Mann-Whitney U tests (see section 3.3.4) 
and t-tests (see section 3.3.5). Another practical advantage of limma was the ease of 
interpretation of significance results; the ‘decideTests()' function reported the results of 
the significance test, incorporating both the FDR-adjusted p-value threshold and the 
difference threshold into the final result and indicated whether the contrast tested was 
significantly negative or significantly positive. This facilitated a straightforward 
determination of a significant inverse methylation-expression relationship in distinct 
subgroups of medulloblastoma (Table 4.6). 
Similar to the investigations reported in Chapter 3, a technical limitation of this study 
was that tumour-matched methylation and expression data was not available. As a 
result, direct correlation of methylation and expression could not be assessed on a 
sample by sample basis to support the subgroup-specific patterns of methylation and 
expression observed, and findings were based on a comparison of means only.  
For the majority of critical CpG sites that showed an association with gene expression 
in cell lines, this relationship was not reflected in the differential patterns of methylation 
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and gene expression observed in the primary tumour subgroups; 9 of the 160 CpG sites 
identified in cell lines (6%) showed differential methylation associated with differential 
gene expression and consistent with their potential epigenetic regulation in distinct 
subgroups of medulloblastoma (see section 4.4.8). The sites encompassed 5 of the 21 
genes (24%) identified in cell lines. These results suggest that patterns of differential 
methylation in medulloblastoma subgroups are not strongly associated with the patterns 
of differential gene expression, consistent with the findings in Chapter 3 which 
investigated Group 3- and Group 4-specific methylation events (see section 3.5.3). 
4.5.4 Functional epigenomics identifies subgroup-specific candidate 
epigenetically regulated genes in medulloblastoma 
By carrying out a functional epigenomics screen in medulloblastoma cell lines, 
followed by a differential methylation/expression analysis of critical events in primary 
medulloblastomas, the investigations reported in this chapter have identified 5 candidate 
genes that showed strong evidence of methylation-dependent expression in distinct 
molecular subgroups of the disease; FAM46A hypermethylation was specific to non-
SHH tumours; ANXA2 hypomethylation, PRPH hypomethylation and S100A4 
hypomethylation were specific to WNT tumours and ACTC1 hypermethylation was 
specific to Group (3+4) tumours (Table 4.7). Epigenetic deregulation of S100A4 has 
previously been reported in medulloblastoma (Lindsey et al., 2007) while the other 4 
genes represent novel genes potentially involved in the pathogenesis of 
medulloblastoma. FAM46A and ACTC1 were the strongest candidate epigenetically 
regulated genes identified in this study as their aberrant methylation patterns extended 
across multiple adjacent CpG residues (Table 4.7).  
Since the 4 distinct molecular subgroups of medulloblastoma potentially arise from 
distinct stem and progenitor cell populations (Schuller et al., 2008; Yang et al., 2008; 
Gibson et al., 2010; Kawauchi et al., 2012; Pei et al., 2012) an accurate assessment of 
tumour versus normal tissue should account for these subgroup-specific differences and 
comparisons should be made to the correct cell type from which the tumour originates. 
Control cerebella samples will contain a heterogeneous population of cells that may 
mask the signal from the actual cell of origin. Until the cell of origin can be identified 
for all the subgroups of medulloblastoma and in the absence of appropriate cell type-
matched controls, the tumour-specificity of the candidate gene methylation events was 
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considered only to appraise the potential functional relevance of methylation-dependent 
gene expression in the tumour subgroups. 
4.5.4.1 FAM46A 
There were 4 critical CpG sites belonging to the FAM46A gene whose methylation was 
associated with methylation-dependent expression changes in medulloblastoma cell 
lines treated with 5-azaCdR (Table 4.3). RNA-Seq results for 6 of the untreated and 5-
azaCdR-treated cell line pairs showed strong correlation with the expression microarray 
results (r=0.9) (Figure 4.23), validating the methylation-dependent expression changes 
observed and providing further supporting evidence of epigenetic regulation. Three of 
the four sites identified in cell lines were differentially methylated in SHH tumours 
compared to the other subgroups and their methylation was in accordance with 
differential expression in the SHH subgroup and potential epigenetic regulation in 
primary tumours (Figure 4.10). The methylation status of the 3 CpG sites in SHH 
tumours was not significantly different to the normal cerebella and they represented 
aberrant hypermethylation events in the WNT, Group 3 and Group 4 tumours (Figure 
4.10). The 3 sites were located in the gene body of FAM46A in a CpG island and island 
shore and assessment of adjacent sites on the 450K array suggests that aberrant 
methylation in non-SHH tumours may be reflective of aberrant methylation across the 
wider CpG island and island shore-associated gene body region (Figure 4.16). These 
findings are based on only 4 gene body CpG probes on the 450K array and would 
require validation by bisulfite sequencing of the CpG island-associated gene body. 
Based on the findings of this investigation, FAM46A represents a potential novel tumour 
suppressor gene in WNT, Group 3 and Group 4 medulloblastomas, which may be 
silenced by aberrant methylation of a CpG island and island shore located in the gene 
body. FAM46A (family with sequence similarity 46, member A) is located on 
chromosome 6q14 and the normal functions of the encoded protein are unknown. There 
is very little reported in the literature on any role for this gene in tumourigenesis. One 
study has reported differential FAM46A expression in breast cancer patients who 
respond and who don’t respond to 5-fluorouracil (5-FU) treatment and suggest that it 
may represent a predictive marker of response to therapy in breast cancer (Tsao et al., 
2010). 
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4.5.4.2 ANXA2, PRPH and S100A4 
ANXA2, PRPH and S100A4 had similar patterns of differential methylation and gene 
expression specific to the WNT subgroup of tumours (Figure 4.11, Figure 4.12 and 
Figure 4.13). There were 6 critical ANXA2 CpG sites, 4 PRPH sites and 5 S100A4 sites 
whose methylation was associated with methylation-dependent expression changes in 
medulloblastoma cell lines treated with 5-azaCdR (Table 4.3). RNA-Seq results for 6 of 
the untreated and 5-azaCdR-treated cell line pairs showed strong correlation with the 
expression microarray results (Figure 4.23), validating the methylation-dependent 
expression changes observed and providing further supporting evidence of epigenetic 
regulation. 
Of the CpG sites that were identified in cell lines, there was 1 critical site in the ANXA2 
gene, 1 in the PRPH gene and 2 in the S100A4 gene that were differentially methylated 
in WNT tumours compared to the other tumour subgroups, and their methylation was in 
accordance with differential expression in the WNT subgroup and potential epigenetic 
regulation in primary tumours (Figure 4.11, Figure 4.12 and Figure 4.13). The 
methylation status of the sites in WNT tumours was significantly different to the normal 
cerebella for the 3 genes and they represented hypomethylation events in the WNT 
tumours (Figure 4.11, Figure 4.12 and Figure 4.13).  
For all 3 genes, assessment of adjacent probes on the 450K array did not support strong 
evidence of the site-specific hypomethylation being reflected across the wider gene 
region. In the case of S100A4 there was only 1 gene body site represented on the array 
and so methylation patterns across the wider gene body region could not be investigated 
by microarray analysis. The findings reported here are based on only those sites that are 
present on the 450K array and they would require validation by bisulfite sequencing of 
the surrounding region for each candidate gene. While aberrant methylation states 
affecting multiple adjacent CpG residues provides more convincing evidence of 
potential epigenetic regulation, methylation at a single CpG residue has been shown to 
be sufficient to negatively affect binding of transcription factors to the DNA (Tate and 
Bird, 1993). In other studies, epigenetic regulation of S100A4 has been shown to occur 
at 2 critical intragenic CpG sites located within its first intron (Rosty et al., 2002; 
Lindsey et al., 2007).  
 278 
 
Based on the results reported here, ANXA2, PRPH and S100A4 represent potential 
oncogenes in WNT medulloblastomas, which may be upregulated by hypomethylation 
of critical CpG sites. S100A4, located on chromosome 1q21, is known to be regulated 
epigenetically by DNA methylation of key intragenic CpG sites (Rosty et al., 2002) and 
hypomethylation of S100A4 has been found in medulloblastoma (Lindsey et al., 2007) 
as well as in other cancers, including pancreatic and colon adenocarcinoma (Nakamura 
and Takenaga, 1998; Rosty et al., 2002). High levels of S100A4 have been shown to be 
associated with metastatic progression of many cancers including medulloblastoma 
(Hernan et al., 2003). This study has found S100A4 hypomethylation to occur almost 
exclusively in the WNT subgroup of tumours (see section 4.4.9.4) and has identified a 
potential critical site located within the gene promoter that may play a role in gene 
regulation.  
PRPH is located on chromosome 12q12-q13 and encodes a cytoskeletal protein found 
in neurons of the peripheral nervous system. A recent study in neuroblastoma has 
identified promoter methylation of PRPH as a prognostic biomarker, reporting that 
reduced expression levels associated with a methylated state contributed to a more 
aggressive phenotype of the disease (Decock et al., 2012). The authors report that high 
levels of PRPH are associated with a more differentiated state and suggest that it may 
also serve as a differentiation marker for tumours derived from the neural crest (Decock 
et al., 2012).  
ANXA2, located on chromosome 15q22.2, encodes a member of the calcium-dependent 
phospholipid binding proteins that play a role in the regulation of cellular growth and 
signal transduction pathways. Increased expression of ANXA2 correlates with malignant 
changes in multiple cancers and in breast cancer elevated expression has been shown to 
drive proliferation, migration and invasion of cells through regulation of downstream 
targets including c-myc and cyclin D1 (Wu et al., 2012). 
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4.5.4.3 ACTC1 
There were 7 critical CpG sites belonging to the ACTC1 gene whose methylation was 
associated with methylation-dependent expression changes in medulloblastoma cell 
lines treated with 5-azaCdR (Table 4.3). RNA-Seq results for 6 of the untreated and 5-
azaCdR-treated cell line pairs showed strong correlation with the expression microarray 
results (r=0.95) (Figure 4.23), validating the methylation-dependent expression changes 
observed and providing further supporting evidence of epigenetic regulation. Two of the 
seven sites identified in cell lines were differentially methylated between Group (3+4) 
and (SHH+WNT) tumours and their methylation was in accordance with differential 
expression between the same groups and potential epigenetic regulation in primary 
tumours (Figure 4.14). Methylation of the 2 CpG sites in control cerebella was variable 
and for 1 probe (cg06048973) it was significantly hypomethylated in (SHH+WNT) 
tumours, while the other probe (cg08190298) was significantly hypermethylated in 
Group (3+4) and significantly hypomethylated in (SHH+WNT) (Figure 4.14). The 2 
sites were located in the non CpG island-associated promoter region of ACTC1, 200bp 
and 1500bp upstream from the TSS (Figure 4.21). Assessment of adjacent promoter 
sites on the 450K array suggests that, while methylation of the critical sites was variable 
in normal cerebella, aberrant dense methylation of the wider promoter region occurred 
in tandem with methylation of these sites in primary tumours (Figure 4.21). These 
findings are based on probes represented on the 450K array and would require 
validation by bisulfite sequencing of the wider ACTC1 promoter.  
Based on the findings of this investigation, ACTC1 represents a potential novel tumour 
suppressor gene in Group 3 and Group 4 medulloblastomas, which may be silenced by 
aberrant dense methylation of its gene promoter. ACTC1 is located on chromosome 
15q14 and encodes for a member of the actin family of proteins, which are involved in 
various types of cell motility. Studies in cancer have found that ACTC1 is commonly 
differentially expressed among subclasses of bladder cancer (Zaravinos et al., 2011), 
and based on its expression profile it has been identified as a cancer-specific biomarker 
in prostate cancer (Huang et al., 2010). 
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4.5.5 Genes previously identified to be regulated by DNA methylation in 
medulloblastoma 
The candidate epigenetically regulated genes identified in this chapter include one gene, 
S100A4, which has previously been found to be regulated by DNA methylation in 
primary medulloblastomas (Lindsey et al., 2007). The 4 remaining genes (ACTC1, 
ANXA2, FAM46A and PRPH) represent novel medulloblastoma genes. COL1A2 
(Anderton et al., 2008), SPINT2 (Kongkham et al., 2008) and the SFRP family of WNT 
inhibitors (Kongkham et al., 2010a) have previously been identified to be epigenetically 
silenced in primary medulloblastomas using the same pharmacological-based genome-
wide functional screening approach in cell lines that was employed for investigations 
reported here, yet it must be noted that they were not identified as candidate genes in 
this study.  
In the studies reported by Kongkham et al. that identified SPINT2 (Kongkham et al., 
2008) and the SFRP family (Kongkham et al., 2010a), the Affymetrix HGU133A+2 
was used to assess gene expression changes following demethylating treatment of cell 
lines with 5-azaCdR. These genes were not found to be upregulated following 5-
azaCdR treatment of cell lines on the Illumina HT12 platform used in this study, 
suggesting that this microarray-based approach is sensitive to the type of platform used 
to assess gene expression alterations. Discrepancies among microarray studies using 
different platforms are frequently reported and this can often be attributed to the 
different analytical frameworks employed for data analysis (Konishi et al., 2008), which 
may explain why these genes were not identified on the different platform used in this 
investigation. 
The Affymetrix HG-U133A platform was used in the study that identified epigenetic 
regulation of COL1A2 in primary medulloblastomas (Anderton et al., 2008). This study 
investigated methylation-dependent expression alterations by microarray analysis of 3 
medulloblastoma cell lines and validated the findings in 2 of the cell lines by qRT-PCR. 
Using the Illumina HT12 microarray and a larger panel of 10 medulloblastoma cell 
lines, COL1A2 expression was upregulated following 5-azaCdR treatment in cell lines 
in the investigations reported in this chapter, however, following analysis of its 
methylation status in the 10 cell lines used in this study, it did not meet the criterion 
required to be considered a candidate epigenetically regulated gene in cell lines; an 
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association between methylation status and expression alterations was not observed in at 
least 6 out of the 10 cell lines. Based on their findings of methylation-dependent gene 
expression in 3 medulloblastoma cell lines, Anderton et al went on to show 
methylation-dependent expression of COL1A2 in primary tumours (Anderton et al., 
2008). This discrepancy in findings by using a larger panel of cell lines may be caused 
by some cell lines acquiring artifactual gains of methylation that are not associated with 
expression alterations (Bender et al., 1998; Smiraglia et al., 2001), reminding us of the 
need to exercise caution with cell line models and of the importance of carrying out 
validation studies in primary tumours. The requirement to show an association between 
CpG methylation and expression alterations in 6 out of 10 cell lines may have been too 
strict for the COL1A2 gene and perhaps this may be explained by the different cell lines 
utilising different mechanisms of COL1A2 gene regulation depending on selective 
pressures operating to maintain their unlimited growth. If this were the case, it 
highlights the importance of analysing the cell lines independently and not assuming 
they will behave collectively.  
In this study, assessment of RASSF1A expression by RT-PCR in the untreated and 5-
azaCdR treated cell line pairs found methylation-dependent transcriptional silencing and 
re-activation of RASSF1A by 5-azaCdR in all 10 cell lines ( see section 4.4.1). These 
results were consistent with the robust evidence for epigenetic regulation of RASSF1A 
by DNA methylation in medulloblastoma cell lines (Lusher et al., 2002). However, 
RASSF1A was not identified as upregulated following 5-azaCdR by microarray analysis 
of the same panel of 10 untreated and 5-azaCdR treated cell lines. RT-PCR primers 
were designed specifically against the isoform A transcript of the RASSF1 gene (see 
section 2.9.3). The Illumina HT12 array does not measure expression of individual 
exons and, therefore, does not distinguish between transcript variants of a particular 
gene and so it is likely that the expression of RASSF1A is being masked by other 
RASSF1 transcript variants. This discrepancy in RASSF1A detection highlights a 
limitation of this array to detect expression alterations that may affect particular 
transcript variants of a gene.  
RHOH was identified in Chapter 3 as a potential oncogene, upregulated in Group 4 
medulloblastomas by hypomethylation of a critical promoter-associated CpG site (see 
section 3.5.6). qRT-PCR assessment of expression changes following 5-azaCdR 
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treatment in medulloblastoma cell lines found RHOH to be re-expressed in 4 cell lines 
following 5-azaCdR treatment and re-expression was associated with methylation in 
these cell lines, consistent with epigenetic regulation (see section 3.4.9.5). In the 
investigations reported in this chapter, microarray analysis of expression changes in the 
same cell lines did not identify upregulated RHOH expression following 5-azaCdR 
treatment. This discrepancy in RHOH detection using different methods suggests that 
high-throughput microarray expression profiling may be limited in its sensitivity to 
detect expression alterations of some genes following demethylating treatment of cell 
lines with 5-azaCdR. 
RNA-Seq is a more sensitive method of quantification of transcripts and their isoforms 
and it has a better dynamic range compared with microarray technologies (Wang et al., 
2009). RNA sequencing results that became available towards the end of this project 
validated the expression alterations detected by microarray in 6 cell lines for the 
candidate genes identified (Figure 4.23). Many of the discrepancies in gene detection 
that have been recognised here as a result of different microarray platforms and 
different methods of detection may be overcome by using the more sensitive and high-
throughput RNA-Seq technology to perform a genome-wide screen of expression 
alterations by demethylating treatment in cell lines. A universal analytic pipeline should 
be developed to facilitate consistency between studies. The use of RNA-Seq technology 
to identify epigenetically regulated genes in medulloblastoma is discussed further in 
Chapter 6. 
4.5.6 Assessment of RHOH methylation using the Illumina 450K methylation 
array 
Using the Ilumina GoldenGate Cancer Panel I methylation microarray, investigations 
reported in Chapter 3 identified RHOH as a potential candidate oncogene in Group 4 
medulloblastomas; upregulated RHOH expression in Group 4 tumours was associated 
with hypomethylation of a critical promoter-associated CpG site (see section 3.5.6). 
Following investigations in this chapter which used the latest generation Illumina 450K 
methylation microarray, it was decided to assess methylation of the wider RHOH 
promoter region using this higher density methylation array.  
The critical RHOH CpG site, which was associated with gene expression and was 
identified from the GoldenGate methylation array in Chapter 3 (RHOH_P121_F), was 
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located 121 base pairs upstream from the transcription start site in the non-CpG island-
associated gene promoter. In the cohort of 216 primary medulloblastomas (see section 
2.1.1) and 21 non-neoplastic cerebellar samples (see section 2.3) that were analysed on 
the GoldenGate methylation array, this site was methylated (β>0.3) in 100% of non-
neoplastic cerebella, 100% of SHH tumours, 82% of WNT tumours and 79% of Group 
3 tumours. In contrast, aberrant hypomethylation (β≤0.3) was observed in 51% of 
Group 4 tumours (Figure 4.24). This same site was represented on the 450K 
methylation array (cg26296101), and showed similar patterns of subgroup-specific and 
tumour-specific methylation in the smaller, and largely independent, cohort of 109 
tumours (see section 2.1.2) and 17 non-neoplastic cerebellar samples (see section 2.3) 
that were analysed on the 450K array. In the 450K cohort, methylation (β>0.3) was 
observed in 100% of non-neoplastic cerebella, 100% of SHH tumours, 100% of WNT 
tumours and 80% of Group 3 tumours. Aberrant hypomethylation (β≤0.3) was observed 
in 30% of Group 4 tumours (Figure 4.24). 
 
 
Figure 4.24 Methylation patterns of the critical RHOH CpG site in primary tumours and non-neoplastic 
cerebella assessed using the GoldenGate methylation microarray and the Infinium 450K methylation 
microarray. Combined boxplots and strip-plots show differential patterns of CpG methylation for the same critical 
RHOH CpG site assessed on the GoldenGate methylation microarray (RHOH_P121_F) and assessed on the Infinium 
450K methylation microarray (cg26296101), in different cohorts of primary tumours and non-neoplastic cerebellar 
samples. A cohort of 216 primary tumours and 21 non-neoplastic cerebella were analysed on the GoldenGate 
methylation microarray. A largely independent cohort of 109 tumours and 17 non-neoplastic cerebellar samples were 
analysed on the 450K methylation microarray. The same differential patterns were observed in different cohorts 
assessed on different microarray platforms. 
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There were 7 adjacent promoter-associated sites in the 450K methylation data for 
RHOH (Figure 4.25). Patterns of aberrant hypomethylation equivalent to the critical 
CpG site (cg2629610), which was observed predominantly in Group 4 tumours, were 
not observed across all promoter-associated sites, but were observed at sites 
immediately adjacent to the critical site on the array (Figure 4.25). The residue 
immediately upstream of this site on the array (cg0565810) showed a consistent 
methylation status; the critical site was aberrantly hypomethylated (β≤0.3) in 17 out of 
109 tumours and in 13 of these hypomethylated tumours (76%) the adjacent upstream 
residue was also hypomethylated. In 99% of methylated tumours (β>0.3) the adjacent 
upstream residue was also methylated. The residue immediately downstream of the 
critical site on the array (cg0080439) was unmethylated (β≤0.3) in 66 out of 109 (61%) 
primary tumours compared with only 2 out of 17 (12%) normal cerebella. Interestingly 
this aberrant hypomethylated state was observed in 100% of Group 4 tumours, which 
represented 56% of the unmethylated tumours. The remaining promoter sites were 
consistently methylated in all primary tumours and non-neoplastic cerebella (Figure 
4.25). Validation studies investigating methylation-dependent upregulation of RHOH in 
Group 4 tumours should focus on the critical CpG site identified (cg2629610) and sites 
which are immediately upstream and downstream of it in the gene promoter. 
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Figure 4.25. Methylation status of RHOH gene promoter in primary tumours and non-neoplastic cerebella. 
The methylation status of the 7 promoter-associated CpG sites represented on the 450K array are shown in a 
representative sample of 15 primary tumours and 15 normal cerebellar samples.. The critical CpG residue identified 
for RHOH is annotated in red. Functional (Fn) genomic region and CpG density were defined by Illumina: TSS1500: 
1500 base pairs upstream of transcription start site; TSS200: 200base pairs upstream of transcription start site; 5’ 
UTR: 5’ untranslated region ; NA: non-CpG island site Filled circles: β≥0.7; half-filled circles: 0.3<β<0.7; empty 
circles: β≤0.3. Consistent aberrant hypomethylation was observed at the CpG site immediately upstream (cg0565810) 
of the critical site on the array. Aberrant hypomethylation was observed predominantly in Group 4 tumours. The site 
immediately downstream (cg0080439) of the critical site was aberrantly hypomethylated in 100% of Group 4 
tumours, representing 56% of all tumours that were hypomethylated at this site. 
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4.6 Further work 
Investigations reported in this chapter have identified 5 candidate genes in 
medulloblastoma (ACTC1, ANXA2, FAM46A, PRPH and S100A4) which show strong 
evidence of DNA methylation-dependent gene regulation and which may play important 
roles in the development of distinct subgroups of the disease. The strongest evidence of 
potential epigenetic regulation was found for FAM46A and ACTC1, with aberrant 
methylation patterns extending across multiple adjacent CpG residues in the gene body 
and in the gene promoter regions, respectively (Table 4.7). Genes were identified using 
high-throughput genome-wide expression and methylation microarrays and it will now 
be essential to validate findings using more sensitive methods. 
RNA-Seq data for the 5 genes provided a useful validation of methylation-dependent 
expression alterations observed by microarray analysis in cell lines following 5-azaCdR 
treatment (Figure 4.23). The methylation status in cell lines before and after treatment 
with 5-azaCdR will need to be validated by bisulfite sequencing and qRT-PCR will 
need to be performed to confirm evidence of a direct association between DNA 
methylation and gene expression. It is known that immortalised cell lines frequently 
contain artifactual gains of methylation at many loci (Bender et al., 1998; Smiraglia et 
al., 2001) and it will be necessary to validate these in vitro methylation findings in the 4 
subgroups of primary medulloblastomas and in the normal cerebellum by bisulfite 
sequencing and to validate the associated gene expression changes in primary tumours 
by qRT-PCR. Expression will also need to be assessed in the normal cerebellum to 
confirm the potential tumour suppressor or oncogenic role of genes identified. 
The high-resolution 450K methylation array permitted an assessment of gene-wide 
DNA methylation. Based on the array results for the candidate genes identified, it will 
be important to assess hypermethylation of the CpG island-associated gene body of 
FAM46A in non-SHH tumours (Figure 4.16) and the dense methylation of the non-CpG 
island-associated promoter of ACTC1 in Group 3 and Group 4 tumours (Figure 4.21) by 
bisulfite sequencing. S100A4 has previously been reported to be epigenetically 
regulated in medulloblastoma by methylation of critical intragenic sites (Rosty et al., 
2002; Lindsey et al., 2007). Investigations in this chapter have identified a site in the 
non-CpG island-associated promoter of S100A4 (Figure 4.20) that may also play a 
critical role in gene regulation and methylation of the wider promoter region will need 
 287 
 
to be investigated by bisulfite sequencing, as well as any associated expression changes 
by qRT-PCR in primary tumours. For ANXA2 validation studies will need to focus on 
the CpG island and island shore-associated promoter to determine if methylation at a 
single CpG site is sufficient to affect transcription (Figure 4.18). For PRPH, both 
promoter and gene body methylation will need to be investigated to determine whether 
hypermethylation of the CpG island-associated gene body is required alongside 
hypomethylation of the gene promoter to cause upregulated expression (Figure 4.19). 
In the case of aberrant gene body methylation that was identified in FAM46A and 
PRPH, it would be interesting to investigate potential alternate promoter usage or 
alternate splicing events as intragenic DNA methylation has been reported in recent 
studies to play a role in these processes (Kulis et al., 2013). PCR primers could be 
designed against alternate transcript variants to assess any differential expression and 
ChIP-seq would allow characterisation of transcription factor binding sites, nucleosome 
positioning and histone modifications that are indicative of active promoters such as 
H3K4me3. 
Following validation of the methylation status and associated gene expression changes 
in primary tumours and the normal cerebella, it will be necessary to determine whether 
the differences in mRNA levels observed are reflected at the protein level by western 
blot analysis or immunohistochemistry. To determine any functional role for the 
epigenetic dysregulation of these genes in medulloblastoma, functional studies 
including proliferation, apoptosis and migration assays will need to be conducted in 
vitro and in vivo following appropriate modulation of gene expression. There are 
currently mouse models for SHH (Gilbertson and Ellison, 2008; Hatten and Roussel, 
2011), WNT (Gibson et al., 2010) and Group 3 (Kawauchi et al., 2012; Pei et al., 2012) 
medulloblastomas. Results from functional assays will reveal any involvement in the 
initiation and progression of the distinct subgroup(s) of medulloblastoma, in which 
epigenetic dysregulation was observed, and identify their potential as therapeutic drug 
targets. High levels of S100A4 expression have previously been reported to be 
associated with metastatic progression of medulloblastoma (Hernan et al., 2003). 
S100A4 was identified to be potentially dysregulated by DNA hypomethylation in the 
discrete subgroup of WNT tumours and, therefore, a more focused study into any 
functional role in the context of WNT tumourigensis should be carried out. Elevated 
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expression of a second WNT-specific gene identified in this study (ANXA2) has also 
been found to correlate with metastasis in cancers (Wu et al., 2012). It is interesting that 
elevated expression of both these metastasis genes has been found in the WNT 
subgroup of tumours which confer the best prognosis of all tumour subgroups (Ellison 
et al., 2005; Clifford et al., 2006; Kool et al., 2012), and any potential role in WNT 
tumourigenesis will need to be investigated further. 
Potential epigenetic dysregulation for 3 of the candidate genes (ANXA2, PRPH and 
S100A4) was specific to the WNT subgroup of tumours. WNT tumour status confers a 
very good long-term prognosis in comparison to the other tumour subgroups (Ellison et 
al., 2005; Clifford et al., 2006; Kool et al., 2012), and long-term survival rates likely 
exceed 90% (Taylor et al., 2012). As a result, the role of WNT-specific methylation 
biomarkers in disease prognostication is limited. For the non-WNT tumours, 
identification of prognostic disease biomarkers which may also have functional 
relevance offers the potential for the development of a more accurate and refined risk 
stratification model.  
FAM46A was hypermethylated in Group 3, Group 4 and WNT tumours. At 1 critical 
CpG site (cg11075693) complete methylation (β≥0.7) was observed in 40% of WNT 
tumours but only in 3% and 9% of Group 3 and Group 4 tumours, respectively (Figure 
4.10). It needs to be investigated whether these methylated Group 3 and Group 4 
tumours share a similar good prognosis as WNT tumours and whether this methylation 
marker has utility as an independent prognostic marker in Group 3 and Group 4 tumours 
to identify a subset of good prognosis tumours which may benefit from less aggressive 
therapy. The ACTC1 critical CpG site (cg08190298) was aberrantly methylated in 40% 
of Group (3+4) tumours compared with only 5% of (SHH+WNT) tumours (Figure 
4.14). It will be important to assess the independent prognostic relevance of this 
methylation marker within Group 3 and Group 4 tumours to determine whether it 
identifies a subset of tumours within these groups that behave differently. It will also be 
important to assess the ability of this marker to improve the accuracy of survival 
prediction alongside established prognostic features. MYC amplification, which is 
enriched in Group 3 tumours, and LCA histology and metastases which are frequently 
present in Group 3 and are also found in Group 4 (Kool et al., 2012) are established 
prognostic features in medulloblastoma (Ellison et al., 2011b). The identification of 
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prognostic disease biomarkers, leading to the development of a more accurate and 
refined risk stratification model, is essential to improve survival and to minimise late 
adverse treatment effects through the delivery of more personalised therapies (Pizer and 
Clifford, 2009). 
4.7 Summary 
This chapter reports a robust and effective genome-wide screen to identify candidate 
epigenetically regulated genes in distinct subgroups of medulloblastoma. Five candidate 
genes were identified (ACTC1, ANXA2, FAM46A, PRPH, S100A4), representing both 
potential candidate tumour suppressor genes and oncogenes, and for four of them they 
represent novel medulloblastoma genes. Aberrant methylation states, which may affect 
gene transcription and play a role in medulloblastoma tumourigenesis, were observed at 
multiple adjacent CpG residues in the FAM46A and ACTC1 genes and provided the 
strongest evidence of epigenetic regulation for these genes. S100A4 has previously been 
reported to be hypomethylated in medulloblastoma and to have a potential oncogenic 
role (Lindsey et al., 2007). Investigations reported here have identified S100A4 
hypomethylation to be specific to the discrete WNT subgroup of tumours and, therefore, 
future studies on this gene should focus on this tumour subgroup. It will now be 
necessary to validate the methylation-expression relationships observed for these genes 
in the distinct tumour subgroups, and to determine any functional role for their 
epigenetic dysregulation in driving tumourigenesis and progression within 
medulloblastoma subgroups. 
The relatively small number of candidate genes that have been identified from this 
genome-wide screen suggests that any direct association between DNA methylation and 
gene expression is highly gene-specific, and while it does exist for select genes, it does 
not hold true for the broader differential patterns of methylation and gene expression 
observed in the subgroups of medulloblastoma. In the investigations reported here, only 
6% of methylation events that were associated with gene expression in medulloblastoma 
cell lines showed a similar association reflected in their differential subgroup-specific 
patterns of methylation and expression in primary tumours. A technical limitation of 
this study is recognised with the lack of matched-tumour methylation and expression 
data available, which would allow for a direct correlation analysis between methylation 
and expression rather than a comparison of means. Using the methods described, the 
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results reported in this Chapter suggest that any functional association between patterns 
of methylation and expression in medulloblastoma subgroups is weak. This is consistent 
with the findings in Chapter 3 which focused on Group 3 and Group 4 tumours, and also 
with the findings of other groups investigating the role of DNA methylation in different 
cancers (Sproul et al., 2011; Jung et al., 2012; Kulis et al., 2012; Sproul et al., 2012).  
As an increasing number of cancer methylomes are being characterised it is becoming 
increasingly recognised that methylation patterns may, to some extent, reflect patterns 
in the distinct cell of origin from which the tumour subgroup arises (Kulis et al., 2012; 
Batora et al., 2013). Additionally, aberrant patterns of methylation have been found to 
represent markers of cell lineage rather than tumour progression, reflecting the 
developmental history and transcriptional state of the different cells of origin (Sproul et 
al., 2011; Sproul et al., 2012). 
Epigenetic gene regulation is complex involving multiple and inter-related chromatin 
components, and it is likely that the roles of DNA methylation within this are complex 
too. It has long been acknowledged that DNA methylation may not always directly 
cause the silencing with which it is associated, but rather may target genes that are 
already silenced by another mechanism, and effectively “lock” or stabilise the 
transcriptionally silent state (Bird, 2002). Epigenetic dysregulation in cancers involves 
all components of chromatin (Jones and Baylin, 2007). Recently, whole exome and 
whole genome sequencing have identified recurrent mutations affecting several 
chromatin-modifying genes and implicating deregulation of the epigenome as an 
important step in medulloblastoma pathogenesis (Jones et al., 2013). It is important to 
consider that the interaction between different epigenetic mechanisms may play a major 
role in transcription regulation in medulloblastoma, rather than DNA methylation alone. 
In future studies it will be important to study aberrant DNA methylation alongside 
histone modifications and nucleosome structure if we are to gain a fuller understanding 
of its role in gene regulation in medulloblastoma. 
Advances in technologies, which have led to the high resolution 450K methylation array 
and now whole genome shotgun bisulfite sequencing (WGSBS) (Lister et al., 2009), 
means that DNA methylation can be studied across the complete gene, to include 
promoter and intragenic sites. Studies to date suggest that a comprehensive assessment 
of gene body methylation has the potential to reveal further candidate epigenetically 
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regulated genes. It has recently been observed in multiple genome-wide epigenomic 
studies that intragenic DNA methylation can be positively correlated with gene 
expression both in normal development and in cancer cells (Kulis et al., 2013). This 
relationship has also been reported in a context-dependent manner relating to whether 
sites were located inside or outside of CpG islands in the gene body (Varley et al., 
2013). These findings will have major implications for future studies into the genome-
wide role of DNA methylation in gene regulation, whereby both positive and negative 
correlations should be investigated in the gene body. Further epigenetically regulated 
genes may be identified if studies are focused on gene regulatory elements, such as 
enhancer sites and transcription factor binding sites which are located outside of typical 
gene promoters and within the gene body. An increasing number of epigenome-wide 
studies are identifying significant correlative relationships between DNA methylation 
and gene expression for these important regulatory regions, revealing potential new 
roles for DNA methylation in epigenetic gene regulation (Kulis et al., 2013). 
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5.1 Background and project summary 
Medulloblastoma, the most common malignant brain tumour of childhood, is an 
invasive embryonal tumour of the cerebellum and accounts for approximately 10% of 
all childhood cancer deaths (Pizer and Clifford, 2009). 5-year survival rates of up to80% 
are currently being achieved using risk-adapted combination therapies (Northcott et al., 
2012a). Despite improved survival, there remains a proportion of high-risk patients for 
whom prognosis is very poor, and survivors of medulloblastoma suffer considerable 
long-term neurocognitive and endocrinologic adverse effects associated with their 
treatment (see section 1.5.5.2). At present, risk stratification is based on clinical features 
alone (see section 1.5.4). In the last 10 years, significant advances have been made in 
understanding medulloblastoma genomics, and have led to the recognition of 
medulloblastoma as a disease that comprises four core transcriptomic subgroups (SHH, 
WNT, Group 3 and Group 4). These subgroups are associated with distinct clinical 
behaviours and genetic features and will likely require different therapeutic strategies in 
the clinic (Kool et al., 2012; Taylor et al., 2012). 
Molecular subclassification is beginning to inform treatment of medulloblastoma. 
Refined risk stratification models have been developed that incorporate molecular 
disease biomarkers and that can identify patients with a favourable prognosis, for whom 
less aggressive treatments could potentially be administered (Pizer and Clifford, 2009; 
Ellison et al., 2011b). Extensive research is underway to individualise treatments 
according to the biology of a patient’s tumour. Despite these advances, more insights 
need to be gained from the underlying molecular pathology of the different disease 
subgroups, and in particular, the less well-defined Group 3 and Group 4 tumours, to 
identify critical driver events in their pathogenesis that could potentially be targeted 
therapeutically. Group 3 medulloblastomas carry the worst prognosis of all the 
subgroups, while the largest subgroup, Group 4, comprises subsets of tumours with poor 
clinical outcome (see section 1.5.8.2). There is an urgent need to understand the 
molecular defects that are driving these particularly aggressive phenotypes and to 
develop better therapies to improve survival. 
The role of the epigenome in medulloblastoma development is increasingly being 
recognised. DNA methylation plays a key role in epigenetic transcriptional regulation 
(see section 1.6.2), and the hypermethylation of promoter-associated GpG islands 
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leading to epigenetic gene silencing is a common feature of medulloblastoma. There are 
approximately 30 genes known to be aberrantly silenced by promoter hypermethylation 
in medulloblastoma (Dubuc et al., 2012). Many of these, including RASSF1A, HIC1 and 
CASP8, which are the most frequent epigenetically inactivated genes in 
medulloblastoma, have been identified using classical candidate gene approaches 
(Lindsey et al., 2005). Furthermore, many of these previous studies have focused on 
hypermethylation of CpG island promoters and did not recognise the distinct molecular 
subgroups of medulloblastoma. 
It is now possible to study DNA methylation on a genome-wide scale and at base-pair 
resolution (see section 1.6.3.3). Profiling primary medulloblastomas on DNA 
methylation microarrays has revealed the existence of four methylomic subgroups of the 
disease that are strongly associated with their transcriptomic counterparts (SHH, WNT, 
Group 3 and Group 4) (Schwalbe et al., 2013). The methylomic subgroups can be used 
to assess the relationship between DNA methylation and gene expression patterns in 
medulloblastoma, and can facilitate a more refined discovery of DNA methylation 
events that are associated with gene expression, and that may play a critical role in the 
development of distinct disease subgroups. Epigenome-wide studies of DNA 
methylation in cancer are also starting to reveal roles for DNA methylation outside of 
the gene promoter and outside of CpG islands (Irizarry et al., 2009; Kulis et al., 2013). 
Using genome-wide approaches, an unbiased assessment of gene-wide DNA 
methylation in distinct medulloblastoma subgroups can now be undertaken to gain 
greater insights into the role of DNA methylation in medulloblastoma development. 
The genome-wide role of DNA methylation in the distinct molecular subgroups of 
medulloblastoma has not been widely investigated. This project aimed to identify 
additional epigenetically regulated genes in medulloblastoma with a focus on subgroup-
specificity, using two high-throughput screening approaches: i). The GoldenGate 
Cancer Panel I methylation microarray (see section 2.7.2) was used to identify Group 3- 
and Group 4-specific promoter-associated DNA methylation events and, combined with 
assessment of in silico transcriptomic datasets, their association with gene expression 
was evaluated for evidence of potential methylation-dependent gene regulation in Group 
3 and Group 4 tumours. Candidate epigenetically regulated genes identified in primary 
tumours were then taken forward for further assessment of a direct relationship between 
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DNA methylation and gene expression in medulloblastoma cell lines treated with the 
demethylating agent, 5’-aza-2’-deoxycytidine (5-azaCdR) (Chapter 3); ii). The Illumina 
HT12v4.0 expression microarray (see section 2.8.1) was used to carry out a genome-
wide screen to identify genes transcriptionally upregulated by demethylation (5-
azaCdR) treatment of medulloblastoma cell lines and, combined with a genome-wide 
analysis of DNA methylation using the Illumina Infinium 450K methylation array (see 
section 2.7.3), methylation events that were associated with 5-azaCdR-induced 
expression alterations in cell lines were identified. Candidate epigenetically regulated 
genes identified in cell lines were then taken forward for further assessment of potential 
methylation-dependent gene regulation in primary medulloblastoma subgroups (Chapter 
4).  
Approach (i) (Chapter 3) identified 73 promoter-associated CpG residues 
(encompassing 63 genes) that significantly distinguished Group 3 and/or Group 4 
medulloblastomas from all other subgroups (Figure 3.5). Of the 63 genes, four (DDR2, 
HDAC1, MET and RHOH) showed strong evidence of an inverse 
methylation/expression relationship in primary tumours and were selected as subgroup-
specific candidate epigenetically regulated genes (Table 5.1). They were investigated 
further for evidence of a direct relationship between methylation and gene expression in 
cell lines treated with 5-azaCdR by qRT-PCR. For two of the candidate genes (MET and 
RHOH), their subgroup-specific methylation event was also tumour-specific (Table 
5.1). 
qRT-PCR assessment of expression changes in cell lines (n=6) following 5-azaCdR 
treatment identified a direct relationship between methylation and gene expression for 
two of the four candidate genes tested (MET and RHOH) (Table 5.1). In primary 
tumours, the inverse methylation/expression relationship observed for MET was seen in 
SHH, Group 3 and Group 4 tumours but did not extend to the WNT subgroup (Figure 
3.7C). As a result, unlike its methylation pattern, the pattern of MET expression was not 
specific to Group (3+4), and the methylation event represented a potential candidate 
mechanism of activation of the known MET oncogene in SHH tumours.  
In primary tumours, the promoter-associated RHOH residue (RHOH_P121_F) was 
hypomethylated in Group 4 tumours and this hypomethylated state was associated with 
significantly higher expression in Group 4 compared with the other tumour subgroups 
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(Figure 5.1). Subsequent assessment of RHOH promoter methylation using the genome-
wide Infinium 450K methylation array suggests that multiple promoter-associated CpG 
residues may play a role in regulating gene transcription (Figure 4.25). Using approach 
(i), a potential novel oncogenic role for RHOH in Group 4 medulloblastoma 
pathogenesis has been identified. 
Gene Subgroup-
specific 
(Group 3 
and/or 
Group 4) 
methylation 
pattern 
Subgroup-
specific 
inverse 
methylation-
expression 
relationship 
Tumour-
specific 
methylation 
event 
Aberrant 
methylation 
state 
Methylation-
dependent 
expression 
in ≥ 4/6 cell 
lines 
(qRT-PCR; 
-/+ 
5azaCdR) 
DDR2 Group (3+4) Y N Hypomethylated 
in SHH + WNT  
N 
HDAC1 Group 4 Y N Hypomethylated 
in SHH, WNT 
and Group 3 
N 
MET Group (3+4) In SHH, 
Group 3 and 
Group 4 but 
not WNT 
Y Hypermethylated 
in Group (3+4) 
Y 
RHOH Group 4 Y Y Hypomethylated 
in Group 4 
Y 
Table 5.1. Summary table of Group 3 and/or Group 4–specific candidate epigenetically regulated genes 
identified in Chapter 3. Candidate genes showed evidence of an inverse methylation/expression relationship in 
Group 3 and/or Group 4 tumours. For two candidate genes, MET and RHOH, their subgroup-specific methylation was 
also tumour-specific, indicating an aberrant event in Group 3and/or Group 4. Candidate genes were investigated 
further for evidence of methylation-dependent gene expression in medulloblastoma cell lines using qRT-PCR. 
Expression was assessed in cell lines before and after treatment with the demethylating agent 5-azaCdR.  
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Figure 5.1. Patterns of CpG methylation and gene expression in primary medulloblastomas for RHOH. 
Combined boxplots and strip-plots illustrate the differential patterns of CpG methylation and gene expression for the 
RHOH promoter-associated CpG residue RHOH_P121_F. Methylation of RHOH_P121_F in control cerebellar 
samples (CB) is also show. The CpG residue is hypomethylated in Group 4 medulloblastomas and hypomethylation 
is associated with significantly higher expression in Group 4 compared with the other tumour subgroups. 
 
The second approach taken by this project was a genome-wide screen that identified 
283 genes that were upregulated in 2 or more medulloblastoma cell lines (n=10) 
following 5-azaCdR treatment (Chapter 4). Using the Illumina 450K methylation array, 
an unbiased assessment of DNA methylation identified 160 CpG residues 
(encompassing 21 of the 283 genes) whose methylation was consistent with gene 
expression alterations observed after 5-azaCdR treatment. These 21 genes were selected 
as candidate epigenetically regulated genes in cell lines and were taken forward for 
further investigation of epigenetic gene regulation in primary medulloblastoma 
subgroups. 
Subgroup-specific differential methylation and gene expression analyses identified 5 of 
the 21 genes that showed evidence of methylation-dependent gene expression in 
primary medulloblastoma subgroups and that may play a role in medulloblastoma 
development (Table 5.2 and Figure 5.2). The genes identified varied with regard to their 
subgroup-specificity, location and number of CpG residues potentially involved, and 
their potential role in medulloblastoma pathogenesis. One gene identified, S100A4, has 
previously been reported to be epigenetically upregulated in medulloblastomas and this 
study refined its epigenetic upregulation to the WNT subgroup of tumours (Figure 5.2). 
The remaining four genes represent novel medulloblastoma genes. 
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Gene Methylation-
dependent 
transcriptional 
silencing and 
upregulation  
by 5azaCdR 
treatment in 
cell lines 
Subgroup-
specific 
methylation 
pattern of 
critical 
CpG sites 
associated 
with 
expression 
alterations 
in cell lines 
Subgroup-
specific 
inverse 
methylation-
expression 
relationship 
Tumour-
specific 
methylation 
event(s) 
Aberrant 
methylation 
state 
Location 
of 
subgroup-
specific 
critical 
CpG 
site(s)  
Aberrant 
methylation 
patterns 
observed 
across 
multiple 
adjacent 
CpG sites 
FAM46A Y SHH Y N Hypermethylated 
in WNT, Group 
3 and Group 4 
Gene 
Body 
Y 
ACTC1 Y Group (3+4) Y Y Hypermethylated 
in Goup (3+4) 
Gene 
promoter 
Y 
PRPH Y WNT Y Y Hypomethylated 
in WNT 
subgroup 
Gene 
promoter 
N 
ANXA2 Y WNT Y Y Hypomethylated 
in WNT 
subgroup 
Gene 
promoter 
N 
S100A4 Y WNT Y Y Hypomethylated 
in WNT 
subgroup 
Gene 
promoter 
and Gene 
body 
N 
Table 5.2. Summary table of subgroup-specific candidate epigenetically regulated genes identified in Chapter 
4. Candidate genes showed evidence of methylation-dependent gene regulation in cell lines, alongside differential 
CpG methylation inversely correlated with gene expression in distinct subgroups of primary tumours. Aberrant 
methylation patterns extended across multiple adjacent CpG residues in FAM46A and ACTC1, making them the 
strongest candidates identified in Chapter 4. CpG residues adjacent to the critical site(s) identified in PRPH, ANXA2 
and S100A4 did not show similar aberrant methylation patterns. 
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Figure 5.2. Patterns of subgroup-specific CpG methylation and gene expression for the 5 candidate 
epigenetically regulated genes identified in Chapter 4. Boxplots depicting methylation patterns are on the left and 
boxplots depicting gene expression patterns are on the right. Patterns of CpG methylation in control cerebellar 
samples (CB) are also shown for each gene. 
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5.2 High-throughput screening approaches to the identification of 
epigenetically regulated genes in medulloblastoma subgroups 
5.2.1 DNA methylation microarrays and the identification of subgroup-
specific methylation markers 
DNA methylation microarrays provide the opportunity to study DNA methylation at 
base-pair resolution and on a genome-wide scale. Tumour profiling on methylation 
microarrays has recognised DNA methylation patterns as cancer-specific markers with a 
high potential for clinical applications (Baylin and Jones, 2011). The four principal 
subgroups of medulloblastoma are associated with distinct methylomic profiles 
(Schwalbe et al., 2013). Investigations in Chapter 3 were focused on the determination 
of DNA methylation events that significantly discriminated the Group 3 and/or Group 4 
medulloblastomas and that were associated with gene expression in these subgroups. 
Methylation profiles generated on the Illumina GoldenGate Cancer Panel I methylation 
microarray were used to identify methylation markers of Group 3 and Group 4 
medulloblastomas. 
The intuitive β-value measure of methylation reported by the GoldenGate array follows 
a non-parametric, bi-modal distribution and, therefore, statistical models that have been 
developed for gene expression microarray analysis, and that largely follow the 
assumptions of normality cannot be applied (Du et al., 2010). By applying non-
parametric Mann-Whitney U tests, novel methylation markers were identified that 
clearly distinguished the Group 3 and/or Group 4 tumours (Figure 3.5). While Group 3 
and Group 4 tumours are considered to be more similar to each other than to SHH or 
WNT tumours (Taylor et al., 2012), the high proportion of Group 4-specific events 
(84%) that also discriminated Group (3+4) tumours suggests that the experimental 
design (combining distinct subgroups together into one test group) and statistical test 
applied may have been limited in accommodating the differences in size and variance 
that exist between the tumour subgroups. This was also apparent in the differential 
expression analysis where the t-test was applied using a similar experimental design; as 
an example, MET was significantly differentially expressed when (SHH+WNT) were 
tested against Group (3+4) but expression profiles revealed similar patterns of 
expression in Group 3, Group 4 and in the smaller WNT subgroup compared with the 
SHH subgroup which had markedly different expression (Figure 3.7C). It is important, 
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therefore, to exercise caution when interpreting significance test results if distinct 
disease subgroups of unequal size and variance are combined together into one test 
group for the purpose of a two group comparison. While the Mann-Whitney U test is 
assumed to be relatively insensitive to unequal sample size, a Kruskal-Wallis test 
accompanied by post hoc Mann-Whitney U tests may have improved test sensitivity to 
detect Group 4 events that do not also discriminate Group (3+4), although these 
methods would be labour-intensive in high-throughput screening methods. 
In Chapter 4, investigations were not initially directed by subgroup-specific methylation 
patterns, but rather, subgroup-specificity was later determined for a subset of CpG sites 
whose methylation was consistent with epigenetic gene regulation in cell lines. The 
limitations associated with subgroup-specific differential methylation analysis in 
Chapter 3 (see above) were not encountered in Chapter 4, because the M-value method 
of measuring methylation could be used with the Infinium 450K methylation array that 
was used for the investigations reported in Chapter 4. M-value measures of methylation 
follow a more normal distribution (Du et al., 2010) and enabled the use of the statistical 
model limma (Smyth, 2004), which is commonly employed for differential expression 
analysis in microarray experiments. Using limma, contrast matrices could be designed 
that tested all possible pair-wise comparisons simultaneously in an automated way, and 
events that were specific to one subgroup but not to any other group could easily be 
determined from the limma output. As well as facilitating a more direct interpretation of 
subgroup-specificity, limma also facilitated a more direct comparison of differential 
methylation and expression results which is discussed further in section 5.2.2.  
5.2.2 Association between differential patterns of DNA methylation and 
gene expression in medulloblastoma subgroups 
5.2.2.1 Identification of subgroup-specific inverse methylation-expression 
relationships 
The lack of primary tumour samples for which matched methylation and gene 
expression data were available has been one of the main limitations of this project. 
Associations between subgroup-specific patterns of differential methylation and gene 
expression have had to be determined, in large part, by a comparison of means based on 
the results of the differential methylation and expression analyses of microarray data. 
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For investigations reported in Chapter 3, genes that were both significantly 
differentially methylated and significantly differentially expressed in Group 3 and/or 
Group 4 tumours were subject to visual assessment of boxplots that illustrated the 
differential patterns and subgroup-specific inverse methylation/expression relationships 
were evaluated. This presents an obvious weakness in that the associations described are 
broad subgroup associations that don’t take into account the expression/methylation 
relationship in individual tumour samples.  
Matched methylation and expression data for the primary tumour cohort would permit 
statistical correlation on a tumour by tumour basis and provide a statistical measure of 
the strength of the inverse methylation/expression relationship observed, both between 
subgroups and within subgroups where methylation patterns were variable. In the 
primary tumour cohort that was used for investigations reported in Chapter 3 (Table 
2.1), there were 9 primary tumour samples for which gene expression data was also 
available. While this permitted a sample by sample statistical correlation analysis, it was 
limited by the small number of tumour samples which did not represent all tumour 
subgroups. Statistical correlation based on the 9 matched samples was calculated 
alongside an in silico analysis of methylation-dependent gene expression changes in cell 
lines (n=3) following 5-azaCdR treatment. Results from these were used to support the 
broad methylation-expression associations observed from inspection of the boxplots and 
the selection of candidate epigenetically regulated genes that would be investigated 
further.  
In the primary tumour cohort used for investigations reported in Chapter 4 (Table 2.2), 
there were no primary tumours for which gene expression data was also available. No 
statistical correlation on a tumour by tumour basis could be performed and inverse 
subgroup-specific associations were inferred from a comparison of means that were 
tested using limma. Using limma to conduct both differential methylation and 
expression analyses facilitated a more direct and automated comparison of significant 
subgroup-specific differential methylation and gene expression; inverse subgroup-
specific relationships could be determined directly from the limma output which 
described whether the contrast was significantly positive or significantly negative using 
the nominal values 1 and -1, respectively (Table 4.6). Overall the application of a 
bioinformatics statistical model to differential methylation and expression analysis 
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provided a more robust experimental design where multiple groups were being 
considered together, and had considerable practical advantages for high-throughput 
analysis in terms of speed and ease of interpretation of results. 
5.2.2.2 Patterns of DNA methylation do not show clear associations with gene 
expression 
Investigations in Chapter 3 identified 73 promoter-associated CpG sites that were 
significantly differentially methylated in Group 3 and/or Group 4 tumours. These CpG 
sites encompassed 63 genes. Only 15 (24%) of these 63 genes were significantly 
differentially expressed in an equivalent subgroup-specific manner and only 4 showed 
strong inverse associations between the subgroup-specific patterns of methylation and 
gene expression observed. Following further analyses, one gene (RHOH) was identified 
that showed the strongest evidence of methylation-dependent gene expression in the 
subgroups that were targeted in this study; RHOH was hypomethylated and upregulated 
in Group 4 medulloblastomas (Figure 5.1). Furthermore, there were no Group 3-specific 
methylation events that showed any evidence of an inverse methylation-expression 
relationship for genes that were also differentially expressed in Group 3. For 
investigations reported in Chapter 4, 160 CpG sites, that represented the 21 genes which 
were upregulated in cell lines following 5-azaCdR treatment consistent with a 
methylated status, were examined. Of the 160 CpG sites tested, 9 (6%) showed 
evidence of subgroup-specific differential methylation concordant with differential gene 
expression, and potential epigenetic gene regulation in medulloblastoma subgroups. 
These 9 sites encompassed 5 candidate epigenetically regulated genes (Figure 5.2).  
Overall this project finds that the patterns of methylation observed in Group 3 and 
Group 4 medulloblastomas, and the patterns observed for the 21 candidate genes tested 
in primary tumours in Chapter 4 do not show strong associations with gene expression 
in medulloblastoma subgroups. While a direct relationship between DNA methylation 
and gene expression clearly exists for some genes (see section 1.6.3) and 6 candidate 
genes have been identified in this study that show strong evidence of methylation-
dependent gene expression, this effect would appear to be gene-specific. A general 
weak association between DNA methylation patterns and gene expression in primary 
tumours has been reported by several studies (Etcheverry et al., 2010; Sproul et al., 
2011; Jung et al., 2012; Kulis et al., 2012; Sproul et al., 2012). In their study, Jung et al. 
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used both a linear and non-linear approach to examine methylation-expression 
correlations in multiple myeloma. Using both approaches they identified between 2.1% 
and 25.3% of promoter-associated CpG probes on the GoldenGate methylation array 
that were correlated, either positively or negatively, with gene expression, suggestive of 
a weak association between DNA methylation and gene expression in multiple 
myeloma for the ~800 genes assayed on the GoldenGate array (Jung et al., 2012). 
DNA methylation interacts with other epigenetic events, including histone 
modifications and nucleosome positioning, to establish chromatin architecture and 
regulate gene expression (see section 1.6.2). The removal of DNA methylation marks is 
required to establish a permissive state for subsequent gene expression, but the exact 
role of DNA methylation in transcriptional regulation has long been a source of debate, 
and it is not always clear whether gene transcription serves to block DNA methylation 
or whether DNA methylation acts to stabilise genes that are already transcriptionally 
silent (Jones, 2012). Emerging studies suggest that DNA methylation may not be the 
predominant mechanism for epigenetic gene silencing (Jones, 2012). Furthermore, 
recent studies have shown that the promoters of active genes are located in nucleosome-
depleted regions of the genome and that DNA methylation occurs secondary to the 
DNA becoming inaccessible by nucleosome occupancy (Han et al., 2011; Jones, 2012; 
Kelly et al., 2012). These studies support the long-held notion that promoter DNA 
methylation acts secondary to other inactivating mechanisms to stabilise 
transcriptionally silent states and strongly suggests that methylation requires the 
nucleosomes to be present. It is possible that the general lack of correlation between 
DNA methylation and gene expression observed may be because, for the majority of 
genes, methylation is necessary but not sufficient for regulating gene expression and 
that other mechanisms, such as histone modifications and nucleosome occupancy are 
more dominant.  
While it has been widely established that gene promoter methylation is associated with 
transcriptional repression, genome-wide studies are beginning to yield interesting 
insights regarding the potential roles of DNA methylation outside of the gene promoter. 
In one study in chronic lymphocytic leukaemia, the authors reported that while DNA 
methylation and gene expression were poorly correlated, the majority of significantly 
correlative relationships were found for CpG sites located in the gene body, and both 
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negative and positive correlations were identified (Kulis et al., 2012). Multiple studies 
have identified a positive correlation between intragenic DNA methylation and gene 
expression, and it is thought that it may impact alternative splicing mechanisms (Ball et 
al., 2009; Irizarry et al., 2009; Shukla et al., 2011; Brown et al., 2012; Jones, 2012; 
Kulis et al., 2012). In their study, Kulis et al. identified 13 genes that had cancer-
specific methylation changes close to alternative splice sites. They found a relationship 
between DNA methylation and alternative splicing for exon 5 of PTPRC (encodes the 
cell surface marker CD45) in CLL patients; DNA methylation was correlated with exon 
skipping, while lack of methylation was correlated with exon inclusion. They also 
identified extensive hypomethylation that targeted mainly enhancer regions within the 
gene body, where methylation was negatively correlated with gene expression and 
enhancer activity (Kulis et al., 2012). In another study, the relationship between gene 
body methylation and gene expression has been reported in a context-dependent manner 
relating to whether CpG sites were located inside or outside of CpG islands in the gene 
body (Varley et al., 2013). 
It would appear from the studies described above, that the function of DNA methylation 
varies with context and that the relationship between DNA methylation and gene 
expression is more complex than what is currently understood. These findings will have 
major implications for future studies into the genome-wide role of DNA methylation 
both in development and in cancer, and it is clear that positive and negative 
methylation-expression correlations will need to be comprehensively studied if the role 
of DNA methylation in gene regulation is to be more fully understood and appreciated. 
A further explanation for the lack of a direct association between DNA methylation 
patterns and gene expression may lie in the increasing recognition that methylation 
patterns may, to some extent, reflect patterns in the distinct cell of origin from which the 
tumour subgroup arises (Kulis et al., 2012; Batora et al., 2013). DNA methylation 
patterns in medulloblastoma could, therefore, hold considerable promise for the 
identification of the cells of origin of medulloblastoma subgroups (cell of origin of 
Group 4 tumours is currently unknown) as well as the potential subtypes that exist 
within the core subgroups (Batora et al., 2013). Furthermore, aberrant patterns of DNA 
methylation have been identified in multiple cancer types that represent markers of cell 
lineage; cancer-specific hypermethylation patterns have been identified that don’t play a 
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direct role in the transcriptional silencing with which they are associated, but rather 
reflect the developmental history and transcriptional state of the different cells of origin 
(Sproul et al., 2011; Sproul et al., 2012). These findings suggest that, for the large part, 
DNA methylation may not play a functional tumour-promoting role but may be a 
passenger event that holds considerable value for the identification of cellular origins in 
cancers. 
5.2.3 Future approaches for the identification of epigenetically regulated 
genes in medulloblastoma 
The development of DNA methylation microarrays was a major step forward in the era 
of epigenomics allowing whole cancer methylomes to be characterised at increasingly 
high resolution. Advances in the technology have seen the coverage offered by Illumina 
microarray platforms increase substantially from 1,505 promoter-associated CpG sites 
in ~800 genes (Bibikova et al., 2006) to more than 450,000 CpG sites spanning 
complete gene regions of more than 20,000 genes (Bibikova et al., 2011). The 
development of the 450K methylation array permits the genome-wide study of DNA 
methylation in an unbiased way; CpG sites outside of the gene promoter and outside of 
CpG islands can be assessed for functional roles in normal development and in cancer 
(Bibikova et al., 2011). Furthermore the high density resolution of the 450K array 
permits the assessment of differentially methylated regions as well as the study of single 
CpG sites. 
The investigations reported in Chapter 4, using the 450K methylation array, assessed 
methylation-expression relationships at the resolution of the single CpG site. There 
were 4,238 CpG sites that encompassed the 283 genes which were upregulated in cell 
lines following 5-azaCdR treatment, and that were assessed for evidence of methylation 
consistent with the upregulated expression observed. By considering the methylation 
status of each site individually, only 160 CpG sites (~4% and encompassing only 21 
genes) were taken forward for further analysis of subgroup-specific methylation-
expression relationships in primary tumours. This approach may have been limited and 
more sites, and genes, may have been identified initially in cell lines if regions of 
methylation were considered as an average measure, rather than single sites. Indeed for 
2 of the candidate genes identified in Chapter 4 (FAM46A and ACTC1), subsequent 
assessment of their gene-wide DNA methylation patterns using probes on the 450K 
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array, identified methylation of multiple CpG residues in the gene body of FAM46A 
(see Figure 4.16) and multiple CpG residues in the non-CpG island promoter of ACTC1 
(see Figure 4.21) to play a potential role in their gene regulation.  
In model systems, DNA methylation has been found to repress transcription in a manner 
that depends on the location and density of CpG sites relative to the gene promoter 
(Bird, 2002). While dense promoter hypermethylation is known to silence gene 
transcription (see section 1.6.2.1), genome-wide studies are identifying roles for DNA 
methylation in other functional genomic regions, such as ‘CpG island shores’ (Irizarry 
et al., 2009), enhancer elements (Kulis et al., 2012) and intragenic alternate promoters 
(Maunakea et al., 2010). As a result, an increasing number of bioinformatics tools are 
being developed that facilitate the identification of functionally important genomic 
regions and that permit methylation to be assessed as an average measure over a defined 
number of CpG residues. 
In a key study, Irizarry et al. used CHARM analysis (see section 1.6.3.3) to interrogate 
the colon cancer methylome alongside matched normal mucosa tissue (Irizarry et al., 
2009). They took the approach of averaging methylation M-values for each probe across 
the cancer samples and across the matched normal samples. Differential tumour versus 
normal methylation was quantified by the difference in averaged M-values and 
contiguous statistically significant values were grouped into regions. Using this method, 
they reported for the first time the presence of CpG island shores (see section 1.6.3.1). 
They found that most differentially methylated regions (DMRs) in colon cancer 
occurred in CpG island shores and that methylation of shores was strongly related to 
gene expression. Their study provides strong support for the study of region-wide DNA 
methylation in non-promoter and non-CpG island regions in medulloblastoma, where 
similar approaches could be taken to the identification of differentially methylated 
regions that characterise individual subgroups and their potential role in gene expression 
regulation.  
Additional epigenetically regulated genes may also be identified by targeting specific 
functional genomic regions, such as enhancer elements, alternate intragenic promoters 
and common alternative splice sites. In their study of CLL, Kulis et al., showed that 
gene body hypomethylation was enriched for enhancer regions in B cells and for 
binding sites of transcription factors such as IRF and OCT1 (Kulis et al., 2012). They 
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identified differentially methylated gene body CpG sites between subtypes of CLL that 
showed both positive and negative correlations with gene expression. A particularly 
interesting finding was that gene body CpG sites whose methylation status was 
negatively correlated with expression were related to enhancer elements, suggesting that 
the methylation status of distal regulatory regions may be more predictive for 
expression levels than promoter methylation (Kulis et al., 2012). A further interesting 
finding from this study was that the PTK2 gene (encodes cytoplasmic protein tyrosine 
kinase 2) exhibited simultaneous negative correlation between gene expression and 
promoter methylation and positive correlation in the gene body, highlighting again the 
importance of searching not only for negative methylation-expression correlations but 
also positive ones. These findings need to be further validated and the mechanisms by 
which DNA methylation at enhancers may regulate transcription are not known, 
however, they provide precedent for the investigation of DNA methylation in regulatory 
genomic regions in other cancers including medulloblastoma. The genome of a cell can 
be characterised into functional chromatin states by carrying out ChIP-Seq followed by 
bioinformatics modelling of a common set of chromatin states to characterise regulatory 
elements and their functional interaction which enable the linking of enhancers to 
putative target genes (Ernst et al., 2011). 
While DNA methylation microarrays have significantly advanced knowledge and 
understanding of cancer methylomes, bisulfite sequencing is considered to be the gold 
standard for validating DNA methylation patterns (see section 1.6.3.3). The availability 
of NextGen sequencing which is a high throughput sequencing technique, offers much 
higher coverage and a relatively lower cost for genome-wide sequencing than previous 
technologies (Zuo et al., 2009). Whole genome shotgun bisulfite sequencing (WGSBS) 
is a NextGen sequencing approach that, unlike other methylation analysis methods, 
generates quantitative genome-wide methylation profiles at the ultimate comprehensive 
single-base pair resolution (Laird, 2010). WGSBS is more sensitive than microarray 
technologies, which are not well suited for the detection of low-frequency DNA 
methylation states in a sample. WGSBS can generate thousands of sequencing reads per 
locus which provides the potential for the detection of rare DNA methylation variants 
that may play a role in the development and progression of the disease phenotype 
(Korshunova et al., 2008). It is likely that WGSBS will supersede all other techniques in 
the near future for the investigation of cancer methylomes. 
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RNA-Seq is another NextGen sequencing application that offers several advantages 
over microarray technologies for the detection of gene expression changes in cell lines 
following 5-azaCdR treatment. RNA-Seq is a powerful method for discovering, 
profiling and quantifying RNA transcripts across the entire transcriptome; it provides 
discreet, digital sequencing read counts that can be aligned to a particular sequence, 
supporting increased dynamic range and fold-change estimates for a more sensitive 
detection of genes, transcripts and differential expression compared with microarray 
methods. It also has the capacity to capture subtle gene expression changes that may be 
masked by noise levels often experienced with microarray studies (Ozsolak and Milos, 
2011). The investigations in Chapter 4 used a microarray-based assessment of gene 
expression changes following 5-azaCdR treatment. Microarray-based approaches are 
sensitive to the type of platform used and discrepancies in the genes detected between 
different studies are observed (see section 4.5.5). The use of RNA-Seq, accompanied by 
a universal analytical pipeline, offers a more sensitive and reproducible method of 
detection of gene expression changes following demethylation treatment and would 
facilitate consistency between studies. In addition to gene expression analysis, RNA-
Seq also enables the identification of alternative splicing events, allele-specific 
expression, the detection of rare and novel transcripts and non-coding RNAs (Ozsolak 
and Milos, 2011). The use of RNA-Seq to determine drug-induced expression changes 
coupled with DNA methylation analysis using WGSBS would provide the most 
comprehensive and refined assessment of the genome-wide role of DNA methylation in 
regulating the expression of genes and their transcript variants. 
Gene transcription is a remarkably complex process and epigenetic regulation relies on 
the interplay between different mechanisms that control chromatin organisation, 
including DNA methylation, histone modifications and nucleosome remodelling (see 
section 1.6.2). As previously discussed in section 3.5.3 and section 4.6, it will be 
important to investigate aberrant DNA methylation alongside histone modifications and 
nucleosome structure if we are to gain a fuller understanding of its role in epigenetic 
gene regulation. Chromatin immunoprecipitation coupled with ultra-high-throughput 
parallel DNA sequencing (ChIP-Seq) allows for the investigation of genome-wide 
protein-DNA interactions (Ma and Wong, 2011). Using antibodies specific for various 
histone modifications, ChIP-Seq can be used to characterise nucleosomal changes that 
accompany DNA methylation changes in cancer cells, providing a greater insight into 
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their interactions in mediating transcriptional responses. A further important aspect of 
epigenetic gene regulation to consider is the role of micro-RNAs (miRNAs). Micro-
RNAs are small non-coding RNAs that target mRNA transcripts for cleavage or 
transcriptional repression and can, therefore, influence the expression of many protein 
coding genes (Bartel, 2004). An important emerging new role for aberrant promoter 
DNA hypermethylation is the transcriptional repression of multiple microRNAs (Baylin 
and Jones, 2011). This repression has been found to be associated with pathway 
disruption and upregulation of oncogenic targets of the microRNAs (Saito et al., 2006), 
as well as the constitutive activation of signalling that promotes metastasis (Lujambio et 
al., 2008). Interestingly, downregulation of the miRNA-29 family has been found to be 
associated with overexpression of the DNA methyltransferases, which may then permit 
aberrant methylation in cancers (Fabbri et al., 2007). A study of DNA methylation 
which extends to non-coding RNAs could reveal further epigenetic events as well as 
key pathways and genes that may play a critical role in medulloblastoma development. 
5.3 Identification of novel putative oncogenes and tumour 
suppressor genes  
Using the two high-throughput approaches described in section 5.1, this project has 
identified six genes that show strong evidence of methylation-dependent gene 
expression in distinct subgroups of medulloblastoma. For five of the genes identified 
(RHOH, FAM46A, ANXA2, ACTC1, PRPH), they represent novel medulloblastoma 
genes. S100A4 has previously been shown to be epigenetically regulated in 
medulloblastoma (Lindsey et al., 2007) and this project has identified its epigenetic 
regulation to be specific to the WNT subgroup of tumours (Figure 5.2). Interestingly, 
for 3 of the 6 genes identified (S100A4, PRPH and ANXA2), the methylation-expression 
relationships were specific to the WNT subgroup, where they all represented putative 
oncogenes in WNT medulloblastoma pathogenesis (Figure 5.2).  
The determination of a putative oncogenic or tumour suppressor role for the candidate 
genes identified was based on their methylation profiles in normal cerebellar tissue. The 
lack of gene expression data for non-neoplastic samples presented a limitation to the 
complete evaluation of the effect of aberrant methylation on gene expression in primary 
tumour subgroups. Control cerebellar tissue contains a heterogeneous population of 
cells and the methylation signals generated will represent an average of these mixed cell 
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types and may mask the true signal from the actual cell of origin. Since the 4 molecular 
subgroups of medulloblastoma potentially arise from distinct stem and progenitor cell 
populations (see section 1.5.9), an accurate assessment of tumour versus normal tissue 
should account for these subgroup-specific differences and comparisons should be made 
to the correct cell type from which the tumour originates. Acquiring accurate cell type-
matched control tissue for the distinct subgroups of medulloblastoma presents a 
significant challenge to researchers, and until the cell of origin can be identified for all 
subgroups, and in the absence of appropriate cell type-matched controls, we must 
consider with caution the utility of non-matched cerebellar samples as controls for the 
evaluation of subgroup-specific events.  
For each of the candidate genes identified, DNA methylation of multiple CpG residues 
could be assessed using the genome-wide 450K methylation array, and the potential role 
of region-wide methylation on gene expression could be evaluated. Three genes 
(FAM46A, ACTC1 and RHOH) demonstrated aberrant hypo- or hypermethylation of 
multiple adjacent CpG residues that may play a potential role in regulating gene 
expression (Figures 4.16, 4.21 and 4.25, respectively). These 3 genes were considered 
the strongest candidate epigenetically regulated genes. Nevertheless, methylation at a 
single CpG site has been shown to be sufficient to negatively affect binding of 
transcription factors to the DNA (Tate and Bird, 1993), and ANXA2, PRPH and S100A4 
still warrant further investigation.  
The candidate genes identified in this project have been shown to be involved in key 
tumourigenic processes, including proliferation, migration and metastasis, in other 
cancer types (see section 3.5.6 and section 4.5.4). Their potential deregulation by 
aberrant DNA methylation may represent driver events and potential therapeutic targets 
in the distinct subgroups of medulloblastoma. Further in vitro and in vivo studies are 
required to validate the subgroup-specific methylation-expression relationships 
identified for each of the candidate genes, and any functional role they may play in 
driving medulloblastoma development (see section 5.3.1). Furthermore, the prognostic 
potential of the aberrant DNA methylation events must be investigated in well-defined 
clinical trial cohorts of medulloblastoma (see section 5.3.2). 
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5.3.1 Further work to investigate their functional significance in 
medulloblastoma 
For the candidate genes identified in this project, bisulfite sequencing (see section 
1.6.3.3) will need to be carried out in medulloblastoma cell lines before and after 5-
azaCdR treatment, to validate their methylation status and the subsequent demethylation 
induced by 5-azaCdR. For the 3 strongest candidates, the gene region of focus will be 
the non-CpG island promoter regions of RHOH (Figure 4.25) and ACTC1 (Figure 4.21) 
and the gene body region of FAM46A (Figure 4.19). For the remaining genes, 
sequencing approaches will need to focus on the critical CpG site identified in cell lines 
and in primary tumours and any immediately adjacent CpG residues in the surrounding 
region.  
To accompany bisulfite sequencing, microarray gene expression changes detected in 
cell lines following 5-azaCdR will need to be validated by a more sensitive method, 
such as qRT-PCR, to confirm a direct relationship between DNA methylation and gene 
expression. Methylation-dependent expression of RHOH in cell lines has been validated 
by qRT-PCR for investigations reported in Chapter 3 of this project (see section 
3.4.9.5). For the genes identified in Chapter 4, methylation-dependent expression of 
S100A4 has previously been validated in medulloblastoma cell lines by RT-PCR 
(Lindsey et al., 2007). This validation has not yet been carried out for FAM46A, 
ACTC1, PRPH or ANXA2. 
Cell lines provide a resource of unlimited amounts of high quality tumour-derived DNA 
and RNA. However, studies have shown that medulloblastoma cell lines may not 
represent all medulloblastoma subtypes. They are known to contain molecular defects 
such as MYC amplification and 17p loss which are associated with more aggressive 
tumours (Langdon et al., 2006). More recently,using a non-negative matrix factorisation 
(NMF) (Brunet et al., 2004) consensus clustering approach, Ed Schwalbe (Newcastle 
University Paediatric Brain Tumour Group) demonstrated that multiple 
medulloblastoma cell line methylation patterns cluster with the worst prognosis MYC-
amplified Group 3 medulloblastomas (Table 2.3; data not yet published). Furthermore, 
cell lines are known to undergo de novo methylation during in vitro cell culture and 
acquire artifactual methylation marks that are not associated with primary tumours 
(Bender et al., 1998; Smiraglia et al., 2001). For these reasons cell lines should be used 
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with caution in methylation studies and careful consideration should be given to the 
subgroup-specific nature of the DNA methylation event being investigated. For the 
candidate genes identified, bisulfite sequencing and qRT-PCR assessment of gene 
expression will be necessary in primary tumour samples to validate the subgroup-
specific methylation-expression relationships observed in this project. Methylation 
status and gene expression will also need to be assessed in control cerebellar tissue 
samples to confirm the potential tumour suppressor or oncogenic role of the genes. 
Medulloblastoma cell lines provide highly valuable models, particularly for the Group 3 
and Group 4 tumour subgroups (see above), for functional assays to investigate the role 
of epigenetic deregulation in tumour development and progression. To determine any 
functional role, gene expression will need to be modulated in cell line model systems. 
This could be achieved through the use of lentiviral vector constructs that would deliver 
siRNA sequences into cells to silence target transcripts that are unmethylated and 
expressed in cell lines. Similarly, lentiviral vector systems could deliver and 
constitutively express genes that are methylated and silenced in cell lines. The effect of 
gene knockdown or overexpression on the phenotype of cells would then need to be 
investigated using assays that assess cell proliferation, migration and apoptosis, 
alongside investigations of any signalling pathways which the genes may function in or 
impact on. 
The use of cancer cell lines in functional studies may be limited by their high 
homogeneity compared with tumours, which contain a heterogeneous population of 
cells. Moreover, cell lines growing in culture lack the complex in vivo environment with 
which tumour cells interact to sustain growth and migration capabilities (Vargo-Gogola 
and Rosen, 2007; Gazdar et al., 2010). It is therefore important to carry out in vivo 
validation studies for those findings that are validated initially in vitro. Mouse models 
are currently available for SHH, WNT and Group 3 medulloblastomas (see section 
1.5.9), and using lentiviral vector systems, gene expression may be similarly modulated 
in animal models as in cell line models. The effects of gene modulation may be 
monitored through the constitutive expression of an optical reporter gene and imaging 
systems. The candidate gene RHOH represents a Group 4-specific event and there are 
currently no mouse models that have been developed that represent this subgroup of 
medulloblastomas. The critical promoter-associated RHOH CpG residue 
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(RHOH_P121_F) was hypomethylated (β≤0.3) in 51% of Group 4 medullloblastomas, 
but was also hypomethylated in a considerable proportion (21%) of Group 3 tumours. It 
may therefore be considered rational to study any functional role of RHOH 
hypomethylation in vivo in Group 3 mouse models. The results from in vitro and 
subsequent in vivo functional studies will reveal any role for epigenetic deregulation of 
the candidate genes in the initiation and/or progression of the distinct subgroup(s) in 
which the aberrant epigenetic event is found and will identify their potential as 
therapeutic targets within these tumours. 
5.3.2 Further work to investigate their clinical relevance in medulloblastoma 
Aberrant DNA hypermethylation events that are associated with aberrant gene silencing 
in tumours, and that demonstrate a functional role in the initiation and/or progression of 
tumours may represent therapeutic targets that could potentially be targeted with 
demethylating agents such as 5’-aza-2’-deoxycytidine (Dacogen), which is currently 
approved for the treatment of MDS (see section 1.6.3.4). For those potential oncogenic 
genes whose expression is upregulated by an aberrant hypomethylation event, it may be 
possible to target their over-expressed protein product or other upstream or downstream 
mediators using either immunotherapy or targeted small molecule inhibitors (see section 
1.2.2.1). The design and development of such targeted therapies would necessitate the 
accurate identification of patients in the clinical setting who carry the aberration and 
who would potentially benefit from the targeted therapies.  
As well as representing potential key driver events in tumourigenesis, aberrant DNA 
methylation markers are beginning to show considerable promise as prognostic 
biomarkers in several cancer types, including in medulloblastoma (see section 1.6.3.4 
and section 1.7.2.2). The identification of subgroup-specific methylation biomarkers 
offers the potential to identify functionally relevant markers that may also be 
prognostically relevant not only between the subgroups but, depending on their intra-
subgroup variability, also within their respective subgroups.  
It will be of great interest to investigate the potential prognostic relevance of the 
aberrant subgroup-specific methylation events associated with the candidate genes 
identified. For 3 of the candidate genes that were identified in Chapter 4 (ANXA2, 
PRPH and S100A4), their potential epigenetic dysregulation was specific to the WNT 
subgroup of tumours. WNT tumour status confers a very good long-term prognosis in 
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comparison to the other tumour subgroups (Ellison et al., 2005; Clifford et al., 2006; 
Kool et al., 2012), with long-term survival rates likely exceeding 90% (Taylor et al., 
2012). As a result, the role of WNT-specific methylation biomarkers in disease 
prognostication is limited. The remaining candidate genes identified (RHOH, FAM46A 
and ACTC1) had aberrant methylation events specific to non-WNT tumour subgroups, 
and it will be important to investigate their prognostic relevance across all 
medulloblastomas in well-defined clinical trial cohorts for which mature event-free 
(EFS) and overall (OS) survival data is available. It will also be important to assess their 
prognostic relevance within their respective subgroups, to determine whether they can 
identify subsets of tumours within the core subgroup that behave differently, and that 
ultimately may benefit from less aggressive or more intensive therapeutic strategies 
depending on their risk. It will be important to assess the ability of the methylation 
markers to improve the accuracy and significance of current survival prediction by 
adding them to survival models, such as a Cox proportional hazards model (see below), 
which contain established medulloblastoma prognostic variables (see section 3.6 and 
section 4.6). The identification of prognostic disease biomarkers offers the potential for 
the development of a more accurate and refined risk stratification that will be essential 
to the delivery of personalised therapies, with the primary goal of improving survival 
and minimising the long-term adverse outcomes of aggressive treatment (Pizer and 
Clifford, 2009). 
Alongside survival analysis, it will be important to investigate any significant 
correlations between the candidate gene methylation biomarkers and selected clinico-
pathological features, such as age, gender, histological subtype and metastatic status. 
Significant associations would need to be considered further in survival analysis studies, 
as it would be important to assess any independent contribution to survival outcome 
prediction that the methylation biomarker confers, particularly if it is associated with an 
established high risk variable such as LCA histology or a positive metastatic status. 
These studies will be of great interest and the clinical data is now available to carry 
them out. 
EFS and OS are defined as the time periods between diagnosis of disease to relapse or 
death, respectively. In medulloblastoma, EFS is considered a more accurate reflection of 
survival risk because patient survival following relapse is rare (Pizer and Clifford, 
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2009), but time to death may be influenced by variable therapeutic strategies in the 
relapse setting or by factors that are unrelated to their disease. Kaplan-Meier survival 
curves and log-rank tests are commonly employed in disease survival analysis. The 
Kaplan-Meier estimator (Kaplan and Meier, 1958) measures the fraction of patients 
living for a certain amount of time with or without an event occurring. The log-rank test 
(Mantel, 1966; Bland and Altman, 2004) is a hypothesis test that can be used to 
compare the survival distributions between different Kaplan-Meier curves for different 
groups tested. It tests the null hypothesis that there is no difference between survival 
curves. The Cox proportional hazards model (Cox, 1972) can also be used to compare 
different survival distributions. Compared to log-rank tests which require DNA 
methylation to be considered as a binary variable (methylated versus not methylated), 
the Cox model tests methylation as a continuous variable as measured by its β-value. 
Cox models can also assess the effects of one or more covariates that may be associated 
with the time that passes before an event occurs. Cox models are widely used in 
multivariate survival analysis studies. 
5.4 Summary 
This project presents a comprehensive investigation into the genome-wide role of DNA 
methylation in distinct molecular subgroups of medulloblastoma. Two high-throughput 
screening approaches have successfully identified six genes that show strong evidence 
of methylation-dependent gene regulation in medulloblastoma subgroups and that may 
play key roles in their distinct pathogenesis. These genes represent both putative 
oncogenes and tumour suppressor genes that are deregulated by aberrant methylation 
states at one or more CpG sites which are located in CpG island and non-island 
promoters and in the gene body. While for the large part, patterns of DNA methylation 
did not show clear associations with gene expression, this project focused only on 
negative methylation-expression correlations and assessment of methylation-expression 
relationships were carried out at the level of single CpG residues. It is likely that further 
epigenetically regulated genes may be identified in future genome-wide studies that 
investigate both positive and negative methylation-expression correlations, and that 
specifically target regions of the genome that contain important regulatory elements 
such as enhancers and transcription factor binding sites. Furthermore, the complete 
characterisation of subgroup-specific epigenetic events, to include DNA methylation 
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patterns alongside accompanying histone modifications and nucleosome structure, may 
provide greater insights into the complexity of epigenetic gene dysregulation in 
medulloblastoma and the complex role that DNA methylation may play in mediating 
any transcriptional responses.  
Alongside the identification of additional epigenetic events that may be critical in the 
development of distinct subgroups of medulloblastoma, the six genes identified in this 
project now merit further investigation. The aberrant DNA methylation events and 
associated gene transcriptional effects may represent potential driver events in 
medulloblastoma subgroup pathogenesis that could be targeted therapeutically. The 
subgroup-specific aberrant DNA methylation events also have the potential to represent 
prognostic markers that could refine and improve current stratification models and 
allow appropriate therapies to be more accurately tailored to a patient’s risk. 
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Group 3 v cerebella  Group 4 v cerebella  Group (3+4) v cerebella 
CpG probe Δβ  p value  CpG probe Δβ p value  CpG probe Δβ p value 
value 
BCAP31_P1072_F 0.59 1.94E-07  ASCL2_P609_R 0.10 0.0002  ASCL2_E76_R 0.05 4.72E-06 
BCR_P422_F 0.40 2.19E-05  CCKAR_E79_F 0.18 8.76E-08  ASCL2_P360_F 0.07 0.0001 
BLK_P668_R 0.73 3.68E-10  CCKAR_P270_F 0.78 1.93E-11  ASCL2_P609_R 0.08 0.0008 
CCL3_E53_R 0.44 1.31E-08  CSF3R_P472_F 0.59 1.93E-11  AXIN1_P995_R 0.09 0.006 
CHI3L2_P226_F 0.66 7.57E-16  DDR2_E331_F 0.02 0.002  BGN_P333_R 0.04 0.31 
FES_E34_R 0.54 2.18E-08  FZD9_E458_F 0.06 0.97  BLK_P668_R 0.41 2.08E-08 
FES_P223_R 0.42 0.000135  HDAC1_P414_R 0.03 0.19  CAPG_E228_F 0.15 3.51E-08 
FGF1_P357_R 0.54 9.77E-11  HIC-
1_seq_48_S103_R 
0.35 0.0004  CCKAR_E79_F 0.14 2.79E-06 
FRZB_E186_R 0.42 0.0009  HLA-DPA1_P28_R 0.14 9.67E-06  CCKAR_P270_F 0.77 1.06E-11 
HFE_E273_R 0.87 3.68E-10  IFNGR2_P377_R 0.36 1.03E-10  CEACAM1_E57_R 0.50 8.21E-11 
HLA-DOB_P357_R 0.56 3.68E-10  IGF1_E394_F 0.15 2.99E-05  CHI3L2_P226_F 0.47 3.07E-11 
IL1RN_P93_R 0.36 1.09E-05  IL16_P93_R 0.64 4.85E-11  CSF3R_P472_F 0.51 5.88E-11 
KRT1_P798_R 0.38 1.94E-07  L1CAM_P19_F 0.80 1.43E-10  CYP2E1_E53_R 0.06 0.973921 
MMP14_P13_F 0.05 0.53  LEFTY2_P719_F 0.16 2.60E-05  DDR2_E331_F 0.01 0.006 
PLA2G2A_E268_F 0.23 0.03  MEST_E150_F 0.13 0.97  FGF1_E5_F 0.40 6.87E-09 
RARRES1_P426_R 0.58 7.20E-09  MEST_P4_F 0.14 0.79  FZD9_E458_F 0.08 0.993912 
SERPINA5_E69_F 0.34 1.17E-06  MEST_P62_R 0.09 0.56  HDAC1_P414_R 0.14 0.73 
TGFB2_E226_R 0.48 0.0007  MET_E333_F 0.65 6.53E-10  HFE_E273_R 0.73 2.53E-11 
THBS2_P605_R 0.52 6.96E-12  MMP10_E136_R 0.71 1.93E-11  HIC-
1_seq_48_S103_R 
0.22 0.11 
TP73_P945_F 0.54 1.34E-07  NOTCH4_P938_F 0.13 0.11  IFNGR2_P377_R 0.29 9.36E-08 
TRIP6_E33_F 0.54 7.18E-12  PADI4_P1158_R 0.02 0.18  IL16_P226_F 0.61 2.53E-11 
WRN_P969_F 0.57 3.07E-09  PIK3R1_P307_F 0.19 2.31E-07  IL16_P93_R 0.63 2.42E-11 
ZNFN1A1_E102_F 0.44 2.45E-07  PLG_E406_F 0.56 1.93E-11  IL1RN_E42_F 0.06 0.20 
    RAN_P581_R 0.02 0.54  IL8_P83_F 0.06 0.681 
    RHOH_P121_F 0.47 7.55E-06  L1CAM_P19_F 0.69 4.12E-09 
    SPP1_E140_R 0.42 2.09E-09  LCN2_P86_R 0.35 1.09E-09 
    TM7SF3_P1068_R 0.28 0.001  LEFTY2_P719_F 0.10 0.003 
    TRIM29_E189_F 0.06 0.05  MEST_E150_F 0.16 0.79 
    WNT10B_P993_F 0.59 1.43E-10  MEST_P4_F 0.17 0.99 
    ZIM3_P718_R 0.57 2.18E-11  MEST_P62_R 0.13 0.99 
    ZNF264_P397_F 0.11 1.06E-05  MET_E333_F 0.65 2.25E-10 
        MMP10_E136_R 0.64 2.89E-11 
        MSH2_P1008_F 0.66 1.06E-11 
        PADI4_P1158_R 0.08 0.99 
        PIK3R1_P307_F 0.13 0.0002 
        PLG_E406_F 0.55 1.06E-11 
        RHOH_P121_F 0.39 0.0004 
        SPARC_P195_F 0.08 0.23 
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Group 3 v cerebella  Group 4 v cerebella  Group (3+4) v cerebella 
CpG probe Δβ  p value   CpG probe Δβ p value  CpG probe Δβ p value 
value 
        SPP1_E140_R 0.39 2.88E-09 
        STAT5A_E42_F 0.00 0.21 
        TAL1_P594_F 0.08 0.79 
        TFPI2_P152_R 0.43 8.21E-11 
        TRIM29_E189_F 0.01 0.31 
        VAV1_E9_F 0.17 5.88E-11 
        VAV1_P317_F 0.28 7.06E-10 
        WNT10B_P993_F 0.51 7.30E-10 
        ZIM3_P718_R 0.51 2.53E-11 
        ZNF264_P397_F 0.05 0.0008 
Results of Mann-Whitney U tests, assessing methylation of Group 3-, Group 4- and Group (3+4)-specific events 
against methylation of non-neoplastic cerebellar samples. Δβ is the absolute difference in mean β values between 
groups tested and p-values were corrected using the Benjamini-Hochberg false discovery rate correction. Probe 
methylation was considered significantly different between tumours and control cerebella, and thus classed tumour-
specific, if the FDR-adjusted p-value was <0.05 and the Δβ value was >0.34.  
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 Kool/Fattet  Cho  Northcott 
 Probe ID Mean log 
ratio 
p-value  Probe ID Mean log 
ratio 
p-value  Probe ID Mean log 
ratio 
p-value 
G
ro
u
p
 3
 v
  
O
th
er
 
200837_at 0.59 2.00E-03  200837_at 0.76 5.59E-09  3528864 1.20 8.44E-06 
205117_at 0.79 0.02  206391_at 0.34 1.00E-04  2702752 0.31 3.32E-05 
205667_at 0.60 0.02  213060_s_at 0.64 1.40E-03  2380590 1.00 3.10E-04 
213060_s_at 0.37 0.02  203697_at 0.73 3.10E-03  4026669 0.47 1.60E-03 
206391_at 0.28 0.04  209129_at 0.82 3.10E-03  3001479 0.15 0.03 
220406_at 0.08 0.36  205117_at 0.71 3.80E-03  2351687 0.12 0.08 
203649_s_at 0.22 0.49  205418_at 0.15 3.80E-03  3015911 0.14 0.09 
205900_at 0.07 0.55  160020_at 0.14 0.01  2899110 0.14 0.10 
206255_at 0.10 0.55  205038_at 0.11 0.05  2879166 0.18 0.14 
209443_at 0.20 0.55  206255_at 0.13 0.09  3608427 0.12 0.15 
203697_at 0.20 0.59  205671_s_at 0.11 0.10  2590715 0.39 0.22 
205038_at 0.04 0.59  211330_s_at 0.08 0.33  2950145 0.08 0.38 
205114_s_at 0.31 0.59  216244_at 0.09 0.33  2317317 0.07 0.41 
209129_at 0.26 0.59  217223_s_at 0.12 0.59  3085990 0.05 0.58 
217223_s_at 0.15 0.59  205114_s_at 0.13 0.67  3549740 0.07 0.59 
232546_at 0.11 0.59  220406_at 0.03 0.69  3092663 0.15 0.62 
235754_at 0.06 0.59  203083_at 0.16 0.80  2985781 0.02 0.86 
203083_at 0.23 0.62  209443_at 0.06 0.80  2400027 0.01 0.88 
160020_at 0.03 0.72  205667_at 0.07 0.95  2501204 0.01 0.88 
205671_s_at 0.03 0.72  203649_s_at 0.01 0.96  3455728 0.01 0.88 
216244_at 0.01 0.74  205900_at 0.01 0.96  3754009 0.03 0.88 
205418_at 0.02 0.86  220804_s_at 0.00 0.96  3939183 0.02 0.88 
            
G
ro
u
p
 4
 v
 O
th
er
 
201209_at 1.99 2.14E-18  201209_at 2.75 8.22E-21  2328868 1.45 9.73E-14 
200750_s_at 0.69 3.70E-13  200750_s_at 0.74 4.61E-11  2458629 0.81 6.89E-07 
205168_at 1.08 8.80E-06  203510_at 2.18 2.45E-09  3448481 0.66 9.14E-07 
209540_at 1.04 1.10E-04  217974_at 0.77 1.39E-07  2364231 1.02 1.80E-06 
203510_at 1.19 2.10E-04  205168_at 0.92 2.55E-06  3020343 1.29 2.63E-06 
206012_at 0.58 1.60E-03  206012_at 0.79 4.47E-06  2724671 0.27 8.80E-04 
202504_at 0.18 2.10E-03  202016_at 0.84 5.80E-04  2950329 0.71 1.20E-03 
207639_at 0.21 6.60E-03  209540_at 0.98 3.90E-04  3438027 0.33 1.20E-03 
217974_at 0.42 6.60E-03  204951_at 0.40 0.01  3872138 0.28 1.20E-03 
205680_at 0.15 0.02  201642_at 0.17 0.04  3468345 0.30 1.30E-03 
205917_at 0.29 0.04  209875_s_at 0.68 0.04  3843058 0.18 0.01 
209977_at 0.09 0.04  211990_at 0.52 0.10  3453513 0.14 0.02 
204951_at 0.40 0.04  204584_at 0.43 0.13  3359224 0.18 0.02 
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 Kool/Fattet  Cho  Northcott 
 Probe ID Mean log 
ratio 
p-value  Probe ID Mean log 
ratio 
p-value  Probe ID Mean log 
ratio 
p-value 
G
ro
u
p
 4
 v
 O
th
er
 
202016_at 0.51 0.10  206213_at 0.19 0.13  2813060 0.31 0.09 
211173_at 0.10 0.10  205247_at 0.20 0.16  2934682 0.07 0.13 
211412_at 0.05 0.10  211412_at 0.10 0.23  2406783 0.08 0.16 
211990_at 0.39 0.19  211173_at 0.09 0.39  3007829 0.08 0.16 
208461_at 0.06 0.24  207607_at 0.00 0.41  3394660 0.05 0.25 
201642_at 0.07 0.29  209827_s_at 0.05 0.59  3604287 0.12 0.25 
203591_s_at 0.07 0.54  212239_at 0.15 0.59  2322848 0.06 0.33 
212239_at 0.17 0.54  205917_at 0.12 0.62  3024025 0.10 0.60 
204584_at 0.17 0.60  205680_at 0.05 0.64  2735027 0.22 0.60 
205247_at 0.05 0.60  209977_at 0.03 0.68  2949901 0.02 0.68 
206213_at 0.03 0.77  208461_at 0.01 0.73  2764478 0.02 0.83 
207607_at 0.01 0.81  203591_s_at 0.01 0.79  3388785 0.02 0.83 
209875_s_at 0.03 0.98  202504_at 0.00 0.87  3706113 0.01 0.83 
1553022_at 0.00 0.99  207639_at 0.01 0.87  3918635 0.03 0.83 
1555016_at 0.00 0.99      4026798 0.04 0.83 
            
G
ro
u
p
 (
3
+
4
) 
v
 (
S
H
H
+
W
N
T
) 
201209_at 1.28 3.25E-06  201209_at 1.68 9.75E-11  2328868 1.00 3.39E-07 
205168_at 1.36 8.80E-06  203510_at 3.13 9.75E-11  3020343 1.75 2.66E-06 
203010_at 0.47 2.78E-05  205168_at 1.70 3.63E-10  2364231 1.34 7.33E-06 
202016_at 1.32 8.01E-05  202016_at 1.50 1.30E-09  3721658 0.51 1.09E-05 
212849_at 0.34 8.01E-05  209421_at 0.59 1.30E-06  2724671 0.26 8.32E-05 
204951_at 0.66 1.40E-03  203010_at 0.67 7.48E-06  3675047 0.17 1.80E-04 
201262_s_at 0.57 1.60E-03  204951_at 0.38 1.40E-04  2899110 0.28 3.60E-04 
209421_at 0.40 1.90E-03  212849_at 0.26 0.01  3995633 0.58 1.10E-03 
201642_at 0.16 7.90E-03  212239_at 0.54 0.01  2480992 0.34 6.30E-03 
203510_at 1.12 0.01  204584_at 0.82 0.02  2764478 0.15 6.30E-03 
207639_at 0.23 0.02  212667_at 0.50 0.02  3863669 0.14 6.50E-03 
202504_at 0.16 0.03  201642_at 0.21 0.02  3453513 0.14 0.02 
206219_s_at 0.12 0.09  211330_s_at 0.16 0.05  3872138 0.20 0.02 
205917_at 0.25 0.16  209875_s_at 0.70 0.09  2411198 0.14 0.04 
206255_at 0.30 0.16  206213_at 0.16 0.15  3394660 0.08 0.05 
213060_s_at 0.28 0.16  206255_at 0.23 0.15  3818547 0.10 0.05 
211412_at 0.04 0.18  1431_at 0.17 0.16  3272981 0.13 0.11 
205117_at 0.41 0.23  211412_at 0.06 0.21  2882098 0.23 0.13 
205680_at 0.09 0.27  211173_at 0.11 0.28  2934682 0.07 0.14 
209498_at 0.13 0.27  206012_at 0.28 0.29  3190190 0.09 0.14 
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 Kool/Fattet  Cho  Northcott 
 Probe ID Mean log 
ratio 
p-value  Probe ID Mean log 
ratio 
p-value  Probe ID Mean log 
ratio 
p-value 
G
ro
u
p
 (
3
+
4
) 
v
 (
S
H
H
+
W
N
T
) 
209875_s_at 0.54 0.29  206219_s_at 0.05 0.29  2458629 0.28 0.17 
206213_at 0.09 0.32  209277_at 0.39 0.29  2879166 0.14 0.17 
212531_at 0.10 0.36  211506_s_at 0.13 0.32  2735027 0.55 0.17 
203591_s_at 0.11 0.37  202504_at 0.03 0.38  2322848 0.07 0.19 
201850_at 0.18 0.45  207639_at 0.09 0.38  3061621 0.44 0.27 
235754_at 0.04 0.45  209827_s_at 0.08 0.38  3024025 0.17 0.28 
209977_at 0.04 0.48  207607_at 0.00 0.41  3843058 0.09 0.28 
200665_s_at 0.18 0.48  205917_at 0.17 0.41  3085990 0.06 0.33 
209277_at 0.08 0.49  209977_at 0.05 0.41  2351687 0.05 0.35 
216244_at 0.02 0.63  209498_at 0.05 0.45  2813060 0.11 0.60 
206012_at 0.09 0.70  216244_at 0.03 0.45  2406783 0.03 0.61 
1555016_at 0.02 0.84  203591_s_at 0.03 0.46  3007829 0.03 0.65 
1431_at 0.02 0.84  212531_at 0.05 0.46  3706113 0.02 0.68 
204584_at 0.07 0.93  205680_at 0.07 0.55  3359224 0.04 0.72 
208461_at 0.01 0.93  213060_s_at 0.17 0.55  3388785 0.04 0.78 
211173_at 0.01 0.93  201850_at 0.14 0.57  3918635 0.03 0.83 
211506_s_at 0.02 0.93  205117_at 0.14 0.63  2731332 0.03 0.84 
212239_at 0.04 0.93  216928_at 0.02 0.64  2501204 0.01 0.84 
207607_at 0.01 0.93  208461_at 0.01 0.66  3604287 0.02 0.85 
1553022_at 0.00 0.98  201262_s_at 0.01 0.82  4026798 0.01 0.98 
216928_at 0.00 0.98      2562271 0.00 0.98 
Results of unpaired t-tests, assessing differential gene expression between medulloblastoma subgroups across 3 
independent transcriptomic datasets. Genes that contained subgroup-specific differentially methylated CpG sites were 
tested for evidence of differential expression in the equivalent subgroup. Mean log ratio is the absolute difference in 
mean log2 signal intensity between groups tested and p-values were corrected using the Benjamini-Hochberg false 
discovery rate correction. The average absolute difference in mean log2 intensities for all tests carried out was 0.3 in 
the Kool/Fattet dataset, 0.4 in the Cho dataset and 0.3 in the Northcott dataset. These values were applied as the mean 
log ratio thresholds. Transcripts with a FDR-adjusted p-value <0.05 and a mean log ratio > threshold in at least 2 out 
of 3 datasets were considered significantly differentially expressed. 
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